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ABSTRACT 
Amino acid variants of PrPC  particularly at codons 136, 154 & 171 have been 
linked to scrapie susceptibility, but do not explain all variation in disease phenotype. 
This study has therefore addressed the hypothesis that unexpected disease occurrence 
may also be linked to different levels of PrP gene expression. In order to investigate 
the role of the ovine PrP gene 3'UTR in the regulation of gene expression, a series of 
ovine PrP mini-gene constructs were produced, which differed only in their 
availability of previously identified polyadenylation signals. Following the transient 
transfection of ovine and murine cell lines with these constructs it became clear that 
they were being incorrectly spliced, despite the fact that sequencing confirmed the 
presence of all of the elements required for correct splicing to occur. 
Gene transcription is also regulated by the binding of sequence specific 
transcription factors to the promoter region and the role of the PrP gene promoter in 
the regulation of gene expression was investigated in the second half of this thesis. 
Sequence analysis using online and offline database resources revealed the presence 
of a number of transcription elements within the ovine PrP gene promoter. It was 
therefore decided to test the hypothesis that the binding of transcription factors to the 
ovine PrP promoter could influence the expression of the PrP gene. Using gel shift 
assays specific binding was observed to selected sequence elements and differential 
binding was demonstrated to a polymorphic variant of at least one of these motifs. 
In addition, binding to four motifs conserved in the mammalian PrP 
promoters was also analysed using a combination of gel shift assay and DNase I 
footprinting. Two of the four motifs showed specific binding and polymorphic 
variants of these motifs exhibited differential binding. The factors bound to these 
sites were identified by gel super-shift assays using antibodies specific for the 
candidate proteins. A specific interaction was shown between the transcription 
factors bound to two of these motifs. This study has demonstrated the functionality 
of a number of transcription elements within the ovine PrP promoter and has 
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A Alanine (amino acid) or adenine (nucleic acid), depending on 
context 
Ala Alanine 
AP-1 Activator protein-1 or ovine AP-1 oligonucleotide, depending 
on context 
AP-2 Activator protein-2 
APP Amyloid precursor protein 




ATF Activating transcription factor 
ATP Adenosine tnphosphate 
BABs Animals born after the 1988 ban on the feeding of ruminant 
material to other ruminants 
BAP Bacterial alkaline phosphatase 
BARBs Animals born after the 1996 ban (termed the real ban) on the 
feeding of meat and bone meal to any food animal species 
n-gal Beta-galactosidase 
bp Base pair 
BoPrP Bovine PrP 
BSE Bovine spongiform encephalopathy 
bZIP Basic leucine zipper protein 
C Cytosine (nucleic acid) or cysteine (amino acid), depending on 
context 
Degrees Celcius 
cAM P Adenosine-3 '-5-cyclic monophosphate 
CAT Chloramphenicol acetyltransferase 
CAT box CCAAAT box DNA sequence 
CIBP cAMP binding protein or C/BP oligonucleotide, depending on 
context 
cDNA Complementary deoxyribonucleic acid 
C/EBP CCAAT/ enhancer binding protein 
CER I Cytoplasmic extraction reagent-1 
CER-11 Cytoplasmic extraction reagent-2 
CFTR Cystic fibrosis transmembrane conductance receptor 
CH 1641 Cheviot scrapie brain homogenate 
ChiP Chromatin immunoprecipitation 
CHO Chinese hamster ovary 
ClAP Calf intestinal alkaline phosphatase 
CJD Creutzfeldt-Jakob disease 
CM Centimetre 
CNS Central nervous system 
CO2 Carbon dioxide 
x 
cpm Counts per minute 
CPSF Cleavage and polyadenylation specificity factor 
CREB cAMP response element binding protein 
CREM-r cAMP-responsive element modulator-tau 
CsCI Caesium chloride 
CSF Cerebrospinal fluid 
(tmprp Carboxy-terminally attached PrP 
C-terminal Carboxy-terminal 
CWD Chronic wasting disease 
Cys Cysteine 
D Aspartic acid 
Da Daltons 
dAP-2s Downstream AP-2 motif (Suffolk) 
dAP-2c Downstream AP-2 motif (Cheviot) 
dNTP 2'-deoxynucleotide-5 '-triphosphate 
ddNTP 2'-3 '-dideoxynucleoside-5 ' -triphosphate 
DEFRA Department for the environment food and rural affairs 
dH20 Distilled H20 
DIM Detergent insoluble microdomain 
DMSO Dimethyl suiphoxide 
DNA Deoxyribose nucleic acid 
DNaseI Deoxyribonuclease I 
DPE Downstream promoter element 
Dpi Prnd gene product designated doppel 
dsDNA Double stranded DNA 
DTT Dithiothreitol 
E Glutamic acid 
E4BP4 bZIP repressor protein 
E DTA Ethylene di aminetetraacetic acid 
EGF Epidermal growth factor 
EGR-1 Early gene transcription factor-i or EGR-1 oligonucleotide, 
depending on context 
ER Endoplasmic reticulum 
ERAD Endoplasmic reticulum associated degradation 
F Phenylalanine 
fCJD Familial Creutzfeldt-Jakob disease 
FCS Fetal calf serum 
FDC Follicular dendritic cells 
FF1 Fatal familial insomnia 
FLAGTh Tagging epitope FLAGTM 
3X FLAGTM TM Three adjacent copies of the tagging epitope FLAG 
FSE Feline spongi form encephalopathy 
F'TIR Fourier transform infrared spectroscopy 
g Gravitational force or grams, depending on context 
G Glycine (amino acid) or guanine (nucleic acid), depending on 
context 






GSS Gerstmann-Straussler-Scheinker syndrome 
GTF General transcription factor 
H Histidine 
HAT Histone acetyltransferase 
HC Heavy chain of precipitating antibody 
hGH Human growth hormone 
His Histidine 
HIV-1  Human immunodeficiency virus 
hM1/M2 Human motif 1 wild type! motif 2 non-ruminant double 
oligonucleotide 
hovMl/M2 Humanised ovine motif 1 variant! motif 2 ruminant double 
oligonucleotide 
hr Hour 
HSE Heat shock element 
HSE-1 Heat shock element-i oligonucleotide 
HSE-2 Heat shock element-2 oligonucleotide 
11SF Heat shock factor 
HuPrP Human PrP 
I Isoleucine 
1411 Institute for Animal Health 
LAP Intracisternal A-particle 
IFN-a Interferon-alpha 
IFN-13 Interferon-beta 
I FN-y Interferon-gamma 
IGF-1 Insulin-like growth factor-i 




mr Initiator element 
IP Immunoprecipitation 
IPTG Isopropyl-beta-D-thiogal actopyranoside 
ISI2OCer Cerebella derived cell culture from Icelandic sheep - genotype 
ARRJARR 
IS12OKid Kidney derived cell culture from Icelandic sheep - genotype 
ARRJARR 
IS12OLiv Liver derived cell culture from Icelandic sheep - genotype 
ARRJARR 




kDa kilo Dalton 
kg Kilogram 
1 Leucine or litre, depending on context 
xii 
LB broth Luna-Bertani broth 
LC Light chain of precipitating antibody 
Leu Leucine 
LRP Laminin receptor protein 
LyF-1 Lymphocyte-specific DNA-binding protein 
Lys Lysine 
SCM Standard complete medium 
M Methionine or molar, depending on context 
M1C Motif 1 variant oligonucleotide 
MiT Motif I wild type oligonucleotide 
M1C/M2C Motif 1 variant/ motif 2 ruminant double oligonucleotide 
M2C Motif 2 ruminant oligonucleotide 
M2T Motif 2 non-ruminant oligonucleotide 
M3 Motif 3 oligonucleotide 
M4i Motif 4 (i) oligonucleotide 
M4ii Motif 4 (ii) oligonucleotide 
M4iii Motif 4 (iii) oligonucleotide 
mA Milli amp 






M-per Mammalian protein extraction reagent 
ME7 A mouse passaged scrapie strain 
MEM Modified Eagle's medium 
Mem-per Mammalian membrane protein extraction reagent 
Mg Microgram 
MoPrP Mouse PrP 
MPP Mg 2+  dependent protein phosphatase 
mRNA Messenger ribose nucleic acid 
n Any nucleic acid 
N Adenosine, cytosine, guanine or thymidine (nucleic acid) or 
asparagine (amino acid), depending on context 
N2a Neuroblastoma cell line 
NC-I Non-competitor-I oligonucleotide 
NC-2 Non-competitor-2 oligonucleotide 
NE Nuclear extract 
NE-PER Nuclear and cytoplasmic extraction reagent 
NER Nuclear extraction reagent 
NF-AT Nuclear factor of activated T cells 
NF-1L3 Nuclear factor of interleukin-3 
NF-1L6 Nuclear factor of interieukin-6 
NF-ic.B Nuclear factor kappa B 
ng Nanogram 
NGF Nerve growth factor 




NMR Nuclear magnetic resonance 
NPU Neuropathogenesis Unit, Institute for Animal Health 
NSE Neurone specific enolase 
NSP National scrapie plan 
N-terminal Amino-terminal 
Ntmprp Amino-terminally attached PrP 
NCM Nerve growth factor (NGF) complete medium 
nt Nucleotide 
OD Optical density 
ON PG o-nitrophenyl-f3-D-galactopyranoside 
ORF Open reading frame 
P Proline 
pA Allele of the Sip gene which is associated with prolonged 
incubation period of SSBP/1 scrapie 
pA80BR Cheviot sheep brain cell culture from the negative line of the 
NPU flock, genotype ARQ/ARR 
PAR Proline alanine rich family of transcription factors 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
pg Picogram 
PH -log io (hydrogen ion concentration) 
Phe Phenylalanine 
PIPLC Phosphatidyl-inositol-specific phospholipase C 
PK ProteinaseK 
PKA Protein kinase A 
pmol Picomoles 
POD Peroxidase 
Prnd Mouse doppel gene 
Prnp Prion protein gene 
Prnp a Allele of the Prnp gene with 108L, 189T 
Prnp" Allele of the Prnp gene with 108F 189V 
Pro Proline 
PrP Protease resistant protein / prion protein 
PrP A Mouse prion protein gene (Prnp) A allotype 
PrP B Mouse prion protein gene (Prnp) B allotype 
PrPC PrP cellular form 
PrP PrP scrapie, disease associated form 
p7 Equivalent of the Prnp" allele 
PVDF Poly vinylidene floride membrane 
Py Pyrimidine 
Q Glutamine 
QTL Quantitative trait loci 
R Arginine 
RCLB Reporter cell lysis buffer 
RFLP Restriction fragment length polymorphism 
RNA Ribose nucleic acid 
RNase Ribonuclease 
rpm Revolutions per minute 
nt Room temperature 
RT Reverse transcription 
RT-PCR Reverse transcription polymerase chain reaction 
S Senne 
s7 Equivalent of the Prnpa  allele 
sA Allele 	of the 	Sip 	gene 	which 	is 	associated 	with 	short 
incubation period of SSBP/l scrapie 
SAF Scrapie associated fibril 
SAP Shrimp alkaline phosphatase 
sA80BR Cheviot sheep brain cell culture from the positive line of the 
NPU flock, genotype VRQ/VRQ which is susceptible to 
SSBP/i and some forms of natural scrapie but exhibits some 
resistance to BSE and CHI 641 
SCID Severe combined immunodeficient mice 
sCJD Sporadic Creutzfeldt Jakob disease 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SCPrP Secreted PrP 
Ser Serine 
sF1 Sporadic fatal insomnia 
SHaPrP Syrian hamster PrP 
Sinc Scrapie incubation time control gene in mice 
Sip Scrapie incubation time control gene in sheep 
Sn RN Ps Small nuclear nbonuleoproteins 
SOD Superoxide dismutase 
SP-1 Specificity protein-i 
SSBP/1 Sheep scrapie brain pool 1 
ssDNA Single stranded DNA 
STAT Signal transducers & activators of transcription 
STAT-A STAT variant oligonucleotide 
STAT-C STAT wild type oligonucleotide 
STE Stop transfer effector domain 
T Threonine (amino acid) or thymine (nucleic acid), depending 
on context 
TAE Tris-acetate-EDTA electrophoresis buffer 
TAFs TATA-binding protein associated factors 
TBE Tris-boric acid-EDTA electrophoresis buffer 
TBP TATA-binding protein 
TBS Iris buffered saline 
TBST Tris buffered saline plus Tween 20 detergent 
TE Tris-EDTA buffer 
TEMED N,N,N ' ,N ' -tetramethylethylenediamine 
TFIIB General transcription factor 
TFIID Protein complex comprised of TBP and TAFs 
TFIIE General transcription factor 
TFIIF General transcription factor 
xv 
TFIIH General transcription factor 
Thr Threonine 
TME Transmissible mink encephalopathy 
TNF-a Tumour necrosis factor 
Tris Tris (hydroxymethyl) amino methane 
Trp Tryptophan 
TSE Transmissible spongiform encephalopathy 
TVP Trypsinl versene solution 
Tyr Tyrosine 
U Uracil or Unit, depending on context 





UTR Untranslated region 
3'UTR 3' untranslated region 
5'UTR 5' untranslated region 
UV Ultraviolet 
V Valine or volt, depending on context 
Val Valine 
vCJD Variant Creutzfeldt Jakob disease 
v/v Volume per volume 
W Tryptophan or Watt, depending on context 
w/v Weight per volume 
X Any amino acid 
X-Gal 5-Bromo-4-Chloro-3- Indolyl-Beta-D-Galactopyranoside 
Y Tyrosine 
YV1 Yin yang I transcription factor 
xvi 
Chapter 1: 	General introduction 
1.1 Scrapie 
Scrapie has been well documented throughout Europe since the 18th  Century 
(Besnoit & Morel, 1898) and the first case of scrapie was reported in 1732 in 
England (McGowan, 1922). Scrapie was first described as a viral infection by 
Besnoit (1899) and scrapie infectivity was first demonstrated to be transmissible to 
other animals by Cuille & Chelle (1936). Scrapie is a naturally occurring slow 
degenerative disorder of the central nervous system (CNS) affecting both sheep and 
goats (Parry, 1962). It is a worldwide problem, however the disease is more 
prevalent in the Northern Hemisphere. Scrapie was eradicated by a rigorous 
slaughter policy in Australia and New Zealand (Brash, 1952), and following the 
introduction of extensive protection measures these countries are still recognised as 
being scrapie free. Most European countries have scrapie infected flocks, and the UK 
has averaged approximately 417 confirmed cases of scrapie a year over the last ten 
years (DEFRA, 2003). Other European countries with reported scrapie problems 
include Norway, the Netherlands, France, Iceland and the Republic of Ireland. 
1.1.1 The transmissible spongiform encephalopathies (TSEs) 
Scrapie is a member of a group of similar diseases, termed transmissible 
spongiform encephalopathies (TSEs) or pnon diseases. This group of diseases 
include bovine spongiform encephalopathy (BSE) in cattle (Bradley, 2002), chronic 
wasting disease (CWD) of mule deer and elk in the USA (Laplanche, 1999, Miller, 
Williams, McCarty et al., 2000), feline spongiform encephalopathy (FSE) in cats 
(Pearson, Wyatt, Gruffyddjones et al., 1992), transmissible mink encephalopathy 
(TME) in captive mink (zu Rhein, Eckroade & Marsh, 1971) and Kuru, Gerstmann-
Sträussler-Scheinker syndrome (GSS) and Creutzfeldt Jakob Disease (Cm) in man 
(Creutzfeldt, 1920, Gerstmann, 1928, Jakob, 1921, Zigas & Gajdusek, 1957) for a 
review see (Collinge, 1999). The TSEs are characterised by a loss of motor control, 
dementia (in human TSEs), paralysis and all are invariably fatal. The hallmark of 
TSEs is the aggregation into partially protease resistant fibrils of a pathological 
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isoform (PrPSC  for PrP scrapie) of a normal cellular protein designated (PrPC  for PrP 
cellular) (Prusiner, 1982). PrPC  is expressed normally in a variety of cellular tissues 
and is a soluble, membrane bound glycoprotein with a predominantly cc-helical 
structure, which is sensitive to proteolytic digestion (Oesch, Westaway, Walchli et 
at, 1985). In contrast, PrP is a disease specific insoluble protein, which has a 
predominantly n-sheet structure and is partially resistant to proteolytic digestion 
(Oesch et a!,, 1985). The detection of PrPSC  in post mortem tissue samples is used as a 
marker for disease, and other pathological markers for TSEs include vacuolation of 
brain tissue, which shows a distinct spongiform appearance and astrocytic gliosis 
(Bruce & Fraser, 1975). The PrPC  protein is expressed by the PrP gene, which is 
involved in the control of scrapie, as transgenic PrP null mice, which do not express 
endogenous PrP', exhibit resistance to scrapie infection (Manson, Jamieson, Baybutt 
et al., 1999). In addition, polymorphisms within the PrP gene open reading frame 
(ORF) are known to be associated with differences in disease incubation period, and 
with disease susceptibility (Hunter, Moore, Hosie et al., 1997, Moore, Hope, 
McBride etal., 1998). 
1.1.2 Scrapie clinical signs 
Following scrapie infection of sheep an incubation period of between 2 and 5 
years (depending on the scrapie strain) typically precedes the development of clinical 
signs. The behavioural signs of scrapie include nervousness, confusion and 
withdrawal from the flock. The physical signs of scrapie include an intense pruritis 
and affected sheep will often rub themselves against fence posts and bite at their own 
limbs or torso in an attempt to relieve this itching (Dickinson, 1976, Parry, 1962). 
This intensive scraping results in wool loss and skin abrasions particularly over the 
flanks and hindquarters and can last from between two weeks to six months, 
although the degree of pruritis can vary between individual animals and between 
breeds (Dickinson, 1976, Parry, 1962). Affected animals show signs of locomoter 
incoordination and ataxia, especially of the hind limbs which is accompanied by 
muscular tremors, resulting in the high stepping gait of the forelimbs often associated 
with scrapie affected animals. The appetite remains largely unaffected, however 
weight loss and emaciation can occur during the terminal weeks of the disease as the 
animals eating and swallowing becomes impaired. After the onset of overt clinical 
signs most animals succumb to scrapie within one to three months, however some 
animals may survive for longer periods (Dickinson, 1976, Parry, 1962). 
1.1.3 Scrapie diagnosis 
At present there are no completely reliable tests available for the diagnosis of 
scrapie in live animals and definitive diagnosis is usually made post mortem. 
Histopathological examination of the CNS of scrapie affected sheep shows 
neurodegeneration with vacuolation of neurones, astrocytosis and characteristic 
spongiform changes (Bruce & Fraser, 1975). Diagnosis of scrapie may be confirmed 
by the detection of scrapie associated fibrils (SAFs) using biochemical purification 
by centrifugation and visualisation by electron microscopy (Rubenstein, Merz, 
Kascsak et al., 1987). These amyloid fibrils can be isolated from brain tissue of 
scrapie-infected animals and consist of aggregates of PrP (Rubenstein et al., 1987). 
PrPSC is more reliably detected by Western blot or by immunohistochemistry (11-IC) 
using antibodies specific to prion protein. However, in order to detect PrPs 
specifically in tissue samples, the tissue must be treated with proteinase K to degrade 
the normal (proteinase K sensitive) isoform of prion protein (PrPC)  prior to 
immunodetection. 
In recent years a number of high throughput post mortem diagnostic tests 
have been developed, which detect PrPs  using a range of specific antibodies. In 
addition, it was noticed that some of these tests were able to diagnose a TSE 
infection at least three months prior to the development of clinical signs (Grassi, 
Comoy, Simon et al., 2001). Methods of ante mortem detection have been developed 
and these include detection of PrP sc in tonsillar tissue (Schreuder, van Keulen, 
Vromans et al., 1998) and third eyelid tissue in sheep over 14 months of age 
(O'Rourke, Baszler, Parish et al., 1998), however, these are not completely reliable. 
The holy grail of ante mortem TSE detection remains a rapid, sensitive and reliable 
blood test capable of detecting the presence of PrPs  prior to the development of 
clinical signs (Grassi, 2003). However, this is currently hampered by the fact that the 
level of infectivity detectable in the blood of infected animals is considerably lower 
than the levels found in, for example, the CNS (Grassi, 2003). Recent studies have 
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shown that it may be possible to amplify the levels of PrP, thus making a test based 
on blood more feasible (Saborio, Permarme & Soto, 2001). PrPSC  has been detected in 
urine samples from animals and humans, raising the possibility of a urine based TSE 
test (Shaked, Shaked, Kariv-Inbal etal., 2001). 
Paramithiotis, Pinard, Lawton et al. (2003) successfully produced both 
polyclonal and monoclonal antibodies which are able to distinguish between P rPC 
and PrP. Their antibodies are targeted to a tripeptide motif (Tyr-Tyr-Arg), which is 
considered to be hidden in PrPC  but exposed upon conversion to PrP. 
Characterisation of these antibodies revealed that most of them showed cross 
reactivity with PrP from mice, hamster, sheep, cattle and humans. It is hoped that 
these antibodies will help to further develop TSE diagnostics and could also have 
potential therapeutic applications. However these antibodies are not completely 
specific for PrPSC  as they also immunoprecipitate partially denatured protease 
sensitive PrP from acid treated healthy brain and this may indicate that they are able 
to detect other alternative conformations of PrP. In addition, these antibodies are 
directed to Tyr-Tyr-Arg motifs it is possible that they may also react with other 
proteins which contain the same motif (Gorochov & Deslys, 2004). 
Although, the presence of PrPSC  is the hallmark of prion diseases, other 
biochemical factors have been identified as potential markers for TSE diagnosis. 
These include the presence of elevated levels of neuron specific enolase (NSE) and 
14-3-3 proteins in the cerebrospinal fluid (CSF) in patients suffering from CJD 
(Hsich, Kinney, Gibbs et al., 1996, Mokuno, Kato, Kawai et al., 1983, Zerr, 
Bodemer, Otto et al., 1996, Zen, Bodemer, Racker et al., 1995, Zen, Bodemer & 
Weber, 1997). These factors are not specific for TSEs and are often elevated in other 
neurological diseases, however they do provide an additional diagnostic tool, which 
can be used in conjunction with other clinical data to improve diagnosis (Weber, 
Otto, Bodemer et al., 1997). More recently, Miele, Manson & Clinton (2001) showed 
that the expression of a transcript specific to erythroid linaege cells is dramatically 
decreased in TSEs. The measurement of this transcript can be made in a number of 
easily accessible tissues including bone marrow, spleen and whole blood, indicating 
a possible role for this marker in TSE diagnosis. 
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1.1.4 Scrapie Control 
Historically scrapie has been controlled by the identification and culling of 
scrapie infected animals and sometimes entire flocks. However, this method can be 
unreliable as it depends on the successful identification of infected animals, and is 
very costly. Scrapie control is hampered by the fact that as yet no reliable pre-clinical 
scrapie test exists, and the long incubation periods associated with the disease. In 
recent years the British government has introduced the National Scrapie Plan (NSP), 
the aim of which is to increase the level of resistance to scrapie in the national sheep 
flock by selectively breeding for animals with recognised scrapie resistant PrP 
genotypes (DEFRA, 2003). The long-term aim of this plan is to completely eradicate 
scrapie and other TSEs from the national flock (Dawson, Warner, Nolan et al., 
2003). 
1.1.5 The pathogenic mechanisms of TSEs 
The principal cause of the clinical symptoms observed with TSEs is the death 
of neurones (Giese, Groschup, Hess et al., 1995, Jamieson, Jeffrey, Ironside et al., 
2001, Kretzschmar, Giese, Brown et al., 1997, Lucassen, Williams, Chung et al., 
1995, Williams, Lucassen, Ritchie et al., 1997). There is evidence that this neuronal 
cell death is the result of apoptosis, as signs of programmed cell death have been 
discovered by numerous researchers in a variety of models (Ferrer, 1999, Forloni, 
Bugiani, Tagliavini et al., 1996, Jamieson et al., 2001, Jesionek-Kupnicka, 
Buczynski, Kordek et al., 1997, Kretzschmar et al., 1997). The apoptosis of neurones 
observed in TSEs is the result of a variety of influences, one of which is an increase 
in oxidative stress which is brought about by the accumulation of reactive oxygen 
species (Beal, 1995, Gotz, Kunig, Riederer et al., 1994). However, altered cellular 
calcium metabolism, has been observed in TSEs, which could associate necrosis as a 
contributing mechanism in neurodegeneration in TSEs (Giese et al., 1995, Lucassen 
et al., 1995). Other potential causative factors include, mitochondrial dysfunction, 
altered iron metabolism leading to the production of highly reactive hydroxyl 
radicals, and increased levels of proinflammatory cytokines, chemokines and 
transcription factors, like nuclear factor-kappa B (NF-KB) (Allen & Tresini, 2000, 
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Choi, Ju, Choi et al., 1998, Hur, Chang, Lee et al., 2001, Kaltschmidt, Baeuerle & 
Kaltschmidt, 1993, McGeer & McGeer, 1995). Ma, Wollmann, & Lindquist (2002) 
demonstrated that misfolded PrP' is itself neurotoxic in both cultured cells and 
transgenic mice. The accumulation of misfolded PrPC  in the cytosol resulted in 
cerebellar degeneration, gliosis and eventually a severe ataxia in transgenic mice, in 
a similar way to that observed with PrPSC  (Ma etal., 2002). 
1.1.6 TSEs of humans 
TSEs of humans can be divided into those that are inherited, sporadic or 
iatrogenic in nature. Inherited TSEs include GSS, fatal familial insomnia (FF1) and 
familial CJD (fCJD), and all of these diseases are associated with variants of the PrP 
protein. The factors involved in familial CJD remain unclear but the disease shows 
an autosomal dominant pattern of transmission, similar to Alzheimer's disease 
(Masters, Gajdusek & Gibbs, 1981, Masters, Harris, Gajdusek etal., 1979, Prusiner, 
1993). Patients with fCJD show early signs of dementia and visual impairment, the 
duration of disease is between 2-5 months and age of onset is generally between 50-
75 years but these signs may vary from case to case (Prusiner, 1993). GSS appears to 
be the result of a missense mutation which substitutes proline for leucine at codon 
102 within the human PrP gene (Collinge, Harding, Owen et al., 1989, Dohura, 
Tateishi, Sasaki et al., 1989, Hsiao, Baker, Crow et al., 1989). GSS is set apart from 
the other human TSEs as it tends to have a much longer duration of disease, normally 
between 2-8 years. The age of onset is generally in middle age at between 35-55 
years of age, early signs are those of ataxia and this develops into full dementia as 
the disease progresses (Prusiner, 1993). 
Sporadic TSEs are limited to sporadic CJD (5CJD), which is a rare condition 
with only 1-2 cases per million worldwide. The mean age at death of sCJD is 63 
years of age and the duration of illness is usually around 4 months (Prusiner, 1993). 
latrogenic CJD, variant CJD (vCJD) and Kuru are all infectious diseases 
which are acquired by transplantation, injection or ingestion of TSE infected material 
(Chazot, Broussolle, Lapras et al., 1996, Gajdusek, 1977, Pfeffer, 1993, Will, 
Ironside, Zeidler et al., 1996). Kuru was first described by Zigas & Gujdusek (1957), 
and is restricted to the Fore tribe in Papau New Guinea's Eastern Highlands 
(Gajdusek, 1963, Gajdusek, 1973). Kuru is the result of ritualistic cannibalism of 
dead relatives, which occurred as part of the mourning ritual, almost exclusively 
amongst the female members of the tribe as a direct result of their involvement in the 
preparation of dead bodies for disposal (Gajdusek, 1963, Gajdusek, 1973). Kuru is 
characterised by ataxia and a shivering like tremor, that later progresses to motor 
incapacity, loss of speech and inevitably death, usually after 3-9 months (Zigas & 
Gajdusek, 1957). vCJD was first described by Will et al. (1996) when it was 
discovered that a small number of cases of CJD had occurred in young adults (mean 
age of 29 at death) referred to the National CJD Surveillance Centre in Edinburgh. 
The average duration of disease in vCJD is longer than that observed with ICJD at 
around 13 months (Will etal., 1996). It was noted that these cases showed a distinct 
clinical and pathological phenotype that differed from that observed with sporadic 
CJD. Will et al. (1996) suggested that these cases of vCJD may have been linked to 
the UK epidemic of BSE in cattle. This theory is supported by studies which have 
shown distinct similarities between the PrPSC  deposited in vCJD and experimental 
BSE cases (Collinge, Sidle, Meads et al., 1996). In addition, transmission studies in 
mice have demonstrated that vCJD and BSE share certain disease characteristics, 
such as incubation period and distribution of pathology in the brain, and that these 
characteristics are distinct from those observed with sporadic CJD (Hill, Desbruslais, 
Joiner et al., 1997, Scott, Will, Ironside et al., 1999). There is now little doubt that 
vCJD is caused by BSE infection. 
1.1.7 Other TSEs of animals 
The most well documented TSE of animals is the epidemic of BSE in cattle 
in the UK from 1986. However, BSE has been diagnosed in cattle in many other 
European countries, including France, Portugal, Germany, Italy, Ireland and 
Switzerland, although almost all of these cases were probably due to cattle or feed 
products imported from the UK (Bradley, 2002, Wells, Scott, Johnson et al., 1987). 
It is believed that BSE in the UK occurred due to a change in rendering procedures in 
the late 1970s and early 1980s that allowed feed products to become contaminated 
with infected material, and that the feeding of this contaminated feed to cattle led to 
the outbreak of BSE (Bradley & Matthews, 1992, Wilesmith, Wells, Cranwell et al., 
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1988). What is less clear is how the infected material entered the cattle food chain in 
the first place. It could have been that it occurred sporadically in cattle and that tissue 
from this animal entered the rendering process or that it developed from scrapie 
infected material (Anil, Love, Williams et al., 1999). 
BSE is characterised by an incubation period of between 2-8 years and most 
affected cattle develop clinical signs of the disease between 3-5 years of age 
(Bradley, 2002). Clinical signs are those of incoordination, tremors and anxiety, and 
death usually follows between two weeks and 6 months after the development of 
these clinical signs (Bradley, 2002). A ban on the feeding of ruminant material to 
other ruminants was introduced in 1988 in the UK, however due to the long 
incubation periods of the disease and difficulties in enforcement of the ban a further 
42,299 cases of BSE (born after the ban (BABs)) occurred after this initial ban 
(Bradley & Wilesmith, 1993). Further, more stringent bans were introduced between 
1988 and 1996, and finally in August 1996 a total ban (termed the real ban) on the 
feeding of meat and bone meal to any food animal species was introduced. Since this 
ban few cases of BSE (born after the real ban (BARBs)) have been reported in the 
UK, compared with a total of 187,870 cases of BSE in the UK in total (Bradley, 
2002). 
Chronic wasting disease (CWD) is a prion disease of both wild and captive 
deer and elk in North America (Laplanche, 1999, Miller et al., 2000). Transmissible 
mink encephalopathy (TME) of captive mink in fur producing farms is believed to be 
caused by contaminated feed, however the source of the food contamination remains 
unclear (Hartsough & Burger, 1965, zu Rhein et al., 1971). A number of other prion 
diseases affecting animals have been reported, for example, feline spongiform 
encephalopathy (FSE) of zoological and domestic cats, in addition, sporadic cases of 
TSE have occurred in zoological ruminants and non-human primates (Jeffrey & 
Wells, 1988, Kirkwood, Wells, Wilesmith et al., 1990, Pearson et al., 1992, Wyatt, 
Pearson, Smerdon et al., 1991). The origins of the TSEs in cats, zoological 
ruminants, and non-human primates are most likely linked to the feeding of BSE 
contaminated meat. 
1.2 The nature of the infectious agent 
The nature of the scrapie infectious agent has been the subject of intense 
research for many years. The infectious agent causing scrapie was described as an 
unconventional slow virus by Sigurdsson (1954) whilst working on scrapie and visna 
of sheep in Iceland. Similar observations were made by Hadlow (1959) who made 
the connection between scrapie and Kuru in New Guinea; concluding that Kuru was 
also caused by a slow virus. It was observed that the scrapie agent was resistant to 
inactivating procedures such as intense ultraviolet light and ionising radiation that 
inactivate or modify nucleic acids (Latarjet & Muel, 1970). It was observed that the 
agent was sensitive to treatments that denature, hydrolyse or degrade proteins 
(Bolton, McKinley & Prusiner, 1982, McKinley, Bolton & Prusiner, 1983). These 
studies indicated that the agent could be a self-replicating protein, which was devoid 
of nucleic acids (Alper, Cramp, Haig et al., 1967, Griffith, 1967, Latarjet & Muel, 
1970). Many methods of inactivation of the scrapie infectious agent have been tested, 
examples of techniques tested so far, include autoclaving, acid, alkaline, oxidising 
agents, detergents and sodium hypochlorite (Taylor, 2000). Combinations of these 
methods, for example, autoclaving carried out in alkaline solutions have been shown 
to inactivate the scrapie agent (Brown, Rohwer, Green et al., 1982, Taylor, Fernie & 
McConnell, 1997). In addition, a strong solution of sodium hypochiorite has been 
shown to completely inactivate the scrapie infectious agent (Taylor, 2000). 
1.2.1 The prion hypothesis 
There are two major hypotheses on the nature of the infectious agent, the 
prion hypothesis and the virino hypothesis. Prusiner (1982) hypothesised that the 
scrapie infectious agent consisted of a novel class of infectious agent which he 
termed, prions (proteinaceous infectious particles). Prusiner, Groth, Bolton et al. 
(1984) used proteinase K digestion and differential centrifugation to purify the 
infectious agent from scrapie infected hamster brains. Rod shaped amyloid particles 
were shown to co-purify with scrapie infectivity as measured in bioassays, and were 
composed largely of a single protein of between 27-30 kDa (PrP 27-30), a protease 
resistant fragment of a 33-35 kDa precursor termed PrPSC  (Hope & Hunter, 1988, 
Prusiner, 1982, Prusiner et al., 1984). Further studies identified PrPSC  as an isoform 
of PrP', a protein encoded by a cellular gene, and therefore not a virally encoded 
protein (Basler, Oesch, Scott et al., 1986, Chesebro, Race, Wehrly et al., 1985, 
Oesch etal., 1985). 
The absence of PrP in the brains of healthy individuals combined with its 
presence in the brains of individuals infected with most of the TSE diseases, suggests 
that PrPsc is either itself the infectious agent, or a component of it, and as such the 
accumulation of PrPSC  is considered to be a biochemical hallmark of the TSEs. The 
prion hypothesis proposes that PrPSC  is the infectious agent and that it is able to 
replicate devoid of any nucleic acid by converting the endogenous PrPC  to PrP 
(Griffith, 1967, Harris, 1999, Prusiner, 1982, Prusiner, 1991, Prusiner, 1998, 
Prusiner, Scott, Foster et al., 1990). Two models have been proposed for the 
conversion of PrPC  to  PrPSC,  the conformational conversion model (Figure 1.1 A) and 
the nucleated polymerisation model (Figure 1.1 B). 
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Figure 1.1 Proposed models for the conversion of PrPc  to PrP 
There are two proposed models for the conversion of PrPC  to PrP. The conformational 
conversion model (A) hypothesises that PrPC & PrP sc interact forming a heterodimer, and 
then the PrPC  in this heterodimer is converted to PrPSC  forming a PrP sc homodimer, which is 
able to dissociate, producing PrPSC  monomers. The nucleated polymerisation model (B) 
hypothesises that PrPC  is converted to PrPSC  when  PrPSC  is present at a concentration that 
favours the conversion of a PrP intermediate into a PrPSC  oligomeric molecule. Models 
adapted from (Prusiner, 1991) & (Jarrett & Lansbury, 1993). 
The conformational conversion model proposes that PrP' and PrPSC  interact 
directly to form a heterodimer, PrPC  is then converted to PrPSC  to form a PrP 
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homodimer. This homodimeric PrPSC  is then able to dissociate, producing two PrP 
monomers, which can go on to convert more PrP' to PrPSC  (Prusiner, 1991). The 
nucleated polymerisation model proposes that PrP' is converted to PrPSC  when PrP 
is present at a concentration that favours the conversion of a PrP intermediate into a 
PrPs oligomeric molecule (Jarrett & Lansbury, 1993). Eigen (1996) performed a 
comparative kinetic analysis of the conformational conversion and nucleated 
polymerisation models and concluded that although both models differ as to which of 
the two monomeric protein conformations are favoured at the equilibrium state (i.e. 
PrP' and PrP for the conformational conversion model, and a PrP intermediate for 
the nucleated polymerisation model) they both require an aggregated state as the 
form which is favoured at equilibrium. 
A prion infection is caused by the passage of PrPSC  from an infected host to a 
recipient animal and this PrP molecule then initiates conversion of endogenous PrP' 
to PrPs  in the recipient (Prusiner, 1991). The major arguments in support of the 
prion hypothesis are detailed below: 
• Prion diseases are invariably associated with the accumulation of PrPs  and 
amyloid plaques (Bolton et al., 1982, Oesch et al., 1985, Prusiner, Bolton, Groth 
etal., 1982). 
• PrP'c and scrapie infectivity co-purify, the unusual properties of PrP mimic 
those of prions and procedures that modify or hydrolyse PrPSC  also inactivate 
prions (Gabizon, McKinley, Groth et al., 1988, Prusiner, 1982, Prusiner et al., 
1984). 
• Certain mutations in the PrP gene are linked to inherited prion diseases and result 
in the formation of PrP (Goldfarb, Petersen, Tabaton et al., 1992, Hegde, 
Mastrianni, Scott et al., 1998a, Hsiao, Cass, Schellenberg etal., 1991). 
• PrP null mice are resistant to prion infection, whilst heterozygotes show an 
increase in incubation period, as compared to wild type mice (Bueler, Fischer, 
Lang et al., 1992, Manson, Clarke, Hooper et al., 1994a, Manson, Clarke, 
McBride et al., 1994b, Weissmann, Bueler, Fischer et al., 1994). 
• Prion diversity is enciphered within the conformation of PrP. Therefore, scrapie 
strains can be maintained by passage through hosts with different PrP genes. 
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Prion strains are themselves maintained by PrPVPrP interactions (Bessen, 
Kocisko, Raymond et al., 1995, Bessen & Marsh, 1994, Caughey, Raymond & 
Bessen, 1998, Ridley & Baker, 1996, Safar, Wille, Itrri et al., 1998, Telling, 
Parchi, DeArmond et al., 1996). 
Protein based instructional (informational) molecules exist. Prion-like molecules 
(i.e. [URE3], [PSI] and [Hets*])  have been discovered in yeast and fungi that 
appear to be responsible for the propagation of non-genetic traits (Chernoff, 
Lindquist, Ono et al., 1995, Coustou, Deleu, Saupe et al., 1997, Cox, 1994, 
Wickner, 1994, Wickner, Edskes, Maddelein et al., 1999). 
Currently no evidence for a virus like particle or a nucleic acid specifically 
associated with TSE infectivity exists. 
1.2.2 The virino hypothesis 
The virino theory postulates that PrPs  is a component of the infectious agent, 
which is recruited into an infectious particle by an as yet unidentified host-
independent molecule, likely to be viral nucleic acid (Dickinson & Outram, 1988, 
Farquhar, Somerville & Bruce, 1998). The virino hypothesis postulates that the 
information-carrying molecule of the infectious agent interacts with host PrPC  and is 
protected from degradation by the conversion of PrPC  to  PrPSC  (Farquhar et al., 1998). 
Attempts to identify a TSE-specific nucleic acid have proved unsuccessful, however, 
it may be that the molecule involved is either too small or present at too low a 
concentration to be detectable (Bruce & Dickinson, 1987, Somerville, 1991). 
Although the accumulation of PrP is associated with the development of 
disease, several studies have demonstrated neurological disease in mice in the 
absence of PrPSC.  Lasmezas, Deslys, Robain et al. (1997) inoculated C57BL/6 mice 
with BSE infected cattle brain homogenate. All the mice showed symptoms of 
neurological disease following incubation periods of between one and two years. 
Intriguingly, more than 55% of the mice failed to show detectable levels of PrPSC  in 
their brains, however PrPSC  was detectable following subsequent sub-passages in 
mice as the agent appeared to adapt to its new host. This study indicated that TSE 
infectivity could exist in the absence of detectable levels of PrP and that another 
unidentified agent may therefore be responsible for disease transmission. 
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Other studies have demonstrated the presence of detectable PrP in the 
absence of clinical disease symptoms. It is generally accepted that mice are highly 
resistant to infection with hamster scrapie, however transgenic mice expressing 
chimeric PrPC  in which the central region (residues 94-188) of the mouse PrP has 
been replaced with the corresponding hamster sequence (termed MH2M PrPC),  are 
susceptible to infection with hamster scrapie (Scott, Groth, Foster et al., 1993). Hill, 
Antoniou & Collinge (1999) used this property to convert the chimeric MH2M PrPC 
to MH2M PrPSC  in vitro by using hamster PrPs,  thus any de novo MH2M PrPs 
would be easily distinguished from the hamster PrPSC  used to promote the conversion. 
The MH2M PrPSC  produced was then used in bioassay experiments in conventional 
mice, however, no infectivity was detected in the inoculated mice, indicating that the 
accumulation of PrP' c is by itself not sufficient for the propogation of infectivity (Hill 
et al., 1999). In further experiments, Hill, Joiner, Linehan et al. (2000) inoculated 
Swiss CD-1 mice with hamster prions and showed that they propagate infectivity, 
produce detectable levels of PrP, and develop typical spongiform degeneration and 
amyloid deposition in their brains. However, all of these mice remained free of 
clinical disease for the duration of their lifetime. 
These studies have demonstrated the existence of sub-clinical forms of TSE 
disease and indicate that PrP alone may not be sufficient as a marker for disease, or 
infectivity. 
The major arguments in support of the virino hypothesis are detailed below: 
• The presence of multiple TSE strains is more clearly explained by the virino 
hypothesis as it is well documented that viral nucleic acids are capable of 
carrying strain-specific information (Dickinson & Outram, 1988). 
• The estimated size of the infectious agent, as determined by ionising radiation 
falls within the range observed with certain viral nucleic acid genomes (1.5 x 106 
Da or 0.90 x 106  Da), depending on whether or not the genome is composed of 
double stranded or single stranded DNA (Rohwer, 1991). 
• Diringer, Beekes, Ozel et al. (1997) noted the presence of virus-like particles in 
TSE affected brains, but this observation has not been repeated by other 
researchers. 
14 
• Finally the prion hypothesis remains unproven, as infectivity has still not been 
produced de novo by experimental manipulation of recombinant or synthetic PrP. 
1.3 TSE strains 
The number of strains occurring in species naturally affected by scrapie is 
unknown, however in mice approximately twenty different scrapie strains have been 
identified (Bruce, McBride, Jeffrey et al., 1994). Scrapie strains were first identified 
in goats, with two distinct strains being present, named scratching and drowsy based 
on their differing clinical signs (Pattison & Millson, 1961). Each strain is described 
by characteristic neuropathological patterns of PrPs  protein deposition and 
vacuolation as well as varying incubation periods i.e. defined by the time elapsed 
between the initial infection and clinical signs of disease (Bruce & Fraser, 1991, 
Bruce et al., 1994, Fraser, 1976). Recent studies by Gonzalez, Martin, Begara-
McGorum et al. (2002) produced profiles of PrPSC  deposition in the brains of 43 
sheep with clinical signs of scrapie using IHC. They concluded that these profiles 
could be successfully used to characterise different scrapie strains in sheep. For the 
most part, each individual strain has been shown to retain its original properties when 
propagated within the same species, between species or in cultured cells (Birkett, 
Hennion, Bembridge et al., 2001, Gabizon & Taraboulos, 1997, Raymond, Hope, 
Kocisko etal., 1997). 
The molecular heterogeneity of PrPs  is another characteristic used to identify 
strains. PrP retains a strain characteristic glycosylation pattern when visualised by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (Collinge 
et al., 1996). This observation led to the conclusion that the attached carbohydrate 
moieties of PrP were able to encipher strain-specific properties. This idea has since 
been dismissed as the glycosylation pattern of PrPSC  purified from different tissues 
within a single host has been shown to differ, suggesting that glycosylation of PrP is 
not determined by the strain but by the cell type and species in which it is produced 
(Hill et al., 1999, Somerville, 1999). However, more recently Pan, Colucci, Wong et 
al. (2001) using two dimensional electrophoresis were able to show that the only 
conformational difference between two PrP species (sporadic fatal insomnia (SF!) 
and sporadic CJD (M/M2 sCJD)) were those determined by the variant glycans. 
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Therefore, this study showed that two PrP species associated with distinct 
phenotypes differed only in the attached glycan chains. 
The presence of different strains of scrapie indicates that the infectious agent 
must contain, or be associated with some form of information-carrying molecule 
(Farquhar el al., 1998). The pnon hypothesis states that scrapie strains are encoded in 
the conformational state of individual PrP molecules, variations in the tertiary 
structure of PFPSC  would therefore be capable of enciphering the information required 
for strain-specific characteristics (Bessen et al., 1995, Bessen & Marsh, 1994, 
Caughey etal., 1998, Ridley & Baker, 1996, Safar et al., 1998, Telling et al., 1996). 
Fourier transform infrared (FTIR) spectroscopy studies, which showed that PrP 
from various hamster-adapted scrapie isolates exhibits differences in the degree of P - 
sheet content support the prion hypothesis (Caughey et al., 1998). The virino theory 
helps to explain scrapie strain characteristics, as a nucleic acid component would be 
capable of carrying the required genetic information (Somerville, 1991). 
1.4 Scrapie transmission 
1.4.1 Ovine transmission 
Although the natural route of scrapie transmission remains unclear, vertical 
transmission has been hypothesised as a possible route of infection. Dickinson, 
Stamp & Renwick (1974) showed that lambs born to ewes infected with scrapie were 
seven times more likely to develop disease than those born to scrapie free ewes. 
Studies on maternal transmission using embryo transfer have investigated whether 
disease can be transmitted early in gestation or in the ovary, by transferring embryos 
from ewes infected with scrapie into recipient ewes shown to be clinically free from 
scrapie (Foote, Clark, Maciulis et al., 1993, Foster, Hunter, Williams et al., 1996, 
Foster, McKelvey, Mylne et al., 1992). However, the results from these studies have 
been inconclusive, Foote et al. (1993) showed that scrapie was not transmissible via 
embryo transfer, whilst studies by Foster et al. (1996, 1992) showed that scrapie 
developed in embryos from both infected and uninfected hosts. In addition, the 
placenta has been shown to harbour infectivity, indicating that the placenta may play 
an important role in the natural transmission of scrapie (Andreoletti, Lacroux, 
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Chabert et al., 2002, Race, Jenny & Sutton, 1998). Therefore, the placenta could be 
considered as a source of scrapie infectivity to newborn lambs, or at the time of birth, 
in addition, it could be considered as a source of horizontal transmission to other 
sheep if consumed directly or through pasture infection (Andreoletti et al., 2002). 
In fact, horizontal transmission has been demonstrated between scrapie 
infected sheep and healthy sheep and goats when housed together, although the exact 
mechanism of transmission remains unclear (Brotherston, Renwick, Stamp et al., 
1968, Haralambiev, lvanov, Vesselinova et al., 1973). More recent studies have 
looked at the possibility of transmission of infectivity through blood (Houston, 
Foster, Chong et al., 2000, Hunter, Foster, Chong et al., 2002). They showed that, at 
the time of publication, 2 out of 24 sheep transfused with blood from BSE challenged 
sheep developed the disease, whilst 4 of 21 sheep transfused with blood from natural 
scrapie infected sheep developed scrapie, and more have since occurred (Houston et 
al., 2000, Hunter et al., 2002). These results indicate that BSE and scrapie could 
certainly be transmitted through blood, or blood products, and this has serious 
implications for human blood transfusions with regard to vCJD (Houston et al., 
2000, Hunter et al., 2002). Attempts to detect PrPSC  and infectivity in buffy coat from 
vCJD patients have proved to be negative, however these studies were limited by 
sample numbers, and more importantly by the sensitivity of the detection methods 
used. Further studies will be required in order to develop more sensitive techniques 
for the detection of PrPSC  in blood, and blood products (Ironside & Head, 2003). The 
issue of blood borne infectivity is highlighted by the case of a UK patient who died 
last autumn of vCJD, which he may have contracted from a blood transfusion he 
received from a donor who died of vCJD back in 1999 (Llewelyn, Hewitt, Knight et 
al., 2004). 
Epidemiological evidence from studies on scrapie management in Iceland had 
suggested that it was possible that in some instances, a vector could be involved in 
the reoccurrence and/or spread of scrapie (Paisson & Sigurdsson, 1959). The possible 
involvement of a vector in scrapie is supported by the absence of scrapie in some 
countries, i.e. New Zealand & Australia (Brash, 1952). Indicating that in these 
countries the vector may be absent and therefore the disease is unable to propagate 
even in the presence of animals with known scrapie susceptible genotypes. The 
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involvement of a vector has been investigated by a number of researchers in the past 
and possible vectors identified include, hay mites or other mites species, and 
nematodes (Fitzsimmons & Pattison, 1968, Wisniewski, Sigurdarson, Rubenstein et 
al., 1996). However, these studies have been limited in number, and the results have 
been inconclusive and often confused by the presence of other infections. 
I .4.2 The species barrier 
It is hypothesised that polymorphisms in the PrP gene may be responsible for 
control of the species barrier. This is a phenomenon that is observed if an infectious 
inoculum from one species (i.e. hamster) is passaged into a different species (i.e. 
mice), resulting in a prolongation of incubation period, or complete lack of clinical 
signs (Farquhar et al., 1998). Another feature of the species barrier is that on 
subsequent serial sub-passage in a new host the incubation period shortens to a 
constant duration (Dickinson, 1976, Pattison & Jones, 1968). For example, the 
Chandler mouse-passaged strain of scrapie is transmissible to mice with an 
incubation period of around 120 days, whilst transmission to Syrian hamsters is 
possible, but with an incubation period of up to 380 days (Kimberlin, Cole & 
Walker, 1987, Kimberlin & Walker, 1978). Furthermore, the hamster-passaged 
scrapie strain, 263K, fails to transmit to mice, despite short incubation periods of 
around 65 days observed with hamster infections (Kimberlin, Walker & Fraser, 
1989). There are, however, situations where scrapie can be transmitted into another 
species with no apparent species barrier effect, for example the transmission of 
scrapie from sheep to goats (Brotherston et al., 1968, Greig, 1950). 
1.4.2.1 Trans genic analysis of the species barrier 
Transgenic studies have allowed the idea of the species barrier to be 
investigated further, for example, Scott et al. (1993) constructed transgenic mice 
which expressed chimeric mouse/Syrian hamster PrP (SHaPrP) genes. These mice 
were susceptible to infection with both Syrian hamster and mouse prions, and upon 
post mortem examination of the brains, chimeric PrPSC  was observed (Scott et al., 
1993). It was shown that this chimeric PrPs  favoured propagation in mice expressing 
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the corresponding chimeric PrPC  (Scott et al., 1993). In addition, the infection of 
transgenic mice expressing the hamster PrP gene resulted in the development of 
disease when infected with hamster scrapie, whilst animals expressing only 
endogenous PrPC  did not become infected (Race, Priola, Bessen et al., 1995, Scott, 
Foster, Mirenda et al., 1989). These results provide evidence for homophilic 
interactions between PrP in the inoculum and host PrPC  and highlight the 
importance of the primary structure of PrPC  encoded by the host in the species barrier 
(Prusiner et al., 1990, Scott et al., 1989, Scott et al., 1993, Scott, Groth, Tatzelt etal., 
1997, Scott, Kohler, Foster et al., 1992, Westaway, Goodman, Mirenda et al., 1987). 
More recently Peretz, Williamson, Legname et al. (2002) inoculated 
transgenic mice expressing a chimeric mouse! hamster PrP (TgMH2M), and 
transgenic mice expressing hamster PrP with two distinct Syrian hamster pnon 
strains, Sc237 & DY. They then assessed the incubation time and phenotype of the 
disease produced in the hosts and correlated this information with data on the 
conformation of the two strains obtained. Following inoculation in TgMH2M mice 
the two strains, Sc237 and DY, behaved very differently. The Sc237 strain showed 
an incubation period of around 83 days, which decreased to around 50 days on 
second passage, indicating a species barrier effect. However, the TgMH2M mice 
inoculated with the DY strain showed no reduction in incubation period following 
second passage, a result consistent with a lack of species barrier. The disease 
phenotype observed with the Sc237 strain differed from that observed with Sc237 in 
hamsters, whilst that observed with the DY strain remained the same. These results 
were interpreted to indicate that the structures of the two strains are different, and 
that the conversion of the Sc237 strain into a distinct isoform in the TgMH2M mice 
was the result of a conformational change, whilst with the DY strain no such change 
was detected (Peretz et al., 2002). 
1.4.2.2 BSE and the species barrier 
There is now a strong body of evidence supporting the transmission of BSE 
to humans in the form vCJD (Will et al., 1996). The appearance of vCJD was first 
noted in 1996, occurring mostly in young adults (Chazot et al., 1996, Will et al., 
1996). Similarities between the BSE agent and that causing vCJD were later 
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discovered by lesion profile and glycoform analysis (Bruce, Will, Ironside et al., 
1997, Collinge et al., 1996, Hill et al., 1997). These similarities have been reflected 
in transgenic analysis of BSE and vCJD transmissions. Transgenic mice expressing 
the bovine PrP gene were infected with primary passage BSE and vCJD and showed 
a high degree of susceptibility to both agents (Scott et al., 1999). Interestingly, 
incubation periods, neuropathology and Western blot analysis of PrP' c failed to 
discriminate between the two agents (Scott et al., 1999). These studies have cast 
doubts over the earlier assumptions that humans were in some way protected from 
BSE infection from cattle due to the presence of a species barrier and it now appears 
that the infectious agent causing BSE may be capable of infecting new host species. 
1.4.2.3 BSE in sheep? 
The possibility that BSE could be present in small ruminants has remained a 
concern ever since Foster, Hope & Fraser (1993) first reported the experimental 
transmission of BSE to sheep and goats. This study involved orally challenging 
Cheviot sheep from the NPU flock with 0.5g BSE infected cattle brain. Only a 
proportion of the challenged sheep succumbed to disease, which was later shown to 
be related to the PrP genotype. The shortest incubation periods were observed in 
sheep of genotypes AXQ/AXQ, whilst animals with one ARR allele showed very 
extended incubation periods (Foster et al., 1993, Foster, Parnham, Chong et al., 
2001, Houston, Goldmann, Chong et al., 2003). For an explanation of sheep PrP 
genotypes please see section 1.7.2. More recent experiments showed that Romney 
sheep of the genotype ARQ/ARQ were susceptible to oral BSE challenge (Jeffrey, 
Ryder, Martin et al., 2001). In addition, subtle differences were observed in the 
peripheral pathogenesis of a BSE infection in sheep when compared to that of natural 
scrapie infection (Jeffrey et al., 2001). In particular, the role of the lymphoreticular 
system in pathogenesis may differ between natural scrapie and BSE infection in 
sheep of the ARQ/ARQ genotype (Jeffrey et al., 2001). Other studies have shown 
that Suffolk, Lacaune and Texel sheep are also susceptible to experimental challenge 
with BSE (Schreuder & Somerville, 2003). However, to date no evidence of BSE in 
sheep under natural conditions has been observed. 
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Small ruminants faced the same risk factors to BSE infection as cattle, as they 
too were exposed to possibly infected meat and bone meal (MBM) albeit at much 
lower levels (Schreuder & Somerville, 2003). In addition, the likely transmission of 
BSE from cattle to humans causing vCJD indicated that BSE was capable of 
bypassing the species barrier and infecting a new host species. Previous studies have 
failed to replicate the likely natural routes of transmission of BSE to sheep. However, 
Foster, McKelvey, Fraser et al. (1999) showed that goats experimentally infected 
with BSE failed to transmit disease to recipient animals following embryo transfer. 
Furthermore, the offspring that developed from the embryos of the infected donor 
animals showed no evidence of disease. This study indicated that BSE was unable to 
transmit maternally in goats (Foster et al., 1999). More recent studies involving 
greater animal numbers are currently under way in the UK and it is likely that these 
experiments will provide more data on the efficiency of the natural transmission of 
BSE to sheep (Foster etal., 2001). 
1.5 The prion protein 
1.5.1 PrPC  biosynthesis 
The mammalian PrP gene encodes for a protein termed PrPC  that is about 250 
amino acids in length and contains several distinct domains. PrP' is a 
sialoglycoprotein with a molecular weight of 33-35 kDa. In most species five copies 
of a proline/glycine-rich octapeptide N-terminal repeat are present, whilst bovine 
PrPC contains between five and seven copies (Goldmann, Hunter, Martin et al., 
1991b, Schlapfer, Saitbekova, Gaillard et al., 1999). In addition, a highly conserved 
hydrophobic motif and a C-terminal region, which is a signal for the addition of a 
glycosyl-phosphatidyl-inositol (GPI) anchor are present (Figure 1.2). 
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Figure 1.2 PrP protein structures 
Unprocessed PrPC  is not fully glycosylated and contains an N-terminal signal peptide and a 
sequence at its C-terminus for the addition of a glycosyl-phospahtidyl-inositol (GPI) anchor. 
Processed PrPC  is cleaved at its N-terminal signal peptide, N-glycosylated at two arginine 
residues (N), a disulphide bridge is formed between two cysteine residues (179 & 214 (ovine 
numbering)) and a GPI anchor is added to its C-terminus. 
As is consistent with other membrane proteins PrPC  is synthesised in the 
rough ER and passes through the golgi apparatus on its way to the cell surface 
(Hegde & Lingappa 1999). During its biosynthesis PrPC  is subjected to a number of 
post-translational modifications. The N-terminal signal peptide, which targets the 
protein to the rough endoplasmic reticulum (ER), is cleaved and N-linked 
oligosaccharide chains are added at two sites. A disulphide bond is formed between 
cysteine residues 179 and 214 (ovine numbering) and a GPI anchor is attached to the 
C-terminal end of the protein (Basler et al., 1986, Hope, Morton, Farquhar et al., 
1986, Stahl, Baldwin, Burlingame et al., 1990a, Stahl, Baldwin, Hecker et al., 1992, 
Stahl, Borchelt, Hsiao et al., 1987, Turk, Teplow, Hood et al., 1988). Whilst in the 
ER the protein is processed and folded into its correct conformation following 
interactions with molecular chaperones. It is possible that these molecular 
interactions could have a role in the conversion of PrPC  to  PrPSC  and this is supported 
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by the findings that PrP' carrying pathogenic mutations showed altered biochemical 
properties within the ER (Daude, Lehmann & Harris, 1997). 
Studies of PrPC  biosynthesis in cultured cells have shown that the protein 
undergoes two post-translational cleavages as part of its normal processing. The first 
occurs within the GPI anchor, releasing the protein from the cell membrane, and the 
second occurs within the conserved hydrophobic region (Harris, Huber, van Dijken 
et al., 1993, Jimenez-Huete, Lievens, Vidal et al., 1998). This second cleavage may 
take place in an endocytic compartment of the cell, or in a cholesterol rich domain of 
the plasma membrane (Hams, 1999, Taraboulos, Scott, Semenov et al., 1995, Vey, 
Pilkuhn, Wille et al., 1996). Cell studies analysing PrP' biosynthesis showed that 
deletion of the C-terminal signal sequence resulted in the failure of the protein to 
attach itself to the cell membrane and as such it was secreted into the cell medium 
(Borchelt, Rogers, Stahl et al., 1993, Rogers, Yehiely, Scott et al., 1993). Cleavage 
of the GPI anchor by bacterial phosphatidyl-inositol-specific phospholipase C 
(PIPLC) had a similar effect, as PrP' was cleaved from the membrane into the 
extracellular milieu (Borchelt et al., 1993, Borchelt, Scott, Taraboulos et al., 1990, 
Caughey, Neary, Buller et al., 1990, Lehmann & Hams, 1995, Stahl etal., 1990a). 
Stahl, Borchelt & Prusiner (1990b) noted, that although PrPC  was released 
from the cell membrane by PIIPLC, PrP, was not cleaved by this enzyme. One 
explanation for this observation is that PrP' and PrPs  are differentially anchored to 
the cell membrane, thus restricting the action of the enzyme on PrP (Stahl et al., 
1990b). It was initially thought that the C-terminal GPI anchor was important in the 
association of PrP' with lipid-rich rafts, however recent studies by Walmsley, Zeng 
& Hooper (2003) showed that this association was still possible after the deletion, or 
substitution of the GPI anchor with a transmembrane domain. This association was 
only prevented when an N-terminal segment was deleted from the protein, indicating 
that the N-terminal region of the protein acts as a cellular raft-targeting signal 
(Walmsley et al., 2003). Further studies by Nunziante, Gilch & Schatzl (2003) 
showed that deletion of the N-terminus of PrPC  inhibited the internalisation of the 
protein, resulting in a prolongation of its cellular half-life and a delay in its 
processing through the secretory pathway. PrPC  is synthesised and degraded very 
rapidly with a half-life of between 3-6 hours, whilst the two cleavage events occur 
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relatively slowly in comparison. It is therefore hypothesised that several different 
cleavage products of the protein may be present in the cell at any one time (Borchelt 
et al., 1990, Caughey, 1993). 
1.5.2 PrPC  glycosylation 
Glycosylation is recognised as being an important aspect of most cell surface 
proteins and PrPC  contains two sites for N-glycosylation at Asn 181 IleThr and 
Asn197PheThr, both of which can be variably glycosylated (Oesch et al., 1985). 
Differential glycosylation of these sites gives rise to three glycoforms of PrP', Un-
glycosylated, mono-glycosylated and di-glycosylated, and the ratio of these three 
glycoforms has been shown to differ between different brain regions (DeArmond, 
Qiu, Sanchez et al., 1999, Rudd, Endo, Colominas et al., 1999, Somerville, 1999, 
Vorberg & Pnola, 2002). Within the ER the molecular weights of these PrPC 
precursors are 25, 28 and 33 kDa for the un-, mono- and di-glycosylated forms, 
respectively. The N-linked oligosaccharide chains on PrPC  are further modified 
within the golgi apparatus, producing highly complex chains containing sialic acid, 
which are resistant to endoglycosidase H (Caughey, Race, Ernst et al., 1989, 
Haraguchi, Fisher, Olofsson et al., 1989). The molecular weights of these matured 
PrP molecules are 30, 33 and 35 kDa, respectively. Recent studies by Pan, Li, Wong 
et al. (2002) using two-dimensional immunoblots have shown that PrPC  glycosylation 
may be far more complex, as many different PrPC  species with differing molecular 
weights, levels of glycosylation and iso-electric points were observed. In addition, 
the N-glycan chains of both Syrian hamster and mouse PrP' have been shown to 
differ, highlighting the complexity of the PrP glycosylation (Stahl, Baldwin, Teplow 
et al., 1993, Stimson, Hope, Chong et al., 1999) 
It is generally accepted that N-glycans serve to stabilise the protein to which 
they are attached and interestingly studies have shown that the conversion of PrP' to 
PrPSC occurs more easily with un-glycosylated PrP' (Imperiali & O'Connor, 1999, 
Taraboulos, Rogers, Borchelt et al., 1990). Ma & Lindquist (1999) showed that PrPSC 
and not PrPC  was expressed in immortalised murine neuroblastoma (N2a) cells 
cultured under reducing conditions, and in conditions shown to block N-
glycosylation. These studies indicated that un-glycosylated PrPC  has a predisposition 
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to convert to PrPs,  or to a PrP like molecule and that the N-glycan chains may offer 
protection against this conversion (Winkihofer, Heske, Heller et al., 2003). 
Furthermore, as the two N-glycan chains of PrP' cover orthogonal faces of the 
protein it is hypothesised that they are capable of protecting large regions of the 
protein from the action of proteases and from non-specific protein-protein 
interactions by way of steric hindrance (Rudd, Wormald, Wing et al., 2001). 
1.5.3 PrPC  trafficking and sub-cellular location 
PrPC is clustered in detergent insoluble microdomains (DIMs), which contain 
cholesterol and glycosphingolipids (Taraboulos et al., 1995). These DIMs are 
associated with signaling molecules, including, members of the Src family of 
tyrosine kinases and G protein subunits (Gorodinsky & Harris, 1995, Mahfoud, 
Garmy, Maresca et al., 2002, Naslavsky, Stein, Yanai et al., 1997a, Naslavsky, Stein, 
Yanai et al., 1997b, Simons & Ikonen, 1997). Most of the information regarding PrPC 
trafficking has been derived from PrP' expression studies using transfected cell 
cultures. Following its biosynthesis PrPC  is trafficked to cell membrane DIMs, 
however it does not remain here and instead is internalised via clathrin-coated pits to 
an endocytic compartment (Gorodinsky & Harris, 1995, Shyng, Heuser & Harris, 
1994, Shyng, Huber & Harris, 1993) (Figure 1.3). It should be noted that certain 
studies have suggested that the C-terminal signal sequence may help to target the 
protein to caveolae-like domains within the cell membrane (Harmey, Doyle, Brown 
et al., 1995, Kaneko, Zulianello, Scott et al., 1997, Peters, Mironov, Peretz et al., 
2003, Vey et al., 1996). However, this is disputed by other researchers who have 
shown that these domains contain no caveolin (Gorodinsky & Harris, 1995). 
Lehmann, Milhavet & Mange (1999) showed that PrP' is endocytosed in 
cultured cells with a half-life of twenty minutes and is recycled back to the cell 
membrane with a transit time of one hour. Whilst in this endocytic compartment 
approximately 5% of the PrPC  molecules are cleaved at the second proteolytic 
cleavage site, which lies within the central hydrophobic domain of the protein 
(Harris, 2003). The remaining 95% of the internalised PrP' molecules are recycled to 
the plasma membrane. In addition, some of this membrane bound PrPC  is released 
into the extracellular milieu following the cleavage of its GPI anchor (Hay, Prusiner 
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& Lingappa, 1987, Shyng et al., 1993). The nature of this pathway suggests that it 
may function to promote the uptake of an as yet unidentified protein or molecule, 
possibly copper, either from the cell surface or from the extracellular milieu (Harris, 
1999, Madore, Johnson-Kraines, Rothstein et al., 1999). Yedidia, Horonchik, Tzaban 
et al. (2001) showed that approximately 10 % of PrPC  is targeted for degradation via 
the ER associated degradation (ERAD) proteasome pathway. During this pathway 
PrPC is shifted into the cytosol where it is ubiquitinated and the authors suggested 
that the presence of ubiquitinated PrPC  within the cytosol could potentially have 
pathogenic implications (Yedidia eral., 2001). 
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Figure 1.3 PrF' biosynthesis, trafficking and subcellular location 
1. PrP mRNA is translated into PrPC  in the rough endoplasmic reticulum and transported 
through the golgi apparatus to the cytoplasm. 2. PrPC is trafficked to the cell membrane, 
where it is attached by its GPI (glycosyl-phosphatidyl-inositol) anchor. 3 .  PrPC is then 
internalised into an endosomal compartment, where 5% of PrPC  is cleaved within the 
hydrophobic domain, the remainder of the internalised PrPC  is recycled back to the cell 
membrane. 4. Some of the PrPc  is cleaved at its GPI anchor and released from the cell 
membrane, but the majority remains on the cell membrane. 
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1.5.4 PrPC  topology 
PrPC is synthesised at the endoplasmic reticulum (ER), in three different 
topological isoforms (Hay et al., 1987, Kim, Rahbar & Hegde, 2001, Lopez, Yost, 
Prusiner et al., 1990, Stewart & Harris, 2003, Yost, Lopez, Prusiner et al., 1990) 
(Figure 1.4). Secretory P rPC (SCPrPC) is fully translocated into the ER lumen and is 
attached to the lipid-bilayer by its C-terminal GPI anchor (Stewart & Harris, 2001). 
Two other forms of the protein have been isolated and these are termed Ntmprpc  and 
CtmppC These two forms may span the lipid-bilayer once via the central hydrophobic 
region of the protein (residues Ala 1 13-Ser 135) (Stewart & Harris, 2001). The N-
terminus of Ntmppc  lies within the ER lumen, whilst it is the C-terminus of ctmprpc 
that lies within the ER lumen (Hegde, Voigt & Lingappa, 1998b, Kim et al., 2001, 
Stewart & Harris, 2001). It is proposed that Ntmprpc  lacks a GPI anchor, whilst 
CtmprpC adopts an unusual mode of membrane attachment as it spans the lipid-bilayer 
via its hydrophobic region, and is also attached to the bilayer via its C-terminal GPI 
anchor (Kim et al., 2001, Stahl etal., 1987, Stewart & Harris, 2001). 
Figure 1.4 Schematic of the three topological iso forms of P rFc 
synthesized in the rough endoplasmic reticulum 
PrPC is synthesized at the rough endoplasmic reticulum in three topological isoforms, SeCPrPC 
ctmprpc and N1mp1pc secprpc is attached to the bilayer via its C-terminus, ctmprpc  is attached 
via its C-terminus and also spans the bilayer via its hydrophobic region. Ntmp1pc  lacks a C-
terminal GPI anchor and spans the bilayer via its hydrophobic region (Stahl etal., 1987). 
('tmppc has been implicated in prion disease pathogenesis, for example, 
transgenic PrP null mice expressing recombinant PrPC  molecules with mutations in or 
around the transmembrane domain, and within the stop transfer effector (STE) 
domain (Lys iO4-Met, 12), were shown to favour the ctmprpc  formation (Hegde et al., 
1998a, Hegde, Tremblay, Groth et al., 1999, Stewart & Harris, 2003). In addition, 
mice expressing ctmprpc  developed a spontaneous neurological disease, but lacked 
detectable PrPSC  (Hegde et al., 1998a, Hegde et al., 1999). Therefore the authors 
suggest that it could be ('tmprpc  and not PrPSC,  which is responsible for the 
neurodegeneration in familial and infectious prion diseases (Hegde et al., 1998a, 
Hegde et al., 1999). In addition, ctmprpc  was shown to accumulate in the brains of 
mice expressing a PrP transgene with an Ala, 17Val mutation, which is associated 
with GSS in humans (Hegde et al., 1998a, Hegde et al., 1999, Mastrianni, Curtis, 
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Oberholtzer et al., 1995, Stewart, Drisaldi & Harris, 2001, Tranchant, Doh-ura, 
Warter et al., 1992). 
It is very likely that secprpc  is the major species present on the cell membrane, 
whilst the amount of CtTflprPC  in the cell is likely to be very low in comparison 
(Stewart & Harris, 2001, Stewart & Harris, 2003). However, it is not yet clear if 
ctmprpc is a byproduct of PrPC  biosynthesis which may have a role in disease 
progression if overexpressed. 
1.5.5 Structural characteristics of PrPC  and PrPSC 
PrP genes have been identified in a number of mammalian species and the 
PrPC protein primary structure is highly conserved with an average of 90 % sequence 
homology (Schatzl, DaCosta, Taylor et al., 1997). Ovine PrPC  comprises of 256 
amino acids, human and hamster PrPC 253 and mouse PrPC  254 (Rivera-Milla, 
Stuermer & Malaga-Trillo, 2003, Schatzl et al., 1997, van Rheede, Smolenaars, 
Madsen et al., 2003). PrPC  has a high content of a-helices and is sensitive to 
proteolytic digestion, in contrast PrPs  has a high content of n-sheet, and is partially 
resistant to proteolytic digestion in its aggregated form, it is also largely insoluble 
(Inouye & Kirschner, 1997, Meyer, McKinley, Bowman et al., 1986, Nguyen, 
Inouye, Baldwin etal., 1995, Oesch etal., 1985, Pan, Baldwin, Nguyen etal., 1993). 
PrPC and PrP do not differ in their primary structure, neither do they appear to differ 
in their post-translational modifications (Stahl et al., 1993). PrPC  and PrPSC  share 
similarities in their SDS-PAGE mobility and in their antigenicity (Barry & Prusiner, 
1986, Oesch et al., 1985). In addition, the proteins are cleaved in a similar manner at 
their N-terminal peptide cleavage sites (Caughey, Race, Vogel et al., 1988, Hope et 
al., 1986, Oesch et al., 1985, Stahl et al., 1990a, Stahl et al., 1990b). PrPC  and PrP 
are glycosylated in a similar manner and a GPI anchor is attached to both proteins 
(Caughey etal., 1988, Hope etal., 1986, Oesch etal., 1985, Stahl etal., 1990a, Stahl 
et al., 1990b). Therefore, the differing properties of the two PrP conformers must be 
reflected in their secondary or tertiary structure, but to date, it is still not clear how 
this takes place. 
Aspects of the structure of PrPC  have been elucidated by nuclear magnetic 
resonance (NMR) studies in mice, Syrian hamster, cattle and humans (Calzolai, 
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Lysek, Guntert et al., 2000, James, Liu, Ulyanov et al., 1997, Riek, Hornemann, 
Wider et al., 1996, Riek, Hornemann, Wider el al., 1997, Riek, Wider, Billeter et al., 
1998, Zahn, Liu, Luhrs et al., 2000). These results, along with other studies have 
shown that PrPC  is a monomeric protein, containing a globular domain stretching 
between residues 125-228, and an N-terminal flexible tail domain (Mehihorn, Groth, 
Stockel et al., 1996, Pergami, Jaffe & Safar, 1996). The PrPC  globular domain 
consists of a single double stranded anti-parallel a-sheet and three cc-helices (Rick et 
al., 1996). In addition, a number of species-specific variations have been identified in 
the structure of PrP' (Riek et al., 1998, Zahn et al., 2000). Peretz, Williamson, 
Matsunaga et al. (1997) utilising recombinant antibody Fab fragments against linear 
epitopes on PrP' and PrPs,  showed that the major conformational changes between 
PrPC and  PrPsc  may exist in the N-terminal region (residues 90-120). They showed 
that epitopes in the C terminal region were accessible in both PrPC  and PrP, but that 
epitopes in the N-terminal region were accessible in PrPC  but were buried or 
inaccessible in PrP (Peretz et al., 1997). Knaus, Morillas, Sweitnicki et al. (2001) 
produced a crystal structure of recombinant human PrPC  in a dimeric form, in 
addition, Meyer, Lustig, Oesch el al. (2000) showed that while PrP c normally exists 
as a monomer, it may adopt a dimenc conformation. 
1.5.6 PrPC  function 
The normal function of PrP' remains elusive although it is highly conserved 
throughout many species suggesting that it plays a key role in cellular metabolism. It 
has been suggested that due to the location of PrP' on the cell surface it may be 
involved in synaptic function, cell to cell communication, cell adhesion, signal 
transduction or ligand uptake, amongst others (Brown & Besinger, 1998, Brown, 
Herms, Schmidt et al., 1997, Herms, Madlung, Brown et al., 1997, Mabbott, Brown 
& Bruce, 1997, Manson, McBride & Hope, 1992, Mouillet-Richard, Ermonval, 
Chebassier et al., 2000). Experiments utilising the yeast two-hybrid system have 
shown that the laminin receptor protein (LRP) may act as a receptor for PrPC  (Rieger, 
Edenhofer, Lasmezas et al., 1997, Rieger, Lasmezas & Weiss, 1999). Laminin and 
PrP' both share the same binding site on LRP, which is a cell surface receptor that is 
highly conserved among mammalian species (Rieger et al., 1997, Shmakov, Bode, 
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Kilshaw et al., 2000). The expression of LRP on the cells of the intestinal brush 
border and in Paneth cell secretory granules is thought to be involved in both 
secretory and endocytotic functions (Rieger et al., 1997, Shmakov et al., 2000). 
More recent studies have shown that PrPC  binds to the laminin receptor in cultured 
cells and that this interaction may be important in mediating neuritogenesis 
(Gauczynski, Peyrin, Haik et al., 2001, Graner, Mercadante, Zanata et al., 2000, 
Hundt, Peyrin, Haik et al., 2001). 
PrPC has been shown to selectively bind copper ions in a highly conserved 
region of its N-terminal domain termed the octapeptide repeat (PHGGGWGQ), thus 
pointing to a role in copper transport (Brockes, 1999, Brown et al., 1997, Garnett & 
Viles, 2003, Prince & Gunson, 1998). Kramer, Kratzin, Schmidt et al. (2001) 
analysed copper binding to full length PrPC,  they showed that the N-terminal domain 
of PrP' binds up to five copper ions and that this binding occurs within the 
physiological range. It has been shown that when PrPC  acquires copper during protein 
folding, it becomes endowned with superoxide dismutase (SOD) activity, and that 
this activity is abolished if the octapeptide repeat region is deleted (Brown & 
Besinger, 1998, Brown, Wong, Hafiz et al., 1999, Rachidi, Vilette, Guiraud et al., 
2003). These experiments suggest that PrPC  function is related to its ability to bind 
copper in a pH dependent fashion and that it may be involved in the cellular response 
to oxidative stress (Brown, Clive & Haswell, 2001, Burns, Aronoff-Spencer, 
Legname el al., 2003, Wong, Pan, Liu et al., 2000). Interestingly, Vassallo & Herms 
(2003) suggested that PrPC  acts as a sensor for either copper ions, or free radical 
stimuli, triggering intracellular calcium signals which may finally result in the 
modulation of synaptic transmission or neuntogenesis. This hypothesis is supported 
by findings that calcium homeostasis and calcium and potassium currents are altered 
in PrP null mice (Herms, Korte, Gall et al., 2000, Herms, Tings, Dunker et al., 2001). 
Tobler, Gaus, DeBoer et al. (1996) showed that PrP null mice, although 
otherwise normal, showed signs of increased brief awakening during sleep, altered 
circadian rhythms and electrophysiological abnormalities in synaptic function. More 
recently, Huber, DeBoer & Tobler (2002) showed that abnormalities in sleep patterns 
and circadian rhythms in PrP knockout mice are region-specific, indicating that 
regions of the brain, such as the frontal cortex, are unaffected by the loss of PrPC 
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expression with regard to sleep regulation, while regions such as the occipital cortex 
are more seriously affected by this loss. The exact implications of these findings are 
not yet clear, but it is accepted that PrPC  may be involved in the function of circadian 
rhythms and that a loss of PrPC  expression acts to disturb brain activity (Huber et al., 
2002). 
Mouillet-Richard et al. (2000) showed that in cultured cells PrPC  becomes 
coupled to tyrosine kinase fyn in a caveolin-1 dependent reaction, indicating that 
PrP' may have a function in signal transduction. PrP' has been shown to interact with 
several factors known to be involved in neuronal signaling in vivo (Spielhaupter & 
Schatzl, 2001). These findings have been added to more recently by studies which 
showed that PrPC  is involved in the transduction of neuroprotective signals through a 
cAMP/PKA-dependent pathway (Chianni, Freitas, Zanata et at., 2002). 
It has been suggested that PrPC  may have a role as a nucleic acid chaperone 
protein (Demngton, Gabus, Leblanc et al., 2002). Derrington et al. (2002) 
investigated this hypothesis by analysing the DNA chaperoning properties of PrPC, 
they were able to show that PrPC  possesses all of the nucleic acid chaperoning 
properties of the retroviral nucleocapsid protein of human immuno-deficiency virus 
(HIV-1). The authors hypothesised that the function of PrPC  may be as a cellular 
defense mechanism against infection with enveloped viruses (Derrington et al., 
2002). This is supported by studies that showed that the expression of PrP mRNA in 
astrocytes is increased following infection with HIV-1 (Muller, Pfeifer, Forrest et al., 
1992, Muller, Rytik, Pfeifer et al., 1990). More recent studies showed that the in 
vitro conversion of PrPC  to a PrPWlike  molecule termed PrPres, was dependent on 
the presence of specific RNA molecules, indicating that RNA molecules may have a 
role in the pathogenesis of TSEs (Deleault, Lucassen & Supattapone, 2003). 
1.5.7 Prnd (Doppel) 
Moore, Lee, Silverman et al. (1999) established the DNA sequence 
downstream of the PrP gene in mice and discovered the open reading frame of a gene 
termed Prnd, located approximately 16 kb downstream of PrP, which encodes for a 
protein termed Doppel (dpi). Doppel genes have been discovered downstream of the 
PrP gene in humans, rats, sheep and cattle, therefore it is highly likely that other 
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mammalian species possess their own Doppel genes (Comincini, Foti, Tranulis et al., 
2001, Mead, Beck, Dickinson et al., 2000, Moore et al., 1999, Tranulis, Espenes, 
Comincini et al., 2001). The Prnd gene encodes for a protein of 179 amino acids, 
which shows approximately 25% homology to the C-terminal part of PrP'. As in 
PrP', Doppel is comprised of three a-helices, with a disulphide bond between a-
helices two and three (Luhrs, Riek, Guntert et al., 2003). In addition, Doppel lacks 
the octa-peptide repeat region located at the N-terminal of P rPC . 
Doppel messenger RNA (mRNA) is expressed at very high levels in testicular 
tissue, at slightly lower levels in other peripheral tissues, such as the heart and at very 
low levels in the brain (Moore et al., 1999, Peoc'h, Serres, Frobert et al., 2002, 
Silverman, Qin, Moore et al., 2000, Tranulis et al., 2001). Doppel is upregulated in 
the brains of the two PrP knock-out lines of transgenic mice, Nagasaki and RcmO 
due to an intergenic splicing event (Moore et al., 1999, Moore & Melton, 1997, 
Sakaguchi, Katamine, Nishida et al., 1996). Both of these lines showed signs of 
ataxia and apoptosis of cerebellar cells at around 70 weeks of age and the Nagasaki 
line showed loss of Purkinje cells (Moore et al., 1999, Moore & Melton, 1997, 
Sakaguchi et al., 1996). However, the two PrP knock-out lines NPU and Zurich I, do 
not over-express Doppel and remain healthy (Bueler et al., 1992, Manson et al., 
1994a, Moore et al., 1999, Moore & Melton, 1997, Nishida, Tremblay, Sugimoto et 
al., 1999, Rossi, Cozzio, Flechsig etal., 2001, Sakaguchi etal., 1996). 
More recently Tuzi, Gall, Melton et al. (2002) showed that the level of 
Doppel expression in the CNS of TSE infected mice had no effect on TSE disease 
incubation period or PrPSC  deposition. The authors concluded that Doppel had no 
detectable influence on TSE disease in the transgenic mice tested and therefore, 
Doppel is unlikely to be involved in naturally occurring TSEs (Tuzi et al., 2002). 
1.6 PrP genetics 
1.6.1 PrP genetics in mice 
Genetic analysis of the length of incubation period of the ME7 scrapie strain 
in mice led to the identification of Sine, a single autosomal locus with two alleles, s7 
and p7 (Dickinson & Mackay, 1964, Dickinson, Meikle & Fraser, 1968). It was 
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shown that these alleles control the incubation period of the ME7 strain, animals with 
the s7 allele have shortened incubation periods, whilst p7 animals have prolonged 
incubation periods (Dickinson & Mackay, 1964, Dickinson et al., 1968). The mouse 
prion protein gene Prnp has been shown to control scrapie incubation time in mice. 
Prnp has two alleles Prnp" and Prnpb  and two Prnp allotypes arise from codon 108 
and 189 dimorphisms, PrP A and PrP B (Manson el al., 1999, Westaway et al., 
1987). PrP A encodes 108 leucine (L)/189 threonine (T), whilst PrP B encodes 108 
phenylalanine (F)/189 valine (V) (Manson et al., 1999, Westaway et al., 1987). 
These polymorphisms have been shown to have a major effect on the incubation 
period of scrapie in mice (Moore et al., 1998). It is known that Sinc and Prnp are 
closely linked genes (Hunter, Hope, McConnell et al., 1987), and a recent study by 
Moore et al. (1998) showed that these genes are congruent, indicating that in mice a 
single gene locus is responsible for the control of scrapie incubation period (Manson 
et al., 1999). However, it is clear that polymorphisms of the PrP gene do not fully 
explain certain observations in experimental prion disease studies. For example, in 
mice, differences in the length of incubation period occur even when the amino acid 
sequence of the PrP genes present are identical (Carlson, Goodman, Lovett et al., 
1988, Dickinson, 1975, Kingsbury, Kasper, Stites et al., 1983, Westaway et al., 
1987). Interestingly, it has been demonstrated that multiple quantitative trait loci are 
linked to the incubation period of prion disease in mice, however the exact nature of 
these loci remains to be investigated (Lloyd, Onwuazor, Beck etal., 2001). 
1.6.1.1 Transgenic studies in mice 
Mice are not a natural host of scrapie, however they serve as a model system 
for transgenic studies and have added to our knowledge of the relationship between 
PrP' expression and disease. For instance, PrP knock-out mice without a functional 
PrP gene appear to develop and behave normally (with the exception of abnormal 
circadian rhythms and disrupted sleep regulation) with a normal lifespan, thus 
eliminating the loss of PrP function as a primary cause of TSEs (Huber, Deboer & 
Tobler, 1999). Further experiments have shown that mice lacking PrPC  seem to be 
resistant to infection with scrapie infectivity, pointing to PrPC  having a major role in 
TSE pathogenesis (Bueler, Aguzzi, Sailer et al., 1993, Weissmann et al., 1994). It 
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has been shown that transgenic mice that over express PrP show shortened 
incubation periods (Race et al., 1995, Raeber, Brandner, Klein et al., 1998, 
Shmerling, Hegyi, Fischer et al., 1998). 
Manson et al. (1994b) used gene knockout technology to produce a mouse 
line (NPU line of 129/01a mice) with an inactive PrP gene. Mice heterozygous for 
this mutation showed levels of PrP mRNA reduced by 50% when compared to the 
wild type mice. Using the ME7 strain of scrapie they infected wild type mice and 
mice heterozygous, and homozygous for the PrP null mutation. A gene dosage effect 
was observed whereby homozygote PrP null mice showed resistance to disease for 
up to 475 days, heterozygotes with one functioning PrP gene copy showed mean 
incubation periods of 220 days and wild type mice with two functioning PrP alleles 
showed shortened incubation periods with a mean of 130 days (Manson et al., 
1994b). The creation of transgenic mice which express mutated PrP gene sequences 
has shown that transgenic mice expressing PrPC  with N-terminal truncations develop 
a spontaneous neurological syndrome and present with ataxia and cerebellar lesions 
(Telling, 2000). In addition, a distinct spontaneous neurological phenotype was 
observed in mice with internal deletions in PrPC  (Raeber et al., 1998). 
Telling et al. (1995) produced two lines of transgenic mice, one expressed 
human PrPC  Tg(HuPrP) and the other line expressed a chimeric human/mouse P rPC 
Tg(Mhu2M). In order to investigate the mechanisms underlying the transformation 
of PrPC  to  PrPSC,  both of these lines of mice were inoculated with human brain 
extracts from inherited or sporadic prion disease cases. The Tg(HuPrP) mice showed 
resistance to disease, even though they were shown to express high levels of human 
PrPC .  However, their susceptibility to disease was promoted by the ablation of the 
mouse PrP gene, suggesting that in some way the endogenous mouse PrP' inhibited 
the conversion of the human PrPC  into PrP. Furthermore, the line of mice expressing 
chimeric PrPC  was found to be susceptible to disease and when the endogenous PrP 
gene was ablated only a moderate effect was observed on disease incubation times 
(Telling et al., 1995). The authors hypothesise that a species-specific molecule, 
possibly a chaperone protein ('Protein X'), aids in the conversion of PrPC  to PrP 
(Kaneko et al., 1997, Telling etal., 1995). 
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Crozet, Flamant, Bencsik et al. (2001) produced a line of PrP knockout 
transgenic mice expressing ovine PrPC  and these mice were inoculated intra-
cerebrally with two natural scrapie isolates. Both isolates caused disease in the mice 
with mean incubation times of 238 and 290 days, whilst C57BL/6 mice, expressing 
only murine PrPC,  failed to develop disease, indicating that the species barrier had 
been bypassed by the expression of ovine PrPC.  In another study, Vilotte, Soulier, 
Essalmani et al. (2001) produced nine lines of PrP knockout transgenic mice 
expressing different ovine PrP vRQencoding transgenes. These mice were inoculated 
intra-cerebrally with two natural scrapie isolates derived from VRQ homozygous 
sheep. All of the inoculated mice developed disease and the incubation times were 
found to be inversely related to the steady state level of PrP in the brain (Vilotte et 
al., 2001). Furthermore transgenic mice which over-expressed murine PrPC  were 
shown to be less susceptible to disease than the ovine PrP' expressing mice, 
indicating that prion replication was favoured in the presence of ovine PrPC  (Vilotte 
et al., 2001). These studies suggested that ovine PrPC  expressing transgenic mice 
lines may provide a viable model for the study of natural scrapie. 
1.6.2 PrP genetics in sheep 
In a similar way to the Sinc gene in mice, scrapie incubation periods in sheep 
are influenced by a gene termed Sip; which has two alleles, sA and pA (Hunter, 
Dann, Bennett et al., 1992). The Neuropathogenesis Unit (NPU) South Country 
Cheviot flock contains two lines of sheep (positive and negative lines); each line is 
defined by the response to infection with the sheep scrapie brain pool number 1 
(SSBP/1) isolate of scrapie (Dickinson et al., 1968). The NPU flock of South 
Country Cheviots was founded in 1960 and has remained closed to the introduction 
of any new sheep since 1962 (Dickinson et al., 1968). Sheep with the genotypes 
Sip/s and Sip"4 are selected into the positive line (high susceptibility) and these 
succumb to subcutaneous challenge with SSBP/1, whilst those with the homozygous 
genotype Sip°' °4 fall into the negative line (low susceptibility) and do not succumb 
to subcutaneous challenge with SSBP/1 (Hunter, Foster, Dickinson et al., 1989). The 
sA allele is at least partially dominant with SSBP/1, and Sip"l"M  offspring generated 
from 5siM  heterozygote positive line sheep do not succumb to SSBP/l 
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subcutaneous challenge (Foster & Hunter, 1991, Hunter et al., 1989). In contrast, the 
scrapie source CH1641 and BSE have been shown to have shortened incubation 
periods in a certain proportion of negative line sheep (Foster & Dickinson, 1988, 
Hunter, 1997). Using molecular genetics it has been shown that the Sip gene encodes 
the PrP protein and although there is a single PrP gene allele associated with Sip 4 , 
there are many PrP alleles associated with Si/4 and sheep TSE genetics is now 
exclusively described in terms of the PrP gene. 
1.6.2.1 Ovine PrP genotypes and polymorphisms 
Many polymorphisms exist in the ovine PrP gene and three of these in 
particular have been associated with the incidence of both natural and experimental 
scrapie. Particular amino acid residues at three positions on the host PrP' protein: 
codons 136, 154 and 171, are associated with disease susceptibility (Bossers, 
Schreuder, Muileman et al., 1996, Goldmann, Hunter, Foster et al., 1990, Hunter, 
Goldmann, Smith et al., 1994a). Studies of the PrP protein encoding regions of 
various Sip alleles by Goldmann, Hunter, Benson ci al. (1991a) identified PrP 
variants at codons 136, 154 and 171. Throughout this thesis, amino acid codon 
numbers are those of ovine PrP unless otherwise stated. The genotypes are described 
by giving the amino acid for each codon (136, 154 and 171) in turn, for each allele, 
in turn. Amino acids are described using the single letter code: A = alanine, H = 
histidine, R = arginine, Q = glutamine V = valine and X = any of the possible amino 
acids at that codon. Valine at codon 136 is encoded by sheep which are susceptible to 
experimental SSBP/1 infection, whilst sheep homozygous for alanine at codon 136 
are resistant to peripheral SSBP/1 challenge. Therefore, NPU VRQ/VRQ 
homozygotes are 100% susceptible to subcutaneous infection with SSBP/1 scrapie 
and show short incubation periods of 167 days, whilst VRQ/ARQ and VRQ/ARR 
heterozygotes show more prolonged incubation periods of 250 days, and 322 days, 
respectively (Goldmann, Hunter, Smith ci al., 1994a). 
PrP gene codon polymorphisms at position 171 show a disease linkage, with 
ARQ/ARQ homozygotes having shorter incubation periods following intracerebral 
inoculation with CH 1641, whilst ARQ/ARR heterozygotes show lengthened 
incubation periods, and ARR/ARR homozygotes show resistance to infection 
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(Goldmann et al., 1994a). Experimental challenge with BSE shows the same 
genotype linkage as CH1641 (Foster el al., 2001, Goldmann et al., 1994a, 
Goldmann, Hunter, Smith et al., 1994b). In other flocks an additional polymorphism, 
histidine, exists for sheep at codon 171, but there is no evidence that it significantly 
influences the disease course (Hunter, 1998). However, different genotypes alone can 
not explain the varying responses of sheep to scrapie infection, as animals of 
different breeds with identical PrPC  protein allotypes show variations in their 
susceptibility to scrapie (Hunter, 1997). For example, Cheviot sheep in the NPU 
flock with the ARQ/ARQ genotype exhibit resistance to natural scrapie, whilst 
Suffolk sheep of the same genotype exhibit a high degree of susceptibility to natural 
scrapie infection (Hunter, 1997). It is therefore possible that other regions of the 
ovine PrP gene may contain disease-associated polymorphisms (Hunter et al., 
1994a). 
1.6.3 PrP genetics in cattle 
As only a small proportion of all infected cattle developed BSE disease, it 
was assumed that there is a similar genetic control of disease susceptibility in cattle 
as has been described for sheep. The bovine PrP gene is the prime candidate for the 
genetic control of disease susceptibility in cattle and there are three known allotypes 
in this gene (Goldmann el al., 1991b). Different forms of the bovine PrP gene 
contain between five and seven copies of a G-C rich element within the protein 
coding exon (Goldmann et al., 1991b, Schlapfer et al., 1999). However, following 
the analysis of 370 cattle in Scotland no difference was observed between the 
frequencies of the different PrP genotypes in healthy and BSE infected animals 
(Hunter, Goldmann, Smith et al., 1994b). Again, it is likely that other regions of the 
bovine PrP gene may contain disease-associated polymorphisms (Hunter et al., 
1994b). 
1.6.4 PrP genetics in humans 
The inherited forms of TSEs in humans i.e. GSS, fCJD & FF1, segregate with 
specific point mutations or insertions of octapeptide repeat regions in the coding 
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region of the human PrP gene (Prusiner, 1998). For example, Hsiao et al. (1989) 
showed that a mutation at codon 102 of the PrP gene which substituted proline for 
leucine is linked with the development of GSS. A number of other point mutations at 
codons 105, 117, 145, 198 & 217 and an insertion between codons 51 & 91 have 
been linked to GSS but are much rarer (Ghetti, Piccardo, Frangione et al., 1996). A 
polymorphic change of methionine to valine at codon 129 appears to play a role in 
disease modulation (Goldfarb et al., 1992). Individuals who are homozygous for 
methionine at codon 129 show an increased risk for developing sCJD, whilst 
individuals who are heterozygous (methioine/ valine) at the same codon exhibit a 
reduced risk of disease occurrence (Palmer, Dryden, Hughes et al., 1991). In 
addition, FF1 and fCJD were shown to segregate with different genotypes determined 
by a mutation at codon 178, which substituted asparagine for aspartic acid and the 
polymorphic change of methionine to valine at codon 129. FF1 segregated with M at 
codon 129 and N at codon 178, whilst fCJD segregated with V at codon 129 and N at 
codon 178. Therefore, two distinct disease phenotypes appear to be linked to a single 
pathogenic mutation at codon 178 but are also determined by a common 
polymorphism at codon 129, when located on the same allele (Goldfarb et al., 1992, 
Medori, Tritschler, LeBlanc et al., 1992, Palmer et al., 1991). However, some CJD 
cases are not associated with known mutations within the PrP gene open reading 
frame, therefore it is hypothesised that other mechanisms may control disease 
susceptibility in humans. For example, McCormack, Baybutt, Everington et al. 
(2002) identified polymorphic intron regions in the human PrP gene that were 
associated with cases of sporadic CJD (sCJD) and could therefore be involved in 
increased susceptibility to disease. The insertion of additional copies of the PrP gene 
octapeptide repeat region is associated with disease occurrence and patients with 
between 1-4 extra copies of the octapeptide repeat present with typical CJD and 
show no family history of neurological disorders. In contrast, patients with 5-9 extra 
copies of the octapeptide repeat show features of CJD, GSS or an atypical dementia, 
with an autosomal dominant pattern of inheritance (Rossi, Giaccone, Giampaolo et 
al., 2000). 
It is not clear how these mutations alter disease susceptibility, but it is 
suggested that inherited TSEs result from mutations in the PrP gene which cause 
amino acid changes that may act to destabilise the tertiary structure of PrPC  (Cohen, 
Pan, Huang et al., 1994, Harrison, Bamborough, Daggett et al., 1997, Huang, 
Gabriel, Baldwin et al., 1994). It is hypothesised that the mutated PrPC  present in 
these inherited TSEs has an increased propensity to convert to PrP (Collinge, 1999). 
1.7 PrP gene structure 
1.7.1 PrP gene structure 
The entire ovine PrP gene, derived from a Suffolk sheep, has previously been 
described (Lee, Westaway, Smit et al., 1998) (Figure 1.5). The gene is conserved 
throughout different species; and comparisons of the open reading frames of non-
human primates and humans revealed homologies of between 92.9-99.6% (Schatzl, 
Dacosta, Taylor et al., 1995). In sheep, hamsters and mice exons I and II encode for 
the 5'untranslated region (UTR), whilst exon III contains a short 5' UTR sequence, 
the open reading frame and the entire 3'UTR (Lee et al., 1998). There is no 
equivalent of exon II in the human PrP gene. 
Intron I 	Intron II 
Human PrP -LD ----I--- 1111J --- 
Exon I 	 Exon II 
Intron I 	Intron II 
Bovine PrP 
Exon I 	Exon II 	 Exon HI 
Intron I 	Intron II 
Ovine PrP 
Exon I 	Exon II 	 Exon III 
Intron I 	Intron II 
Murine PrP 	 LDI 
Exon I 	Exon II 	 Exon III 
PrP Promoter 
• PrP Open reading frame 
ES 3' Untranslated region (3'UTR) 
• Exon DNA 
• Cryptic exon If-like sequence (human only) 
4 	Retroviral DNA (6593 bp insert - only in murine Prnj? allele) 
Figure 1.5 Mammalian PrP gene organization 
Mammalian PrP gene structure consists of three exon sequences, exon ill (exon ii in 
humans) contains the open reading frame (ORE), a short 5' untranslated region (UTR) and 
the full 3'UTR. Human PrP gene exon I is -130 bp in length, whilst exon I in the bovine, 
ovine and murine PrP genes is -50 bp in length. Exon II has been experimentally defined in 
bovine, murine and ovine PrP but not in human PrP where a cryptic exon 11-like sequence is 
found. Diagram is not accurately to scale. Human, murine & ovine PrP gene structures 
adapted from (Lee et al., 1998), bovine adapted from (Hills, Comincini, Schlaepfer et al., 
2001). 
Despite the variation in size of exon III throughout different mammalian 
species, the size of the protein-coding region of normal PrP genes remains relatively 
constant at approximately 760 bp. The location of the open reading frame remains 
constant, lying 10 bp from the intronlexon border, which is composed of a short 
5'UTR sequence (Goldmann el al., 1990). 
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1.7.2 PrP gene promoter region 
In all mammalian species analysed so far the PrP gene promoter has been 
shown to lack typical regulatory elements associated with the initiation of 
transcription, such as a TATA box element (Funke-Kaiser, Theis, Behrouzi et al., 
2001, Inoue, Tanaka, Horiuchi et al., 1997, Mahal, Asante, Antoniou et al., 2001, 
Saeki, Matsumoto, Matsumoto et al., 1996). However, the PrP gene promoter does 
possess a defined G-C rich region located proximal to the transcription start site 
(Baybutt & Manson, 1997, Westaway, Cooper, Turner et al., 1994a, Westaway, 
Zuliani, Cooper et al., 1994b). It is believed that these G-C rich elements act as 
potential binding motifs for zinc finger transcription factors such as specificity 
factor-1 (SP-1), and activator protein-2 (AP-2), which feature prominently in the 
regulation of genes which lack a TATA-box (Dynan, Saffer, Lee et al., 1985, Dynan, 
Sazer, Tjian et al., 1986, Dynan & Tjian, 1983, Mackay & Crossley, 1998, McKnight 
& Tjian, 1986, Rhodes & Kiug, 1993, Struhl, 1989, Suske, 1999). As with other 
TATA-less gene promoters, a number of other transcription factor binding motifs are 
present in the PrP gene promoter, some of which appear to be species-specific 
(Baybutt & Manson, 1997, Funke-Kaiser et al., 2001, O'Neill, Donnelly, Marshall et 
al., 2003). In addition, the PrP promoter contains four motifs, which are conserved 
between all the mammalian species tested to date, forming candidate binding sites 
for, as yet unidentified transcription factors (Westaway et al., 1994a, Westaway et 
al., 1994b). O'Neill, Donnelly, Marshall et al. (2003) identified three polymorphisms 
in the ovine PrP gene promoter, one of which creates an SP- 1 transcription factor 
binding motif in Cheviot sheep, which is otherwise absent in the ovine PrP gene 
promoter. 
1.7.3 PrP gene introns 
The ovine PrP gene contains two intronic sequences. The smaller intron I is 
approximately 2.4 kb in length, whilst intron II is some 14 kb in length (Goldmann et 
al., 1990, Lee et al., 1998). The bovine PrP gene introns are of the same size, 
however the introns of the other mammalian PrP genes do vary (Horiuchi, Ishiguro, 
Nagasawa et al., 1998). Intron I of the mouse and hamster PrP genes is 2.2 kb and 
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intron II of the hamster PrP gene is 7.7 kb (Li & Bolton, 1997, Westaway et al., 
1994a). However, intron II in the mouse PrP gene varies between mouse strains, with 
an 18 kb intron 11 sequence being observed in mice with the Pm-p0 allele and a 12 kb 
sequence in mice carrying the Prn-j}' allele (Westaway et al., 1994a). This difference 
is caused by the insertion of a 6.6 kb intracistemal A-particle (lAP) within intron II 
of the Pm-p0 allele (Kuff& Lueders, 1988, Lee et al., 1998). 
The human PrP gene contains one intron sequence of approximately 12.7 kb 
(Lee el al., 1998). The role of the PrP gene intron regions in regulation of gene 
expression remains unclear, however, studies have revealed that the introns may 
influence the level of PrP gene expression in a tissue-specific manner. Baybutt & 
Manson (1997) showed that two independent sequences in the mouse PrP gene intron 
I were capable of repressing and activating PrP gene promoter activity. Fischer, 
Rulicke, Raeber et al. (1996) showed that by deleting intron II from a mouse PrP 
transgene expressed in PrP knockout mice it was possible to suppress the expression 
of PrP in the Purkinje cells of the cerebellum; in contrast, PrP gene expression in the 
other brain areas tested remained unaffected. These results indicated that in mice 
intron II contains sequences, which could be involved in the tissue-specific 
expression of the PrP gene. Inoue et al. (1997) characterised the bovine PrP gene 
promoter linked to a chloramphenicol acetyltransferase (CAT) reporter gene in 
cultured bovine fibroblast cells. They showed that the promoter was only able to 
function properly in conjunction with a section of intron I (+123 to +891). It is 
hypothesised that this section of intron I is involved in the promotion of the PrP gene 
and that this promotion may be carried out in a tissue specific manner (Inoue et al., 
1997). Finally, Lee et al. (1998) discovered the presence of three intron regions, 
which are conserved in the human, sheep and mouse PrP genes. One of these regions 
is located at the beginning of intron II and it is hypothesised that this region could be 
involved in the transcriptional regulation of the PrP gene in these species (Lee et al., 
1998). 
1.7.4 PrP gene exons 
The PrP gene contains three exons in all but the human PrP gene, which only 
has two exons. Exons I and II are both non-coding exons, whilst exon III (exon II in 
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humans) contains the full open reading frame and the complete 3'UTR (Lee et al., 
1998). The sequences of the PrP gene exons I and II are conserved between 
mammalian species, exon I is approximately 50 bp in size in all mammalian species, 
whilst exon H is approximately 100 bp in size in all except the human PrP gene. The 
human PrP gene lacks a defined exon II sequence but it does contain a cryptic exon 
11-like sequence (Lee et al., 1998). The exon III sequence in ruminants is 
considerably longer than that observed in the other mammalian species and a variety 
of polymorphisms are observed in this region in different sheep breeds (Goldmann et 
al., 1990, Lee et al., 1998). The ruminant exon HI sequence is approximately 4 kb in 
length, whilst in humans the equivalent exon II is 2.35 kb and in rodents exon II is 2 
kb (Chesebro el al., 1985, Goldmann et al., 1990, Lee et al., 1998, Puckett, 
Concannon, Casey etal., 1991). 
1.7.5 Ovine PrP gene 3' untranslated region (3'UTR) 
Based on homology between PrP of different species the 3 'UTR of the 4.6 kb 
PrP mRNA has been divided into regions A-G, with the 2.1 kb transcript containing 
only regions A-C (Goldmann et al., 1990, Goldmann, O!NeilI,  Cheung et al., 1999) 
(Figure 1.6). The human PrP gene 3 'UTR shows sequence homology with regions A, 
B, C, E and G of the ovine 3'UTR, whilst the rodent 3'UTR only shows sequence 
homology to regions A, C, E and G (Goldmann et al., 1990). The bovine PrP gene 
3'UTR shows 85% homology to the ovine 3'UTR with the differences observed 
being spread throughout the 3'UTR (Honuchi et al., 1998). The disparity in size of 
exon III sequences between ruminants and non-ruminants is due to the presence of 
both long and short ruminant-specific interspersed repetitive sequences within the 
3'UTR, which resemble transposable elements (Lee et al., 1998). The largest of these 
ruminant-specific sequences displays homology to a mariner DNA transposon relic 
from the Me11fera (honeybee) subfamily of mariner elements and is present in all 
bovine and ovine 3'UTRs sequenced to date. 
The 3'UTR of the ovine PrP gene has been shown to contain three potential 
sites for alternative polyadenylation, two of which are known to be functional 
(Goldmann et al., 1990, Goldmann et al., 1999). Sequence analysis has revealed the 
presence of a number of polymorphisms within the ovine 3'UTR, and has shown that 
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it contains several instability motifs (Goldmann et al., 1999). The mRNA 
degradation in eukaryotic cells is a highly regulated process and may influence the 
level of gene expression, the presence of consensus instability motifs in the 3' UTR 
of the ovine PrP gene indicate that they may play a role in the degradation of PrP 
mRNA. These motifs are particularly prevalent in mRNAs encoding for proteins 
related to the inflammatory response (Caput, Beutler, Hartog et al., 1986, Sachs, 
1993). It is not clear if these sequences have an influence on the expression of the 
PrP gene and further studies are required to analysis any potential role. 
0 k 	 1 k 	 2 k 	 3 k 
PoIyA Site (1)— 1523 bp 
I 	ORF  IAIBICI 	D 	E 	I F 
PoIyA Site (2)- 2667 bp 
Fj Sheep Specific Regions (D and F) 
• Ovine PrP Open Reading Frame 
4 kb 
PoIyA Site (3) - 4038 
Figure 1.6 Ovine PrP 3' untranslated region (3'UTR) 
Three alternative sites for polyadenylation are marked as PolyA Sites 1-3. The ovine PrP 
3'UTR has been divided into seven distinct regions A-G based on sequence homology 
(Goldmann et al., 1990). Regions D and F are sheep specific regions. Human PrP 3'UTR 
shows sequence homology with regions A, B, C, E and G, whilst the rodent 3'UTR shows 
sequence homology to regions A, C, E and G. 
1.8 PrP gene expression 
PrP' expression is of critical importance to TSE development (Glatzel & 
Aguzzi, 2000). Manson et al. (1994b) showed that in mice both PrP deposition and 
vacuolation are dependent upon PrP' expression, and that this dependence is 
manifested in a dose dependent manner. To date, no significant difference has been 
reported in the level of PrP gene expression between normal and scrapie infected 
brain tissue. However, overexpression of the PrP gene in transgenic mice results in 
shortened incubation periods following inoculation with natural scrapie (Vilotte et 
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al., 2001). This study also showed that the incubation period appeared to be inversely 
related to the level of PrPC  expressed in the brain. Polymorphisms within the PrP 
open reading frame which contribute to disease susceptibility are well documented, 
however, they do not fully explain certain observations in disease transmission. It is 
therefore hypothesised that other regions of the PrP gene, such as the promoter 
region, or the structure of PrP mRNA are involved in scrapie susceptibility! 
resistance. The exact mechanisms regulating PrP gene expression are not clear, 
however, unraveling these mechanisms is clearly of vital importance to our 
understanding of TSE pathogenesis. 
1.8.1 PrP mRNA 
In other eukaryotic genes the 3'UTR has been shown to carry a variety of 
regulatory motifs including sequences for mRNA processing, stability, transport and 
translocation and often contains several sequences for polyadenylation signals, which 
if present in the pre-mRNA can lead to the production of mRNAs with different 
sequences at the 3' end (Jackson & Standart, 1990, Mitchell & Tollervey, 2000). As 
mentioned above (Sections 1.8.4 & 1.8.5) the 3'UTR in ruminants is longer than that 
observed in other mammalian species and this seems to be due to the insertion of 
ruminant-specific sequences (Lee et al., 1998). Two such regions of about 0.5 kb and 
1.4 kb are linked with possible roles in ruminant-specific RNA processing and 
translation (Goldmann et al., 1990, Goldmann et al., 1999). 
PrP mRNA of 4.6 kb is detectable in all tissues analysed and is at its highest 
in ovine brain tissue (Goldmann et al., 1990, Horiuchi, Yamazaki, Ikeda et al., 
1995). In addition, a PrP mRNA of 2.1 kb is detectable by Northern blot in ovine 
peripheral tissue (Hunter, Manson, Charleson et al., 1994c). The 2.1 kb mRNA is 
found in goats but has not been detected by this method in bovine tissue and is very 
rarely observed, if at all, in ovine brain (Goldmann et al., 1999, Horiuchi et al., 
1995). There is no equivalent of the short 2.1 kb mRNA in rodents or humans. The 
4.6 kb mRNA arises from a polyadenylation signal at position 4063, 25 bp 
downstream of the polyadenylation sequence at position 4038 (Polyadenylation site 
3, Figure 1.6). The 2.1 kb mRNA arises from an alternative polyadenylation signal at 
position 1546, 23 bp downstream of the polyadenylation sequence at position 1523 
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(Polyadenylation site 1, Figure 1.6). In addition, a 3.3 kb mRNA transcript was 
detectable in ovine kidney tissue and this mRNA species made up between 1-5 % of 
the total PrP mRNA in this tissue (Polyadenylation site 2, Figure 1.6) (Goldmann et 
al., 1999). Goldmann et al. (1999) isolated mRNAs from sheep lymph node and 
showed that the 5'UTRs of both the 4.6 kb and 2.1 kb transcripts are identical. 
However, as would be expected the shorter transcript is lacking several motifs 
present in the 3'UTR of the longer transcript i.e. instability motifs, transposable 
elements, repetitive sequences, although, both transcripts encoded for the same 
protein coding ORF (Goldmann et al., 1999, Hunter et al., 1989). The fact that both 
transcripts are observed in different tissues at varying levels leads to the possibility 
that alternative polyadenylation may be responsible for tissue-specific expression of 
PrP. 
1.8.2 Developmental expression of P rPC 
Prenatal PrPC  expression can be detected in rat and hamster brain tissue 
immediately prior to birth. McKinley, Hay, Lingappa et al. (1987) showed that PrP 
mRNA expression was undetectable until 1 day after birth in hamsters and that it 
remained at a very low level of expression until 10 days after birth, peaking between 
10 and 20 days of age, which was continued throughout adulthood. Lieberberg 
(1987) showed that PrP mRNA levels increased in a transcriptionally dependent 
manner during normal development. Manson, McBride & Hope (1992) detected PrP 
mRNA by in situ hybridisation in the developing mouse brain and spinal cord during 
embryonic development. PrP mRNA was detectable at 13.5 days and was also 
detected in the peripheral nervous system, ganglia, nerve trunks of the sympathetic 
nervous system and in neural cell populations of sensory organs (Manson et al., 
1992). Peripheral expression of PrP mRNA was observed in specific cell populations 
of 13.5 and 16.5 day-old embryos, and was also found to be present in extra 
embryonic tissues after 6.5 days (Manson et al., 1992). 
Moser, Colello, Pott et al. (1995) showed that the level of glial cell PrP 
mRNA expression in neonatal animals was comparable to that observed in neurones 
and that it increased by two-fold during postnatal development. Miele, Alejo Blanco, 
Baybutt el al. (2003) showed that in the developing mouse brain PrP mRNA 
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expression and PrPC  levels both increased during postnatal development. PrP mRNA 
expression is detectable throughout all stages of development in sheep, and 
expression of both the 2.1 kb and 4.6 kb ovine PrP mRNA species has been 
demonstrated in the foetus, lamb and adult sheep brain (Goldmann et al., 1999). PrP 
mRNA is detectable from day 98 of gestation and increases by 100 fold at day 134 
and doubles in lambs, this level of expression is then maintained throughout 
adulthood (Goldmann et al., 1999). The developmental levels of the 2.1 kb and the 
4.6 kb mRNA species vary depending on the type of tissue tested. The expression of 
the 2.1 kb species was found to be at its highest levels in spleen and kidney and at its 
lowest in brain tissue (Goldmann et al., 1999). 
1.8.3 Tissue-specific expression of the PrP gene 
PrP gene expression, as measured by Northern blot analysis, is generally at its 
highest in the brain, intermediate levels of expression are detected in peripheral 
tissues, such as the heart and lungs, whilst the lowest levels are found in the liver 
where PrP expression is almost undetectable (Brown, Goller, Rudelli et al., 1990, 
Caughey et al., 1988, Goldmann et al., 1999, McLennan, Rennison, Bell et al., 2001, 
Oesch et al., 1985). The PrPC  protein is widely expressed in a large variety of tissue 
types, it is abundant in neurones, and has been detected in both the neuronal cell 
body and in the axon (Ford, Burton, Morris et al., 2002). PrPC  has been detected in 
the spleen, lymphoid tissues and lymphoid cells, such as follicular dendritic cells, 
lung, heart, kidney, skin, skeletal muscle, uterus, testes, blood vessels and red blood 
cells, adrenal gland, parotid gland, intestine, pancreas, proventriculus, abomasum and 
mammary gland (Barclay, Houston, Halliday et al., 2002, Brown, Stewart, Ritchie et 
al., 2000, Ford et al., 2002, Horiuchi etal., 1995, Vostal, Holada & Simak, 2001). 
Horiuchi et al. (1995) observed that PrP mRNA levels in sheep were five 
times higher in brain than in kidney, whilst the amount of PrP' protein detected in the 
brain was forty times higher than that seen in the kidney. It is therefore hypothesised 
that the levels of translational efficiency, protein synthesis and protein degradation 
differ between these different tissue types. In addition, Ford et al. (2002) showed that 
in mice there is a distinct lack of correlation between the expression of PrP' and the 
expression of PrP mRNA in neurones, indicating that the steady state level of PrPC 
may be controlled in a post-transcriptional manner and may therefore be regulated by 
protein degradation or differential protein trafficking. PrP gene expression can differ 
within the same tissue; certain areas of the brain show very low, or no PrP mRNA 
expression i.e. caudate nucleus, neocortex and the granular layer of the hippocampus 
(DeArmond, Kristensson & Bowler, 1992, Kretzschmar, Prusiner, Stowring et al., 
1986). In contrast, other areas of the brain in hamsters show much higher levels of 
PrP gene expression, such as the cortex, striatum, cerebella Purkinje cells and 
neurones of the septum, thalamus and the caudate putamen (DeArmond, Mobley, 
DeMott et al., 1987, Manson et al., 1992, Sales, Rodolfo, Hassig et al., 1998). 
Finally, Liu, Zwingman, Lee et al. (2001) demonstrated differential expression of 
PrPC throughout different areas of the brain in mice using a panel of anti-PrP 
monoclonal antibodies. Interestingly they found no detectable PrPC  in the cerebellar 
Purkinje cells. 
Collectively these studies indicated that PrP gene expression is subject to 
regulation in both a tissue and cell type-specific manner and it is hypothesised that 
this regulation is controlled by specific sequences within the non-coding regions of 
the PrP gene such as the promoter and the 3'UTR. 
1.8.4 Factors that influence PrP expression 
Wion, Lebert & Brachet (1988) showed that PrP mRNA levels are affected 
by nerve growth factor (NGF) which acted to increase PrP mRNA in PC 12 cells. The 
highest levels of PrP mRNA were observed 7 days post treatment, however, a 
significant increase was detected at 48 hours post treatment. Lazarini, Castelnau, 
Chermann et al. (1994) demonstrated that NGF increases levels of PrP mRNA in 
cultured PC12 cells, a four-fold increase was observed after seven days of treatment 
and the same increase was observed following treatment with the cytokine 
interleukin-6 (IL-6). Kuwahara, Kubosaki, Nishimura et al. (2000) showed enhanced 
expression of PrPC  by NGF in immortalized mouse neuronal precursor cell cultures. 
Furthermore, Mobley, Neve, Prusiner et al. (1988) were able to show that PrP 
mRNA levels were induced by NGF in the developing hamster brain. 
Lasmezas, Deslys & Dormont (1993) showed that recombinant human 
growth hormone (hGH) treatment of cells resulted in a 30 % increase in PrP mRNA 
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levels by 7 days post-treatment and the treatment of cells with insulin-like growth 
factor I (IGF-I) resulted in a dose dependent increase in PrP mRNA levels. In 
addition, Kuwahara et al. (2000) demonstrated that insulin acts to enhance PrP gene 
expression. Sauer, Wefer, Vetrugno et al. (2003) observed that PrP' expression was 
increased following treatment of cells with ATP, NGF, epidermal growth factor 
(EGF) and tumor necrosis factor-alpha (TNF-alpha). Furthermore, Satoh, Kurohara, 
Yukitake et al. (1998) tested the effect of a panel of cytokines on PrP gene 
expression in human neuronal cell cultures, increases in expression of between 2.7-
4.2 fold were observed following treatment with IL-1, TNF-a, and phorbol 12-
myristate 13-acetate, whilst a 50 % decrease in expression was observed following 
treatment with interferon-gamma (IFN-y). Finally, Rybner, Hillion, Sahraoui et al. 
(2002) showed that all-trans retinoic acid acted to down regulate PrP mRNA levels in 
cultured cells, the authors hypothesised that this factor may be useful as a 
preventative strategy to slow down the development of TSE disease. These results 
show that the expression of the PrP gene is constitutive in a wide variety of human 
neuronal cell cultures and is controlled by a wide selection of cytokines, hormones 
and other growth factors. 
1.9 Post transcriptional regulation of PrP mRNA 
Studies in murine N2a cells, employing reporter gene constructs, showed that 
levels of expressed protein were affected by the length of the 3'UTR (Goldmann et 
al., 1999). The highest protein levels were associated with the shortest 3'UTR, whilst 
the lowest levels were associated with the full length 3'UTR (regions A-G) 
(Goldmann et al., 1999). Regions D-F contain almost 2 kb of ruminant-specific 
transposable elements (Lee et al., 1998), which are present in the 4.6 kb transcript, 
but are missing in the 2.1 kb transcript. It is therefore possible that sequences within 
this region may interact with sheep-specific factors to regulate PrP gene expression 
(Goldmann etal., 1999). 
Further work carried out at the NPU by Marshall (2000) involved developing 
transient transfection methods for the introduction of reporter gene constructs into 
various ovine cell cultures including; Immortalised Cheviot cell cultures, sA80BR 
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(susceptible brain cell culture of genotype VRQ/VRQ) and pA80BR (resistant brain 
cell culture of genotype ARQ/ARR); Primary Icelandic cell cultures (of genotype 
ARQ/ARQ), IS I 2OCer (cerebellum derived cell culture) and IS I 2OLiv (liver derived 
cell culture) (Sections 2.5.1-2.5.3). This work resulted in the identification of a 
region between nucleotides 2000-2700 that showed a tendency to reduce P rPC 
expression levels in ovine brain cells derived from Cheviot sheep (Marshall, 2000). It 
was hypothesised that this region could contain a sheep-specific binding site(s) for an 
inhibitory binding protein(s) that could regulate gene expression by interfering with 
the transcription of the PrP gene, or by affecting the stability of the PrP mRNA 
transcripts (Marshall, 2000). Finally, Schroder, Nickodemus, Jurgens et al. (2002) 
showed that upstream AUG sequences in mouse PrP mRNA may act to regulate its 
translational efficiency in vitro in murine N2a cells. 
1.9.1 mRNA processing in eukaryotes 
Messenger RNA (mRNA) acts as a template for the synthesis of protein and 
is produced by the transcription of a particular gene by RNA polymerase II within 
the nucleus (Wahle & Keller, 1996). The initial mRNA transcript is termed the pre-
mRNA and contains the non-coding intron sequences, which are removed by splicing 
(Staley & Guthrie, 1998). Splicing can be regulated by the availability of more than 
one splice site (alternative splicing) and the selection of one site over another can be 
further regulated by the action of hormones (Webster & Huang, 1999). Furthermore, 
splicing can be controlled in a tissue-specific manner by limiting the availability of 
specific splicing factors to certain tissue types (Venables & Eperon, 1999). 
The 5' end of the mRNA is then capped by the addition of a modified 
nucleotide termed, 7-methylguanosine to the first nucleotide of the mRNA (Varani, 
1997). Capping acts to protect the mRNA from degradation by 5' exonucleases in the 
cytoplasm and it is also a signal, which aids in the recognition of the start of the 
mRNA by the ribosome (Varani, 1997). The 3'end of the mRNA is then modified by 
polyadenylation, which is the addition of a poly A tail to the mRNA (Wahie & 
Keller, 1996). Polyadenylation involves the cleavage of the mRNA approximately 20 
bp downstream of the polyadenylation site by a group of proteins termed the 
cleavage and polyadenylation specificity factor (CPSF) which bind to the signal 
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sequence AAUAAA (Bienroth, Keller & Wahie, 1993, Bienroth, Wahle, Suter-
Crazzolara et al., 1991, Gilmartin & Nevins, 1989, Murthy & Manley, 1992). Poly A 
polymerase then adds a string of adenine residues to the 3' tail of the mRNA, which 
act to prevent degradation by 3' exonucleases (Wahle & Keller, 1996). The number 
of adenine residues added can vary greatly but is generally between 20-200 
nucleotides (Wahie & Keller, 1996). 
1.9.2 Control of gene expression by alternative polyadenylation 
In many eukaryotes a particular pre-mRNA species can give rise to more than 
one type of mRNA as a result of alternative polyadenylation. The choice of which 
sequence to use may be asserted in a tissue-specific manner. Therefore, mature 
niRNAs containing identical coding regions, but with differing stabilities or locations 
are capable of being produced by the same gene. For example, alternative 
polyadenylation of a cAMP-responsive element modulator-tau (CREM-t) pre-
mRNA is controlled by follicle stimulating hormone (FSH) (Foulkes, Schlotter, 
Pevet et al., 1993). This results in the use of an upstream polyadenylation site, which 
excludes an instability element from the final mRNA transcript and results in an 
increase in CREM-t levels (Foulkes et al., 1993). 
1.9.3 Alternative polyadenylation of ovine PrP mRNA 
As mentioned previously two sheep PrP mRNAs of varying size (a result of 
alternative polyadenylation) have been identified (4.6 kb and 2.1 kb) in different 
tissue types in sheep. In addition, an intermediate sized mRNA transcript may exist 
(Goldmann et al., 1999). Alternative polyadenylation is used to alter the translational 
efficiency of the -amy1oid precursor protein (APP), where two mRNA transcripts 
are observed, 3.2 and 3.4 kb (DeSauvage, Kruys, Marinx et al., 1992). The longer 
mRNA transcript produces more protein than the shorter mRNA species as tested in 
Xenopus oocytes. The authors concluded that, as it is generally accepted that long 
mRNA transcripts are no more stable than short mRNA transcripts, the sequence 
between the two polyadenylation sites of the APP mRNA must act to increase 
mRNA translation (DeSauvage et al., 1992). However, the use of alternative 
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polyadenylation sites does not explain why a PrP construct with a full length 3'UTR 
is expressed at lower levels than PrP constructs with shorter 3'UTRs (Goldmann et 
al., 1999)? Inhibitory regions within the 3'UTR may have been deleted in the shorter 
constructs, but remain present in the longer constructs, thus explaining the anomalies 
in protein expression. 
1.10 Transcriptional regulation of PrP gene expression 
Each cell in the body contains identical genetic information, and the wide 
variety of cell types observed arises from the differential expression of this 
information, producing different combinations of proteins at any time (Tjian, 1995, 
Tjian & Maniatis, 1994). Gene expression is regulated by specific sequence elements 
within the promoter region which form specific binding motifs for transcription 
factors (Mitchell & Tjian, 1989). Transcription factors either aid in the formation of 
the basal transcription complex, in conjunction with RNA polymerase II, or they act 
to regulate the level of transcription of a particular gene through specific interactions 
with other transcriptional elements (Mitchell & Tjian, 1989, Tjian, 1995). 
Transcription is the first stage in gene expression and involves the synthesis of RNA 
from a DNA template, which is catalysed by RNA polymerase II (Buratowski, 1994, 
Chalut, Moncollin & Egly, 1994). Gene transcription can be conveniently divided 
into three stages, initiation, elongation and termination, and each of these stages are 
described below. 
1.10.1 Transcriptional initiation in eukaryotes 
Promoter sequences commonly contain a TATA box sequence approximately 
25 bp upstream of the transcription start site (consensus site TATA(AJT)A(AIT)); 
and RNA polymerase II binds specifically to this sequence in conjunction with a 
number of general transcription factors (GTFs) (Chalut et al., 1994, Orphanides, 
Lagrange & Reinberg, 1996). The TATA-binding protein (TBP) is a GTF, which 
binds to DNA at the TATA box, unwinding the DNA (Burley, 1996, Hampsey, 
1998) (Figure 1.7). TBP binding to the TATA box is aided by various TAF 11s in a 
complex known as TFIID (Burley & Roeder, 1996, Conaway & Conaway, 1993, 
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Green, 2000, Ptashne, 1988, Verrijzer & Tjian, 1996). The binding of TFIID to the 
DNA is further enhanced by another GTF termed TFIIA, which acts to prevent the 
binding of inhibitory factors (Roeder, 1996). In addition, transcription factors like 
SP-1 are able to activate transcription through interactions with TAF11s (Hilton & 
Wang, 2003, Hoey, Weinzierl, Gill et al., 1993). Another GTF termed TFIIB is able 
to bind to this multi-protein complex and consequently enables RNA polymerase II 
to bind (Figure 1.7). A whole series of additional GTFs (TFIIE, TFIIF, & TFIIH) can 
subsequently bind, forming the basal RNA polymerase II transcription initiation 
complex (Goodrich & Tjian, 1994, Roeder, 1996) (Figure 1.7). 
Genes that lack a TATA box, such as PrP and APP, usually have an initiator 
(Inr) element, which overlaps the transcription start site. The transcription of genes 
whose promoter lacks a TATA box is often mediated by a combination of factors 
that bind to SP-1 and AP-2 motifs, and mr elements (Hilton & Wang, 2003, Smale, 
1997, Zhou & Chiang, 2001). In a similar way to the TATA box, the Inr element acts 
as a binding site for the GTF complex TFIID (Conaway & Conaway, 1993, Verrijzer 
& Tjian, 1996). As in TATA box containing promoters, once TFIID is bound it aids 
in the binding of other members of the basal transcription complex, allowing RNA 
polymerase II to bind to the promoter, and initiating transcription (Goodrich & Tjian, 
1994, Roeder, 1996) (Figure 1.7). Therefore, the TATA box and the mr element are 
functionally analogous to each other, as they both accurately direct transcription 
(Burley, 1996, Smale, 1997). 
The expression of genes whose promoter region lacks a TATA box can be 
further regulated by the presence of a downstream promoter element (DPE), located 
at approximately 30 bases downstream of the transcriptional start site / mr element 
(Burke & Kadonaga, 1996). The DPE is a 7 bp sequence that is involved, along with 
the mr element, in the binding of the GTF complex TFIID (but not TBP) to the 
promoter (Burke & Kadonaga, 1997). In this way the cell is able to initiate 
transcription from genes which lack a TATA-box by utilising the mr element and 
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Figure 1.7 Transcriptional initiation from a eukaryotic promoter, with 
& without TATA box 
Gene transcription from a promoter that contains a TATA box is performed in conjunction 
with TATA box binding protein (TBP), hA & TAF250 and involves a direct interaction 
between TBP and the TATA box DNA sequence. Gene transcription from a TATA-less 
promoter involves the same factors but does not require a direct interaction between TBP 
and the DNA. RNA polyrnerase II (RNA p0111) is then able to bind in conjunction with a series 
of general transcription factors (IIB, lIE, lIE, IIH) to initiate gene transcription. 
Transcriptional initiation of genes whose promoters lack a TATA-box is 
often associated with the regulatory transcription factors SP-1 & AP-2 (Kadonaga, 
Carrier, Masiarz et al., 1987, Philipsen & Suske, 1999, Salbaurn, Weidemann, 
Masters etal., 1989). For example, SP-1 has been shown to interact specifically with 
a GTF termed TAF 11 I 10 (Hilton & Wang, 2003, Hoey et al., 1993, Laity, Lee & 
Wright, 2001). It is thought that regulatory transcription factors act to alter the rate of 
transcription of specific genes by interacting with the basal transcription complex. It 
is likely that the binding of regulatory transcription factors represents a major 
method of controlling the rate of transcriptional initiation from TATA-less promoters 
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and is likely to be involved in the transcription of the PrP gene (Mitchell & Tjian, 
1989). Additional promoter elements such as the CCAAT box (CAT box) can act as 
binding motifs for other transcription factors that may influence the rate of 
transcription initiation, however the PrP gene promoter contains no obvious CAT 
boxes (Tjian, 1995). Furthermore, upstream elements may act to influence gene 
transcription, such as enhancers, which can greatly stimulate transcription, and 
silencers which act to inhibit transcription (Atchison, 1988, Tjian, 1995). Finally, in 
the bovine PrP gene, sequences within intron I may act to regulate PrP gene 
expression, by interacting with the promoter region via an as yet undefined 
mechanism (Inoue et al., 1997). A similar situation may exist in humans, as 
polymorphic intron regions in the human PrP gene are associated with cases of 
sporadic CJD (sCJD) (McCormack et al., 2002). 
1.10.2 Transcriptional elongation and termination in eukaryotes 
Following transcriptional initiation, RNA polymerase II proceeds to produce 
the mRNA transcript by transcriptional elongation. It has been demonstrated that 
several families of RNA polymerase II elongation factors and nuclear proteins aid in 
this process and that this elongation stage is critical in the regulation of gene 
expression (Conaway, Shilatifard, Dvir et al., 2000, Reines, Conaway & Conaway, 
1996). Transcriptional elongation is regulated by the alteration of the RNA 
polymerase II catalytic site, by the modification of chromatin structure, 
phosphorylation of RNA polymerase II and by interactions with other transcriptional 
components (Kobor & Greenblatt, 2002, Maldonado & Reinberg, 1995, Reines et al., 
1996, Shilatifard, 1998). Termination is believed to occur at a point after the end of 
the open reading frame of the protein being transcribed, however, it is still not clear 
if a defined termination signal actually exists, or if the dissociation of a transcription 
factor acts to destabilise the complex and cause the release of RNA polymerase II 
(Reeder & Lang, 1997, Tjian, 1995, von Hippel, 1998). 
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1.10.3 Transcription factors 
Eukaryotic transcription factors are proteins, which bind specifically to DNA 
regulatory regions and by doing so they influence the degree of transcription of 
specific genes (Mitchell & Tjian, 1989). Transcription factors are made up of a 
number of different domains, each of which has a distinct function; these include 
DNA binding domains, dimerisation domains, activation domains, and repressor 
domains (Dynan & Tjian, 1985, Tjian, 1995). DNA binding domains act to couple 
the protein to its DNA binding motif and these include helix-turn-helix domains 
(homeodomain transcription factors), zinc finger domains (SP-1) and basic domains 
(bZIP factors) (Harrison, 1991). 
Dimerisation domains aid in the coupling of dimenc transcription factors 
such as the bZIP family and the MyoD family of helix-loop-helix factors (McKnight, 
1991, Muller & Schaffner, 1990, Rhodes & Kiug, 1993). Transcription activation 
and repressor domains are the most important aspects of transcription factors, and it 
is through these domains that the function of the individual factors is realised 
(Herschbach & Johnson, 1993). The exact mechanisms by which transcription 
factors influence transcription are unclear, however, it is thought that they may alter 
chromatin structure to expose, or to bury specific DNA sequences (Cosma, Tanaka & 
Nasmyth, 1999, Kornberg & Lorch, 1999, Korzus, Torchia, Rose et al., 1998, 
Ogryzko, Schiltz, Russanova et al., 1996). Transcription factors may also interact 
with specific elements of the basal transcription complex to either promote or repress 
the level of transcription initiation (Laity et al., 2001). In addition, it is well 
documented that different transcription factors are able to interact with each other, 
and they are able to do this even when they are bound to distant regions of DNA 
(Seto, Lewis & Shenk, 1993, Tjian, 1995). This may well represent another method 
of transcriptional regulation in eukaryotes and adds to the increasing complexity of 
gene expression control. 
1.10.4 Transcription factor binding motifs in the PrP gene promoter 
The PrP promoter contains binding motifs for a variety of transcription 
factors, however, these motifs vary between the different mammalian species and the 
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exact position and number of certain motifs is also species-specific. The mouse PrP 
promoter contains three adjacent binding motifs for SP-1 and single motifs for the 
AP-1 and AP-2 transcription factors (Baybutt & Manson, 1997). The human PrP 
gene contains binding motifs for SP-1 (two adjacent), AP-1, AP-2, GATA 
transcription factors, nuclear factor of activated T cells (NF-AT) and for nuclear 
factor of IL-6 (NF-1L6) (Funke-Kaiser et al., 2001, Mahal et al., 2001). The bovine 
promoter contains an AP-2 motif and three adjacent SP- 1 motifs, whilst the ovine 
PrP promoter contains two AP-2 binding motifs (Figure 1.8) (Inoue et al., 1997, 
O'Neill et al., 2003). A polymorphic change of C to G within the downstream ovine 
AP-2 motif creates a single SP-1 binding motif in Cheviot sheep (O'Neill et al., 
2003). Figure 1.8 shows the first 442 bases upstream of the ovine PrP promoter, the 
known transcription factor motifs are marked and the start sites used are those 
described by Westaway et al. (1 994b). 
-445 TGACGGCAGGTGATGGCTAATATCCTTTCTAGGCCTCAAATTTTAATCTGAAAATTCACAAACATTGGGC 
-375 TTAATCCAGGGTAGTAGAATTTTTGTCCTTTTCAGWTTTCTGGTTACCAGAGTTCCCGAAATTGCATT 
-305 GCTTTCTCATTCCCTAATCTTTcA FT F1C CLAIiACGTAACGAGAGCTGGGGCTTTGGCCGATTTTCC 
Motif I 	Motif 2 
-235 CTCTAAAGATGATTTTTATCGTCAACAAGCAATTTCAGGGAGTGATGAGCCAGGGAGGCGGTGTTAGTTG 
Motif 3 	 Motif 4 i 	 Motif 4 ii 
-165 ATGCTAGCGTTTATGCTAGTCTCPJCTCGTTTTTCCCAGGGACTTAGATTCCTGGGTCTGCCGGTpJpCC 







+46 GAGGCAGGTAAATAGCCGCGTAGTCCTTTAJACTCC +81 
5' Splice Motif 
Figure 1.8 Putative transcription factor binding motifs within the ovine 
PrP gene promoter 
Motifs 1-4 are conserved sequence elements found in ovine, murine, hamster, cattle and 
human PrP gene promoters, as identified by Westaway et al. (1994a) which may form 
binding sites for as yet unidentified transcription factors. Arrowheads indicate location of 
transcription start sites as experimentally shown by Westaway et al. (1994a). Suffolk sheep 
PrP gene promoter sequence from -445 to +81 bp, numbering based on the use of the 5' 
transcription start site (Genbank = U67922). Also highlighted are a potential binding site for 
the AP-2 transcription factor and a polymorphic AP-2/SP-1 site seen in Cheviot sheep 
(O'Neill et al., 2003). Polymorphic or species specific base changes are indicated by base 
change (different colour) under the wild type (Suffolk, Genbank = U67922) sequence. 
1.10.5 PrP gene conserved promoter motifs 
Westaway et al. (1994a) discovered the presence of four motifs that are 
conserved within sheep, mouse, rat, human and Syrian hamster PrP genes which may 
be candidate binding motifs for as yet unspecified transcription factors. Motifs 1 and 
3 (Figure 6.1) contain a high proportion of adenine (A) and thymine (T) residues, 
whilst motifs 2 and 3 form imperfect palindromic sequences, similar to binding 
motifs of dimeric transcription factors (Figure 6.1). Motif 2 shares homology with 
the human bZIP repressor protein consensus sequence (Cowell, Skinner & Hurst, 
1992, O'Neill et al., 2003). Motif 4 is repeated in degenerate copies in both the sheep 
and Syrian hamster PrP promoters and has been identified as sharing homology with 
certain muscle-specific genes and with the binding motif of the lymphocyte-specific 
DNA-binding protein (LyF-1) (Hahm, Ernst, Lo et al., 1994, Westaway et al., 
1994a). Experiments carried out at the NPU have revealed polymorphisms within the 
ovine PrP motif 1, which makes it especially interesting to investigate its role in PrP 
gene regulation and therefore scrapie disease control (O'Neill et al., 2003). In order 
to understand the mechanisms regulating PrP gene expression it is vital to define the 
role of these transcription factor binding motifs, and to identify candidate binding 
factors for the conserved motifs in a variety of cell types. 
1.11 Aims and objectives 
Natural scrapie must start as an infection in peripheral tissues, and how that 
infection proceeds may be determined by the location and amount of PrPC  expressed 
on specific cell types. It is hypothesised that firstly the presence of small differences 
in PrP' expression levels could lead to measurable differences in the survival time, or 
scrapie pathology of individual sheep. Secondly, that these effects will be especially 
important in the periphery as the location of infectivity uptake and transport to the 
CNS. Thirdly, that the temporal and spatial regulation of these PrP' expression 
differences may be linked to the PrP gene promoter and/or 3' untranslated region 
(3'UTR) and fourthly, that polymorphisms in the regulatory gene regions may lead to 
the genetic variability of the phenotypes proposed in propositions I to 3. The overall 
aims of this thesis were to investigate the regulation of ovine PrP gene expression, 
and to provide further insights into the role of the PrP gene non-coding regions in 
this regulation. These aims were addressed by answering the following questions: 
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1. 	At what level is endogenous PrPC  expressed in a series of ovine cell lines 
derived from CNS and peripheral tissues? 
The ovine cell lines were to be used in transient transfection experiments 
using ovine PrP mini-gene constructs. In order to determine if the detection of PrP' 
protein expressed from the transfected constructs was to be reliable it was first 
important to establish the endogenous level of PrP' expression in the ovine cell lines 
in comparison with the established mouse N2a cell line to be used as a control. 
The following objectives were set: 
To determine if endogenous PrPC  expression within the ovine cells could be 
detected by immunoprecipitation and Western blot analysis. 
• To verify that the detected protein has the characteristics of PrP', i.e. the expected 
molecular weight and glycosylation pattern. 
• To compare ovine brain and peripheral cell lines 
• To compare PrPC  expression from the ovine cell lines to that seen in the mouse 
N2a neuroblastoma cell line. 
2. 	Can alternative potyadenylation of ovine PrP mRNA, as observed in 
sheep tissues, be associated with the control of PrPC  expression? 
In sheep the PrP gene mRNA is alternatively polyadenylated producing two 
different sized mRNA transcripts, 2.1 & 4.6 kb. To date, the level of PrPC  protein 
expression attributable to each of these transcripts is not known. In order to 
determine the role of alternative polyadenylation in ovine PrPC  expression, a series of 
ovine PrP mini-gene constructs were produced which differed only in the availability 
of polyadenylation signals. The ovine cell lines were transfected with these 
constructs with the objective of analysing the level of recombinant PrPC  expression 
from each of the cell lines. 
The following objectives were set: 
• To label the recombinant PrP with the 3XFLAG epitope within the open reading 
frame of the PrP gene in order to be able to distinguish between endogenous and 
recombinant PrP expression. 
• To determine if epitope-tagged PrPC  protein can be expressed in ovine cell lines 
from a transgene, which is able to encode various mRNA transcripts. 
To investigate whether alternatively polyadenylated PrP mRNA in transiently 
transfected cell lines can be associated with changes in the levels of epitope-
tagged PrPC  protein. 
To verify that the 2.1 kb mRNA transcript is actively translated and to investigate 
whether its level of translation varies when compared to the 4.6 kb mRNA 
transcript. 
To analyse the possible connection between transcript translation level and 
specific RNA binding factors that may prevent or limit the expression of one or 
the other transcript in the brain 
3. 	Do sequence specific transcription factors bind to sequence motifs within 
the ovine PrP promoter? 
Sequences within the ovine PrP promoter, including the four conserved motif 
sequences identified by (Westaway et al., 1994a), may form potential binding sites 
for sequence specific transcription factors and thus could act in the control of gene 
expression. The aim was to establish if these sequences are bound by transcription 
factors present in nuclear extracts prepared from ovine cell cultures and to consider if 
the binding of these factors indicated potential mechanisms by which the expression 
of the PrP gene could be controlled. 
The following objectives were set: 
• To identify potential binding sites for sequence specific transcription factors in 
the ovine PrP gene promoter sequence, using a variety of online and offline 
sequence analysis packages. 
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To assess the binding of transcription factors present in nuclear extracts derived 
from ovine and murine cell lines using gel shift and DNase I Footprinting 
techniques. 
To identify the factors which bind to motifs within the ovine PrP promoter with 
antibodies specific for the candidate proteins using the gel super-shift assay and 
to elucidate potential pathways by which, PrP gene expression may be regulated. 
Do single nucleotide polymorphisms within the ovine PrP promoter 
affect transcription factor binding? 
A number of single nucleotide polymorphisms (SNPs) have been identified 
within the ovine PrP gene promoter. These polymorphisms may affect the binding 
specificity of transcription factors for the ovine PrP gene promoter, by either altering 
the composition of existing motifs or by creating novel motifs. It is hypothesized that 
differences in the binding of transcription factors to the ovine PrP promoter could 
result in different levels of PrP gene expression and so the aim was to determine if 
these polymorphisms affect the binding affinity of sequence-specific transcription 
factors by comparing mutant and wild type sequences in gel shift assays. 
The following objectives were set: 
. To establish whether or not SNPs affect the composition of DNA binding motifs 
within the ovine PrP promoter. 
. To determine the effect of these SNPs on binding activity to oligonucleotides 
containing the wild type and mutant promoter motif sequences using gel shift 
assays. 
Is the binding of transcription factors to the ovine PrP promoter cell/ 
tissue specific? 
Ovine cell lines derived from Cheviot sheep of both known scrapie 
susceptible and resistant genotypes are available at the NPU. The promoter 
sequences are identical however there may be other features of the make up of these 
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cell lines which could affect PrP gene expression, for example different mixtures of 
transcription factors may be available in the scrapie susceptible and resistant cell 
lines. There may also be tissue-specificity in the mixture of available transcription 
factors in cell lines/ tissue samples of central nervous system (neuronal) and 
peripheral origin and these differences may affect the regulation of PrP gene 
expression. 
The following objectives were set: 
• To determine if there are tissue-specific differences in the availability of 
transcription factors between nuclear extracts prepared from the ovine cell lines 
derived from neuronal and peripheral tissues and also between nuclear extracts 
prepared from ovine and murine tissue samples of neuronal and peripheral origin. 
• To determine if there are differences in the mixture of available transcription 
factors between the cell lines derived from sheep of known scrapie susceptible 
and resistant genotypes. 
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Chapter 2: Materials & Methods 
2.1 General chemicals and solutions 
All solutions used in this thesis were prepared with high quality chemicals 
and were sterilised by autoclaving when necessary. The water used to make up 
solutions was obtained from a Milli-QUF system (Millipore, UK), and was further 
autoclaved before use when necessary. All temperature-controlled incubations were 
performed in a hot block (Techne Dri-Block® DB-3), with thermometer monitoring, 
unless otherwise stated. All centrifugations were carried out at full speed (14,000 
rpm) in and Eppendorf 5417C centrifuge unless otherwise stated. Standard solution 
recipes are detailed in Appendix A.I. 
2.2 General methods for DNA cloning 
The experimental procedures described below were performed according to 
the methods described in Sambrook & Russell (2001) or following the 
manufacturer's instructions, unless stated otherwise. 
2.2.1 Restriction enzyme digestions 
Restriction enzyme digestions were prepared as follows: 0.2-1 tg sample 
DNA, lox restriction enzyme buffer (Roche, UK) and 10 units of restriction enzyme 
were mixed in a 0.5 ml microcentrifuge tube (Corning, UK) with sterile dH 20 to a 
total volume of 30 .tl. A brief centrifugation at full speed was followed by incubation 
at the appropriate temperature (mostly 37 °C, but enzyme dependent) for 1-2 hours. 
The digestion was stopped by the addition of 5X gel loading buffer and results were 
visualised by agarose gel electrophoresis (Section 2.2.6). 
2.2.2 DNA polymerase I large fragment (Kienow) 
The Klenow enzyme is the large fragment of DNA polymerase I. Klenow 
catalyses the addition of mononucleotides from deoxynucleosides-5'-phosphates to 
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the 3'-hydroxyl terminus of a DNA template and is also used for the removal of 3'-
overhangs. For the removal of a 3'-overhang, 1 unit of Klenow (2 units/pd, Roche, 
15K) was added for every tg of DNA in a 0.5 ml microcentrifuge tube, along with I 
tl of i OX reaction buffer (Roche, UK) and dH 20 to 10 tl. The reaction was mixed 
by vortexing and incubated at room temperature for 20 minutes. In order to fill a 5'-
overhang, 40 mM of each dNTP (Roche, UK), and 1 unit of Kienow was added for 
every jtg of DNA, mixed with I .tl iox reaction buffer (Roche, 15K), dH 20 to a total 
of 10 t1 and incubated for 1 hour at 37 °C. Klenow enzyme was inactivated by 
heating to 75 °C for 10 minutes. 
2.2.3 Dephosphorylation of 5'- phosphates of DNA 
Shrimp alkaline phosphatase (SAP) catalyses the dephosphorylation of 5'-
phosphates from DNA and is used to dephosphorylate restricted cloning vectors in 
order to prevent re-ligation. For overhang cloning, SAP (Roche, UK) was added 
directly to the completed restriction enzyme digestion (Section 2.2.1). Three point 
six units of SAP (1 unit/tl) were added to the 30 j.tl restriction digestion along with 
3.6 p.1 lOX dephosphorylation buffer and the mixture was incubated at 37 °C for 10 
minutes. For blunt-end cloning, SAP was added to the completed restriction 
digestion as above and incubated for 60 minutes at 37 °C. SAP was inactivated by 
heating to 65 °C for 15 minutes. 
2.2.4 Covalent ligation of DNA ends 
T4 DNA ligase is an ATP-dependent enzyme, which covalently joins blunt or 
compatible cohesive DNA ends, as well as filling in nicks in double-stranded DNA. 
Twenty five ng of linearised (Section 2.2.1), dephosphorylated (Section 2.2.3) 
plasmid DNA, 100-200 ng of insert DNA, 1 unit of T4 DNA ligase (1 unit/p.!, Roche, 
UK) and I p.! lOX T4 DNA ligase buffer were mixed in a 0.5 ml microcentrifuge 
tube with sterile dH 20 to a total volume of 10 p.1. The reaction was then incubated at 
12 °C overnight in a thermal cycler (Techne PHC-3). 
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2.2.5 Labeling of DNA with 32P 
T4 polynucleotide kinase (T4 PNK) catalyses the transfer of the y-phosphate 
from ATP to the 5'-terminus of polynucleotides or mononucleotides and is used in 
the radiolabeling of probes for differential hybridisation experiments. Two .il of 
oligonucleotide (2.5 pmolJ.d), I p.1 of ['y- 32P]-ATP (3,000 Ci/mmol at 10 mCiIml) 
(Amersham, UK), lox kinase buffer (Promega, UK) and 5 units of T4 PNK (5-10 
units/p.!, Promega, UK) were mixed in a 0.5 ml microcentrifuge tube with sterile 
dH20 to a total volume of 10 p.1. The reaction was mixed and incubated at 37 °C for 
10 minutes in a hot block in a lead-shielded vessel. 
2.2.6 Agarose gel electrophoresis 
For analysis of PCR products and restriction digestion samples the method 
described by Helling, Goodman & Boyer (1974) was used. Samples were prepared 
for loading by the addition of 115th  the sample volume of 5X gel loading buffer, 
mixed and loaded directly onto a I % agarose gel. The gel was run at 120 V, 25 mA 
in lx TBE buffer until sample separation was achieved. DNA bands were visualised 
over UV light using an UV trans-illuminator (Appligene, UK). 
2.2.7 Isolation of DNA bands from agarose gels 
Working over UV light, the required band (-0. I g) was cut from the agarose 
gel (Section 2.2.6) using a clean disposable sterile scalpel and placed into a sterile 
1.5 ml microcentrifuge tube (Corning, UK). The DNA was then extracted from the 
agarose using a gel extraction kit (Qiagen, UK) following the manufacturer's 
protocol. 
2.2.8 Transformation of JMI 09 competent E. coil cells 
In a 1.5 ml microcentrifuge tube 30 p.! of JMI09 competent cells (Promega, 
UK) and 3 p.1 of a 10 p.1 ligation reaction (Section 2.2.2) were mixed and incubated 
on ice for 30 minutes. The cells were heat-shocked at 42 °C in a hot block for 1.5 
minutes and then incubated on ice for a further 10 minutes. LB broth (500 p.1, Roche, 
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UK) was added and shaken for 1 hour at 37 °C in a shaking incubator (Brunswick 
Series 25). Four 120 jtl aliquots of transformed competent cells were plated out onto 
ampicillin supplemented agar (1 .d/ml) and incubated overnight at 37 °C 
(Gallenkamp Size I economy incubator). For blue/white selection transformed 
competent cells were spread onto ampicillin positive IPTG/X-Gal agar plates and 
incubated as above. 
2.2.9 Selection of bacterial colonies for amplification 
Single colonies were selected and placed into 4 ml LB amp broth (1 j.dlml 
ampicillin) in a 15 ml centrifuge tube and incubated overnight with shaking at 37 °C. 
For blue/white selection, only white colonies; those with an interrupted Lac Z gene, 
indicating that the desired fragment had been incorporated, were selected. 
2.2.10 Plasmid DNA minipreps by alkaline lysis method 
For the small scale preparation of DNA from transformed E. co/i cells the 
following protocols were used (Birnboim & Doly, 1979, Ish-Horowicz & Burke, 
1981). In a 1.5 ml microcentnfuge tube I ml of a bacterial culture of transformed E. 
co/i cells (Section 2.2.8) was spun for 1 minute at full speed. The supernatant was 
discarded and a further I ml of bacterial culture was loaded into the same tube. The 
tube was spun again as detailed above and the supernatant was again discarded. The 
cells were lysed by the addition of 100 p1 miniprep solution A, producing a bacterial 
suspension, which was incubated at room temperature for 10 minutes. Proteinaceous 
material was precipitated by the addition of 200 l miniprep solution B. The solution 
was mixed by vortexing and incubated on ice for 5 minutes. Finally, nucleic acids 
were precipitated by the following method: miniprep solution C (150 tl) was added 
and the sample was mixed, incubated on ice for 10 minutes and spun at full speed for 
1 minute. The supernatant was transferred to a fresh 1.5 ml microcentrifuge tube and 
45 l d of sodium acetate (NaAc, pH 5.2) and 450 i.tl of iso-propanol were added. The 
tube was vortexed briefly and placed at —20 °C for 1 hour. The preparation was then 
spun at full speed for 10 minutes, the supernatant was discarded and the pellet 
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containing nucleic acids was washed with 500 tl ice-cold 70 % ethanol, vortexed 
briefly and spun at full speed for 5 minutes. Excess ethanol was discarded and the 
tube was blotted dry and air dried for about 1 hour at room temperature. The pellet 
was dissolved in 50 j.tl RNase solution to remove residual RNA, incubated at room 
temperature for 20 minutes and stored at —20 °C. 
2.2.11 Ethanol precipitation of plasmid DNA 
To purify the DNA preparation (Section 2.2.10) the sample was ethanol 
precipitated as follows: Two times the sample volume of 100 % ethanol was added to 
the plasmid DNA preparation, the solution was vortexed briefly and incubated at —20 
°C for at least 30 minutes. The sample was spun at full speed for 10 minutes and the 
supernatant was discarded. The DNA pellet was dissolved in 50 pi of RNase solution 
to remove residual RNA, incubated at room temperature for 20 minutes and stored at 
—20 °C. 
2.2.12 Plasmid DNA maxipreps by bulk alkaline lysis method 
For the large scale preparation of DNA from transformed E. co/i cells the 
following protocols were used (Birnboim & Doly, 1979, Ish-Horowicz & Burke, 
1981). A starter culture of 4 ml ampicillin LB amp broth was inoculated with a single 
colony of transformed E. coli cells and incubated overnight at 37 °C with shaking 
(Section 2.2.8). This culture was added to 300 ml LB amp broth and incubated as 
before. The culture was spilt into 2 x 250 ml GSA bottles (Beckman, USA), 
centrifuged at 6,000 rpm for 10 minutes at 4 °C (Beckman JL-21) and the 
supernatant was discarded. The pellets were dissolved in 30 ml miniprep solution A 
(cell lysis solution) plus 0.1 g of lysozyme (10jig/ml, Sigma, UK) and the bottles 
were incubated at room temperature for 10 minutes. Sixty ml of miniprep solution B 
was added to precipitate proteinaceous material and the bottles were mixed well and 
incubated on ice for 5 minutes. Miniprep solution C (30 ml) was added to precipitate 
nucleic acids, and after mixing, the bottles were again incubated on ice for 15 
minutes and spun at 6,000 rpm for 10 minutes at 4 °C. The supernatants were pooled, 
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filtered through gauze into a 500 ml cylinder and 0.6 times the sample volume of iso-
propanol was added. The contents were poured into a clean GSA bottle and spun at 
8,000 rpm for 10 minutes at 4 °C (Beckman JL-21). The supernatant was discarded, 
residual liquid was blotted from the bottle neck and the pellet was air dried for 1 
hour. The pellet was dissolved in 4 ml of TE buffer (pH 7.4) and transferred to a 
glass tube (Corex, USA), to which 4 ml of phenol/chloroformliso-amyl alcohol 
(25:24:1, Sigma, UK) was added. The tubes were covered in Parafilm (American 
National Can, USA), mixed carefully by slow vortexing and spun for 5 minutes at 
8,000 rpm at 4 °C. The upper aqueous layer was removed to a fresh glass tube. To 
this tube 1/10 the sample volume of 3M NaAc (pH 5.2) and 2.5 times the sample 
volume of absolute alcohol were added, the solution was mixed and placed at -20 °C 
for 1 hour. The tube was spun at 8,000 rpm for 5 minutes at 4 °C, the supernatant 
was discarded and the pellet was air dried and dissolved in 2 ml TE buffer. A 
caesium chloride (CsC1) gradient was prepared in 5 ml Quickseal tubes (Beckman, 
UK) by adding 4.75 g CsCI to 2 ml DNA preparation, along with 100 i.l ethidium 
bromide solution (0.5 p.glml). The tubes were then filled to the top with TE buffer, 
sealed using a Beckman tube sealer and spun overnight at 80,000 rpm at 20 °C 
(Beckman Optima TLX Ultracentrifuge). The lower plasmid band (-1 ml) of the 
CsCl preparation was removed with a wide bore needle syringe and made up to 5 ml 
with TE buffer in a 15 ml plastic centrifuge tube. The ethidium bromide was 
removed by adding 5 ml butan- I -ol, mixing by inversion and the removal of the top 
DNA layer to a fresh tube. This wash procedure was repeated three times or until all 
ethidium bromide was removed. Ethanol precipitation (Section 2.2.11) was used to 
recover the DNA followed by centrifugation at 8,000 rpm for 10 minutes at 4 °C, the 
pellet was air dried, dissolved in I ml of TE buffer (pH 7.4) and stored at -20 °C. 
2.2.13 Spectrophotomeric determination of DNA sample concentration 
and purity 
DNA sample concentration was determined by spectrophotomeric analysis. 
An aliquot of the DNA sample (8 j.tl) was added to 800 j.tl of dH 20, mixed well and 
transferred to a silica spectrophotometer cuvette (Sigma, UK). Absorbance at 260 rim 
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and 280 nm was determined using a UV spectrophotometer (Beckman DU 0650). 
DNA concentration (pg/ml) was calculated by multiplying the absorbance value at 
260 nm by 5000 to take into account the dilution value. DNA purity was determined 
by dividing the absorbance value at 260 rim by the value at 280 nm. A value greater 
than 1.9 was considered as being a good quality sample, with minimal protein 
contamination. 
2.2.14 Polymerase chain reaction (PCR) 
First described by Kary Mullis in 1986 the polymerase chain reaction (PCR) 
is a process by which Thermus aquaticus DNA polymerase I (Taq DNA polymerase 
I) synthesises a complementary strand to a given DNA strand (Mullis, Faloona, 
Scharf et al., 1986). This reaction takes place in a mixture containing dNTPs and 2 
complimentary primers, which flank the target DNA sequence. The mixture is first 
denatured to produce single stranded template DNA containing the target sequence 
then cooled to allow the primers anneal to their complementary sequences. The 
primers are then extended by the Taq polymerase into newly synthesised 
complementary strands. As each new double strand separates to two individual 
templates, multiple cycles allow the target DNA to multiply exponentially. In just 20 
cycles of PCR, target template can be amplified by a million-fold. The concentration 
of each primer (Table 2. 1, MWG, DE) used for PCR reactions was 25 pmol per 50 tl 
reaction and dNTPs (Roche, UK) were used at a final concentration of 200 mM. The 
following reaction was used: 1 unit Taq polymerase (1 unit/pd, Roche, UK), 0.4 i.tl 25 
mM dNTPs (Roche, UK), lOX Taq buffer (Roche, UK), I jtl each primer (25 pmol, 
MWG, DE), 30 ng plasmid DNA (10 ng/pJ) were mixed in a 0.5 ml microcentrifuge 
tube with sterile dH 20 to a final volume of 50 p1. Negative reactions with no DNA 
template added were used as controls. PCR reactions were incubated in a PCR 
thermal Cycler (Techne PHC-3). The following is an example cycle used for PCR 
reaction: DNA was denatured at 94 °C for 1 minute, primers and template DNA were 
annealed at 60 °C (temperature optimised for particular primer) for 1 minute and new 
DNA strand was synthesised behind the primers on each template strand at 72 °C for 
71 
2 minutes. Commonly this cycle was repeated at least 30 times. PCR reactions were 
analysed by agarose gel electrophoresis (Section 2.2.6) and stored at —20 °C. 
2.2.15 Pre-ligation treatment of PCR products 
PCR products (Section 2.2.14) were cleaned and prepared for ligation into the 
chosen plasmid by the following method. Forty tl PCR product, 2 tl 10 % SDS 
(Sigma, UK), I .il 0.25 M EDTA (pH 8,) and 1 .tl (20 mg/ml) proteinase K (Sigma, 
UK) were mixed in a 0.5 ml microcentnfuge tube and incubated at 37 °C for 30 
minutes. To precipitate DNA, 4.5 uI of NaAc (pH 7) and 125 u1 absolute alcohol was 
added and incubated overnight at —20 °C. The precipitated DNA sample was spun at 
full speed for 10 minutes and the supernatant was discarded. The pellet was washed 
in 500 j.tl ice cold 70 % ethanol and vortexed briefly. The sample was spun at full 
speed for 5 minutes, the supernatant was discarded, the pellet was blotted dry and air 
dried for 1 hour at room temperature. The dried pellet was dissolved in 20 j.tl dH20 
and stored at -20 °C. Pre-ligation treated PCR product was then ligated into the 
appropriate vector as described in Section 2.2.4. 
2.2.16 Reverse Transcriptase - PCR (RT-PCR) with Superscript II 
Superscript II (Invitrogen, UK) was used to synthesise complementary DNA 
(cDNA) from total RNA extracts isolated from ovine cell lines (Section 2.5.8) 
following the manufacturer's protocol. Briefly, 1-5 g  total RNA (Section 2.5.8), 1 
p.1 sequence specific primer (2 pmol) (Table 2. 1), 1 p.110 mM dNTP mix (Roche, 
UK) were mixed in a 0.5 ml microcentrifuge tube with dH 2 0 to 12 p.1. The reaction 
was heated to 65 °C for 5 minutes, the contents were collected by brief centrifugation 
at full speed and chilled on ice. To the reaction was added 4 p.1 5X first strand buffer 
and 2 p.1 0.1 M DTT (Invitrogen, UK). The contents were mixed gently and 
incubated at 42 °C. Two hundred units of Superscript 11 (200 units/p.l, Invitrogen, 
UK) were added, the contents were mixed by pipetting and incubated at 42 °C for a 
further 50 minutes. The reaction was inactivated by heating to 70 °C for 15 minutes. 
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The cDNA prepared was used as a template for PCR amplification as described in 
Section 2.2.14. 
Primer Target sequence DNA Primer sequence 
name (Suffolk sheep strand 
Genbank =_U67922)  
AG23 3 end of ovine PrP gene Top 5'CTGACAGCCGCAGA 
promoter (5675-5696 bp) GCTGAGAG' 3 
580SH 5' end of ovine PrP gene Bottom 5'GTGGTGGTGACTGT 
ORF (23125-23144 bp) GTGTTG'3 
643 5' end of ovine PrP gene Bottom 5'GCTCCACCACTCGCT 
ORF (22902-22921 bp) CCATT'3 
13741 5' end of ovine PrP gene Bottom 5'GAGGCCTGAGGTGG 
ORF (22423-22447 bp) ATAGCGGTTGC'3 
Flag 5' end of 3XFLAGTM DNA lop 5'TCTCTACCCGGGAG 
Forward sequence ACTACAAAGAC'3 
Flag 3' end of 3XFLAGTM DNA Bottom 5'CTAAATCCCGGGTA 
Reverse sequence CTTGTCATCGTC'3 
Table 2.1 PCR & RT-PCR primer sequences 
Sequence used for primer design was the Suffolk sheep sequence (Genbank = U67922). 
Primers were designed to recognise sequences (top = top strand, bottom = bottom strand) 
within the sheep PrP gene open reading frame (ORE), the sheep PrP gene promoter or the 
3XFLAG DNA sequence (Sigma, UK). 
2.3 Sanger (dideoxy mediated) chain termination 
sequencing of DNA 
2.3.1 Chain termination sequencing reaction 
This technique which was first described by Sanger, Nicklen & Coulson 
(1977) involves the in vitro synthesis of a DNA strand by a DNA polymerase with 
the use of a specifically primed single-stranded DNA template (Section 2.3.2). The 
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first step is a labeling procedure in which the primer is extended using limiting 
concentrations of deoxynuleotides (dNTPs), including a radioactively labelled dATP. 
These primer extensions form a population of chains of various lengths from several 
to hundreds of nucleotides. The second step involves the addition of chain 
terminating nucleotide analogue, 2' ,3 '-dideoxynucleoside-5 ' -triphosphates 
(ddNTPs). These analogues lack the 3'-OH group required for DNA chain elongation 
and processive DNA synthesis occurs until all extending chains terminated by a 
ddNTP. When mixtures of dNTPs and one of the four ddNTPs are used 
polymerisation will be terminated in a fraction of the population of chains at each 
site where the ddNTP can be incorporated. Using four separate reactions, each with a 
different ddNTP, it is possible to obtain complete DNA sequence information 
(Section 2.3.3). Sequencing reactions are halted by the addition of EDTA and 
formamide, denatured by heating, separated by high resolution denaturing gel 
electrophoresis (Section 2.3.4) and visualised by autoradiography. 
2.3.2 Preparation of single strand DNA (ssDNA) template 
Twenty l of miniprep DNA (2 mg/ml) (Section 2.2.10), 2 .il of 2M NaOH 
and 2 t1 of 2 mM EDTA were mixed in a 0.5 ml microcentrifuge tube and incubated 
for 30 minutes at 37 °C. The reaction was neutralised by the addition of 2.5 .tl of 3M 
NaAc (pH 5.2). DNA was precipitated by adding 100 tl of absolute alcohol and 
incubated at —70 °C for 15 minutes. The DNA was pelleted for 10 minutes at full 
speed, the pellet was washed with 500 .tI ice cold 70 % ethanol and spun at full 
speed for 5 minutes before discarding the supernatant. The pellet was blotted and air 
dried for 1 hour, before being dissolved in 25 .tl TE buffer (pH 7.4) and stored at —20 
oc. 
2.3.3 Chain termination sequencing protocol 
To prepare the annealing mixture the following were added together in a 0.5 
ml microcentrifuge tube: 7 il single stranded plasmid DNA (Section 2.3.2), 2 .tl 
reaction buffer (Amersham, UK) and 1 tl sequencing primer (1 pmol/tl) (Table 2.2). 
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The mixture was heated for 2 minutes at 65 °C in a water bath and allowed to cool 
slowly to 35 °C before being centrifuged briefly at full speed and further chilled on 
ice. Whilst the annealing mixture was cooling the termination mixtures (ddNTPs, 
Amersham, UK) were prepared by the addition of 2.5 pi of each termination mix (G, 
A, T and C) into labelled microcentrifuge tubes and incubated at 37 °C. The labeling 
mix (Amersham, UK) was prepared by diluting the stock I in 5 with dH20. The 
Sequenase (Version 2.0, Amersham, UK) was prepared by diluting 1 in 10 with 
Sequenase buffer (Amersham, UK). The labeling reaction was prepared by adding 
the following to the chilled DNA mix (10 tl): I tl 0.1 M DTT (Amersham, UK), 2 
tl diluted labeling mix, 0.75 p1 [S35]  dATP (Amersham, UK), 1 p.1 manganese buffer 
(Amersham, UK) and 2 p.1 diluted sequenase version 2. The labeling reaction was 
incubated at room temperature for 2 minutes, 3.5 p.1 was transferred to each of the 
four termination mixtures (G, A, T and C), mixed by vortexing and incubated at 37 
°C for 5 minutes. The reactions were stopped by the addition of 4 p.1 of stop solution, 
which contains EDTA and formamide (Amersham, UK). Samples were heated to 75 
°C for 2 minutes immediately prior to loading onto sequencing gel (Section 2.3.4). 
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Primer Target (Suffolk sheep DNA Primer sequence 
name Genbank = U67922) strand 
Flag 5' end of 3XFLAGTM DNA lop 5'TCTCTACCCGGGAG 
Forward sequence  ACTACAAAGAC'3 
Flag 3' end of the 3XFLAGTM Bottom 5'CTAAATCCCGGGTA 
Reverse DNA sequence  CTTGTCATCGTC'3 
AG28 3' end of ovine PrP gene Top 5'AGCCGCAGAGCTGA 
promoter (5680-5702 bp)  GAGCGTCTT'3 
B007 5' end of ovine PrP gene Bottom 5'GCTTCTTGCAGAGG 
ORF (22335-22356 bp)  CCCACGTC'3 
Promseql 3' end of ovine PrP gene Top 5'TCCTCTGCACGGCG 
promoter (5636-5655 bp)  ACTCAC'3 
Promseq2 3' end of ovine PrP gene Top 5'GGCGACTCACCAGC 
promoter (5646-5655 bp)  CCTAGT'3 
Promseq3 3' end of ovine PrP gene Top 5'AGATTCCTGGGTCT 
promoter (5546-5565 bp)  GCCGGT'3 
FP1 5' end of ovine PrP gene Top 5'TGACGGCAGGTGAT 
promoter (5226-5245 bp)  GGCTAA'3 
Table 2.2 Sequencing primers used to sequence Cheviot PrP promoter 
sequence and PrP mini-gene construct DNA 
Sequence used for primer design was the Suffolk sheep sequence (Genbank = U67922). 
Primers were designed to recognise sequences (top = top strand, bottom = bottom strand) 
within the sheep PrP gene open reading frame (ORF), the sheep PrP gene promoter or the 
3XFLAG DNA sequence (Sigma, UK). 
2.3.4 Denaturing gel electrophoresis for sequencing 
A 3 p.l aliquot of each sample was loaded onto a 4 % acrylamide gel, the gel 
was run for 20 minutes at 2,000 V, 50 watts, then run at 2,000 V, 35 watts for a 
further 1 hour. In order to remove urea the gel was placed into a bath with 5 % 
glacial acetic acid for 20 minutes. The gel was then transferred to a sheet of 
Whatman 3MM filter paper, wrapped in cling film and dried on a gel dryer at 80 °C 
for 1.5 hours. Once dried the gel was transferred to a cassette (Genetic Research 
Instrumentation Ltd., UK) and exposed to Kodak Biomax MR-1 X-ray film (Kodak, 
UK) for 24 hours at room temperature. 
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2.3.5 Automated sequencing 
Automated sequencing was performed using an ABI Prism 377 automated 
sequencer. Prior to sequencing, PCR or RT-PCR products (Sections 2.2.14 and 
2.2.16) of the DNA sequence to be sequenced were purified and concentrated using a 
Microcon YM-100 filter (Millipore, USA). To the filter, 360 j.tl of TE buffer and 40 
tl PCR or RT-PCR product was added, the filter was then spun at 510 x g 
(Eppendorf 5417C) for 9 minutes, leaving approximately 20-30 j.il of product on the 
filter. The filter was then inverted and placed in a clean 1.5 ml microcentnfuge tube, 
the tube was spun at full speed for 30 seconds to collect the sample, which was 
stored at —20 °C. 
2.3.6 Automated sequencing reaction 
The sequencing reaction consisted of the following components: 3 il Big 
Dye kit (Microzone Limited, UK), 3 .il Better Buffer (Microzone Limited, UK), 2 p.1 
sequencing primer (1 pmollp.1), 7 p.1 concentrated PCR product sample, for a total 
volume of 15 p.1. The reaction was performed on a PCR thermal cycler (Hybaid, UK) 
with 25 cycles of the following programme: 96° C for 10 seconds, 50° C for 5 
seconds and 60 °C for 4 minutes. To each reaction, 80 p.1 of isopropanol was added, 
the samples were then precipitated at room temperature for 20 minutes, prior to 
centrifugation at 3,000 rpm for 20 minutes at 4 °C. Samples were air dried, dissolved 
in 4 p.1 of Red Loading Buffer (Microzone Limited, UK) and denatured at 94° C for 
two minutes prior to loading onto a sequencing gel. The sequencing reaction utilises 
four separate fluorescent dyes, one for each base. The ABI sequencer then reads the 
signal from each dye using a laser, and in this way a sequence is derived from the 
sample as it is separated on the sequencing gel. 
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2.4 General methods for promoter analysis 
2.4.1 Preparation of double stranded oligonucleotide probe 
Complementary single stranded synthetic oligonucleotides (50 pmollp.l, 
MWG, DE) were annealed by mixing and incubating equal volumes (50 tl) of each 
strand in a hot block at 90 °C for 10 minutes. The hot block was then placed on the 
bench and the oligonucleotides were allowed to cool slowly to room temperature. 
The annealed oligonucleotides were diluted in dH 20 to a working concentration of 
2.5 pmol/tl, aliquoted and stored at —20 °C. The sequences of the oligonucleotides 




Abbreviation DNA binding motif 
oligonucleotide sequence (Top 
 strand) 
NC-i (Promega, UK) NC-I 5 ATTCGATCGGGGCGGGGCGAG 3 
NC-2 (Promega, UK) NC-2 5'GATCGAACTGACCGCCCGCGGCCCGT' 
3 
Wild type STAT site STAT-C 5'AGAGTTCC GAAATTGC1Tf'3 
Variant STAT site STAT-A 5'AGAGTTCC GAAATTGCTTT'3 
AP- 1 AP- 1 5'GGAGTGATGAGCCAGGGAGG'3 
GATA-1 GATA- 1 5 'TGACGGCAGGTGATGGCTAA '3 
EGR- I EGR- 1 5'GGGCGCCCGCAGCGGGCGCG '3 
HSE- I HSE- 1 5 'ATCTGAAAATTCACAAACAT'3 
FISE-2 HSE-2 5 'TGTCCCTTTTAGAAATTTCT'3 
Upstream AP-2 uAP-2 5 'TAAACCCCGGGCGCCCGCAG '3 
Downstream AP-2 (Suffolk) dAP-2s 5'CCTCCCCCCCCCCGCAGCTC'3 
Downstream AP-2 (Cheviot) dAP-2c 5 'CCTCCCC CCCCCGCAGCTC '3 
Wild type motif! MIT S'TAATCTT CATTUCTCCAT'3 
Variant motif 1 M1C 5'TAATCTT CATTTTCTCCAT'3 
Ruminant motif 2 M2C S'TTCTCCATTA GTAACGAGA'3 
Non-ruminant motif 2 M2T 5'TTCTCCATTA GTAACGAGA'3 
Motif 3 M3 5'CTCTAAAGATGATITVTATC'3 
Motif 4(i) M4i 5 'GCAATTTCAGGGAGTGATGA'3 
Motif 4 (ii) M4ii 5 'GATGAGCCAGGGAGGCGGTG '3 
Motif 4 (iii) M4iii 5'TTTTTCCCAGGGACTTAGAT'3 
Variant Ml + Ruminant M2 M1C/M2C 5'TAATCTTCCATTTTCTCCATTACGTAAC 
GAGA'3 








Wild type Ml± Ruminant M2 M1TIM2C 5'TAATCTTTCATTTTCTCCATTACGTAAC 
GAGA'3 
Humanised Ovine Ml + M2 hovMl/M2 5'GAGCCTTCCATTTTCTCGATTTCTCCAT 
TACGTAACGGGGG'3 
Human M  + M2 hMl/M2 5'GAGCCTTTCATTTTCTCGATTTCTCCAT 
TATGTAACGGGG'3 
Table 2.3 	Binding motif oligonucleotide sequences used in gel shift 
& super-shift assays 
Oligonucleotides (20-40 bp) were designed to contain the appropriate putative transcription 
factor binding motif sequence along with the native flanking sequences (5' & 3'). Top strand 
sequence only is detailed in the table. Red letters indicate presence of polymorphic or 
species specific base changes 
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24.2 Labeling of double stranded DNA probe with [y- 32P] ATP 
The double stranded oligonucleotide was labeled with [y- 32P] ATP as detailed 
in Section 2.2.5. The reaction was stopped by the addition of I pl of 0.5M EDTA and 
diluted in 89 il of TE buffer. The radiolabeled oligonucleotide was separated from 
the unincorporated nucleotide by chromatography through a G-50 ProbeQuant 
column (Amersham, UK) following the manufacturer's protocol. The radiolabeled 
oligonucleotide was counted in a 1.5 ml microcentrifuge tube using a Beta Scout 
2007 liquid scintillation tester (Perkin-Elmer, USA). Only radiolabeled 
oligonucleotides with a count of 500,000 cpm or greater were used for gel shift assay 
analysis. 
2.4.3 Preparation of nuclear extracts from cultured cells 
Nuclear extractions were performed with the nuclear and cytoplasmic 
extraction reagents (NE-PER, Pierce, UK) following the manufacturer's protocol 
based on the method described by (Dignam, Lebovitz & Roeder, 1983). Cells were 
cultured to confluency in 75 cm  flasks yielding approximately 2 x 106  cells at 80 % 
confluency. Cultured cells were trypsinised (Section 2.5.3) and cells were pelleted by 
centrifugation at 3,000 x g for 2 minutes. The supernatant was removed and the 
pellet was re-suspended in 200 j.tl of ice cold Cytoplasmic extraction reagent I (CER 
I, Pierce, UK) buffer. The sample was vortexed for 15 seconds to fully re-suspend 
the pellet and incubated on ice for 10 minutes. At this stage 50 .il Complete Mini - 
proteinase inhibitor solution (Roche, UK) was added to the sample. Eleven tl of ice 
cold Cytoplasmic extraction reagent II (CER II, Pierce, UK) buffer was added, the 
sample was vortexed for 5 seconds, incubated for 10 minutes on ice and vortexed 
again for a further 5 seconds. The sample was centrifuged at 4 °C for 5 minutes at 
16,000 x g in an Eppendorf 5415R centrifuge. The supernatant was discarded and the 
pellet containing nuclei was re-suspended in 50 l of ice cold nuclear extraction 
reagent (NER, Pierce, UK) buffer, vortexed for 15 seconds and incubated on ice. The 
sample was vortexed for 15 seconds every 10 minutes for a further 40 minutes. The 
sample was then centrifuged at 4 °C for 10 minutes at 16,000 x g and the supernatant 
EII] 
(nuclear extract) was transferred to a clean pre-chilled microcentrifuge tube, 
aliquoted and stored at —70 °C until use. 
2.4.4 Preparation of nuclear extracts from tissue samples 
The extraction of nuclear extracts from tissue was carried out using the same 
protocol and reagents for cultured cells (Section 2.4.3) but with the following 
changes: Fresh or frozen tissue (50 mg) was homogenised using a pellet pestle motor 
(Kontes, UK). Five hundred .tl CER I buffer was added to the tissue homogenate and 
this was mixed further with the pellet pestle motor until a homogenous solution was 
achieved. At this stage 50 .tl Complete Mini - proteinase inhibitor solution was 
added. The same protocol for cultured cells was followed from this point (Section 
2.4.3), however 27.5 j.tl of CER II buffer was added and the nuclei were re-
suspended in 100 tl of NER buffer before being aliquoted and stored at —70 °C. 
2.4.5 Determination of total protein concentration in nuclear extracts 
Concentration of total protein in nuclear extracts was determined using 
spectrophotomeric analysis. In a 1.5 ml microcentnfuge tube, an 8 .tl aliquot of the 
nuclear extract was added to 800 p.1 of dH20, mixed well and transferred to a silica 
spectrophotometer cuvette (Sigma, UK). Absorbance at 260 nm and 280 nm was 
determined using a UV spectrophotometer. The following calculation was performed 
to determine the total protein concentration (p.g/p.l): 
Protein concentration (g/j.tI) = 
(Absorbance 280 nm x 1.55) — (Absorbance 260 nm x 0.76) 
The value obtained above was multiplied by 100 to correct for the dilution 
factor, giving the total protein concentration in the nuclear extract in p.g/p.l. 
Concentrations of the nuclear extracts varied between the cell lines and tissue 
samples but were consistently between 5-20 p.g/p.l. 
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2.4.6 Gel shift (DNA binding) assay 
The gel shift assay technique was first described by Freid & Crothers (1981) 
and Garner & Revzin (1981). The assay is used for the analysis of protein-DNA 
interactions. The assay separates free DNA from protein-DNA complexes by non-
denaturing gel electrophoresis. It relies on the production of a positive signal, which 
is produced when a transcription factor binds specifically to its 32P labeled DNA 
binding site, causing a band shift to occur. For each binding assay four separate 
reactions were prepared as follows: 
Reaction I = Negative control: labelled probe only. 
Reaction 2 = Positive control: labelled probe and nuclear extract (NE). 
Reaction 3 = Specific competitor: labelled probe, NE & same unlabelled probe. 
Reaction 4 = Non-specific competitor: labelled probe, NE & a different unlabelled 
probe. 
The amount of NE added varied depending on the batch concentration and 
this was corrected for by varying the amount of nuclease free water added to each 
reaction. In general the amount of NE added was between 1-2 p.1, providing between 
10-20 p.g of total nuclear protein per binding assay (Sections 2.4.3-2.4.4). Great care 
was taken to ensure that the same batch of nuclear extract was used for each reaction 
in a single binding assay. Gel shift assays were performed using the Gel Shift Assay 
Kit (Promega). Reactions consisted of 2 p.1 5X binding buffer (250 mM NaCl, 50mM 
Tris-HC1, pH 7.5, 2.5 mM EDTA, 2.5 mM DTT, 5 mM MgCl2, 20 % glycerol, 0.5 
p.g poly(dI.dC).poly(dI.dC)), 1-2 p.1(10-20 p.g) NE and dH 20 to a total volume of 9 
p.1 incubated at 25 °C for 10 minutes. Each reaction was prepared as detailed below: 
Reaction I (Negative control) 
7 .tl Nuclease free water 
2 id Gel shift binding buffer 5X (Promega, UK) 
QIA! Nuclear extract (NE) 
9 jil Total volume 
Reaction 3 (Specific competitor) 
5 iAl Nuclease free water 
2 tl Gel shift binding buffer 5X (Promega, UK) 
1 i.tl NE 
.Liai unlabelled competitor oligo (2.5 pmol4il) 
pmolI.tl) 
9 j.tl Total volume 
Reaction 2 (Positive control) 
6 i.tl Nuclease free water 
2 .t1 Gel shift binding buffer 5X (Promega, UK) 
J1NE 
9 .t1 Total volume 
Reaction 4 (Non-specific competitor) 
5 j.tl Nuclease free water 
2 ltl Gel shift binding buffer 5X (Promega, UK) 
1 jil NE 
LjtJ unlabelled non-competitor oligo (2.5 
9 M1  Total volume 
The above reactions were incubated at room temperature for 10 minutes 
before the addition of 1 .il 32P labeled double stranded DNA probe (0.025 pmol, 
10,000-50,000 cpmI10-100 fmol) to give a total reaction volume of 10 p.1 (Section 
2.4.2). The reaction was further incubated at 25 °C for 20 minutes prior to being 
loaded onto a 4 % non-denaturing acrylamide gel (Section 2.4.8). For competition 
experiments 100-fold molar excess of unlabeled (cold) competitor and/or non-
competitor double stranded DNA probes were added. 
2.4.7 Super-Shift Assay 
Gel super-shift assays are a modification of the gel shift assay that involves 
the addition of an antibody that is specific for the DNA binding factor being 
analysed. If the factor in question is present in the gel shift reaction, then the initial 
shift will be further shifted or blocked by the binding of the antibody to the protein. 
Gel super-shift assays were performed as for gel shift assays, the specific antibody 
(1-2 p.1 of a 1 p.g/p.l antibody solution in PBS) was added immediately after the 
addition of the appropriate 32P-labelled oligonucleotide. The super-shift reaction was 
incubated at room temperature for either 20 minutes or 45 minutes, or overnight at 
+4 °C prior to gel electrophoresis (Section 2.4.8). 
2.4.8 Electrophoresis of DNA-Protein complexes 
The assays were analysed by gel electrophoresis on a 4 % non-denaturing 
acrylamide gel. The gel was pre-run in 0.5X TBE buffer for 10 minutes at 250 V 
prior to loading, and after the samples were loaded on to the gel it was run at 250 V 
for one hour. The gel was transferred to a sheet of Whatman 3MM filter paper, 
covered in plastic wrap and dried on a gel dryer at 80 °C for 1 hour. The gel was then 
exposed to Kodak Biomax MS-I X-ray film (Kodak, UK) for 1 hour, 12 hours and 
72 hours respectively at —70 °C with an intensifying screen. 
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2.4.9 DNase I Footprinting 
DNase I Footprinting works on the basis that the interaction of DNA with a 
regulatory protein protects that region of the DNA from the action of DNase I (Galas 
& Schmitz, 1978). The amount of DNase I added to the reaction is regulated so that 
it does not completely degrade the DNA probe, instead the aim is to cut each 
molecule at a single phosphodiester bond. If no protein is bound to the DNA then the 
result is a family of labelled fragments, differing in size by one base each, which 
appear as a ladder after gel electrophoresis. However, the bound protein protects 
certain bonds from degradation by DNase I, resulting in an incomplete family of 
labelled fragments. This shows up after gel electrophoresis as a gap in the ladder, 
allowing control sequences to be identified. 
	
2.4.9.1 	Preparation of DNA probe 
The DNA probe used for DNase I Footprinting was the 0.5 kb Cheviot PrP 
gene promoter fragment as determined by O'Neill et al. (2003). This fragment 
contains the PrP gene 5'UTR from position 5226 to 5665, exon I from 5666 to 5717, 
and part of intron I from 5718 to 5748, using the numbering of the Suffolk PrP gene 
(GenBank accession number = U67922). This fragment was cleaved from the 
plasmid pNPU-110 with HindIII and EcoRI restriction enzymes (Section 2.2.1) to 
release a 526 bp fragment with 5' overhanging ends, which was agarose gel purified 
(Section 2.2.6). 
2.4.9.2 	Dephosphorylation of 5' ends 
The 5' overhanging ends of the DNA probe were dephosphorylated using calf 
intestinal alkaline phosphatase (ClAP) (Promega, UK) in the following reaction: 10 
jtl of lox ClAP buffer (Promega, UK), 3 pmol ends of DNA probe, 2 p.1 of ClAP 
(Promega, UK) and dH20 to a total volume of 100 p.1. The reaction was incubated at 
37 °C for 30 minutes, a further 1 p.1 of ClAP (Promega, UK) was added and the 
incubation continued for a further 30 minutes. The reaction was stopped by the 
addition of 2 j.il of 0.5 M EDTA and the sample was heated at 65 °C to inactivate the 
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CLAP. The DNA probe was extracted by the addition of 90 jil of 
phenol/chloroformlisoarnyl alcohol (25:24:1), the sample was vortexed and spun at 
full speed for 5 minutes and the upper aqueous layer was transferred to a fresh tube. 
The sample was then ethanol precipitated (Section 2.2.11), air dried and dissolved in 
20 il dH20. 
	
2.4.9.3 	Labeling (32P) and digestion of probe DNA 
The DNA probe (Sections 2.4.9.1-2.4.9.2) was radiolabeled with [y- 32P]ATP 
using T4 PNK in the following reaction: 10 j.tl  DNA probe (3 pmol ends of 0.5 kb 
promoter DNA), 2 tl lox kinase buffer (Promega, UK), I tl T4 PNK (Promega, 
UK), 1 pi [y- 32P]ATP (3,000Ci/mmol, lOmCi/ml, Amersham, UK) and dH 20 to a 
total volume of 20 p1. The reaction was incubated at 37 °C for 30 minutes, an 
additional I tl of T4 PNK was added and the incubation was continued for a further 
30 minutes. The labeled DNA probe was then digested for 1 hour at 37 °C with XbaI 
(Section 2.2.1) to remove the 3' end 32P-label, leaving a 526 bp fragment. The 
digested sample was then phenol extracted (Section 2.4.9.2) and ethanol-precipitated 
(Section 2.2.11). The DNA probe was air dried, dissolved in 100 p1 of TE (pH 7.4) 
and stored at 40  C. The radiolabeled probe was then counted in a 1.5 ml 
microcentnfiige tube using a Beta Scout 2007 liquid scintillation tester (Perkin-
Elmer, USA). Specific activity of the 0.5 kb promoter fragment was between 1 x 10 6 
and 2 x 106  cpmlpmol of DNA. 
2.4.9.4 	DNase I Footprinting reaction 
Two separate reactions were set up for a basic footprint, Reaction I contained 
only the DNA probe and was used to obtain an unprotected DNA ladder. Reaction 2 
contained all the components of Reaction I along with the nuclear extract. The two 
reactions were treated identically throughout. Reactions were prepared as follows: 
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Reaction I (Negative control) 	 Reaction 2 (Positive control) 
20jil Nuclease free water 	 18 j.tl Nuclease free water 
25i1 Binding buffer (Promega, UK) 	 25 i.tl Binding buffer (Promega, UK) 
5 i1 DNA probe (0.15 pmoll 80,000 cpm) 	5 il DNA probe (0.15 pmoll 80,000 cpm) 
Qiii Nuclear extract (NE) 	 2 W NE 
50 .tl Total volume 	 50 .t1 Total volume 
The reactions were mixed and incubated on ice for 10 minutes. To each 
reaction 50 .tl room temperature Ca 2 /Mg2 solution (Promega, UK) was added, 
samples were mixed and incubated at room temperature for one minute. Three ti 
(0.15 units) of diluted RQ1 RNase-Free DNase I (Promega, UK) was added, and the 
reactions were mixed and incubated at room temperature for exactly one minute. The 
reactions were immediately terminated by the addition of 90 tl of 37 °C stop 
solution (Promega, UK). The samples were phenol extracted (Section 2.4.9.2), 
ethanol precipitated (Section 2.2.11) and air-dried, before being dissolved in 10 tl 
Loading Buffer (Promega, UK). Finally, the samples were denatured at 95° C for 2 
minutes, chilled on ice and 5 il was loaded onto a 4 % sequencing gel (Section 
2.3.4). 
2.5 General methods for cell culture 
2.5.1 Ovine immortalised cell cultures - sA80BR and pA80BR 
Immortalised ovine cell cultures, derived from brain tissue from NPU 
Cheviot sheep of the VRQ/VRQ genotype (scrapie susceptible sheep - sA80BR) and 
the ARQ/ARR genotype (scrapie resistant sheep - pA80BR), were available at the 
NPU (Figure 2.1). Cell cultures were produced from NPU Cheviot sheep by Dr Huw 














Figure 2.1 Ovine neuronal and peripheral cell cultures 
Photographs of the cell lines were kindly provided by Dr. Gerry O'Neill, NPU. sA80BR 
sheep neuronal cell line derived from scrapie susceptible sheep of genotype VRQNRQ. 
pA80BR = sheep neuronal cell line derived from scrapie resistant sheep of genotype 
ARQ/ARR, lS1201-iv = Liver cell line, lS12OCer = Cerebellum cell line, derived from an 
Icelandic sheep of the genotype ARQ/ARQ shown to be susceptible to scrapie in Icelandic 
sheep. Magnifications are given in the bottom right corner of each photograph. 
2.5.2 Ovine primary cell cultures - IS12OCer, lS1201-iv, lS12OMed & 
lSl2OKid 
A series of primary ovine cell cultures were produced by Dr Gerry O'Neill 
from Icelandic sheep tissue (Ovis brachyura borealis pall). The sheep used was one 
and half years old and its scrapie genotype was ARQIARQ, shown to be scrapie 
susceptible in Icelandic sheep. Cell cultures included a cerebellum derived cell 
culture (IS12OCer), a liver derived cell culture (IS12OLiv), a kidney derived cell 
culture (IS12OKid) and a brain medulla derived cell culture (ISl20Med) (IS12OKid 
not shown, Figure 2.1). 
2.5.3 Characterisation of the ovine brain derived cell cultures 
Marshall (2000) charactensed the ovine brain derived cell cultures, sA80BR, 
pA80BR and IS I 2OCer. Antibodies specific for astrocytes/glia (anti-glial fibrillary 
acidic protein (GFAP, Sigma G-3893)), neurons (anti-neurofilament 200 (N200, 
Sigma N-0142)) and fibroblasts (anti-fibronectin (Sigma F-3648)) were used to 
characterise the cell types present in the ovine brain cell cultures. These experiments 
indicated that the immortalised cell cultures, sA80BR and pA80BR, contained 
glialastrocytes and neurones and were free of fibroblast cells. The primary Icelandic 
cell culture IS12OCer reacted positively for neuronal cells, and negatively for 
glialastrocytes and fibroblast cells. 
2.5.4 Culturing of ovine neuronal cell lines sA80BR and pA80BR 
Cells were grown in Nerve growth factor (NGF) complete medium (NCM) 
which consisted of 500 ml Dulbecco's Modified Eagle's Medium (MEM) + 
Glutamax (Invitrogen, UK), 0.5 ml NGF (Munne 7-s-NGF, Sigma, UK, 10 ng/ml), 
50 ml fetal calf serum (Globeparm, UK) and 5 ml penicillin/streptomycin 
(Invitrogen, UK, 100 U/mi). Cells used for the studies in this thesis were of low 
passage number (between passage number 10-20). Cells were incubated at 33 °C 
(due to being immortalized with a temperature-sensitive form of SV40 Large T 
antigen) with 5 % CO2 in 75 cm 2 flasks (Corning, UK) until confluency was reached. 
Cultured cells were fed every 2-3 days with fresh NCM. 
2.5.5 Culturing of murine neuroblastoma cell line N2a and Icelandic 
sheep primary cell lines 
The cell growth requirements of the N2a and the Icelandic sheep primary cell 
lines differ from those of the ovine neuronal cell lines (sA80BR and pA80BR, 
Section 2.5.1). These cells were incubated at 37 °C with 5 % CO2 in 75 cm  flasks 
and cultured in standard complete medium (SCM) which has the same composition 
as NCM with the exception of NGF. Icelandic sheep cell lines were of low passage 
number (between passage number 10-20) and the murine N2a cells were of passage 
number 100-200. Cultured cells were fed every 2-3 days with fresh SCM. 
2.5.6 Handling cells for passage 
Culture medium was removed and the cells were rinsed twice with pre-
warmed (37 °C) sterile PBS (Invitrogen, UK). Five hundred p.l trypsin/versene 
solution (Invitrogen, UK) was added and the flask was rocked gently for 1 minute, or 
until all the cells had detached from the base of the flask. Ten ml of fresh culture 
medium was added to the cells to inactivate the trypsin. An aliquot of the trypsinised 
cells was transferred to a fresh flask along with 8 ml of fresh culture medium and the 
cells were cultured as described previously (Sections 2.5.1 - 2.5.2). 
2.5.7 Calculating cell counts using a haemocytometer 
Cells were harvested (Section 2.5.3) and re-suspended in 2 ml of the 
appropriate culture medium (Sections 2.5.1 - 2.5.2). The haemocytometer slide and 
coverslip were cleaned with 70 % ethanol. The coverslip was lightly moistened and 
placed on top of the haemocytometer before pressing the coverslip into position. An 
aliquot of the cell suspension was transferred to the haemocytometer using a glass 
Pasteur pipette (Bilbate, UK) and the cells were allowed to settle before counting 
began. Cells were counted in 10 primary squares using the following rules: 
If too many cells were present to count, a 1:2 dilution in PBS was performed. 
The middle of the triple lines separating each primary square was regarded as the 
boundary. Cells that touched the upper or left boundaries were included, those 
that touched the bottom or right boundaries were excluded. 
When the haemocytometer was loaded, the volume of the cell suspension that 
occupied one primary square was 0.1 mm  (1.0 mm 2 x 0.1 mm) or 1.0 x10 ml. 
Counting 10 primary squares gave the number of cells within 1.0 mm 3 (10 x 0.1 
mm 3 ) or 1 x 10 ml. Total cell concentration in the original suspension (cells/ml) 
was calculated by the following equation: 
Cells/ml = total count x 1000 x dilution factor 
2.5.8 Preparing cells for PrPC  protein analysis 
Cultured cells for PFPC  protein analysis were cultured in six well plates 
(Coming, UK). Following the inactivation of trypsin during passage (Section 2.5.3) 
500 tl of cell suspension was transferred to each well of a six well plate. A further 
1.5 ml of fresh culture medium was added and cells were cultured as described 
previously for 48 hours or until confluency was reached (Sections 2.5.1 - 2.5.2). 
2.5.9 Preparation of cell lysates from cultured cells and tissue samples 
Three different methods of cell lysate production were utilised throughout 
this thesis. The protocols for these methods are described below. In all cases the 
culture medium was removed from the cells cultured in six well plates (Section 
2.5.5) and cells were washed once in 2 ml ice cold PBS. 
	
2.5.9.1 	Preparation of murine tissue for protein extraction 
Whole mouse brain samples were homogenised in 250 tl ice cold PBS. An 
aliquot of 75 p.1 was removed from this homogenate and further diluted in 500 p.1 ice 
cold PBS, cells were then isolated by centrifugation at 1,000 g for 10 minutes. 
Protein extracts were produced using either the RCLB, M-per or Mem-per methods 
described below. 
2.5.9.2 	Reporter cell lysis buffer (RCLB) method 
A sufficient volume of IX RCLB (Promega, UK) was added to cover the 
cells (-- 400 p.1 for a single well of a six well plate) along with 50 p.1 Complete Mini - 
proteinase inhibitor solution. The plate was rocked gently for 15 minutes at room 
temperature. The wells were scraped using a sterile cell scraper (Corning, UK), 
ensuring that all visible cell debris was collected and using a pipette the cell lysate 
was transferred to a pre-chilled 1.5 ml microcentrifuge tube and placed on ice for no 
more than two minutes prior to centrifugation. The cell lysate was cleared of cell 
debris by centrifugation at 1,000 x g for 10 minutes and the supernatant containing 
Ef 
the protein fraction (-500 tl) was transferred to a fresh, pre-chilled microcentrifuge 
tube ready for immunoprecipitation (Section 2.7.3). 
	
2.5.9.3 	Mammalian protein extraction reagent (M-per) method 
To each well, 400 .i1 of M-per (Perbio, UK) and 50 111 Complete Mini - 
proteinase inhibitor solution were added drop-wise onto the cells and the plate was 
shaken gently at room temperature for 5 minutes. The cell lysate (.- 500 p1 per well) 
was transferred to a pre-chilled 1.7 ml microcentrifuge tube (Coming, UK) and spun 
at 1,000 x g for 10 minutes at 4 °C to remove cell debris. The supernatant containing 
the protein fraction (- 500 tl) was transferred to a fresh pre-chilled microcentrifuge 
tube ready for immunoprecipitation (Section 2.7.3). 
2.5.9.4 	Mammalian membrane protein extraction reagent (Mem- 
per) method 
To each well, 500 p1 of sterile PBS (Invitrogen, UK) was added and the cells 
were scraped using a sterile cell scraper (Corning, UK). Scraped cells were 
transferred to a pre-chilled 1.7 ml microcentrifuge tube and spun at 3,000 x g for 2 
minutes in a pre-chilled rotor. The supernatant was discarded and the cell pellet was 
re-suspended in 150 tl of Mem-per Reagent A (Pierce, UK) and incubated at room 
temperature for 10 minutes with occasional vortexing. During this incubation 50 .tl 
of Complete Mini - proteinase inhibitor solution was added and the solution was 
placed on ice. Mem-per Reagent C was diluted in a ratio of 2:1 with Mem-per 
Reagent B and placed on ice. Reagent C (450 tI) was added to the cell lysate and 
placed on ice for 30 minutes with vortexing every 5 minutes. The tube was spun at 
10,000 x g for 3 minutes at 4 °C and the supernatant was transferred to a fresh tube. 
The supernatant was incubated at 37 °C for 10 minutes to separate the membrane 
protein fraction. The tube was spun at 10,000 x g for 2 minutes at room temperature 
to isolate the hydrophobic fraction. The bottom layer containing the membrane 
proteins ( 250 p1) was then transferred to a fresh pre-chilled microcentrifuge tube 
ready for immunoprecipitation (Section 2.7.3). 
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2.5.10 Determination of total protein concentration in cell lysates - Bio-
Rad protein assay II 
Total protein concentration of cell extracts (Section 2.5.6) was determined 
using the Bio-Rad protein assay II, following the manufacturer's protocol. A protein 
standard curve was produced by diluting the protein standard (1.4 mg/ml) as follows: 
1.4 mg/ml = Standard 
1.05 mg/ml = 25 p.1 dH20 + 75 p.1 standard 
0.7 mg/ml = 50 p.1 dH20 + 50 p.1 standard 
0.35 mg/ml = 50 p.1 dH20 + 50 p.1(0.7 mg/ml solution) 
0 mg/ml = 100 p.1 dH20 
A protein standard curve was prepared as follows: 
1 = Standard (1.4 mg/ml) 
2 = Standard (1.05 mg/ml) 
3 = Standard (0.7 mg/ml) 
4 = Standard (0.35 mg/ml) 
5 = Blank (0 mg/ml) 
The protein assay was performed, according to the manufacturer's 
instructions, briefly, 100 p.1 of the appropriate standard (or dH 20 for the blank 
sample) and 5 ml diluted dye reagent was added to each tube. Samples were 
incubated at room temperature for 1 hour, 1 ml aliquots were removed and the 
absorbance at 595 nm was read on a spectrophotometer. A standard curve was 
plotted of absorbance against protein concentration and the equation of the curve was 
determined using the Microsoft Excel package (Microsoft, USA). The reaction 
detailed above was then repeated for the protein samples (cell extracts) and total 
protein concentration present in the extracts was determined from the absorbance 
value at 595 imi using the equation of the standard curve. 
2.5.11 Total RNA extraction from cultured cells with RNAzol reagent B 
Total RNA was extracted from cultured cells using the RNAzoI B reagent 
(AMS Biotechnology, UK). Cells were cultured in six well plates (Section 2.5.5), 
culture medium was removed and the wells were washed twice in 2 ml ice-cold PBS. 
One ml of RNAzo1 B reagent was added to each well, the cells were disrupted by 
gentle rocking and the RNA was solubilised by pipetting. The RNA solution was 
transferred to a pre-chilled 1.5 ml microcentrifuge tube, 0.2 ml chloroform (BDH, 
UK) was added, the solution was mixed by vortexing and incubated on ice for 15 
minutes. The sample was centrifuged at 12,000 x g for 15 minutes at 4 °C and the 
upper aqueous layer was transferred to a fresh pre-chilled microcentrifuge tube. The 
RNA was precipitated in an equal volume of iso-propanol and incubated for 5-10 
minutes at room temperature. The sample was spun at 12,000 x g for 5 minutes at 4 
°C and the supernatant was discarded. The RNA pellet was washed in 1 ml of 75 % 
ethanol, spun as before, air dried, re-suspended in 75 % ethanol and stored at —20 °C 
until required. 
2.5.12 Freezing cells for long term storage 
Trypsinised cells (Section 2.5.3) were collected into a 15 ml plastic centrifuge 
tube, centrifuged at 1,000 x g for 2 minutes and the supernatant discarded. The cell 
pellet was re-suspended in 3 ml freezing down medium and 1 ml aliquots of the re-
suspended cells were transferred to 1.8 ml cryovials (Corning, UK). The cryovials 
were then wrapped in tissue paper and stored overnight at - 70 °C. The following 
day the cryovials were transferred into liquid N2 until required. 
2.5.13 Thawing cells from liquid nitrogen storage 
The cryovial containing the frozen cells (Section 2.5.9) was removed from 
liquid N2 and the cells were thawed slowly in a water bath at 37 °C. To prevent 
contamination of the contents the outside of the cryovial was sprayed with 70 % 
ethanol. The contents of the cryovial were transferred to a clean 15 ml plastic 
centrifuge tube and 10 ml of culture medium was added to dilute out the dimethyl 
suiphoxide (DMSO). The cells were pelleted at 1,000 x g for 2 minutes and the 
supernatant was discarded. The cell pellet was re-suspended in 10 ml of fresh culture 
medium and transferred to a 75 cm 2 flask. The cells were then cultured as described 
previously (Sections 2.5.1 - 2.5.2). 
2.5.14 Testing cell cultures for presence of mycoplasma 
All cell cultures were tested for the presence of mycoplasma contamination 
on a three-monthly basis and always found to be negative. This test was carried out 
using the Mycoplasma Plus PCR primer set (Stratagene, UK) following the 
manufacturer's instructions. 
2.6 General methods for transient transfection 
2.6.1 Preparation of DNA for transfection 
DNA used for transfections was purified using CsCl gradients (Section 
2.2.12). For transfections an optical density (OD) ratio at 013 260 :013280 of 
approximately 1.9 indicating a good level of purity was used, with a final DNA 
concentration of approximately 1 mg/ml (Section 2.2.13). 
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2.6.2 Control vector - pSV--galactosidase 
The control vector pSV-3-galactosidase (Promega, UK) was used to optimise 
transfection conditions and as a control for transfection efficiency by analysing 
reporter gene activity in transfected cell lysates. It was assumed that both the reporter 
vector and the transfected DNA would be transfected with equal efficiency in a 
single reaction, but that different cell populations would be transfected at varying 
efficiencies. Therefore measuring the amount of -ga1actosidase activity in the 
transfected cell extracts allowed the level of efficiency to be determined for 
individual cell populations. The volume of each cell lysate used for protein analysis 
was then adjusted according to the efficiency of the transfection reaction (Section 
4.2.3) 
2.6.3 Beta-galactosidase enzyme assay 
The -ga1actosidase enzyme assay system (Promega, UK) was used to 
measure -galactosidase activity in the transfected cell lysates. A 250 tl aliquot of 
the cell extract was added to 250 p1 of 2X assay buffer, hixed and incubated at 37 °C 
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for 30 minutes. The reaction was stopped by the addition of 500 .t1 of 1M NaCO3 
and the colour reaction was measured by reading the absorbance at 420 rim. The 
absorbance value at 420 rim was compared to a standard curve (Section 2.6.4) 
prepared using a -galactosidase standard (Promega, UK), to determine the 
concentration of-galactosidase in the cellular extract (Section 2.6.6). 
2.6.4 Preparation of a -gaIactosidase standard curve 
A -Galactosidase standard curve was prepared using a f3-galactosidase 
standard (1 U/tl, Promega, UK). The standard was diluted in the appropriate cell 
lysis reagent i.e. M-per (Pierce, UK), Mem-per (Pierce, UK), or RCLB (Promega, 
UK). Ten .tI of -galactosidase standard (1 U/pi) was diluted in 990 tl of the 
appropriate lysis buffer and mixed. Ten l of this 1:100 dilution was further diluted 
in 990 .tl of lysis buffer and mixed to create a 1:10,000 stock solution. A range of 
dilutions was prepared between 0 and 6 milli-units of 3-galactosidase using the 







0 0 150 
2 1 10 140 
3 2 20 130 
4 3 30 120 
5 4 40 110 
6 5 50 100 
7 6 60 90 
Table 2.4 	/3-ga/act osidase standard curve dilutions 
Table details the preparation of the dilutions of the fi-galactosidase enzyme for the standard 
curve used to determine the level of /3-ga/actosidase activity in cell lysates following transient 
co-transfection with /3-galactosidase DNA and ovine PrP mini-gene DNA. f3-galactosidase 
stock solution was diluted with the above detailed volume of the appropriate cell lysis 
reagent (M-per or Mem-per) to produce the standard solutions used for the standard curve. 
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The standards were processed using the -galactosidase assay (Section 2.6.3) 
and the absorbance values at 420 nm were determined for each standard using a 
spectrophotometer. Using these values a standard curve was plotted of protein 
concentration against absorbance and the equation of the line was determined using 
the Microsoft Excel package (Microsoft, USA). 
2.6.5 Dendrimer technology - Superfect 
Superfect reagent (Qiagen, UK) was chosen as the transfection agent for the 
ovine neuronal cell lines as previous work had shown that it was the most efficient 
method of transfecting the ovine cell lines (Marshall, 2000). Superfect consists of 
activated dendrimer molecules with a defined spherical shape. Branches terminating 
in charged amino groups radiate out from a central core and these are able to interact 
with the negatively charged phosphate groups of nucleic acids. The DNA is 
packaged into compact structures of uniform size and defined shape, therefore 
optimising the entry of DNA into the cell. 
2.6.6 Superfect transfection reagent protocol 
Cells were transfected with Superfect transfection reagent according to the 
manufacturer's instructions. Cells were split into six well plates 2-3 days prior to 
transfection to ensure that they would be 60-80 % confluent on the day of 
transfection (Section 2.5.5). CsCl prepared plasmid DNA (Section 2.2.12) was 
diluted in TE buffer (pH 7.4) to the optimum concentration required for the cell line 
to be transfected (Section 2.6.7). To the diluted DNA, 100 tl growth medium 
containing no serum or antibiotics was added. The appropriate amount of Superfect 
reagent (Qiagen, UK) for the cell line used was added (Section 2.6.7), the solution 
was mixed and incubated at room temperature for 10 minutes to allow DNA-
dendnmer complexes to form. While the complexes were forming, the growth 
medium was removed from the cells in each well, the cells were washed twice with 
1 ml pre-warmed PBS (37 °C). At this stage 600 1.11 of growth medium, containing 
serum and antibiotics, was added to the DNA-dendrimer complex solution. The 
solutions were mixed by pipetting and immediately added drop-wise to the cells in 
gel 
each well. The cells were incubated as normal for 3 hours (Sections 2.5.1 - 2.5.2), 
after which time the remaining complexes were removed and fresh culture medium 
(containing serum and antibiotics) was added. The cells were then incubated as 
normal (Sections 2.5.1 - 2.5.2) until harvested for protein analysis (Section 2.5.3), 
between 24-72 hours later. 
2.6.7 Optimisation of transfection conditions for individual cell lines 
Superfect transfection conditions for the ovine cell lines were optimised using 
the following protocol and utilising the 3-galactosidase assay (Section 2.6.3). Cells 
were cultured as described in Section 2.6.6. DNA mastermixes (A, B & C) were 
prepared as described below: 
A = 4 jig -galactosidase DNA in 400 p.1 culture medium (no serum/antibiotics) 
B = 8 p.g -ga1actosidase DNA in 400 p.1 culture medium (no serum/antibiotics) 
C = 16 jig 3-ga1actosidase DNA in 400 p.1 culture medium (no serum/antibiotics) 
The DNA mastermixes were mixed by vortexing, incubated at room 
temperature for 5 minutes and centrifuged briefly at full speed. Eleven 0.5 ml 
microcentrifuge tubes were labelled (1-11) and pre-chilled on ice. One hundred p.1 of 
DNA mastermix A were placed into tubes 1-3, 100 p.1 of DNA mastermix B were 
placed into tubes 4-6 and 100 p.! of DNA mastermix C were placed into tubes 7-9. As 
controls 100 p.1 growth media (no serum/antibiotics) were placed into tubes 10 & 11. 
Superfect reagent was added to each tube as detailed in Table 2.5, the tubes were 
mixed by vortexing and incubated at room temperature for 10 minutes. 
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Table 2.5 	Quantities of Superfect added to each cell culture transfection 
reaction 
Shows the quantity (tl) of Superfect reagent added into each cell culture transfection 
reaction for the optimisation of the transfection conditions as used for each individual cell 
line. 
During this incubation the culture medium was removed from the cells and 
they were washed once in 2 ml ice cold PBS. Six hundred d of culture medium 
(containing serum and antibiotics) was added to each of the tubes (numbered 1-11), 
the contents of each of the eleven tubes were then added drop-wise to eleven of the 
twelve wells of the two six well plates. To the twelfth well 1 ml of culture medium 
(containing serum and antibiotics) was added. The six well plates were swirled 
gently to evenly distribute the culture medium and the cells were incubated as 
previously described (Sections 2.5.1 - 2.5.2) for 3 hours. The media was removed, 
the cells were washed in 2 ml ice cold PBS, 2 ml fresh culture medium (containing 
serum and antibiotics) was added and the cells were cultured as previously described 
(Sections 2.5.1 - 2.5.2) for a further 24 hours. Cells were harvested (Section 2.5.3), 
lysed (Section 2.5.6) and cell lysates were then analysed for -galactosidase activity 
using the j3-galactosidase assay (Section 2.6.3). The optimum amount of transfected 
DNA and Superfect to be added for each individual cell line was then determined. 
2.7 General methods for isolation of PrPC  from cell lysates 
2.7.1 Methanol precipitation 
For isolation of total protein from a 500 tl cell lysate (Section 2.5.6), nine 
times the sample volume of pre-chilled (-20 °C) methanol was added, the sample 
was mixed and incubated at —20 °C for at least one hour. Precipitated proteins were 
centrifuged at 1,000 x g for 10 minutes. The pellet was re-suspended in 30 .tl of 
NuPage sample buffer (Invitrogen, UK), 3 jtl sample reducing agent (Invitrogen, 
UK) was added and the sample was denatured at 70 °C for 10 minutes prior to 
electrophoresis (Section 2.8.1). 
2.7.2 Chloroform/methanol precipitation 
For isolation of total protein from a 500 .tl cell lysate (Section 2.5.6), 1.6 ml 
methanol, 0.8 ml chloroform and 1.2 ml dH20 was added to the 500 p.1 cell lysate in 
a 15 ml centrifuge tube (Coming, UK). The preparation was vortexed and spun at 
1,000 x g for 10 minutes. Pellets were re-suspended in 30 p.1 of NuPage sample 
buffer, 3 p.1 sample reducing agent (Invitrogen, UK) was added and the sample was 
denatured at 70 °C for 10 minutes prior to electrophoresis (Section 2.8.1). 
2.7.3 lmmunoprecipitation of PrPC  from cell lysates 
For the isolation of PrPC  from cell lysates the following immunoprecipitation 
method based on that described by Firestone & Winguth (1990) was developed. For 
isolation of PrPC  from a 500 p.1 cell lysate (Section 2.5.6), 1 p.1 of the appropriate 
precipitating antibody was added (Table 2.6) and incubated at 4 °C for 1 hour with 
end over end shaking on a SBI blood tube rotator (Stuart Scientific, UK). To the 
same tube 50 p.d bed volume of protein G sepharose (stored in PBS at 4 °C, 
Pharmacia Biotech, SE) was added and incubated at 4 °C with overnight with 
shaking to allow the formation of immuno-complexes. The immuno-complexes were 
collected by centrifugation for 25 seconds at full speed and the supernatant was 
discarded. The sample was re-suspended in I ml immunoprecipitation (IP) buffer 1 
We 
(0.05 M iris, 0. 15 M NaCl, I % nonidet P-40) and incubated for 20 minutes at 4 °C 
with end over end shaking. Immuno-complexes were again collected by 
centrifugation and the sample was re-suspended in 1 ml fresh IF buffer I and 
incubated as before. This procedure was repeated a further two times using [P buffer 
2 (0.05 M tris, 0.5 M NaCl, I % nonidet P-40) and then once using EP buffer 3 
(0.05M tris). The beads were collected as before and any last traces of the final wash 
from the walls and lid of the tube were blotted dry with tissue. The pellet was re-
suspended in 30 t1 of sample buffer and 3 jil of sample reducing agent was added. 
Samples were denatured by heating to 70 °C for 10 minutes, protein A sepharose was 
removed by centrifugation at full speed for 1 minute and the supernatant was 
analysed by electrophoresis (Section 2.8.1). 
2.7.4 Precipitating antibodies 
The PrP specific polyclonal antibodies 1A8 and I B3 (Farquhar, Somerville & 
Ritchie, 1989) were used as the major antibodies for immunoprecipitation studies. In 
addition to these a number of monoclonal antibodies (Jacquie Manser & Dr. Sandra 
McCutcheon, IAH Compton, unpublished) raised against both full length and 
truncated PrP' were analysed for their ability to precipitate PrPC  from a variety of cell 
lines (Table 2.6). In addition the anti-FLAG T11  monoclonal antibody M2 and an anti-
FLAG T11  polyclonal antibody were used to immunoprecipitate 3XFLAGTM tagged 
recombinant PrP (Table 2.6). 
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Antibody Epitope(s) Specificity Concentration Supplier  
and subclass  
lAS \lultiple Sheep, goat. mouse. I 	ig PI. Rabbit. lg(i Christine 
epitopes on PrP hamster, cattle, pig, cat Farquhar (NPU) 
and human  
1133 Multiple Sheep, goat, mouse, I .tg4tl, Rabbit, tgG Christine 
epitopes on PrP hamster, cattle, pig, cat Farquhar (NPU) 
and human  
AB 1 PrP C-terminal Sheep, hamster, cattle, 2 tg/1l S. McCutcheon 
region human and mouse  (IAH-Compton) 
AB2 PrP C-terminal Sheep, hamster, cattle, 2 .ig/.tl S. McCutcheon 
region human and mouse  (IAH-Compton) 
AB3 PrP C-terminal Sheep, hamster, cattle, 2 tg/tl S. McCutcheon 
region human and mouse  (IAH-Compton) 
AB4 PrP C-terminal Sheep and cattle 2 .tg4tl S. McCutcheon 
region  (IAH-Compton) 
AB5 PrP C-terninal Sheep and cattle, 2 	ig/.tl S. McCutcheon 
region human and mouse  (IAH-Compton) 
AB6 PrP C-terminal Sheep, hamster, cattle, 2 j.tg/j.d S. McCutcheon 
region human and mouse  (IAH-Compton) 
AB7 PrP C-terminal Sheep, hamster, cattle, 2 p.tg4tl S. McCutcheon 
region human and mouse  (IAH-Compton) 
AB8 PrP C-terminal Sheep, hamster, cattle, 2 .tg/1l S. McCutcheon 
region human and mouse  (IAH-Compton) 
BE 12 PrP N-terminal Human, hamster, cattle, 1.3 j.tg/tl, IgG I J. Manser 
region sheep, mouse  (IAH-Compton) 
AH6 PrP N-terminal Human, hamster, cattle, 1.4 1g/.tl, IgG2a J. Manser 
region sheep, mouse  (IAH-Compton) 
AG4 PrP N-terminal Human, hamster, cattle, 1.3 xg/il, lgG2b J. Manser 
region sheep, mouse  (IAH-Compton) 
M2 FLAG TM FLAG TM  sequence at 2-5 tg!il, IgG I Sigma-Aldrich 
monoclonal sequence any location on (Cat. No. 
DYKDDDDK recombinant protein  F3165), UK 
a-FLAG FLAG TM FLAG T"  sequence at I 	ig/sl Rabbit, IgG Sigma-Aldrich 
polyclonal sequence any location on (Cat. No. 
DYKDDDDK recombinant protein  F7425), UK 
Table 2.6 Antibodies used to immunoprecipitate PrP 
Details the antibodies used for the immunoprecipitation of endogenous and recombinant 
(3XFLAG tagged) PrP from cell cultures. Epitope, specificity, concentration and subclass of 
the antibodies is given where appropriate and when known, as is the source of the antibody. 
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2.8 General methods for analysis of PrPC  isolated from cell 
lysates 
2.8.1 SDS-PAGE and Western blot analysis of PrPC  isolated from cell 
culture extracts 
The following protocols were used as first described by Laemmli (1970) and 
Towbin, Staehelin & Gordon (1979). Denatured, immunoprecipitated cell culture 
extracts (Section 2.7.3) were loaded onto a pre-cast 4-12 % bis-tris gel (Invitrogen, 
UK). In addition 5 jd of molecular weight marker (Invitrogen, UK) was loaded on 
the gel to give an approximation of band size, and 0.0Ig of scrapie positive sheep 
brain sample was also loaded as a PrP sc positive control (Angie Chong, NPU). The 
gel was run for 50 minutes at 200 V constant/I 10-125 mA on an XCe11 Surelock Gel 
System (Invitrogen, UK). Whilst the gel was running two (6 x 8.5 cm) pieces of IF 
filter paper (Munktell, SE) were cut and soaked in transfer buffer (Invitrogen, UK) 
along with 5 foam blotting pads (Invitrogen, UK). One piece (6 x 8.5 cm) of 
Inimobilon-P PVDF transfer membrane (Millipore, UK) was soaked in methanol for 
5-10 seconds, washed in distilled water for 2 minutes and soaked in transfer buffer 
for 5 minutes. Once the gel run was completed the gel cassette was disassembled 
and the foot and wells of the gel were removed with a gel knife. A piece of pre-
soaked filter paper was placed on top of the gel, the gel was turned over and the pre-
soaked PVDF was placed on top of the gel and a further piece of filter paper was 
then placed on top of the PVDF. The gel sandwich was carefully placed into the 
XCe11 II blot module (Invitrogen, UK), sandwiched on either side by two pre-soaked 
blotting pads and a further blotting pad was added to ensure a tight fit. The XCell II 
blot module was placed into the XCell Surelock cell and filled with 250 ml of 
transfer buffer (Invitrogen, UK), the outer chamber was filled with 800 ml dH20 and 
protein samples were transferred to the PVDF membrane at 30 V constant /170 mA 
for 1-1.5 hours. The gel sandwich was disassembled carefully and the PVDF blot 
was removed with clean tweezers, washed in methanol for 5 seconds and left to dry 
in a fume cabinet for 10-15 minutes at room temperature on a piece of Whatman 
3MM filter paper. The blot was re-wetted with methanol, washed with water and 
washed twice in TBS. The blot was blocked with 25 ml of I % blocking solution 
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(Roche, UK) at room temperature for 1 hour with shaking on a Belly Dancer (Stovall 
Life Sciences, USA). The primary antibody 6H4 (Section 2.8.2), diluted in 1 % 
blocking solution (1:10,000 dilution, Prionics, CH) was added and incubated 
overnight at room temperature with shaking. The blot was washed twice for 10 
minutes with 25 ml of 0.5 % blocking solution, then the secondary antibody (Section 
2.8.3), diluted in 0.5 % blocking solution (1:25,000 dilution, Jackson Immuno-
research Lab Inc, USA) was added and incubated at room temperature for 60 minutes 
with shaking. The blot was washed for 1 hour with four changes of TBST (20 ml) 
and finally rinsed with water for 90 seconds. The blot was overlaid onto pre-mixed 
detection reagent (Roche, UK), incubated at room temperature for 60 seconds, excess 
detection reagent was drained and the blot was placed between two pieces of 3M 
transparent film (Fisher, UK). The blot was exposed to Kodak XAR-5 film (Roche, 
UK) for 30 seconds, 3 minutes and 10 minutes respectively. 
2.8.2 Primary antibodies 
At the time of writing no antibody was available that could reliably 
distinguish between PrP' and PrP. In addition, most antibodies will cross-react with 
PrP protein from two or more species, due to the high level of conservation between 
PrP molecules of different species. The commercially available monoclonal antibody 
6H4 (Prionics, CH) was used as the major primary antibody for chemi luminescence 
blotting throughout this thesis. This antibody shows good specificity to PrP from 
humans, cattle, sheep, mouse, hamster, mink and a variety of primates (Table 2.7). In 
addition the FLAG specific M2 antibody was used to detect 3XFLAGTM tagged 
recombinant PrP (Table 2.7). 
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Antibody Epitope (s) Specificity Concentration 
and subclass  
Supplier  
M2 Flag"' sequence FLAGTM sequence at 2-5 pgvpl, IgGi Sigma- 
monoclonal DYKDDDDK any location in Aldrich. UK 
recombinant protein (Cat. No. 
F3165) 
6H4 DYEDRYYRE Human, cattle, sheep, I 	ig/.tl, IgG I Prionics, 
rabbit, mink, mouse, Switzerland 
hamster, rat and a (Cat. No. 01- 
variety of primates  010) 
Table 2.7 	Primary antibodies 
Details the primary antibodies used for the Western blot detection of endogenous and 
recombinant (3XFLAG tagged) PrP from cell cultures. Epitope, specificity, concentration and 
subclass of the antibodies are given along with the source. 
2.8.3 Secondary antibody 
The secondary antibody used in these studies was a peroxidase conjugated 
affinipure rabbit anti-mouse IgG (Stratech, UK). This antibody was used for the 
detection of primary antibody bound to PrP following chemiluminescence blotting 
(Table 2.8). 
Antibody Epitope (s) Specificity Concentration Supplier 
Peroxidase Heavy chains on Mouse but may 0.8 ig/il Jackson Immuno- 
conjugated mouse IgG and also react with Research 
affinipure rabbit light chains on other species. Laboratories, USA 
anti-mouse IgG most mouse 
imniunoglobulins. 
Table 2.8 Secondary antibody 
Details the secondary antibody used for the Western blot detection of endogenous and 
recombinant (3XFLAG tagged) PrP from cell cultures. Epitope, specificity and concentration 
is given along with the source. 
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2.8.4 Optimisation of primary and secondary antibody blotting 
conditions using dot blots 
In order to determine the optimum dilution of primary antibody used for 
Western blotting, six single strips (6 cm x 4 cm) of nitrocellulose membrane 
(Schleicher & Schuell, DE) were prepared, and each strip was divided into six 
sections with a pencil. All of the strips were soaked in TBS for 2 minutes, then kept 
moist by placing them onto a pre-soaked bed of filter paper (3MM, Whatman, UK). 
Six serial dilutions of the antigen (3XFLAGTM-BAP fusion protein, Sigma-Aldrich, 
UK) were produced in TBS (I pg to 10 pg). A 1.tl aliquot of each antigen dilution 
was carefully spotted onto the divided nitrocellulose membrane, and this was 
repeated for all six nitrocellulose strips, which were allowed to dry at room 
temperature for 5 minutes. Each strip was blocked for 1 hour in I % blocking 
solution at room temperature. Five serial dilutions of the primary antibody (M2 anti-
FLAG TM,  Sigma-Aldrich, UK) were produced (1:500, 1:1,000, 1:2,000, 1:5,000, 
1:10,000) in I % blocking solution. One strip was not incubated in primary antibody, 
instead it was incubated in TBST to provide a background control. The remaining 
five strips were each incubated in one of the primary antibody dilutions at room 
temperature for 2 hours, with constant shaking. All six strips were washed briefly 
three times in TBST, then incubated with the secondary antibody (Section 2.8.3; 
1:20,000) at room temperature for 1 hour. The strips were washed five times in 
TBST, and samples were detected as described in Section 2.8.1. 
In order to determine the optimum dilution of the secondary antibody, the 
procedure described above was repeated, however, the optimum primary antibody 
dilution determined above was used for all six strips. Five serial dilutions of the 
secondary antibody (Section 2.8.3; 1:50,000, 1:40,000, 1:25,000, 1:20,000, 1:10,000) 
were produced and five of the six strips were each incubated in one of the secondary 
antibody dilutions, the remaining strip was not incubated in secondary antibody, 
instead it was incubated in TBST to provide a background control. Samples were 
then detected as described in Section 2.8.1. 
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Chapter 3: Development of techniques for the 
extraction and analysis of PrPC  from cell culture 
extracts and tissue samples 
3.1 Introduction 
The detection of PrP mRNA has been used to determine the level of PrP gene 
expression, however, it may not give an accurate picture of the cellular level of PrP' 
(Caughey etal., 1988). For example, Gygi, Rochon, Franza etal. (1999) showed that 
for certain genes in yeast, mRNA and protein levels varied by up to 20-fold. 
Furthermore, Ford et al. (2002) showed that although the level of PrPC  expression 
varies between different cell-types in the brain, the level of PrP mRNA remains high, 
even in neurones which showed no detectable PrPC.  The authors concluded that the 
steady state level of PrP' is primarily controlled in a post transcriptional manner, and 
that this is probably regulated by differences in protein trafficking or degradation. As 
such, the cellular level of PrP mRNA could be high in comparison to the level of the 
PrPC protein because of the relatively short half-life of PrPC  (3-6 hours) and the 
detection of PrP mRNA may not necessarily reflect the actual level of PrP' protein 
(Borchelt et al., 1990, Caughey, 1993, Pfeifer, Bachmann, Schroder et al., 1993). 
Therefore, the determination of PrP gene activity via mRNA analysis alone may not 
be sufficient. In order to obtain a more accurate picture of ovine PrP gene expression, 
it is important to be able to isolate and quantify the level of endogenous PrP' from 
cell culture extracts and tissue samples. 
The isolation of PrP from tissue samples is a well-established technique 
(Hope et al., 1986), however, methods for the isolation of PrP' protein are less well 
defined (Pan, Stahl & Prusiner, 1992). Methods used for the isolation of PrPSC  tend to 
use very stringent techniques that would easily degrade PrP'. By definition PrP' is far 
less stable than PrP and is easily degraded, for example, PrPC  is sensitive to 
digestion by proteinase K (PK), whilst PrP sc is partially resistant to PK digestion 
(Oesch et al., 1985). In addition, the half-life of PrPC  has been shown to be much 
shorter than that of PrPSC  (Caughey, 1993). The level of PrPC  expression has been 
shown to vary in different cell types and tissues, with the highest amounts of PrP' in 
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sheep in the brain (Caughey et al., 1988, Oesch et al., 1985). Within the brain the 
highest concentrations of PrPC  are found in neurones and astrocytes (Harris et al., 
1993, Raeber, Race, Brandner et al., 1997). In contrast, the lowest levels of PrPC  are 
found in peripheral tissues, such as the liver (Caughey et al., 1988, Horiuchi et al., 
1995, Moudjou, Frobert, Grassi et al., 2001). Previous studies showed that the 
immortalised ovine cell cultures sA80BR and pA80BR used in the work in this 
thesis, contained both neurones and glial cells (Sections 2.5.1 & 2.5.3), whilst the 
Icelandic sheep cerebellum derived cell culture IS12OCer (Sections 2.5.2 & 2.5.3) 
contained only neurons (Marshall, 2000), although the relative proportion of these 
cell types may vary and could be influenced by culturing conditions. Whilst it has 
been shown that of brain derived cells, neurones and astrocytes express the highest 
levels of PrPC,  the amount of PrPC  expression in glial cells remains unclear (Harris et 
al., 1993, Raeber et al., 1997). It was therefore necessary to determine the levels of 
endogenous PrP' expression in the ovine cell cultures prior to transient transfection 
studies with recombinant PrPC. 
For the study in this thesis it was decided to develop novel methods of cell 
lysis with the specific aim of extracting protein from ovine cell cultures. Marshall 
(2000) investigated a number of different methods of isolating endogenous PrPC  from 
cultured cells, including immunoprecipitation, detergent extraction, and 
chloroform/methanol extraction. Endogenous PrPC  could not be detected from 
cultured cell extracts (approximately 2 x 107  cells) without a prior concentrating step, 
and PrPC  was not detected in extracts prepared by detergent or chloroform/methanol 
extraction (Marshall, 2000). Immunoprecipitation was identified as being the most 
promising method of isolating endogenous PrPC  from the cultured cell extracts, 
although the overall level of PrPC  isolated was still low (Marshall, 2000). In order to 
detect endogenous PrP' it was important to develop a system that would be capable 
of isolating sufficient quantities of PrPC  from the available cultured cells. It was 
expected that once established the same system could be used to isolate recombinant 
PrPC from transiently transfected cell cultures, thus providing a method of assessing 
how well reporter gene constructs expressed recombinant PrP' (Chapter 4). 
Immunoprecipitation not only allowed the efficient isolation of the target antigen, it 
also resulted in the disposal of non-target protein from the sample, thus reducing 
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contamination, and provided a sample concentration step. It was therefore, decided to 
use immunoprecipitation to isolate and quantify the level of endogenous PrPC  in the 
cultured cells in these studies. 
For all of the samples used in this study cells cultured in single wells of a six 
well plate (approximately 2 x 105  cells per well) were used for the detection of 
endogenous PrPC.  The main benefits of this culture format are that samples are easier 
to handle, allowing faster treatment of cultures, thus providing a more uniform 
management of cells. In addition, it was expected that the possibility of variations in 
the number of cells used in each sample would be reduced with the six well plate 
format and this would prove to be very important when cultured cells were 
transiently transfected with ovine PrP mini-gene DNA (Chapter 4). In order to 
improve the overall PrPC  recovery from the cultured cells different methods of cell 
lysis specifically designed for mammalian cells (mammalian protein extraction 
reagent (M-per) and mammalian membrane protein extraction reagent (Mem-per), 
Pierce, UK) were utilised in these studies. Immunoprecipitation will only work if 
reliable antibodies specific for the target antigen are available. Two PrP specific 
polyclonal antibodies (1A8 & 1133) (Farquhar et aL, 1989) were used in this study 
and in addition, a range of monoclonal antibodies were tested for their ability to 
capture PrP' in inimunoprecipitation from cell extracts. The immunoprecipitation 
technique was further enhanced by utilising a range of different sepharose matrices 
and buffering systems. 
3.2 Results 
3.2.1 Development of methods for lysis of murine N2a cells 
Novel methods for isolating PFPC  were developed in the murine N2a cells. 
The main reason for using the N2a cells was that methods for lysing them had 
already been successfully developed, and could be used as a basis for the further 
development of PrPC  extraction techniques. Comparisons were made between the 
lysis reagent used in previous studies, i.e. reporter cell lysis buffer (RCLB, Roche, 
UK) (Marshall, 2000) and the mammalian protein extraction reagent system (M-per, 
Pierce, UK), in order to determine the effectiveness of each of the lysis reagents at 
lflr.1 
extracting PrP' from N2a cells. Cell extracts were prepared from N2a cells cultured 
to confluency in a single well of a six well plate (approximately 2 x 105  cells) using 
either RCLB or M-per (Section 2.5.9). The concentration of total protein within each 
lysate was determined by comparing the absorbance values at 595 nm obtained for 
each sample against a protein concentration standard curve (Section 2.5.10). The 
experiment was performed in total three times and the results were combined to 
provide a mean value for each protein extraction method (Figure 3.1). Cell extracts 
prepared with M-per contained on average 0.14 mg/ml total protein whilst those 
prepared with RCLB contained on average 0.019 mg/ml protein (Figure 3.1). A 
slight increase to 0.15 mg/ml was observed with M-per in the presence of proteinase 
inhibitors, whilst the level of total protein almost doubled to 0.035 mg/ml in cell 
extracts prepared with RCLB in the presence of the same inhibitor solution (Figure 
3.1). Therefore a four-fold increase in total protein concentration was observed with 
M-per, as compared to RCLB in the presence of proteinase inhibitors (Figure 3.1). 
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Figure 3.1 Comparison of M-per and RCLB protein extraction systems 
Two different cell lysis reagents mammalian protein extraction reagent (M-per) and reporter cell 
lysis buffer (RCLB) were used to isolate total protein from murine neuroblastoma (N2a) cells. 
Protein extractions were performed both with and without the addition of proteinase inhibitors. 
3.2.2 Immunoprecipitation of purified PrPSC  samples and endogenous 
P rPC from murine N2a cell extracts and their analysis by 
Chemiluminescence blotting 
To develop the immunoprecipitation technique ovine brain tissue samples 
positive for PrP' c were used. The main benefits of using PrPSC  samples are that they 
are of a consistent concentration, are more stable than PrPC  and give a strong reaction 
with the monoclonal antibody 6H4 in a Western blot. The polyclonal antibodies 1A8 
and 1B3 (Farquhar et al., 1989) were used to precipitate PrP (Section 2.7.4). 
Throughout this chapter precipitated samples were separated by SDS-PAGE and PrP 
was detected immunologically by Western blotting (Section 2.8) using the primary 
antibody 61­14 at a 1:10,000  dilution (Section 2.8.2) and a peroxidase conjugated 
affinipure rabbit anti-mouse IgG at a 1:25,000 dilution as the secondary antibody 
(Section 2.8.3). Proteinase K (PK) treated purified PrPSC  ovine brain samples were 
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Reekes et al. (1988) and used as positive control samples. The purified PrPSC  brain 
samples (100 mg starting wet brain tissue weight) were re-suspended in 100 tl SDS 
loading buffer and 20 tl (equivalent to 20 mg tissue) of this was loaded as a positive 
control. The positive controls were further diluted 1 in 3, and I in 9 with loading 
buffer, and again 20 l.tl (equivalent to 7 mg, or 2 mg of tissue, respectively) of the 
diluted sample was loaded. Non-immunoprecipitated purified PrPSC  samples were 
analysed by SDS-PAGE and Western blotting with 6H4 (Section 2.8), alongside 
purified PrP samples that had been diluted in TBST (400 jil) and 
immunoprecipitated (Section 2.7.3) as normal with the polyclonal antibody 1A8 






KEY: Lane 1, Purified PrP control sample treated with proteinase K (PK) (equivalent to 20 
mg brain tissue); Lane 2, 1 in 3 dilution of Lane I sample (equivalent to 7 mg brain tissue); 
Lanes 3-4, Purified PrPc  control samples, pre-adsorbed & immunoprecipitated with 1A8 
(equivalent to 20 mg brain tissue); Lane 5, Purified PrPSC  control sample (equivalent to 2 mg 
brain tissue); Lane 6, Purified PrPc  control sample (equivalent to 20 mg brain tissue) diluted in 
400 .t1 TBST, imrnunoprecipitated with lA8 without pre-adsorption step; Lane 7, Purified PrPc 
control sample (equivalent to 20 mg brain tissue) diluted in 400 pi TBST, pre-adsorbed with 
protein A sepharose & then immunoprecipitated with lA8. PrP positive controls used in lanes 
5 & 6 were from separate samples. 
Figure 3.2 PrPSc  positive controls: Immunoprecipitated & non- 
immunoprecipitated with 1A8 positive control samples 
Western blot shows PrP sc positive ovine brain samples either pre-adsorbed or non pre-
adsorbed with protein A sepharose and then immunoprecipitated with anti-PrP polyclonal 
antibody 1A8 and detected with anti-PrP monoclonal antibody 6H4 or loaded directly without an 
immunoprecipitation step. 
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PrP immunoprecipitated from purified PrPs  brain samples was not detected, 
however, PrPSC  was clearly visible in non-immunoprecipitated samples (Lanes 1-2, 
Figure 3.2). The possibility that this was due to the pre-adsorption of the extracts 
with protein A sepharose was investigated. Purified PrP brain samples were 
immunoprecipitated both with and without the initial pre-adsorption step (Section 
2.7.3), the results were separated by SDS-PAGE and analysed by Western blotting 
with 6H4 (Section 2.8) (Lanes 5-7, Figure 3.2). The pre-adsorption of the purified 
PrPSC samples with protein A sepharose resulted in the removal of PrP, probably via 
non-specific binding to the sepharose matrix (Lane 7, Figure 3.2). As a consequence 
of this observation, endogenous PrPC  isolated from N2a cell extracts prepared with 
M-per and RCLB was compared with methods omitting this initial pre-adsorption 
step. Finally, the PrP sample (equivalent to 20 mg brain tissue) diluted in 400 j.tl of 
TBST appeared to be successfully immunoprecipitated with I A8, indicating that the 
immunoprecipitation step had worked and had resulted in the concentration of PrP 
(Lane 6, Figure 3.2). 
Attempts were made to isolate endogenous PrP' from the murine N2a cell 
extracts using purified PrP' c brain samples as a positive control. During the 
extraction of PrP, the samples are treated with PK, which results in the isolation of 
a truncated form of PrP. Treatment with PK results in the degradation of 
endogenous PrPC,  which is sensitive to the action of proteinase K and when 
visualised on a gel, PrPC  is located at a higher molecular weight band than the 
truncated PrPSC  (compare lanes 7 (PrPC) & 8 (PrPSC),  Figure 3.3). In addition, PrP is 
normally seen on Western blots as three separate glycoforms, un-, mono- and di-
glycosylated PrP. Furthermore the mono-glycosylated band is actually a doublet as 
there are two mono-glycosylated forms of PrP. For each sample a single well of a six 
well plate of confluent N2a cells (approximately 2 x 10 5 cells) was lysed with RCLB 
(Section 2.5.9.2) or M-per (Section 2.5.9.3). Endogenous PrPC  was 
immunoprecipitated (Section 2.7.3) with the polyclonal antibody 1A8 and samples 
were separated by SDS-PAGE and analysed by Western blotting with 6H4 (Section 
2.8). Comparisons of the RCLB and M-per extraction systems showed that PrP' was 
successfully inimunoprecipitated with 1 A8 from N2a cell extracts prepared with M-
per (Lanes 5-7, Figure 3.3), however, no PrPC  was detected in the cell extracts 
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prepared with RCLB (Lanes 3 & 4, Figure 3.3). PrP was successfully detected from 
the diluted purified PrPSC  samples (Lanes I & 2, Figure 3.3). It was noted that only 
two of the three glyco forms of PrPC  and PrP were visible in the immunoprecipitated 
samples (Lanes 1, 2, 5, 6 & 7, Figure 3.3). It appears that the mono-glycosylated 
forms are missing in the immunoprecipitated PrPSC  samples (Lanes I & 2, Figure 
3.3), whilst the unglycosylated band appears to be absent in the imniunoprecipitated 
PrPC samples (Lanes 5-7, Figure 3.3). 
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KEY: Lanes 1-2, Purified PrPSC  control samples treated with PK (equivalent to 20 mg brain 
tissue) diluted in 400 p1 TBST & immunoprecipitated with 1A8; Lanes 3-4, N2a cell 
extracts prepared with RCLB, irnmunoprecipitated with 1A8; Lanes 5-7, N2a cell extracts 
prepared with M-per, immunoprecipitated with 1A8; Lane 8, Purified PrP control sample 
(2 mg). PrP is observed as three different glycoforms by Western blot analysis: Di- = di- 
glycosylated PrP, Mono- = mono-glycosylated PrP, Un- = un-glycosylated PrP. 
Figure 3.3 N2a cell extracts: PrPC  immunoprecipitated with 1A8 from 
extracts prepared with either M-per or RCLB 
Western blot shows endogenous PrPc  isolated from N2a cell extracts produced with either M-per 
or RCLB lysis agents and immunoprecipitated with anti-PrP polyclonal antibody 1A8. Samples 
were loaded alongside PrPSC positive ovine brain samples either immunoprecipitated with 1A8 or 
loaded directly without an immunoprecipitation step. Western blot was detected with the anti-PrP 
monoclonal antibody 61-14. Endogenous PrPC  can be clearly seen in the M-per samples but not at 
all in the RCLB samples. 
The use of two other anti-PrP antibodies, I B3 (polyclonal) and 6H4 
(monoclonal) as precipitating antibodies was investigated (Figure 3.4). As can be 
seen from Figure 3.4, the amount of PrP' detected in N2a cell extracts 
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immunoprecipitated with 1B3 was comparable to that observed with 1A8 (Lanes 1 & 
2, Figure 3.4). Again only the di- and mono-glycosylated PrPC  bands were present in 
extract immunoprecipitated with 1133 (Lane 2, Figure 3.4). No endogenous PrP' was 
detected in the raw N2a cell extract (30 p1 of total 400 p1 N2a extract loaded), 
indicating that the concentrating step provided by the immunoprecipitation reaction 
was required in order to be able to detect endogenous PrPC  from the N2a cell extracts 
(Lane 5, Figure 3.4). The use of 61-14 failed to isolate any detectable PrPC  from the 
N2a cell extracts, however, two additional bands were observed (25 and 50 kDa), 
these are presumably the light (LC) and heavy chains (HC) of the denatured 
precipitating 6H4 antibody (Lanes 3 & 4, Figure 3.4). These bands are visible due to 
cross reactivity of the precipitating antibody with the secondary antibody (rabbit anti-
mouse IgG). It will also react lightly with the rabbit derived polyclonal antibodies 
lA8 and 1B3, and this can be seen as much fainter bands at 25 and 50 kDa (Lanes 1 
& 2, Figure 3.4). The polyclonal antibody 1B3 is in very short supply, and so most of 
the immunoprecipitations in this study were carried out with I A8. 
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KEY: N2a cell extracts prepared with M-per and immunoprecipitated with the stated 
antibody. Lane 1, 1A8; Lane 2, 1133; Lanes 3-4, 6H4; Lane 5, 30 lal aliquot of a raw non- 
immunoprecipitated N2a cell extract (400 111 total) produced with M-per. PrPC  marked with 
red arrowheads. LC = light chain of precipitating antibody, HC = heavy chain. 
Figure 3.4 N2a cell extracts: PrPc immunoprecipitated from 
M-per extracts with 1A8, 1B3 or 6H4 
Western blot shows endogenous PrPC  isolated from N2a cell extracts prepared with M-per and 
immunoprecipitated with the anti-PrP polyclonal antibodies 1A8 or 1B3, or with the anti-PrP 
monoclonal antibody 6H4. Samples were then detected with 6H4. As can be seen endogenous 
PrPC was successfully isolated using the 1A8 and 1B3 polyclonal antibodies but not with the 6H4 
monoclonal antibody (Red arrowheads). 
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3.2.3 Analysis of different sepharose matrices for immunocomplex 
capture 
The immunoprecipitations to this stage had been carried out using a protein A 
sepharose matrix. The effectiveness of a protein G sepharose matrix for the PrPC 
immunoprecipitations was tested, as it has been shown to react more strongly with 
antibodies of the same IgG sub-type as I A8 & 1 B3, and with the same antibody class 
and sub-types as many monoclonal antibodies. The use of a protein G sepharose 
matrix resulted in a significant increase in the level of endogenous PrP' isolated from 
the N2a cell extracts using 1A8 and following this result a protein G sepharose 
matrix was used for most of the immunoprecipitations in this study (Figure 3.5). 
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KEY: Lanes 1-2, N2a cell extracts prepared with M-per, immunoprecipitated with 1A8 
using a protein A sepharose matrix; Lanes 3-4, N2a cell extracts prepared with M-per, 
immunoprecipitated with 1 A8 using a protein G sepharose matrix. PrP' marked with red 
arrowheads. LC = light chain of precipitating antibody, HC = heavy chain. 
Figure 3.5 N2a cell extracts: PrP' immunoprecipitated from M-per extracts 
with lAS, using two different sepharose matrices 
Western blot shows endogenous PrPC  (Red arrowheads) isolated from M-per produced N2a cell 
extracts and immunoprecipitated using the anti-PrP polyclonal antibody 1A8 with either a protein A 
or protein G sepharose matrix and detected with the anti-PrP monoclonal antibody 6H4. As can be 
seen the use of the protein G sepharose resulted in the isolation of more PrPC  than the protein A 
sepharose matrix. 
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3.2.4 Comparison of M-per and Mem-per cell lysis systems 
PrPC is a membrane-associated protein and as such it was decided to test a cell 
extraction technique that was specific for membrane proteins. The extraction system 
used until now was M-per, which is a mammalian-cell specific lysis agent. However, 
as M-per isolates both cytoplasmic and membrane attached proteins, it was decided 
to try the Mern-per system. N2a cell extracts were prepared with Mem-per (Section 
2.5.9.4), immunoprecipitated with 1A8 using a protein G sepharose matrix (Section 
2.7.3), samples were separated by SDS-PAGE and analysed by Western blotting 
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KEY: Lanes 1-3, N2a cell extracts prepared with Mem-per, and immunoprecipitated with 
1A8 using a protein G sepharose matrix; Lane 4, Purified PrP control sample treated with 
PK (equivalent to 2 mg brain tissue). PrPC  marked with red arrowheads. * marks the 
location of an additional band which may represent a processed or degraded PrP' product. 
Figure 3.6 N2a cell extracts: PrPc  immunoprecipitated from 
Mem-per extracts with 1A8 
Western blot shows enciogenous PrPC  (Red arrowheads) isolated from Mem-per produced N2a 
cell extracts immunoprecipitated with the anti-PrP polyclonal antibody 1A8 using a protein G 
sepharose matrix and detected with the anti-PrP monoclonal antibody 6H4. 
As can be seen in Figure 3.6, all three PrPC  glycoforms were 
immunoprecipitated with 1A8 and successfully detected using 6H4 from the Mem-
per produced N2a cell extracts. A further band was observed (marked with , Lanes 
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1-3, Figure 3.6) although it is not clear if this band represents cross reactivity with 
the precipitating antibody light chain or a processed or degraded PrPC  product. 
3.2.5 Immunoprecipitation of endogenous PrPC  from murine brain 
tissue samples 
The immunoprecipitation system was developed further by testing its ability 
to successfully isolate PrPC  from uninfected murine brain tissue samples. PrP null 
transgenic mice, which do not express endogenous PrPC,  and PrP wild type mice are 
available at the NPU, and brain samples were obtained from each of these animals 
and processed identically. Tissue extracts were produced as described in section 
2.5.9.1, and protein extracts were prepared with either M-per (Section 2.5.9.3) or 
Mem-per (Section 2.5.9.4), in the presence of proteinase inhibitors and 
immunoprecipitated with 1A8 using a protein G sepharose matrix (Section 2.7.3). 
Samples were separated by SDS-PAGE and analysed by Western blotting (Section 







KEY: Lanes 1-2, PrP null mouse brain tissue extracts prepared with M-per, and 
immunoprecipitated with 1A8; Lanes 3-4, PrP wild-type mouse brain tissue extracts prepared 
with M-per, and inimunoprecipitated with lA8; Lanes 5-6. PrP null mouse brain tissue extracts 
prepared with Mem-per, and immunoprecipitated with 1A8; Lanes 7-8, PrP wild-type mouse 
brain tissue extracts prepared with Mem-per, and immunoprecipitated with 1A8; Lane 9, Purified 
PrP" control sample treated with (PK) (equivalent to 2 mg brain tissue). PrPC  marked with red 
arrowheads. LC = light chain of precipitating antibody, HC = heavy chain. 
Figure 3.7 Murine brain extracts: PrPc  immunoprecipitated from tissue 
extracts prepared with either M-per or Mem-per 
Western blot shows endogenous PrPC  (Red arrowheads) isolated from M-per and Mem-per 
produced PrP null and wild-type mouse brain extracts immunoprecipitated with the anti-PrP 
polyclonal antibody 1A8 using a protein G sepharose matrix and detected using the anti-PrP 
monoclonal antibody 61-14. As can be seen PrPC  was only observed in the wild-type mouse brain 
extracts. 
As can be seen from Figure 3.7 endogenous PrPC  (red arrowheads, Figure 3.7) 
was successfully immunoprecipitated from the wild-type mouse brain tissue (Lanes 
3, 4, 7 & 8), whilst as expected the PrP null mouse brain tissue showed no detectable 
PrPC (Lanes 1, 2, 5 & 6). No significant difference was observed in the level of P rPC 
recovery between M-per and Mem-per produced tissue extracts (Figure 3.7). 
However, all three glycoforms may have been isolated in the Mem-per produced 
wild-type mouse brain tissue extract (Lanes 7 & 8, Figure 3.7), whilst the un-
glycosylated band is less clear in the M-per produced wild-type brain extract (Lanes 
3 & 4, Figure 3.7). This result is consistent with that seen with PrP' extracted with 
Mem-per from the N2a cell extracts where all three glycoforms were clearly detected 
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(Figure 3.6). In addition, no PrPC  was detected in Mem-per produced wild type mice 
brain extracts, which were extracted without a precipitating antibody (data not 
shown). This result demonstrated that the immunoprecipitation system was working 
effectively as a sample concentration step, and that the presence of a precipitating 
antibody was crucial. As would be expected endogenous PrPC  was undetectable in 
murine liver tissue (data not shown). 
3.2.6 Extraction and analysis of endogenous PrPC  from ovine cell 
culture extracts and the determination of background levels of 
P rPC expression 
The extraction and immunoprecipitation techniques developed with the use of 
purified PrP control samples, munne N2a cell extracts, and murine brain tissue 
samples were used to isolate endogenous PrPC  from ovine cell culture extracts. Cell 
extracts were prepared from a single, confluent well of a six well plate of sA80BR 
cells (approximately 2 x 10 5 cells) using Mem-per (Section 2.5.9.4), and 
immunoprecipitations were carried out with 1A8 (Section 2.7.3) using a protein G 
sepharose matrix. Samples were separated by SDS-PAGE and analysed by Western 
blotting (Section 2.8) using 6H4 (Figure 3.8). The results showed that PrP' was 
clearly detectable (albeit at low levels) in sA80BR cell extracts prepared with the 
Mem-per system (Lane I, Figure 3.8). The fact that this sample was first 
immunoprecipitated with a PrP specific antibody (1 A8), and then separately detected 
with another PrP specific antibody (6H4), indicates that these bands are very likely to 
be PrPC.  However, only two glycoforms were detected in the ovine sA80BR cell 
extract prepared with Mem-per (Lane I, Figure 3.8). The molecular weights of these 
bands are approximately 33 kDa and 22 kDa, respectively (Lane 1, Figure 3.8), 
indicating that they may be the di- and un-glycosylated bands of PrP', respectively. 









KEY: Lane 1, sA80BR cell extract prepared with Mem-per, and immunoprecipitated with 
1A8; Lane 2, Purified PrPc  control sample treated with PK (equivalent to 2 mg brain 
tissue). Red arrowheads indicate PrPC  bands. 
Figure 3.8 Ovine sA80BR extracts: PrF" immunoprecipitated with 
1A8 from Mem-per extracts 
Western blot shows endogenous PrPC  (Red arrowheads) isolated from Mem-per produced ovine 
sA80BR (isolated from a sheep of a scrapie susceptible genotype) neuronal cell extract, 
immunoprecipitated with the anti-PrP polyclonal antibody 1A8 using a protein G sepharose matrix 
and detected with the anti-PrP monoclonal antibody 6H4. 
Further immunoprecipitations were performed using Mem-per (Section 
2.5.9.4) cell extracts produced from the Icelandic sheep cell cultures IS12OCer and 
ISl2OLiv (approximately 2 x 10 5 cells). Extracts were immunoprecipitated with 1A8 
(Section 2.7.3), using a protein G sepharose matrix, samples were separated by SDS-
PAGE, and analysed by Western blotting (Section 2.8) using 6H4 (Figure 3.9). The 
results showed that endogenous PrP' (Lane 2, Figure 3.9) was successfully isolated 
from the IS1 2OCer cell extracts, although only one glycoform was observed (red 
arrowhead, Figure 3.9). This is likely to be the di-glycosylated form of PrPC  as its has 
a molecular weight of approximately 33 kDa. Again, the fact that these samples were 
immunoprecipitated and detected with separate PrP specific antibodies indicates that 
the observed band is very likely to be that of PrP'. In contrast no endogenous PrPC 
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KEY: Lane I, IS I 20Liv cell extract prepared with Mem-per, and ininiunoprecipitated with 
1A8; Lane 2, ISl2OCer cell extract prepared with Mem-per, and immunoprecipitated with 
1A8; Lane 3, Purified PrPs  control sample treated with PK (equivalent to 2 mg brain 
tissue). PrPC  marked with red arrowheads. LC = light chain of precipitating antibody, HC = 
heavy chain. 
Figure 3.9 Ovine 1S120 cell extracts: PrPc immunoprecipitated with 
1A8 from Mem-per extracts 
Western blot shows endogenous PrPC  (Red arrowhead) isolated from Mem-per produced ovine 
lS12OLiv (liver) and lS12OCer (cerebellum) cell extracts, immunoprecipitated with the anti-PrP 
polyclonal antibody 1A8 using a protein C sepharose matrix and detected with the anti-PrP 
monoclonal antibody 6H4. As can be seen PrPC  was detected in the lS12OCer cell extract but not 
in the lS12OLiv cell extract. 
3.2.7 Characterisation of PrP-specific monoclonal antibodies as 
immunoprecipitating antibodies 
A number of mouse derived PrP-specific monoclonal antibodies showing 
cross reactivity with PrP from a number of different mammalian species (Table 2.6) 
are available in the Institute for Animal Health (IAH). It was expected that the use of 
these antibodies would improve the immunoprecipitation system further, and their 
availability raised the possibility of using an inimunoprecipitating cocktail of 
monoclonal antibodies to give multiple epitope recognition of PrP. Two sets of 
antibodies are available; set one consists of BE12, AH6 and AG4 (Jacquie Manser, 
IAH, Compton) and these antibodies recognise N-terminal epitopes on PrP (Table 
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2.6). Set two consists of eight antibodies named AB1-AB8 (Dr Sandra McCutcheon, 
IAH, Compton) and these antibodies recognise C-terminal epitopes on PrP (Table 
2.6). The ability of these antibodies to precipitate endogenous PrPC  from the murine 
N2a cells was assessed in the immunoprecipitation system developed during this 
study (Section 2.7.3). N2a cell extracts (approximately 2 x 10 5 cells) prepared with 
Mem-per (Section 2.5.9.4) were immunoprecipitated with the appropriate 
monoclonal antibody. Samples were separated by SDS-PAGE, and analysed by 
Western blotting with 61 -14 (Section 2.8). The results of these immunoprecipitations 
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KEY: N2a cell extracts prepared with Mem-per, and immunoprecipitated with the stated 
monoclonal antibody. Lane 1, BE12; Lane 2, AH6; Lane 3, AG4; Lane 4, 1A8; Lane 5, 
Purified PrPs  control sample treated with PK (equivalent to 2 mg brain tissue). PrPC  marked 
with red arrowheads. LC = light chain of precipitating antibody, HC = heavy chain. 
Figure 3.10 N2a cell extracts: PrPc immunoprecipitated from Mem-per 
extracts, with PrP-specific monoclonal antibodies (set one) 
Western blot shows endogenous PrPC  (Red arrowheads) isolated from Mem-per produced N2a 
cell extracts immunoprecipitated with the anti-PrP monoclonal antibodies BE12, AH6 or AG4 
(directed towards epitopes at the PrP N-terminal region) using a protein G sepharose matrix and 
detected with the anti-PrP monoclonal antibody 6H4. The PrPC  isolated appeared to be of a 
truncated form of approximately 20 KDa. 
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As can be seen from Figure 3.10, immunoprecipitations with the set one 
antibodies showed mixed results. The monoclonal antibodies BE 12 and AG4 failed 
to immunoprecipitate any detectable PrPC  from the N2a cell extracts (Lanes 1 & 3, 
Figure 3.10). The monoclonal antibody AH6 showed promise with a small amount of 
PrPC detectable (Lane 2, Figure 3.10), however, the PrPC  observed appeared to be 
slightly truncated with an approximate molecular weight of 20 kDa (red arrowhead, 
Figure 3.10). In addition, strong bands were observed at 25 and 50 kDa, which 
presumably represent cross reactivity of the light (LC) and heavy chains (HC) of the 
precipitating antibody with the secondary antibody. 
MW 
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KEY: N2a cell extracts prepared with Mem-per, and immunoprecipitated with the stated 
monoclonal antibody. Lane 1, AB 1; Lane 2, AB2; Lane 3, AB3; Lane 4, AB4; Lane 5, 
AB5; Lane 6, Cocktail of all set two monoclonal antibodies; Lane 7, AB6; Lane 8, AB7; 
Lane 9, AB8; Lane 10, Purified PrPc  control sample treated with PK (equivalent to 2 mg 
brain tissue). PrPC  marked with red arrowheads. LC = light chain of precipitating antibody, 
HC = heavy chain. Red arrows indicate location of possible truncated PrPC  bands. 
Figure 3.11 N2a cell extracts: PrP' immunoprecipitated from Mem-per 
extracts with PrP-specific monoclonal antibodies (set two) 
Western blot shows endogenous PrPC  (Red arrowheads) isolated from Mem-per produced N2a 
cell extracts using the anti-PrP monoclonal antibodies AB1-AB8 (directed towards epitopes at the 
PrP C-terminal region) using a protein G sepharose matrix and detected using the anti-PrP 
monoclonal antibody 61-14. The PrPC  isolated appeared to be of a truncated form of approximately 
20 KDa. 
123 
The set two antibodies showed mixed results (Figure 3.11). Positive results 
were observed with AB2, AB6 and AB8, whilst AB1, AB3, AB4, AB5 and AB7 
failed to show any detectable PrPC  (Figure 3.11). The set two antibodies that isolated 
endogenous PrPC  from the N2a cell extracts showed very promising results with 
strong levels of PrPC  clearly detectable (AB2, AB6 & AB8) (Lanes 2, 7 & 9, Figure 
3.11). In addition, a cocktail of all of the set two monoclonal antibodies added 
together in a single immunoprecipitation reaction resulted in a strong signal for PrPC 
(Lane 6, Figure 3.11). This reaction was very likely to be the result of the antibodies 
AB2, AB6 and AB8 as these showed individual reactivity with PrP' in this system. 
Again the endogenous PrPC  isolated from the N2a cells during these 
inmiunoprecipitations appeared to be of a truncated form, of approximately 20 kDa 
(red arrowheads, Figure 3.11). Cross reactivity between the secondary antibody and 
the light (LC) and heavy chains (HC) of the precipitating antibody produced strong 
bands at 25 and 50 kDa (Figure 3.11). 
3.2.8 Coupling of the AB2, AB6 & AB8 monoclonal antibodies to an 
amino-link matrix 
As seen with all of the mouse derived monoclonal antibodies, strong bands 
due to the light and heavy chains of the precipitating antibodies (25 and 50 kDa, 
respectively) were observed (LC & HC, Figures 3.10 & 3.11). The PrP' detected here 
appeared to be of a truncated form (approximately 20 kDa) and unfortunately this 
meant that the PrP' bands fell across the line of the precipitating antibody light chain. 
This made it very difficult to clearly identify the PrPC  bands and it would have been 
desirable to remove these heavy and light chain bands from the samples prior to 
loading. These bands appeared because after the immunoprecipitation reaction the 
immunocomplexes were denatured in order to release the antigen, however this 
caused the dissociation of the precipitating antibody chains. The protein G sepharose 
matrix was pelleted by centrifugation, leaving the isolated PrP' and the heavy and 
light chains of the precipitating antibody free in the supernatant. In order to prevent 
this it was necessary to use a matrix that would not be denatured by heating, but that 
would still allow the immunoprecipitated PrPC  to be released. It was decided to use 
an amino-link matrix (Pierce, UK) which would enable the permanent coupling of 
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the monoclonal antibodies. The bonds formed between the amino-link matrix and the 
precipitating antibody are not broken by heat denaturation, however the antigen 
(PrPC) can be released from the antibody/matrix by using a specific elution buffer 
(Pierce, UK). It was hoped that the use of this matrix would allow PrPC  to be 
immunoprecipitated with the monoclonal antibodies, whilst preventing the release of 
the antibody heavy and light chains into the SDS-PAGE samples. The set two 
antibodies that proved successful in precipitating PrPC  from the N2a cells (AB2, AB6 
& AB8) were individually coupled to the amino-link matrix, following the 
manufacturers instructions. Immunoprecipitations (Section 2.7.3) were performed 
using these antibody/matrix combinations, and samples were separated by SDS-
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KEY: N2a cell extracts prepared with Mem-per, and immunoprecipitated with the stated 
monoclonal antibody coupled to an amino-link matrix. Lanes 1-2, A132; Lanes 3-4, AB6; 
Lanes 5-6, A138; Lane 7, Purified PrPSC  control sample treated with PK (equivalent to 2 mg 
brain tissue). 
Figure 3.12 N2a cell extracts: PrF' immunoprecipitated from Mem-per 
extracts with PrP -specific monoclonal antibodies directly coupled 
to an amino-link matrix 
Western blot shows an attempt to isolate endogenous PrPC from Mem-per produced N2a cell 
extracts immunoprecipitated with the anti-PrP monoclonal antibodies AB2, AB6 or A138 covalently 
attached to an amino-link matrix in order to be able to isolate PrP without the contaminating bands 
of the precipitating antibody light and heavy chains. Samples were detected using the anti-PrP 
monoclonal antibody 6H4. As can be seen no endogenous PrPC  was detected, neither were the 
light or heavy chains of the precipitating antibodies. 
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As can be seen from Figure 3.12 the immunoprecipitations carried out with 
the amino-linked monoclonal antibodies failed to isolate any detectable PrPC  from the 
N2a cell extracts. However, it was noted that no precipitating antibody bands (25 and 
50 kDa, respectively) were observed on the Western blot, indicating that the 
antibodies may have been successfully coupled to the matrix. 
3.3 Discussion 
3.3.1 Technical aspects 
Previous studies have shown that methods used successfully for the 
extraction of PrP' from certain cell types do not necessarily work as effectively with 
other cell types (Madec, Groschup, Buschmann et al., 1998, Marshall, 2000). 
Marshall (2000) was able to detect endogenous PrPC  in murine N2a cell extracts 
using immunoprecipitation, however the same method failed to extract detectable 
quantities of endogenous PrP' from the ovine sA80BR cell extracts. It was 
hypothesised that differences in the concentration of endogenous PrPC,  the type of 
membrane association or cell and species-specific differences in membrane 
composition could explain the varying results observed in these studies (Madec et 
al., 1998, Marshall, 2000). Previous studies had used approximately 2 x 107  cells for 
the detection of endogenous PrPC,  however, in this study cells cultured in a single 
well of a six well plate (approximately 2 x 105  cells) were used. The M-per system 
was chosen as a suitable cell lysis agent as it is designed specifically for this task and 
the results showed that M-per was a more effective lysis reagent than RCLB in terms 
of total protein recovery (Figure 3.1). The experiments also showed that M-per is far 
less reliant on the action of proteinase inhibitors than RCLB and that the use of M-
per overall gave a four-fold increase in total protein recovery from the N2a cells. 
Applied to PrP detection, comparisons between M-per and RCLB showed that 
endogenous PrPC  protein was easily detectable in the M-per prepared N2a cell 
extracts whilst no PrPC  was detected in the RCLB prepared cell extracts (Figure 3.3). 
M-per had already been shown to recover far higher concentrations of total protein 
than RCLB, and this result showed that M-per was able to recover a detectable 
amount of PrPC  whilst RCLB was not. The amount of endogenous PrPC  visualised on 
126 
the Western blots in the present study was comparable to that shown by Marshall 
(2000). However, in the present study approximately 2 x 105  cells were used, whilst 
Marshall (2000) used approximately 2 x 10 7 cells. Therefore, the 
immunoprecipitation system developed in the present study appears to be two orders 
of magnitude more efficient at isolating PrPC  from the N2a cells than the isolation 
system used by Marshall (2000). Information regarding the sensitivity of the 
immunoprecipitation system developed during this study was provided by the use of 
purified PrP' c samples (20 mg) diluted in 400 p.1 of TBST (0.05 mg/p.l) and 
immunoprecipitated with 1A8. PrP' c was clearly detectable from these diluted 
purified PrPs  samples and the amount of PrPSC  detected, as judged by Western blot, 
was comparable to that observed with 2 mg of a purified PrP sample loaded directly 
onto the same gel and detected in the same blot. Therefore, the immunoprecipitation 
step had concentrated the PrPs  from the 400 p.1 of TBST, in which it was diluted 
(Lane 6, Figure 3.2; Lanes 1 & 2, Figure 3.3), although most of the PrPSC  was lost 
presumably in the immunoprecipitation wash steps. This experiment indicated that 
the immunoprecipitation system may have reached a detection ceiling, above which 
the amount of PrPSC  added would potentially have little effect on the outcome and 
this was possibly due to the availability of free I A8 antibody. Therefore, the 
sensitivity of the immunoprecipitation system may be raised further by increasing the 
amount of free 1A8 antibody available. 
For immunoprecipitations it is more desirable to use a polyclonal antibody, 
which is able to recognise multiple epitopes on the same protein molecule, thus 
increasing the chances of capturing the protein. The PrP specific monoclonal 
antibody 61­14 as an immunoprecipitating antibody failed to isolate PrP' from the N2a 
cell lysates (Figure 3.4). 6H4 is a monoclonal antibody, as such it recognises only 
one epitope meaning that it is not an ideal antibody for immunoprecipitation. In 
contrast, both anti-PrP polyclonal antibodies 1 A8 and 1133 functioned equally as 
effectively as precipitating antibodies in this system (Figure 3.4). 
A number of mouse-derived PrP specific monoclonal antibodies, produced at 
IAH, Compton, were analysed for their ability to isolate endogenous PrPC  from N2a 
cell extracts. In particular three of the antibodies (AB2, A136 & AB8) successfully 
isolated endogenous PrP' from the N2a cell extracts (Figure 3.11). The monoclonal 
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antibodies BE 12 and AG4 failed to immunoprecipitate any detectable PrP' from the 
N2a cell extracts, however, the monoclonal antibody AH6 showed promise with a 
small amount of PrP' detectable. The monoclonal antibodies BEI2 and AG4 
recognise epitopes close to the N-terminus of PrP, and as a result they fail to 
recognise truncated murine PrPC  on Western blots (J. Manser, Personal 
communication). This may explain why they failed to recognise the PrPC  observed 
from the N2a cells, as this PrPC  appeared to be of a truncated form (Figure 3.10). In 
contrast AH6 recognises an epitope that is further from the N-terminus of PrP, and 
has been shown to react with truncated murine PrPC  on Western blots (J. Manser, 
Personal communication). Interestingly, AH6 showed a degree of reactivity with the 
PrP' isolated from the N2a cells in this study, indicating that it may be a suitable 
antibody for immunoprecipitation studies (Figure 3.10). However, the monoclonal 
antibodies BE 12 and AG4 may have shown the same reactivity as AH6 if a non-
truncated form of PrP' were present in the N2a cell extracts during these 
experiments, and as such their use as precipitating antibodies in this system cannot 
be ruled out. The presence of the light (LC) and heavy chains (HC) of the 
precipitating antibodies on the Western blots proved to be a problem. This was 
further complicated by apparent changes in the molecular weight of the endogenous 
PrPC isolated from the N2a cells during the monoclonal antibody analysis, which 
appeared to result in the presence of a truncated form of PrPC  (approximately 20 kDa) 
(Figures 3.10 & 3.11). It is not clear why the PrPC  isolated from the N2a cell extracts 
with these monoclonal antibodies appeared to be truncated, but it could be due to 
cellular changes within the N2a cells in culture or it could be due to proteolytic 
activity. 
It was noted that the pre-adsorption of the PrPSC  samples with protein A 
sepharose resulted in the removal of PrPSC  (Figure 3.2). This is likely to be due to 
non-specific interaction between the PrPSC  and the sepharose matrix, as such this pre-
adsorption step was omitted in further immunoprecipitations. Protein A sepharose 
had already been shown to be a successful matrix in this study and the use of a 
protein G sepharose matrix was examined. The results showed that the use of a 
protein G sepharose matrix for the immunoprecipitations considerably improved the 
128 
recovery of PrPC  and as a result all subsequent immunoprecipitations were performed 
with protein G (Figure 3.5). 
The same methods used for the immunoprecipitation of PrPC  from the murine 
N2a cells also proved to be successful in isolating PrP' from murine brain tissue. 
PrPC was readily detectable in wild-type mice brain extracts, however, PrP null mice 
brain extracts showed no detectable PrPC  (Figure 3.7). 
3.3.2 Endogenous P rPC 
The methods developed for the murine N2a cells were successful at isolating 
endogenous PrPC  from the ovine cell cultures sA80BR and ISl2OCer (Figures 3.8 & 
3.9). Only one distinct PrPC  glycoform was detected from the ISl2OCer cell extracts 
produced with Mem-per, due to its estimated size of approximately 33 kDa it is 
likely that this is the di-glycosylated band. However, as discussed previously, the 
lack of detection of the mono- and un-glycosylated bands could be due to the lower 
levels of PrPC  observed in the ovine cell culture samples. These results indicate that 
the ovine sA80BR and IS 1 2OCer cell cultures both express endogenous PrP', albeit 
at a lower level than that observed with the murine N2a cells. The Icelandic liver 
derived cell culture ISl2OLiv showed no detectable endogenous PrPC  (Figure 3.9). 
However, this result was not unexpected as PrPC  is normally expressed at far lower 
levels in sheep liver than in brain (Caughey et al., 1988, Horiuchi et al., 1995, 
Moudjou et al., 2001). The immunoprecipitation system developed in these studies 
was therefore capable of isolating PrPC  from a variety of mammalian cell cultures 
and was adaptable to isolate endogenous PTPC  from murine tissue samples. 
The PrPC  and  PrPSC  immunoprecipitated samples appeared to be missing a PrP 
glycoform following immunoprecipitation (Figures 3.2 & 3.3). It is not clear if the 
same glycoform was absent in both PrPC  and PrPs,  although it appears that the 
mono-glycosylated form was missing from the PrPSC  samples, whilst the Un-
glycosylated from appears to be absent in the PrP' samples (Figure 3.3). The 
observation that one glycoform is undetectable after the immunoprecipitation would 
indicate that either the precipitating antibody is unable to bind to its epitope in that 
glycoform, or that the missing PrP glycoform has not been extracted from the cell 
lysates. It is likely that in the PrP samples the mono-glycosylated forms are not 
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precipitated by the 1A8 antibody, thus explaining why these glycoform bands are 
absent in the Western blots. As the antibody is capable of precipitating di-
glycosylated PrP, there is either a conformational change between mono- and di-
glycosylated PrP or these isoforms are differentially integrated into the membrane 
and are therefore extracted with different efficiencies. In contrast, the un-
glycosylated band appears to be missing from the endogenous PrPC  due to a failure to 
isolate a sufficient quantity of total PrPC  from these samples. This is supported by the 
successful extraction of all three glycoforms of endogenous PrPC  from N2a cell 
extracts prepared with Mem-per, which is an extraction reagent specific for 
membrane proteins. It is possible that the missing glycoform band observed in the 
M-per samples was likely to be due to a failure to isolate that glycoform from the cell 
lysates. This may be due to the un-glycosylated form of PrP' being strongly 
membrane associated/attached. The un-glycosylated band was consistently observed 
at lower levels than the di- and mono-glycosylated isoforms in the murine N2a cell 
extracts, therefore the intensity of the lower band may be greater in the Mem-per 
samples as more PrPC  is present overall. 
There is evidence for the existence of truncated forms of PrPC  in cell culture 
and previous studies at the NPU have noted the presence of truncated PrPC  in murine 
N2a cells (Angie Chong, Personal communication). Other studies have revealed the 
presence of N-terminally truncated forms of PrPC.  Harris et al. (1993) showed that 
chicken PrPC  expressed in murine N2a cells was truncated within its N-terminal 
region at a point distal to the proline/glycine-rich repeat region. Lehmann & Harris 
(1996) showed the presence of N-terminally truncated forms of PrP in transfected 
Chinese hamster ovary (CHO) cells. In addition, studies by Chen, Teplow, Parchi et 
al. (1995) showed that truncated PrPC  is present in normal and prion infected human 
brain. Furthermore, Jimenez-Huete et al. (1998) revealed the presence of amino-
truncated PrP' in human brain with estimated molecular weights of 21-22 and 18 
kDa. 
The apparently truncated PrPC  isolated from the N2a cell extracts in the 
studies in this thesis was located at a molecular weight similar to the precipitating 
antibody light chain on Western blots, which meant that it was difficult to visualise 
the PrPC.  To overcome this problem the monoclonal antibodies were coupled 
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permanently to an amino-link matrix, which enabled the PrPC  antigen to be released 
from the immunocomplex without releasing the antibody heavy and light chains. It 
was hoped that this would have left the antibody coupled to the matrix following heat 
denaturation, and would enable the antibody/matrix to be re-used up to twenty times, 
therefore cutting the costs of the immunoprecipitation procedure. However, it 
appeared that although the monoclonal antibodies were successfully coupled to the 
amino-link matrix, the coupling procedure may have caused an alteration in the 
antibody structure, resulting in it being unable to bind to PrPC  (Figure 3.12). 
3.3.3 Conclusions 
In summary, during this study techniques for the extraction, isolation and 
detection of endogenous PrPC,  from ovine and murine cell extracts and murine tissue 
have been successfully developed. Previous studies had detected endogenous PrPC 
from approximately 2 x 10 7 N2a cells, in this study endogenous PrP' has been 
successfully detected from cell extracts prepared from approximately 2 x 10 5 cells. 
Enhancements made to this system, such as, the use of a protein G sepharose matrix 
and a novel buffering system have further improved the recovery of endogenous 
PrPC .  The cell lysis and immunoprecipitation techniques developed here were then 
used for the extraction of recombinant PrPC  from ovine and murine cell cultures 
transiently transfected with ovine PrP mini-gene constructs (Chapter 4). It was 
expected that the level of PrPC  extracted with this system would be sufficient to allow 
the detection of recombinant P rPC expression in transiently transfected cells. The 
level of PrP' isolated from the cultured cells with the present system was comparable 
to that achieved by other researchers from cultured neuronal cells using similar 
methods (Lehmann & Harris, 1996, Parizek, Roeckl, Weber et al., 2001, Winklhofer 
et al., 2003). Therefore, it was anticipated that the immunoprecipitation system 
developed during this study would successfully isolate recombinant PrPC  from 
transiently transfected cell cultures. Finally, it was expected that the techniques 
would prove to be important tools in the isolation of PrP in other research projects. In 
particular this system lends itself to the extraction of PrP from samples that may 
contain only low levels of PrP that would be undetectable without the use of the 
sample concentration step that immunoprecipitation provides. 
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Chapter 4: Control of ovine PrP gene expression, a 
role for alternative polyadenylation? 
4.1 Introduction 
Work described in Chapter 3 of this thesis resulted in the development of 
methods for the specific isolation and detection of endogenous PrP' from ovine cell 
lines and from ovine tissue samples using the immunoprecipitation technique. These 
methods were applied in this chapter to the isolation and detection of recombinant 
PrP expressed by a series of ovine PrP mini-gene constructs. Polymorphisms within 
the open reading frame of the PrP gene do not completely explain why sheep of some 
genotypes are more susceptible than others to scrapie infection, as animals of 
different breeds with identical genotypes show variation in susceptibility to disease 
(Hunter, 1997, Hunter et al., 1994a). It is hypothesised that other regions of the ovine 
PrP gene may influence scrapie susceptibility, for example, untranslated regions of 
the mRNA may regulate the translation of the PrPC  protein. Two mRNA transcripts 
of PrP have been isolated from sheep tissues, a 2.1 kb and a 4.6 kb species, in 
addition, a third 3.3 kb transcript may exist in peripheral tissues (Goldmarm et al., 
1999). These different mRNA transcripts are the result of alternative polyadenylation 
of the PrP gene (Goldmann etal., 1999, Horiuchi et al., 1995, Hunter etal., 1994c). 
The shorter 2.1 kb transcript lacks several features which are present in the 4.6 kb 
transcript, and these include sequences that resemble instability motifs, repetitive 
sequences and a highly conserved region (Goldmann et al., 1999). It is known that 
the relative levels of PrPC  protein and PrP mRNA differ in certain tissues, suggesting 
that PrP gene expression may be regulated in a post-transcriptional manner, which 
could be linked to alternative polyadenylation (Ford et al., 2002, Goldmann et al., 
1999, Horiuchi et al., 1995). It is possible that alternative polyadenylation could be 
involved in the tissue-specific expression of the PrP gene, as the two PrP mRNA 
transcripts are found at different levels in different tissue-types (Goldmann et al., 
1999). The tissue specific regulation of PrP expression could involve the absence of 
tissue-specific factors from certain ovine tissues. Alternatively, both mRNA 
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transcripts could be produced in all ovine tissue types, but one may be degraded 
more quickly than the other due to the presence of instability motifs. 
Studies by Marshall (2000) found evidence that the sequence between 2000-
2700 bp in the ovine PrP 3'UTR has an inhibitory role in CAT reporter gene 
expression. It was hypothesised that sequences within this region act as binding sites 
for RNA binding proteins, which may have an inhibitory effect on the translation of 
mRNA transcripts containing this sequence (Marshall, 2000). The 2.1 kb transcript is 
polyadenylated at position 1546, therefore it lacks the putative inhibitory region, and 
perhaps explains why a PrP construct with a full length 3'UTR was expressed at 
lower levels than those containing a shorter 3'UTR (Goldmann et al., 1999, 
Marshall, 2000). However, it is possible that these observations were an artifact of a 
recombinant mRNA, generated by the combination of the CAT reporter gene and PrP 
3'UTR sequences. These cell culture results were also in contradiction to the in vivo 
observations that sheep brain (4.6 kb mRNA) contains a much higher content of PrPC 
than peripheral tissues (4.6 kb & 2.1 kb mRNAs). Furthermore, the analysis of subtle 
changes in RNA levels can be complicated by the longevity of the CAT reporter 
protein, which has a half-life of approximately 50 hours in mammalian cells. In order 
to avoid these problems, PrP' was itself used as a reporter for the action of the 
3'UTR. 
The work described in this chapter has investigated the influence of 
alternative polyadenylation on the expression of the ovine PrP gene. A series of five 
PrP mini-gene constructs (plasmids pConstructl -pConstruct5) were produced (Figure 
4.1) and placed under the control of a 0.5 kb ovine PrP gene promoter, which had 
previously been shown to be effective at promoting the expression of a CAT reporter 
gene (Marshall, 2000, O'Neill et al., 2003). The constructs contain the complete 
ovine PrP gene exon III, which consists of a short 5'UTR sequence, the complete 
ovine PrP gene ORF, and the 3'UTR. The constructs differ only in the 
polyadenylation signals located within the 3' UTR (Figure 4.1). 
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1 	 Key: 
2 	f:' 	 , 	 1-5 = pConstruct 1-5 
3 	: 	_________________ 	
A = Polyadenylation sites 1, 2 and 3 
- = Ovine PrP promoter/intron 
< =ORF 
5 _I U =3'(JTR 
Figure 4.1 The ovine PrP mini-gene constructs (pConstructl- 
p Construct5) 
Ovine PrP mini-gene constructs 1-5. Each construct contains a 0.5 kb Cheviot sheep PrP gene 
promoter fragment, a 700 bp intron sequence and the Suffolk sheep PrP gene exon lii, which 
contains a short 5' UTR sequence, the full ovine PrP gene ORE and a 3'UTR sequence. The 
contructs differ only in the length of the 3'UTR sequence and the available polyadenylation 
signals. 
The ovine PrP mini-gene constructs were used to investigate the influence of 
the 3'UTR on PrPC  expression following transient transfection of ovine and munne 
cell cultures (Sections 2.5.1-2.5.3). Immunoprecipitation has been shown to be a 
successful method of purifying PrPC  from N2a cell extracts (Marshall, 2000). In 
addition, work carried out during this study successfully developed techniques for 
the efficient extraction of endogenous PrP' from munne N2a cells, ovine sA80BR 
and IS12OCer cells, and murine brain tissue (Chapter 3). These techniques were 
applied to the immunoprecipitation of recombinant PrPC  from the ovine and murine 
cell cultures transiently transfected with the ovine PrP mini-gene constructs. 
Marshall (2000) modified the sequence of the ovine PrP gene ORF to carry a 
hamster specific epitope (valine to methionine substitution at codon 115) that was 
specifically recognised by the 3F4 antibody. The use of this epitope was believed to 
be a suitable method to enable the detection of recombinant PrPC  against a 
background of endogenous PrPC  (Kascsak, Rubenstein, Merz et al., 1987, Marshall, 
2000). The results of transient transfections showed that the 3174 antibody cross 
reacted with endogenous murine and ovine PrPC  and this was also shown by Baron, 
Betemps, Groschup et al. (1999). The 3F4 epitope was therefore unsuitable for the 
detection of recombinant PrPC  against a background of endogenous PrP'. Another 
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tagging epitope (3X FLAGTM, Sigma, UK) was chosen for this study. Previous work 
by Telling, Tremblay, Torchia et al. (1997) had shown that the incorporation of a 
single FLAG TM epitope at the N-terminus of the mature murine PrP' protein had no 
effect on its normal cellular processing. For the present study the 3X FLAGTM  
epitope was inserted C-terminal of the signal peptide. A XrnaI restriction site in the 
ORF (codons 42-43) was used for the insertion of the 3XFLAGTM coding DNA 
fragment. Therefore, the 3XFLAGTM  epitope will be positioned between ammo acid 
codons 43 and 44 of ovine PrP. By using PrP mini-gene expression constructs with 
differing combinations of the available polyadenylation signals, the role of these 
signals in PrP gene expression could be investigated, and it was expected that the 
studies would provide further insights into the role of the 3'UTR inhibitory region 
(Goldmann et al, 1999, Marshall, 2000). By expressing these constructs in a range 
of ovine cell types, including cells derived from animals of differing PrP genotypes, 
an attempt was made to investigate the role of alternative polyadenylation in the 
tissue-specific expression of the PrP gene. 
4.2 Results 
4.2.1 Cloning of the 3XFLAGTm tagged ovine PrP mini-gene constructs 
4.2.1.1 Generation of a 3XFLAG 7m DNA sequence for cloning into 
exon Ill of the ovine PrP gene 
The expression vector p3XFLAG-CMV-8TM (Sigma, UK) was used as a 
source of the 3XFLAGTM DNA sequence. PCR primers (Flag Forward and Flag 
Reverse, Table 2.1) were designed to amplify the 3XFLAGTM DNA sequence of 66 
bp from the p3XFLAG-CMV-8 1M vector. The primers were designed to include XmaI 
restriction endonuclease sites at either end (Figure 4.2, red text). The XmaI sites were 
subsequently used to clone the 3XFLAGTM  DNA into an XmaI site in the ovine PrP 
gene ORF. In order to maintain the reading frame with both the ovine PrP gene and 
the 3XFLAGTM DNA sequence, an additional base (A) was added to the primer at the 
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S'end of the 3XFLAGT 11  sequence (Flag Forward primer) and two additional bases 
(TA) were added at the 3 'end (Flag Reverse primer) (Figure 4.2, green text). 
Flag forward 	I 
primer TCTCTACCC AGACTACAAAGAC' 3 
Flag reverse 	 5 CTAAATCCCGGGTACTTGTCATCGTC' 3 
primer 
KEY: 
Leader sequence for XmaI binding 
Vnu, I restriction enzyme binding .itc 
•(ldiliOflal 	added to nai,itairi rcadiiig 11-mile 
3XFLAGTm DNA sequence 
Figure 4.2 Primers used for the PCR amplification of the 
modified 3XFLAG TMDNA sequence from the plasmid p3XFLAGCMV8r4l 
The primers used for the amplification of the 3XFLAGTM DNA sequence were modified to 
incorporate additional bases (green bases) into the 3XFLAGTM sequence in order to 
maintain reading frame with the ovine PrP ORF and the 3XFLAGTM epitope and Xmal 
restriction sites for use in DNA cloning. 
To reduce the risk of erroneous amplification of the p3XFLAG-CMV-8TM 
vector DNA, the vector was first digested with the restriction endonucleases SpeI and 
Age! (Section 2.2. 1) producing a 1317 bp fragment containing the 3XFLAGTM DNA 
sequence and a 3446 bp plasmid DNA fragment. The 3446 and 1317 bp fragments 
were separated by gel electrophoresis (Section 2.2.6), the 1317 bp fragment was 
isolated by gel extraction (Section 2.2.7) and used as template DNA for PCR 
amplification (Section 2.2.14) of the 3XFLAGTM DNA sequence. Following PCR 
amplification, the presence of the 93 bp 3XFLAGTM DNA sequence (66 bp 
3XFLAGTM DNA, 3 bp additional bases added to maintain frame 12 bp XmaI site 
DNA and 12 bp additional bases (six bases 5' and six bases 3') added to ensure that 
the restriction enzyme XmaI would be able to bind to the DNA fragment) was 






KEY: Lane 1, Molecular weight marker VI (Roche, UK); Lane 2, PCR product negative for 93 
bp 3XFLAGTM DNA fragment; Lanes 3 + 4, PCR products positive for 93 bp 3XFLAGT 4 DNA 
fragment. indicates location of 93 bp 3XFLAGTM DNA fragment. 
Figure 4.3 Successful amplification of the 93 bp 3XFLAG I'm DNA sequence 
by PCR from vector p3XFLA G-CM V-8 TM  analysed by gel electrophoresis 
The amplification of the 3XFLAGTM DNA sequence was confirmed by gel electrophoresis of the 
PCR reaction product which showed the presence of an approximately 90-100 bp DNA 
fragment, corresponding to the 93 bp modified 3XFLAGTM DNA sequence. 
The PCR amplified 3XFLAGTM DNA sequence was isolated by gel extraction 
(2.2.7), and ligated into the vector pGEM-T EasyTM (Promega, UK) to produce the 
vector pFLAG. The incorporation of the modified 3XFLAGTM DNA sequence into 
pFLAG was confirmed by Sanger sequencing (Section 2.3) using Flag forward and 
Flag reverse (Table 2.1) PCR primers (Figure 4.4), the final sequence of the 
3XFLAGTM PCR fragment within the vector pFLAG is shown in Figure 4.5. 
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1 Mod::fied - 	r XmaI 
restriction 
- 	 site 
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S 	 - 
-- 	 3XFLAG 
DNA 5- 	 - S 	 - — 
- 	 sequence 
5- 
S5 	 S 
- 
GATC G A T C 
Flag forward 	Flag reverse 
KEY: G = guanine, A = adenine, T = thymine, C = cytosine 
Figure 4.4 Sanger sequencing gel of pFLAG mini-prep DNA 
using the Flag forward & Flag reverse primers 
Sanger sequencing gel shows the correct sequence for the modified 3XFLAGTM DNA 
fragment within the vector pFLAG, including the Xmal restriction site and the additional 




3X FI.s.(;' DNA 
5' 	 \GACTACAAAGACCATGACGGTGATTATAAAGATC 
t 
.Additional Base 
Additional Bases XrnaI Site 
ATGACATCGATTACAAGGATGACGATGACAAG I [ 
Figure 4.5 Final sequence of the 3XFLAG r" DNA PCR fragment (top 
strand) as confirmed by manual sequencing of the vector pFLA G 
Diagram shows the modified 3XFLAGTM DNA sequence in the 5' - 3' direction. The 
positions of the additional bases (green text) and the Xmal restriction sites (red text) 
and the 3XFLAGTM sequence are indicated. 
The modified 3XFLAGTM DNA sequence was removed by digestion of 
pFLAG with X,nal (Section 2.2.1), producing a 76 bp fragment which was isolated 
by gel extraction (Sections 2.2.6 & 2.2.7) ready for cloning into the XrnaI site in exon 
III of the ovine PrP gene (Section 4.2.1.4). 
4.2.1.2 Insertion of the ovine PrP gene exon III into the vector 
pBluescript-SK to produce the plasmid pSK7 
In order to produce a plasmid which contained the ovine PrP gene exon III 
with all three polyadenylation sites the plasmid pBluescript-SK (Stratagene, UK) was 
used. pBluescript-SK was digested with the restriction endonucleases EcoRI and Spel 
(Section 2.2.1) within its multi-cloning site (Figure 4.7, Page 141). This resulted in 
the removal of a XmaI restriction site from the multi-cloning site of the plasmid, 
which allowed the 3XFLAGTM  DNA sequence to be inserted into a unique XmaI site 
within the ovine PrP gene exon III. The ovine PrP gene exon III was then removed 
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from the plasmid p71 (Wilfred Goldmann, NPU) with the EcoRI and SpeI restriction 
enzymes (Section 2.2.1). The ovine PrP gene exon III EcoRI site lies at position 
21532 bp, whilst the SpeI site lies at position 27363 bp, using the Suffolk PrP gene 
numbering (GenBank accession number = U67922). The digestion resulted in the 
removal of a short section of DNA at the 3'end of exon III, leaving all three 
polyadenylation sites intact and producing an exon III fragment of approximately 6 
kb (Figure 4.7). The EcoRL'SpeI exon III fragment was ligated (Section 2.2.4) into 
pBluescript-SK to produce the plasmid pSK7 (Figure 4.7). The presence of the ovine 
PrP gene exon III fragment was confirmed by digestion of pSK7 with XrnaI (Section 
2.2. 1) and analysis by gel electrophoresis (Section 2.2.6). The XmaI restriction site is 
only present in the ovine PrP gene exon III fragment and is not present in the plasmid 
pBluescnpt-SK once digested with EcoRI and SpeI, therefore, only clones which 




KEY: Lane 1, Molecular weight marker VII (Roche, UK); Lane 2, XmaI digest & linearisation 
of pG3 DNA; Lane 3, XmaI digest & linearisation of pSK7 DNA. 
Figure 4.6 Confirmation of the presence of the 3XFLAG I'm DNA sequence in 
the plasmids pSK7 & pG3 by digestion with XmaI 
Presence of 3XFLAGTM DNA sequence was confirmed by digestion with the restriction enzyme 
Xmal which cleaved the plasmids pSK7 (8.8 kb) and pG3 at one site only, confirming that the 
3XFLAGTM DNA sequence (containing a unique Xmal site) was successfully inserted into the 
plasmids which did not contain an Xmal site. 
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Figure 4.7 Cloning strategy for ovine PrP mini-gene Construct 1 
(pConstructl) 
The Suffolk sheep (Genbank U67922) PrP gene exon Ill, including the ovine PrP gene ORF, a short 
5'UTR, the 3UTR (cleaved at the Spel restriction site) and a 700 bp intron sequence (5') (total 
fragment size of 5.8 kb) was cloned into pBluescript-SK (3 kb) using EcoRl & Spel restriction sites to 
produce pSK7 (total plasmid size of 8.8 kb). The modified 3XFLAGTM sequence (76 bp) was cloned 
into a unique Xmal restriction site within the ovine PrP gene ORE in pSK7 to produce p7FLAG (8.9 
kb). The 0.5 kb Cheviot PrP promoter fragment was cloned 5' of the ovine PrP gene exon Ill 
fragment in p7FLAG using Apal & EcoRl restriction sites to produce pConstructi (approximately 9.4 
kb). Polyadenylation sites are marked A-i to A-3. 
4.2.1.3 Insertion of the ovine PrP gene exon III into the vector pGEM 
to produce the plasmid pG3 
In order to produce a plasmid which contained the ovine PrP gene exon Ill 
with only two polyadenylation sites, numbers 1 and 2, the plasmid pGEM-7Zf(+) 
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(Promega, UK) was cut with the restriction endonucleases EcoRI and C/al (Section 
2.2.1) within its multi-cloning site (Figure 4.8). This resulted in the linearisation of 
the plasmid and in the loss of a X,nal site from this vector, which aided in the later 
cloning of the 3XFLAGTM DNA sequence (Figure 4.8). The ovine PrP gene exon III 
fragment was removed from the plasmid pGEM.3kb (Elaine Marshall, NPU) with the 
EcoRI & Gal restriction enzymes (Section 2.2.1). The ovine PrP gene exon III 
EcoRl site lies at position 21532 bp, whilst the C/al site lies at position 25297 bp, 
using the Suffolk PrP gene numbering (GenBank accession number = U67922). This 
digestion resulted in the removal of a section at the 3'end of exon III, including the 
removal of the third polyadenylation site, producing an exon III fragment of 
approximately 4 kb. The EcoRI/ClaI exon III fragment was ligated into pGEM-
7Zf(+), producing the plasmid pG3 (Section 2.2.4). The presence of the ovine PrP 
gene exon III fragment was confirmed by digestion of pG3 with Xmal (Section 2.2. 1) 
and analysis by gel electrophoresis (Section 2.2.6). The XmaI site is only present in 
the ovine PrP gene exon III fragment and is not present in the plasmid pGEM-7Zf(+) 
once digested with EcoRI and Cia I, therefore, only clones which contained the exon 
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Figure 4.8 Cloning strategy for ovine PrP mini-gene Construct 2 (pConstruct2) 
The Suffolk sheep (Genbank U67922) PrP gene exon III, including the ovine PrP gene ORE, a short 
5'UTR, the 3'UTR (cleaved at the Cial restriction site) and a 700 bp intron sequence (6) (total 
fragment size of 3.8 kb) was cloned into pGEM-7Zf(+) (3 kb) using EcoRl & Clal restriction sites to 
produce pG3 (6.8 kb). The modified 3XFLAGTM sequence (76 bp) was cloned into a unique Xmal 
restriction site within the ovine PrP gene ORF in pG3 to produce p3FLAG (6.9 kb). The 0.5 kb 
Cheviot PrP promoter fragment was cloned 5' of the ovine PrP gene exon Ill fragment in p3FLAG 
using Apal & EcoRl restriction sites to produce pConstruct2 (7.4 kb). Polyadenylation sites are 
marked A-i to A-3. 
4.2.1.4 Insertion of the 3XFLA G 11w DNA sequence into the ovine PrP 
gene exon III within the plasmids pSK7 & pG3 
The plasmids pSK7 (Section 4.2.1.2) & pG3 (Section 4.2.1.3) were cut at the 
unique XmaI restriction site within the ovine PrP gene exon III (Section 2.2.1) and 
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the 3XFLAGTM  DNA sequence fragment, flanked by XmaI restriction sites (Section 
4.2.1.1) was ligated into the linearised plasmids (Section 2.2.4), producing the 
plasmids p7FLAG and p3FLAG, respectively (Figures 4.7 & 4.8, Pages 141 & 143). 
4.2.1.5 Sequencing of p7FLAG and p3FLAG DNA 
The correct sequence of the 3XFLAGTM  DNA within the ovine PrP gene exon 
III in the plasmids p7FLAG and p3FLAG was confirmed by Sanger sequencing 
(Section 2.3) using the Flag Reverse primer (Table 2.1) (Figure 4.9). The full 
sequence is shown in Figure 4.10 (Page 146). 
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G A T C 	GATC 
Figure 4.9 Sanger sequencing gel of p3FLAG & p7FLAG 
plasmid DNA using the Flag reverse primer 
Sanger sequencing gel shows the correct sequence for the modified 3XFLAGTM DNA fragment 
within the vectors p3FLAG & p7FLAG, including the XmaI restriction site and the additional 
bases included to maintain reading frame. It also shows the correct sequence and location of 
the 3XFLAGTM DNA sequence within the ovine PrP gene ORF. 
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gtactgtagctaatgttcctactgctactgttc -iI  
Hi sAspi 1 eAspTyrLyaAspAspAspAspLyBTyrPrOGlYGlflGlY 
KEY: 
=Ovine PrPexon III DNA 
(;rceii Text 	= Modified DNA (i.e. Additional Bases and XmaI site) 
Blue Text 	= 3XFLAGTM DNA 
Figure 4.10 3XFLAG TMDNA sequence within the ovine PrP exon III 
in the plasmids p7FLAG and p3FLAG 
Diagram shows the modified ovine PrP gene ORF including the 3XFLAGTM sequence incorporated into 
the unique Xmal restriction site. The diagram also shows how reading frame of both the 3XFLAGTM 
sequence and the ovine PrP gene ORE were maintained by the use of additional bases. 
4.2.1.6 Insertion of the Cheviot PrP promoter fragment into the 
plasmids p7FLAG and p3FLAG to produce the ovine PrP mini-
gene constructs (pConstructl & pConstruct2) 
The 0.5 kb ovine PrP gene promoter fragment was isolated from the plasmid 
pNPU-1 10 (O'Neill et al., 2003), using the restriction endonucleases EcoRl and SphI 
(Section 2.2.1). The promoter fragment was then ligated (Section 2.2.4) into the 
plasmid pGEM-T EasyTM using the same restriction sites. The reason for cloning the 
0.5 kb promoter into pGEM-T Easy 1M was that it contained EcoRI and ApaI 
restriction sites, which would allow the insertion of the promoter into the plasmids 
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p7FLAG and p3FLAG, in the correct position and orientation. The 0.5 kb promoter 
fragment was cleaved from pGEM-T EasyTM  with the restriction endonucleases 
EcoRI and ApaI (Section 2.2.1) and isolated by gel extraction (Sections 2.2.6 & 
2.2.7). The resulting ovine PrP gene promoter fragment was ligated into linearised 
plasmids p7FLAG and p3FLAG using the EcoRI and ApaI restriction sites (Section 
2.2.4), which positioned the promoter in the correct orientation 5' to the ovine PrP 
gene exon III fragment, producing the ovine PrP mini-gene Constructs 1 
(pConstructl) and 2 (pConstruct2), respectively (Figures 4.7 & 4.8, Pages 141 & 
143). The presence of the ovine PrP gene promoter within these plasmids was 
confirmed by digestion with EcoRI and ApaI (Section 2.2.1) and analysis by gel 
electrophoresis (Section 2.2.6) (Figure 4.11). 
Linearised 	 -' 	 Linearised 
plasmid DNA - 	 - 	plasmid DNA 
4 0.5 kb promoter 
4 0.5 kb promoter 
DNA M DNA 
	
12 	 34 
KEY: Lanes I & 3, Molecular weight marker VI (Roche, UK); Lane 2, pConstructl DNA 
digested with EcoRI & ApaI; Lane 4, pConstruct2 DNA digested with EcoR! & ApaI. 
Figure 4.11 Confirmation of the presence of the 0.5 kb Cheviot promoter 
sequence within p Construct 1 & pConstruct2 by digestion with EcoRl & Apal 
Figure shows the presence of the 0.5 kb Cheviot promoter DNA fragment as confirmed by gel 
electrophoresis of pConstructl and pConstruct2 DNA following digestion with EcoRl & Apal 
restriction enzymes. The linearised plasmid DNA can also be clearly seen, indicating the 
successful digestion of the construct DNA. 
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4.2.1.7 Generation of the ovine PrP mini-gene Construct 3 
(pConstruct3) by manipulation of the plasmid pConstruct2 
pConstruct2 was digested with the restriction endonucleases KpnI and NsiI 
(Section 2.2.1), producing KpnI/NsiT digestion fragments of 5.6 kb, 0.95 kb and two 
NsiI digestion fragments of 0.3 kb each (Set A, Figure 4.12). 
B 
4 5.6 kb 
4 0.95 kb 
0.55 kb 
4 0.3 kb 	 0.4 kb 
12 
KEY: Set A: Lane 1, Molecular weight marker VII (Roche, UK); Lanes 2 & 3, pConstruct2 
DNA digested with KpnI & NsiI. Set B: Lane 1, Molecular weight marker VI (Roche, UK); 
Lane 2, 0.95 kb fragment digested with the restriction enzyme PstI. 
Figure 4.12 Preparation of pConstruct3 by digestion of pConstruct2 
Figure A shows the presence of the 0.3 kb, 0.95 kb and 5.6 kb bands following digestion of 
pConstruct2 with KpnI & Nsil restriction enzymes. The 5.6 kb band was isolated by gel 
extraction and the 0.3 kb band was discarded. Figure B shows the presence of the 0.55 kb & 
0.4 kb bands following digestion of the 0.95 kb band with the Pstl restriction enzyme. 
The 5.6 kb and 0.95 kb fragments were separated by gel electrophoresis 
(Section 2.2.6) and isolated by gel extraction (Section 2.2.7), whilst the two 0.3 kb 
NsiI digestion fragments were discarded. The 0.95 kb fragment was further digested 
with the restriction endonuclease PstI (Section 2.2.1), producing a 0.4 kb fragment 
and a 0.55 kb fragment. These two fragments were further separated by gel 
electrophoresis (Section 2.2.6), and the 0.55 kb fragment, containing the second 
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polyadenylation sequence was discarded (Set B, Figure 4.12). The 0.4 kb fragment, 
flanked by PstI and KpnI sites was isolated by gel extraction (Section 2.2.7) and re-
ligated into the initial 5.6 kb KpnL'NsiI fragment using the homologous PstIINsiI 
restriction sites (Section 2.2.4) and the KpnI restriction site to produce pConstruct3 
(Figure 4.13). 
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Figure 4.13 Generation of pConstruct3 from the plasmid pConstruct2 
The plasmid pConstruct2 was digested with Ns,1 & Kpnl producing fragments of 5.6 kb, 0.95 kb and 
two of 0.3 kb. The 5.6 kb & 0.95 kb fragments were recovered by gel extraction and the 0.95 kb 
fragment was further digested with Pstl to yield fragments of 0.4 kb & 0.55 kb. The 0.4 kb fragment 
was isolated by gel extraction and annealed to the 5.6 kb fragment using the homologous Pstl/Nsil 
restriction sites to produce pConstruct3. Polyadenylation sites are marked A-i & A-2. The sizes given 
(kb) indicate the full length of the fragment in each case and are not to scale. 
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The successful production of the plasmid pConstruct3 was confirmed by 
digesting pConstruct3 with the restriction enzymes XbaI, ClaI, KpnI & NsiI (Figure 
4.14). Digestion with Xbal produced two fragments of 2.6 & 3.4 kb, consistent with a 
successful ligation (Figure 4.14). Digestion with ClaI and KpnI both linearised the 
plasmid pConstruct3 producing a 6 kb fragment as expected, whilst digestion with 
NsiI did not cut pConstruct3 (Figure 4.14) consistent with the NsiI site being ablated 
following the ligation of this site with the PstI site (Figure 4.13). 
123456 
KEY: Set A: Lane 1, Molecular weight marker VII (Roche, UK); Lane 2, pConstruct3 DNA 
digested with the restriction enzyme XbaI; Lane 3, pConstruct3 DNA digested and linearised 
with the restriction enzyme Clal; Lane 4, pConstruct3 DNA digested and lineansed with the 
restriction enzyme KpnI; Lane 5, pConstruct3 DNA digested and not linearised with the 
restriction enzyme NsiI; Lane 6, Molecular weight marker VI (Roche, UK). 
Figure 4.14 Confirmation of the successful production of the plasmid 
pConstruct3 by digestion with restriction enzymes 
The successful production of pConstruct3 was confirmed by digestion of the plasmid DNA with 
the following restriction enzymes: Xbal producing two fragments of 2.6 & 3.4 kb consistent with 
a successful ligation, C/al or Kpnl producing a linearised DNA fragment of 6 kb, Nsil which 
failed to cut the plasmid consistent with the successful ablation of this site following the re-
ligation of the pConstruct3 DNA via the Pstl/Nsil restriction sites. 
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4.2.1.8 Ablation of polyadenylation site I within the plasmids 
pConstructl and pConstruct2 to produce the plasmids 
pConstruct4 and pConstruct5 
The ovine PrP mini-gene Constructs 4 (pConstruct4, polyadenylation sites 2 
& 3) and 5 (pConstruct5, polyadenylation site 2) were produced from the plasmids 
pConstructl (polyadenylation sites 1, 2 & 3) and pConstruct2 (polyadenylation sites 
1 & 2), respectively. The first polyadenylation site in the ovine PrP gene exon HI 
fragment within the plasmids pConstructl and pConstruct2 lies within a unique Pad 
restriction endonuclease site, and these plasmids were linearised with Pad (Section 
2.2.1), leaving 3'overhangs on both ends (Figure 4.15). The 3' overhangs were then 
digested with the Kienow fragment of DNase I (Section 2.2.2), deleting the two 
bases from the first polyadenylation sequence and leaving blunt ends. The blunt 
ended plasmids were re-ligated (Section 2.2.4) to produce the plasmids pConstruct4 
and pConstruct5 (Figure 4.15). 
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Figure 4.15 Ablation of the first polyadenylation site within the ovine PrP exon I/I 
within the plasmids pConstruct2 & 510 produce pConstruct4 & 5 
The first polyadenylation signal in the plasmids pConstructl & pConstruct2 was ablated by digestion of 
the plasmids at the unique Pacl restriction site that lies within this signal. Digestion with Pacl left 3' 
overhangs on both ends of the digested DNA, which were digested with the Klenow fragment of DNase 
I leaving blunt ends. The blunt ends were then annealed to produce the plasmids pConstruct4 & 
pConstruct5 which contained the now ablated first polyadenylation signal. Polyadenylation sites are 
marked A-i to A-3. Size bar indicates approximate length of 1 kb of DNA. 
The ablation of the Pacl restriction site within the plasmids pConstruct4 and 
pConstruct5 was confirmed by digestion with the Pact restriction endonuclease, 
which did not cut the plasmids, indicating that the site had been successfully deleted 
(Figure 4.16). Finally, maxi-prep DNA of all five ovine PrP mini-gene constructs 
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(plasmids pConstructl-pConstruct5) was produced (Section 2.2.12), ready for 
transient transfection into the ovine cell cultures (Section 4.2.5). 
KEY: Lane 1, Molecular weight marker VII (Roche, UK); Lanes 2 & 3, pConstruct5 DNA 
digested and not linearised with the restriction enzyme Pad; Lanes 4 & 5, pConstruct4 DNA 
digested and not linearised with the restriction enzyme Pad. 
Figure 4.16 Confirmation of the ablation of the Pacl restriction site 
within exon Ill in the plasmids pConstruct4 & pConstruct5 
The successful ablation of the first polyadenylation site within the ovine PrP gene 3'UTR was 
confirmed by digestion of the pConstruct4 & pConstruct5 DNA with Pad. The construct DNA 
was not cleaved by Pacl indicating the successful ablation of the first polyadenylation site and 
re-annealing of the construct DNA. 
4.2.1.9 Sequencing of the plasmids pConstructl & pConstruct2 
pConstruct 1 and pConstruct2 were sequenced in order to confirm that the 
required elements were in place in the PrP mini-gene constructs that would allow the 
mini-gene RNAs to be correctly spliced and processed. pConstructl and 
pConstruct2, upon which plasmids pConstruct3-pConstruct5 were based, were 
sequenced by the Sanger method (Section 2.3), using a series of three ovine PrP gene 
promoter-specific primers (Promseq 1-3, Table 2.2). Sanger sequencing confirmed 
that all of the splicing elements were in place, including the 5' splice donor sequence 
(red text, Figure 4.17, Page 155), the 3' splice acceptor sequence (green text, Figure 
4.17) and the branch-point sequence (blue text, Figure 4.17). This figure shows a 
line-up of the pConstructl sequence (1-1067 bp) with the Suffolk PrP gene sequence 
(5701-22422 bp, GenBank accession number = U67922). The ovine PrP mini-gene 
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sequence is homologous to the U67922 promoter/intron sequence, however, it does 
highlight the four single base changes between the Suffolk promoter sequence 
(U67922), and the Cheviot promoter sequence used in this study (Figure 4.17). A 
short 27 base segment of DNA from the multi-cloning site of the plasmid pNPU- 110 
(based on the original plasmid pT7/T3c- 18) from which the 0.5 kb Cheviot promoter 
was obtained (Section 4.2.1.6), was incorporated into all of the constructs. The 27 bp 
sequence was lined-up against the original pT7/T3a- 18 plasmid sequence (211-237 
bp) with no base changes observed, and is shown in Figure 4.17. In addition, a 702 
bp gap was introduced in this sequence diagram to allow the 5' end of exon III to be 
shown (Figure 4.17). The line-up highlights the incorporation of the 3XFLAGTM 
sequence into the ovine exon III DNA, and demonstrates how the frame of both the 
PrP ORF (magenta text, Figure 4.17), and the 3XFLAGTM epitope was maintained by 
the incorporation of additional bases (bold text, Figure 4.17). These results showed 
that the plasmids pConstructl and pConstruct2 contained all of the sequence 
elements required for correct splicing and indicate that they should be spliced 
normally in transient transfection assays. 
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Figure 4.17 Line-up of pConstruct 1 plasmid DNA & Suffolk PrP gene DNA 
sequences (GenBank accession number = U67922) 
Figure shows the sequence line-ups of the pConstruct 1 DNA with: 1. Suffolk sheep (Genbank = 
U67922) promoter/exon I sequence. 2. pT7IT3a-18MS promoter sequence used in the cloning of 
the 0.5 kb Cheviot promoter fragment. 3. Suffolk sheep (U67922) exon Ill sequence. 
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4.2.2 Transient transfection of ovine PrP mini-gene constructs 
(pConstructl -pConstruct5) 
A wide variety of techniques are available to achieve the delivery of DNA 
molecules into cultured cells. However, no single method will work for all cell types 
and the conditions used must be optimised for each individual cell culture. There are 
two basic methods for introducing nucleic acids into cultured cells; biochemical and 
physical methods. Biochemical methods include DEAE-dextran, calcium phosphate, 
and liposome mediated transfection methods, whilst physical transfection methods 
include direct microinjection, biolistic particle delivery, and electroporation. 
Previous studies by Marshall (2000) analysed the ability of a selection of 
these techniques to transfect the ovine cell cultures (sA80BR, IS! 2OLiv and 
ISl2OCer) with a plasmid consisting of the ovine PrP 0.5 kb promoter linked to a 
CAT reporter gene. Marshall (2000) showed that the Superfect transfection reagent 
(Qiagen, UK) was the most efficient method of transfecting the ovine cell cultures, 
showing a 40-80 % transfection efficiency with the sA80BR cell culture and with no 
observed cell death. It was decided to use Superfect transfection reagent for the 
transient transfection of the ovine PrP mini-gene DNA into the ovine cell cultures. 
However, it was first necessary to optimise the transfection conditions for each of the 
ovine cell cultures (sA80BR, pA80BR, ISl2OLiv, ISl2OMed and ISl2OCer, Sections 
2.5.1-2.5.3). The two most important aspects of the Superfect transfection process to 
be optimised are the amount of DNA added and the charge ratio of Superfect to 
DNA, and these factors were optimised for all of the ovine cell cultures and for the 
murine N2a cells. 
4.2.3 Optimisation of transient transfection conditions for ovine & 
murine cell cultures 
The reporter vector pSV--galactosidase (Promega, UK) was used to 
optimise Superfect transfection conditions in the cell cultures by analysing reporter 
activity in transfected cell lysates using the f-Galactosidase enzyme assay system 
(Promega, UK). The assay involves incubating the extract with the -galactosidase 
enzyme substrate ONPG (o-nitrophenyl--D-galactopyranoside), -ga1actosidase 
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then hydrolyses the colourless substrate to o-nitrophenyl, which is yellow in colour. 
The colour reaction is then assayed by measuring the absorbance at 420 nm (Section 
2.6.3). Optimisation was carried out as previously described (Section 2.6.7), using a 
range of DNA concentrations and differing volumes of Superfect reagent. The 
optimum conditions for each of the cell cultures are detailed below (Table 4.1). 
The vector pSV-3-galactosidase was then used to control for transfection 
efficiency, and the cell cultures were co-transfected with the ovine PrP mini-gene 
DNA and the pSV-3-galactosidase DNA at a ratio of 2:1. The assumption was made 
that the reporter vector and the ovine PrP mini-gene construct DNA would be 
transfected with equal efficiency in the cell cultures, but that the different cell 
populations would be transfected with differing efficiencies. Therefore, measuring 
the amount of -galactosidase activity in the transfected cell extracts allowed the 
level of transfection efficiency to be determined for an individual cell lysate. The 
volume of each cell lysate used for protein analysis was then adjusted according to 
the efficiency of the transfection reaction. This was achieved by giving a score of 
100 to the extract with the lowest absorbance value at 420 nm (therefore considered 
as having the lowest transfection efficiency) and all of this extract was added into the 
immunoprecipitation reaction. The volume of the other transfected cell extracts 
added into the immunoprecipitation reactions was then corrected accordingly, by 
dividing their absorbance values by the absorbance of the lowest efficiency extract. 
This value was then divided by the total volume of the extract (-S 250 l.Ll following 
the use of 250 p1 for the -Galactosidase assay) to give a volume in microlitres of the 
extract to be added for immunoprecipitation. 
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sA80BR 4 20 5:1 
pA80BR 4 20 5:1 
IS12OLiv 4 8 2:1 
ISI2OCer 4 20 5:1 
ISI2OMed 4 40 10:1 
Murine N2a 4 20 5:1 
Table 4.1 	Optimum conditions for Superfect transfection of ovine and 
murine cell cultures 
Details the optimum transfection conditions with Superfect for each of the ovine and murine 
cell lines as determined by transient transfection with the pSV-3-galactosidase plasmid. 
Transfection efficiency was then calculated by measuring the amount of 13-galactosidase 
enzyme activity in the cell lysates of the transfected cell lines for each of the DNA 
concentrations and volumes of Superfect as detailed in the table. 
4.2.4 Optimisation of anti-FLAGm antibody conditions for detection of 
3XFLAG tagged PrPC  by Western blot 
Attempts to detect 3XFLAGTM  tagged PrPC  with an antiFLAGTM  monoclonal 
antibody (M2, Sigma-Aldrich, UK) following transfections with the ovine PrP mini-
gene constructs in ovine sA80BR and IS 1 2OCer, and murine N2a cell cultures failed 
(data not shown). These initial experiments were repeated again using the 
manufacturers recommended conditions for Western blotting with the M2 antibody, 
however, no 3XFLAGTM P rPC was detected in the transfected cell lysates, and the 
background observed on the Western blot with the M2 antibody was very high (data 
not shown). It was decided to optimise the blotting conditions for the M2 antibody 
for the detection of the 3XFLAGTM epitope. A control FLAG TM  protein (amino-
terminal FLAG TM-bacterial alkaline phosphatase (BAP) fusion protein (FLAG TM_ 
BAP), molecular weight 49 kDa, Sigma-Aldrich, UK) was utilised to optimise the 
Western blotting conditions for the M2 antibody. The FLAG TM-BAP protein would 
also serve as a positive control protein on Western blots, as such it was important to 
determine the optimum amount of FLAGTMBAP  protein to load as a positive control. 
The dilution of the M2 antibody recommended by Sigma-Aldrich is 1:500, however, 
the use of the antibody at this dilution resulted in very high levels of background 
(data not shown). It was therefore decided to attempt to detect the FLAG TM-BAP 
protein with the M2 antibody on Western blots (Section 2.8) at dilutions of 1:2500 
and 1:5000 in order to reduce the background reaction (Figure 4.18, only 1:5000 blot 
shown). The secondary antibody used throughout this chapter was a peroxidase 
conjugated affinipure rabbit anti-mouse IgG (Stratech, UK) and this was used with 









KEY: Lane 1, FLAG-BAP control protein (I rig); Lane 2, FLAG TM-BAP (100 ng); Lane 3, 
FLAG TM-BAP (10 ng); Lane 4, FLAG TM-BAP (1 ng); Lane 5, FLAG T11-BAP(100 pg). Primary 
antibody = M2 (anti-FLAGTM) at 1:5000 dilution. Secondary antibody at 1:25,000. 
Figure 4.18 FLAG 1-44BAP  control protein detected by Western blot with anti- 
FLAG TMM2 antibody 
Western blot shows a dilution series of the FLAG-BAP control protein (1 Vg - 100 pg). Red 
arrowhead indicates the location of the FLAG-BAP control protein (Molecular weight = 49 KDa). 
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The use of the M2 antibody at a dilution of 1:5000 resulted in the detection of 
the FLAG TM-BAP protein (Figure 4.18). The FLAG TM-BAP protein was observed 
over a range of concentrations down to I ng, but not at the 100 pg level (Figure 
4.18). The use of the M2 antibody at a dilution of 1:2500 resulted in similar levels of 
FLAG TM-BAP protein detection, however, the background reaction was elevated 
(data not shown). The optimum concentration of the FLAGTMBAP  protein would 
appear to be between 10 ng and I ng, as at these levels the protein is clearly 
detectable and the background is relatively low in comparison (Figure 4.18). The 
ability of the M2 antibody to detect the FLAG TM-BAP protein was further analysed 
by immunoprecipitating the FLAG TM-BAP protein with the M2 antibody (Section 
2.7.3). The samples were analysed on Western blot (Section 2.8) for the presence of 
the immunoprecipitated FLAG TMBAP  protein using M2 as the detecting antibody 
(Figure 4.19). 
MW 







KEY: Lane I, FLAG TM-BAP control protein (100 ng) + M2 antibody as precipitating antibody; 
Lane 2, FLAG TM-BAP (10 ng) + M2 antibody; Lane 3, FLAG TM-BAP (1 ng) + M2 antibody; 
Lane 4, M2 antibody only; Lane 5, FLAG TM-BAP (1 ng) only. Primary antibody = M2 (anti- 
FLAGTM) at 1:5000 dilution. Secondary antibody at 1:25,000. LC = precipitating antibody light 
chain, HC = precipitating antibody heavy chain. 
Figure 4.19 FLAG T"-BAP control protein immunoprecipitated with 
anti-FLAGTM M2 antibody 
Western blot shows a dilution series of the FLAG-BAP control protein immunoprecipitated with the 
anti-FLAG M2 monoclonal antibody and detected with the same antibody. Red arrow indicates the 
location of the immunoprecipitated FLAG-BAP control protein (Molecular weight 49 KDa). 
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As can be seen from Figure 4.19 it appeared that the antiFLAGTM 
monoclonal antibody M2 was successful at immunoprecipitating the FLAG TM-BAP 
protein, and again the optimum concentration of control was between 10 ng and I ng. 
The levels of background on this blot were notably high and two of these bands (25 
and 50 kDa) are likely to be the result of cross reactivity between the secondary 
antibody and the light (LC) and heavy chains (HC) of the precipitating M2 antibody 
(Figure 4.19). It was therefore decided to try and further dilute the M2 antibody for 
Western blotting and to include on these Westerns, molecular weight markers as 
control proteins, in order to assess the M2 antibodies cross reactivity with non-
specific proteins (data not shown). The results showed that M2 reacted with proteins 
in the molecular weight marker mixture at dilutions of between 1:500- 1:2500, whilst 
the antibody still reacted with the FLAG TM-BAP protein (1 ng) at these 
concentrations (data not shown). When M2 was diluted to between 1:5000 and 
1:7500 the cross reactivity with the molecular weight markers was prevented, and the 
antibody was still able to detect the FLAG TM-BAP protein (1 ng). These results 
indicated that M2 would still function if diluted out to 1:7500 but that the 
background reaction may be reduced. This was tested further, by analysing the 
ability of M2 to cross react with elements in raw M-per produced (Section 2.5.9.3) 
N2a cell lysates (Figure 4.20). M2 was diluted out from 1:5000 to 1:10,000 and a 15 
xl aliquot of a 500 tl M-per produced N2a cell lysate was loaded adjacent to 1 ng 
of FLAG TM-BAP protein at each antibody dilution (Figure 4.20). Even at a dilution of 
1:10,000 M2 was still able to detect 1 ng of FLAGTMBAP protein, however, even at 
this dilution the background observed with the N2a cell lysate was still very high, 
raising concerns about the quality of the M2 antibody and its ability to function in 
this system without producing high levels of background. 
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KEY: Lanes 1, 3 & 5, FLAG TM-BAP control protein (1 ng); Lanes 2, 4 & 6, 15 il of a 500 iii 
M-per produced N2a cell lysate. Primary antibody = M2 (anti-FLAG T"), Lanes 1-2, 1:5000 
dilution; Lanes 3-4, 1:7500 dilution; Lanes 5-6, 1:10,000 dilution. Secondary antibody, 
1:25,000. 
Figure 4.20 FLAG rMBAP control protein and N2a cell lysates 
Western blot shows 1 ng of FLAG-BAP control protein alongside 15 .tl of a 500 j.tl M-per 
produced N2a cell lysate detected using the anti-FLAG M2 antibody. As can be seen 1 ng of the 
FLAG-BAP control protein produces a strong signal, however the N2a cell lysate also produces 
a high background signal with the M2 antibody, indicating a lack of specificity. 
An anti-FLAG T11  polyclonal antibody (Sigma-Aldrich, UK) was tried as an 
immunoprecipitating antibody as it was hoped that this would provide more options 
for immunoprecipitating the 3XFLAGTM  tagged PrPC  expressed from the ovine PrP 
mini-gene constructs. In addition, it would provide the option of using of an anti-PrP 
monoclonal antibody like 6H4 as the detecting antibody, which may get around the 
problem of high background observed with M2 when used as a detecting antibody 
(Figure 4.20). Attempts to immunoprecipitate (Section 2.7.3 & 2.8) the FLAG TM_ 
BAP protein using the antiFLAGTM  polyclonal antibody were inconclusive (data not 
shown). The antibody did not successfully immunoprecipitate the FLAG TM-BAP
protein and it appeared to react strongly with the secondary antibody, resulting in 
strong light (LC) and heavy chain (HC) bands on the Western blots. In addition, high 
levels of background were observed with the M2 antibody on samples 
162 
immunoprecipitated with the antiFLAGTM  polyclonal antibody (data not shown). 
Finally, it was decided to optimise the conditions for the M2 antibody using the 
FLAG TM-BAP protein on dot blots (Section 2.8.4, data not shown). The dot blots 
confirmed that the optimum dilution of the M2 primary antibody for detecting down 
to 1 ng of FLAG TM-BAP protein was 1:5000. Dot blots (Section 2.8.4) were also used 
to optimise the dilution of the secondary antibody whilst using the primary antibody 
at the optimum dilution of 1:5000, the results showed that the optimum dilution of 
the secondary antibody was 1:20,000 (data not shown). It was decided to attempt to 
detect 3XFLAGT11  tagged PrPC  in cell cultures transiently transfected with the ovine 
PrP mini-gene constructs using the optimum antibody dilutions determined from the 
dot blots. 
4.2.5 In vitro analysis of recombinant 3XFLAG tagged PrPC  in ovine 
and murine cell cultures by Western blotting 
The expression of 3XFLAGTM  tagged recombinant ovine PrPC  was analysed 
from ovine and munne N2a cell cultures transfected (Section 2.6) with the ovine PrP 
mini-gene constructs. Cultured IS12OLiv and munne N2a cells were transiently 
transfected with the plasmids pConstructl-pConstruct5, using 20 .tl (N2a cells) or 8 
il (IS l2OLiv cells) of Superfect reagent (Section 2.6.5). In addition, a total of 4 tg of 
DNA, at a ratio of 2:1 of ovine PrP mini-gene construct DNA: reporter vector DNA, 
was added (i.e. 2.6 .tg of mini-gene construct DNA and 1.4 tg of -ga1actosidase 
reporter DNA). Following incubations of 3, 6 or 24 hours the transfected cells were 
lysed with Mem-per reagent (Section 2.5.9.4) and transfection efficiency, as 
determined by 3-galactosidase activity (Section 2.6.3), was measured in the cell 
extracts. The amount of each individual cell lysate added into the 
immunoprecipitation reaction was determined, as described in Section 4.2.3, and the 
cell extracts were analysed for recombinant PrP' expression. Recombinant ovine P rPC 
was isolated by immunoprecipitation using the PrP specific polyclonal antibody 1A8 
(Section 2.7.3). Immunoprecipitated proteins were separated by SDS-PAGE, 
transferred to a PVDF membrane, and recombinant PFPC  was detected on Western 
blot (Section 2.8) with the anti-FLAG TM  M2 monoclonal antibody (using the 
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optimum primary and secondary antibody dilutions as determined by dot blots in 
Section 4.2.4). Figure 4.21 shows N2a cells transfected with the plasmids 
pConstructl-pConstruct5, which were analysed for the expression of 3XFLAGTM 
tagged PrPC  expression following 3 hour, or 6 hour post-transfection incubation 
periods. The transfections did not appear to have been successful, and no 
3XFLAGTM-tagged PrPC was detected (Figure 4.21). Two antibody bands were 
observed, which represent the light (LC) and heavy chains (HC) of the precipitating 
1 A8 antibody (Figure 4.21). Two bands (marked with red arrowheads) can be seen 
located between the two antibody bands, however, these bands are also present in the 
cell lysates that were transfected with, either 3-galactosidase DNA only, or with no 
DNA (Figure 4.21). These bands may represent a cross-reaction of the antiFLAGTM 
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KEY: N2a cell extracts prepared with Mem-per and transfected with the stated plasmid. Lanes 
1+ 7, pConstruct5 DNA; Lanes 2+ 8, pConstruct2 DNA; Lanes 3 + 9, pConstruct4 DNA; Lanes 
4 + 10, pConstructl DNA; Lanes 5 + 11, 3-galactosidase DNA only; Lanes 6 ± 12, no DNA; 
Lanes 1-6 were analysed 3 hours post transfection; Lanes 7-12 were analysed 6 hours post 
transfection. Primary antibody = M2 (anti-FLAG"), 1:5000 dilution, Secondary antibody 
1:20,000 dilution. LC = precipitating antibody light chain, HC = precipitating antibody heavy 
chain 
Figure 4.21 Trans fected N2a cell lysates immunoprecipitated with 1A8, 
analysed for 3XFLA GTM  tagged PrP, 3 & 6 hours post transfection 
Western blot shows Mem-per extracts from N2a cells transfected with the ovine PrP mini-gene 
construct DNA, cell extracts were produced 3 & 6 hours post-transfection. As can be seen two 
unidentified bands (Red arrowheads) were observed between the bands for the light (LC) and 
heavy chain (HG) bands of the precipitating antibody (1A8), however these bands are also 
present in the control samples, indicating that they do not correspond to recombinant PrP. 
Figure 4.22 shows N2a cells transfected with the plasmids pConstructl-
pConstruct5 (Section 2.6) which were analysed for the expression of 3XFLAGTM 
tagged PrPC  expression following a 24 hour post-transfection incubation period 
(Section 2.7.3 & 2.8). Again the transfections do not appear to have been successful, 
and no 3XFLAGT11-tagged PrPC  was detected (Figure 4.22). The two antibody bands 
representing the light (LC) and heavy chains (HC) of the precipitating 1A8 antibody 
were again observed (Figure 4.22). The same bands (marked with red arrowheads), 
as observed in Figure 4.21, are present at a molecular weight indicative of PrPC, 
however this band is also present in the non-transfected control samples. Again, as in 
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Figure 4.2 1, it is likely that these bands represent a cross-reaction of the antiFLAGTM 
M2 antibody with unknown proteins present in the cell extracts. 
MW S 
(kDa) 
43 	 - 	
p 
- 	 Unidentified 
29 	 bands 
'4 LC 
18.4 - 
1 	2 3 4 	5 6 	7 	8 9 10 11 12 13 14 
KEY: N2a cell extracts prepared with Mem-per and transfected with the stated plasmid. Lanes 
1-2, pConstruct5 DNA; Lanes 34, pConstruct2 DNA; Lanes 5-6, pConstruct4 DNA; Lane 7, 
FLAG"'-BAP control protein (10 ng); Lane 8, Purified PrP control sample (20 mg); Lanes 9-
10, pConstructl DNA; Lanes 11-12, pConstruct3 DNA; Lanes 13-14, non-transfected N2a 
cells. Primary antibody = M2 (anti-FLAGTM), 1:5000 dilution, Secondary antibody 1:20,000 
dilution. LC = precipitating antibody light chain, HC = precipitating antibody heavy chain 
Figure 4.22 Trans fected N2a cell lysates immunoprecipitated with 
1A8 and analysed for 3XFLAGTM  tagged  PrPc,  24 hours post transfection 
Western blot shows Mem-per extracts from N2a cells transfected with the ovine PrP mini-gene 
construct DNA, cell extracts were produced 24 hours post-transfection. As can be seen two 
unidentified bands (Red arrowheads) were observed between the bands for the light (LC) and 
heavy chain (HG) bands of the precipitating antibody (1A8), however these bands are also 
present in the control samples, indicating that they do not correspond to recombinant PrP. 
No 3XFLAGT11  tagged PrPC ,  was detected in any of the transfected cell 
cultures. Negative results were observed with all of the transfections using the PrP 
specific polyclonal antibody I A8 as an immunoprecipitating antibody and the anti-
FLAG TM M2 antibody to detect 3XFLAGTM tagged PrPC  expression from the 
transfected cell lysates. A variety of cultured cells were analysed, including, murine 
N2a, ovine sA80BR, IS 1 2OCer and IS! 2OLiv, and unfortunately none of these 
166 
transfected cell cultures have indicated any expression of recombinant PrPC  from the 
ovine PrP mini-gene constructs (only N2a data shown). As it was not possible to 
detect 3XFLAGTM  tagged PrPC  from the transiently transfected ovine and murine cell 
cultures, it was decided to check for the presence of PrP mini-gene construct mRNA 
in transiently transfected cell cultures using reverse transcriptase-PCR (RT-PCR). 
4.2.6 In vitro analysis of ovine PrP mini-gene construct mRNA by RT-
PCR 
The expression of ovine PrP mini-gene construct mRNA was analysed by 
RT-PCR (Section 2.2.16) in IS12OLiv cells transiently transfected with the plasmids 
pConstructl and pConstruct2 (Section 2.6). The ovine PrP specific primers used for 
the reverse transcription (RT) reaction were either AG23 or 643 (Table 2.1). The 
primers used in the PCR reaction were AG23, 580SH, 13741 or Flag Reverse (Table 
2.1). The two, 3XFLAGTM specific primers are specific for the ovine PrP mini-gene 
construct mRNA reverse transcriptase products, whilst the PrP specific primers 
(AG23, 580SH & 13741) will react with both endogenous PrP mRNA and ovine PrP 
mini-gene construct mRNA RT products. The expected size of the RT-PCR products 
from the mini-gene RNA with the primers AG23 and 13741 (if the RNAs are 
correctly spliced) was approximately 230 bases (Table 4.2). If splicing of the 
construct RNAs failed then a product of approximately 1000 bases would be 
expected as the 3' sequence of intron II would not be removed (encoded by 713 
bases plus 27 bases of the multi-cloning site of the plasmid pNPU-llO, between the 
0.5 kb promoter fragment and the ovine PrP gene exon III fragment) (Table 4.2). The 
expected size of the RT-PCR products with the primers AG23 and 580SH if the 
construct RNAs were correctly spliced was 580 bases and 1300 bases if not correctly 
spliced (Table 4.2). Finally the fragments expected with AG23 and Flag Reverse 
would be 215 bases if the construct RNAs were correctly spliced and 1000 bases if 
incorrectly spliced (Table 4.2). Endogenous PrP mRNA from the cultured cells 
would produce a RT-PCR product of approximately 330 bases with the primers 
AG23 & 13741, and 680 bases with the primers AG23 & 580SH (identical to that 
seen with the correctly spliced construct RNA plus 100 bases of ovine PrP gene exon 
II DNA). 
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Primer combination Size (bp) if correctly 
spliced 
Size (bp) if incorrectly 
spliced 
AG23 + 13741 230 mini-gene mRNA 1000 
330 endogenous PrP mRNA  
AG23 + 580SH 580 mini-gene niRNA 1300 
680 endogenous PrP mRNA  
AG23 + Flag Reverse 215 1000 
Table 4.2 Expected sizes of RT-PCR products from ovine PrP 
mini-gene mRNA 
Details the expected product size following RT-PCR with the stated primer combinations. 
Expected sizes are detailed for the correctly spliced and incorrectly spliced ovine PrP mini-
gene mRNA and for the endogenous PrP mRNA in bp. 
Prior to transient transfections with the ovine PrP mini-gene construct DNA, 
RNA was isolated from cultured ISl2OLiv cells (Section 2.5.11) and the presence of 
endogenous PrP mRNA was confirmed by RT-PCR (Figure 4.23). These results were 
compared to PCR products from ovine kidney cDNA (Wilfred Goldmann, NPU) 
using the PrP specific primer AG23 for the RT reaction and AG23 & 13741, and 
AG23 & 580SH for the PCR reactions (Figure 4.23). RT-PCR products of the 
expected sizes from endogenous PrP mRNA (approximately 330 bases for AG23 & 
13741 and approximately 680 bases for AG23 & 580SH) were detected confirming 
that endogenous PrP mRNA was detectable by this method in the lS12OLiv cells 
(Figure 4.23). 
680 bp 
I 330 bp 
1 	234 	567 
KEY: Ovine ISI2OLiv cell RNA samples analysed by RT-PCR. Lane 1. Molecular weight 
marker VI (Roche, UK); Lanes 2-3, IS 1 20Liv RNA using AG23 & 580SH primers; Lane 4, 
Ovine kidney cDNA sample using AG23 & 580S1-1 primers; Lanes 5-6, ISl2OLiv RNA using 
AG23 & 13741 primers; Lane 7. Ovine kidney cDNA using AG23 & 13741 primers. 
Figure 4.23 RT-PCR analysis of lS12OLiv cell RNA for endogenous 
ovine PrP mRNA expression 
Agarose gel shows untransfected ovine lS12OLiv (liver) cell total RNA analysed for the 
presence of endogenous PrP mRNA expression, expected sizes for RT-PCR fragment are: 680 
bp using the AG23 & 580SH primers or 330 bp using the AG23 & 13741 primers. 
Cultured IS12OLiv cells were transiently transfected with the plasmids 
pConstructl and pConstruct2, using 8 p.1 of Superfect reagent and a total of 4 p.g of 
mini-gene construct DNA per transfection (Section 2.6). Following a 24-hour 
incubation, RNA was isolated from the cells using RNAzo1 reagent (Section 2.5.11). 
The RT reaction was performed on the isolated RNA samples, using the ovine PrP 
ORF specific primer 643 (Section 2.2.16). The PCR reactions (Figure 4.24) were 
carried out using the following primer combinations AG23 & 580SH, AG23 & 





4 680 bp 
1 	23 	45 	678 
KEY: RNA isolated from ovine IS! 20Liv cells transiently transfected with plasmids 
pConstructl-pConstruct5, analysed by RT-PCR. Lanes I + 6, Molecular weight marker VI 
(Roche, UK); Lane 2, pConstruct2 using AG23 & Flag Reverse primers; Lane 3, pConstructl 
using AG23 & Flag Reverse primers; Lane 4, pConstruct2 using AG23 & 13741 primers; Lane 
5, pConstructl using AG23 & 13741 primers; Lane 7, pConstruct2 using AG23 & 580SH 
primers: Lane 8, pConstructl using AG23 & 580SH primers. 
Figure 4.24 RT-PCR analysis of transiently transfected IS12OLiv cell 
RNA for ovine PrP mini-gene mRNA expression 
Agarose gel shows total RNA from ovine lS12OLiv (liver) cells transfected with ovine PrP mini-
gene construct DNA analysed for the presence of recombinant PrP mRNA expression. 
Expected sizes for RT-PCR fragment are: 230 bp if spliced correctly, 330 bp endogenous PrP 
mRNA or 1000 bp non-spliced using the AG23 & 13741 primers. 580 bp if correctly spliced, 680 
bp endogenous PrP mRNA or 1300 bp if non-spliced. 215 bp if correctly spliced or 1000 bp if 
non-spliced using the AG23 & Flag Reverse primers. As can be seen only bands corresponding 
to non-spliced and endogenous PiP mRNA were observed and at no time were bands 
corresponding to the correctly spliced mRNA seen. 
As can be seen in Figure 4.24, RT-PCR failed to reveal bands of the expected 
size for correctly spliced ovine PrP mini-gene RNA, instead bands of approximately 
1000 bases with AG23 and Flag Reverse primers were observed, indicating one of 
two possibilities: i) that only non-spliced construct RNA was present or ii) that due 
to the failure to treat the RNA samples with DNase the 1000 base band corresponds 
to amplified ovine PrP mini-gene construct DNA. Bands of approximately 1000 
bases (faint) and 330 bases were observed with AG23 and 13741 primers, indicating 
that endogenous PrP mRNA (330 bases) and either non-spliced construct mRNA or 
contaminating ovine PrP mini-gene construct DNA (1000 bases) bands were present. 
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Finally only endogenous PrP mRNA bands (680 bases) were observed with the 
580SH and AG23 primers, indicating that neither spliced, nor non-spliced construct 
mRNA or indeed contaminating ovine PrP mini-gene construct DNA was detectable 
with this primer combination (Figure 4.24). 
4.2.7 Sequencing of ovine PrP mini-gene construct mRNA RT-PCR 
products 
In order to confirm that the ovine PrP mini-gene construct RNA had not been 
correctly spliced, the pConstructl and pConstruct2 RT-PCR products (Section 4.2.6) 
were sequenced on an ABI 377 automatic sequencer (Sections 2.3.5-2.3.6). 
Sequencing was carried out with the primers B007 and AG28 (Table 2.2). The 
interpretation of the results is affected by the fact that the tested RNA samples were 
not treated with DNase, and thus any RT-PCR products could have originated from 
contaminating ovine PrP mini-gene construct DNA. One interpretation is therefore 
that the construct RNAs had not been correctly spliced as the intron II sequence was 
still intact 5' to the ovine PrP mini-gene exon III DNA and the splice donor, splice 
acceptor sites and the branchpoint sequence were also present (data not shown). 
However, it could also be that what was amplified was in fact from the construct 
DNA and would not be expected to be spliced as a result. 
4.3 Discussion 
Previous work identified a potential role for the 3'UTR in the regulation of 
PrP gene expression (Goldmanri et al., 1999, Marshall, 2000). It is hypothesised that 
the differential use of alternative polyadenylation sites incorporates sequence 
elements into the 3 'UTR that exert differing functions. In order to investigate the 
regulated control of alternative polyadenylation and the function of the 3'UTR 
sequence elements in PrP gene expression, a series of ovine PrP mini-gene constructs 
were produced (pConstructl-pConstruct5). The expression of these constructs was 
placed under the control of a 0.5 kb ovine PrP gene promoter fragment, which was 
known to be functional (Marshall, 2000, O'Neill et al., 2003). In addition, the 
constructs were designed to express recombinant ovine PrP' tagged with the 
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3XFLAGTM epitope within its N-terminal region to allow the detection of 
recombinant PrPC  against a background of endogenous PrPC. 
Previous work by Telling et al. (1997) had shown that the incorporation of a 
single FLAG IM epitope at the N-terminus of the mature murine PrP protein (in a 
position similar to that utilised in the ovine PrP gene in this study) had no effect on 
its normal cellular processing. It was shown that it was possible to immuno-purify 
FLAG TM tagged munne PrPC  from the brains of transgenic mice using antiFLAGTM 
monoclonal antibodies (Telling et al., 1997). Any tagging epitope used had to be 
capable of being inserted and detected at a position that would not interfere with the 
normal processing of PrP'. The insertion of the 3XFLAGTM  epitope C-terminal of the 
signal peptide sequence ensured that it would not be cleaved following the post-
translational modification of PrP. Another reason for inserting the 3XFLAGTM 
epitope in the N-terminal region of PrP, was that this section of the PrP' protein is 
believed to be relatively unstructured (Mehihorn et al., 1996, Pergami et al., 1996). It 
was hoped that this would reduce the possibility of the 3XFLAGTM epitope becoming 
buried within the fully folded PrPC  protein. The cleavage of the N-terminal signal 
sequence in mature PrPC  ruled out the use of other tagging epitopes (such as 6 x His), 
which could only be inserted at the N- or C-terminus of the recombinant protein. The 
reason for this is that these tagging epitopes would either have been removed during 
post-translational modification (N-terminal attachment), or may have interfered with 
the membrane attachment of the mature protein via its GPI-anchor (C-terminal 
attachment). The 3X FLAG TM epitope had been shown to be a more sensitive method 
of detection of recombinant protein than other tagging epitopes such as 6 x His and 
FLAG TM  (Hernan, Heuermann & Bnzzard, 2000, Zhang, Hernan & Bnzzard, 2001). 
Transient transfection of the ovine and murine cell cultures with the ovine 
PrP mini-gene constructs was used as a model to examine the activity of the 3'UTR 
in differing cell types. The expression of these constructs in a range of ovine cell 
types may offer some clues as to the role of alternative polyadenylation in the tissue-
specific expression of the PrP gene, and could provide further insights into the 
mechanisms of scrapie disease pathogenesis. Methods for the immunoprecipitation 
of endogenous PrPC  from ovine & murine cell cultures, and murine tissue were 
developed during this study (Chapter 3). These techniques were applied to the 
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isolation of the recombinant 3XFLAGTM-tagged PrPC  from the transiently transfected 
cells, using PrP- and FLAG T11  specific antibodies. However, the use of the 
3XFLAGT 11  tag proved to be very problematic and major difficulties were 
encountered whilst attempting to detect a purified control FLAG TM-BAP protein 
using the M2 antibody (Figures 4.18 & 4.19). The level of background observed with 
this antibody was very concerning, and even at very low concentrations the M2 
antibody still reacted non-specifically with raw N2a cell lysates (Figure 4.20). It is 
not clear why this cross reactivity occurred but it could be due to the presence of 
endogenous FLAG T"  like epitopes in the cell cultures analysed, thus providing 
serious problems for the detection of FLAG T11  tagged proteins in this system. 
Following these problems, literature searches revealed that other researchers had 
encountered problems with the antiFLAGTM  M2 antibody. For example, Schafer & 
Braun (1995) showed that the Mg 2+  dependent protein phosphatase (MPP) reacted 
strongly on Western blot with the antiFLAGTM  M2 antibody. Furthermore, sequence 
analysis of MPP revealed a sequence motif containing five out of eight amino acid 
residues, which were identical to the FLAG T" epitope (Schafer & Braun, 1995). 
These results indicated that the FLAG T" epitope may not be mono-specific, as was 
previously thought and that naturally occurring homologues of this sequence may 
exist. 
No 3XFLAGTM-tagged PrPC  expression was detected in any of the transiently 
transfected cell cultures (Figures 4.21 & 4.22), including the ovine ISl2OLiv cells. 
The ovine IS12OLiv cell culture was a model system for the expression of 
recombinant PrP' as it had shown no detectable PFPC,  thus providing an effective PrP 
null background (Chapter 3). However, it could be argued that the liver cells, in 
which there was no endogenous PrPC  expression, did not support the expression of 
the transfected ovine PrP mini-genes. The results were unexpected as a series of 
ovine PrP mini-gene constructs similar to those produced in this study, but without 
the 3XFLAGTM tag, had previously been shown to be correctly transcribed and 
spliced during a previous PhD project (Marshall, 2000). In addition, the transfection 
reagent selected (Superfect) had previously been shown to be very effective at 
transfecting the ovine cell cultures (Marshall, 2000) and the conditions for its use had 
been optimised for each individual cell culture during the present study. Sequencing 
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of the ovine PrP mini-gene constructs (plasmids pConstructl & pConstruct2) 
confirmed the sequence integrity of these constructs and showed the presence of all 
of the required sequence elements identified to date. These included, 5' & 3' splice 
sites, a branch-point sequence, and the plasmids also contained an ovine PrP gene 
intron region of approximately 700 bases (Figure 4.17). RT-PCR analysis of 
transiently transfected ovine cell culture RNA failed to detect any correctly spliced 
construct RNA (Figures 4.23 & 4.24) but the experiment was compromised by the 
likely presence in the reaction mixture of contaminating construct DNA due to the 
failure to treat the RNA samples with DNase. In addition there was no control 
sample included without the use of the reverse transcriptase reaction (a minus RT 
control). 
Due to the absence of important controls it is still unclear if the ovine PrP 
mini-gene construct RNAs were being correctly spliced or not, however incorrect 
splicing could have been due to the design of the constructs themselves, as they 
could be lacking sequence elements other than those identified in this study. For 
example, the constructs are missing most of the ovine PrP gene intron I, all of exon II 
and some of intron II, and the presence of sequence elements required for the correct 
processing of PrP mRNA in these sequences cannot be ruled out. Inoue et al. (1997) 
identified elements within the bovine PrP gene intron I that were required, in 
conjunction with the bovine PrP gene promoter, for the efficient expression of the 
bovine PrP gene. In addition, Fischer et al. (1996) showed that in mice the PrP gene 
intron II was vital for the expression of PrPC  in cerebella Purkinje cells, and mice that 
lacked the intron II region failed to show detectable levels of PrPC  expression. The 
failure of the ovine PrP mini-gene constructs, generated during this study, to 
successfully express recombinant P rPC could be due to an inherent problem with the 
constructs themselves that has not been identified to date. The constructs were 
produced in a way that ensured that the reading frames of the ovine PrP gene ORF, 
and the 3XFLAGT 11  epitope were maintained. However, in order to maintain reading 
frame of the 3XFLAGTM epitope sequence it was necessary to repeat three codons 
(Tyr41 Pr042Gly43) of the ovine PrP gene ORF (Figure 4.10). Although reading frame 
was maintained it is unlikely that the introduction of these extra bases into the PrP 
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ORF could have had a detrimental affect on the expression of the ovine PrP mini-
gene constructs. 
Attempts were made during this study to produce a series of identical ovine 
PrP mini-gene constructs that contained a much more complete, 3.2 kb promoter 
fragment, including intron I and exon II (data not shown). However, this 3.2 kb 
promoter fragment proved to be very difficult to clone, the reasons for this are 
unclear and many different methods of introducing this fragment were attempted by 
myself and by other researchers at the NPU. As a result the production of this 
additional series of mini-gene constructs was halted, and only the constructs 
containing the 0.5 kb promoter were used in this study. The main reason for using a 
PrP mini-gene was that due to its small size, it could be easily transiently transfected 
into the cell cultures. Previous studies had shown that this was possible, and had 
identified the Superfect reagent as being the most efficient method of transfecting the 
ovine cell cultures (Marshall, 2000). This method allows cultured cells to be 
transfected in an efficient and reproducible manner with very little damage to the 
cells. However, by using a PrP mini-gene, the size constraints meant that certain 
regions of the gene, deemed to be unnecessary were omitted from the final 
constructs, i.e. most of intron I, exon II and most of intron II. The use of a full-length 
PrP gene would have been more desirable, as the omission of sequences within the 
introns may have led to the failure of the construct RNAs to be spliced correctly. 
However, a full-length PrP gene construct would have been some 30 kb in length and 
would have been much more difficult to clone, and to introduce into the ovine cell 
cultures. 
4.3.1 Conclusions 
Considering the problems that have been highlighted during this study, such 
as the lack of specificity observed with the FLAG TM antibodies, and a lack of obvious 
sequence defects in the constructs it was decided not to pursue the present constructs 
any further. It is possible however that DNase treatment would allow the RT-PCR 
reaction to work on the RNA rather than on any contaminating DNA and the 
constructs remain available for future studies. The possibility of producing a new 
series of constructs was ruled out due to the amount of cloning required and the time 
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that this would entail. In addition, it is possible that even if a working series of ovine 
PrP mini-gene constructs were produced, the lack of specificity of the antiFLAGTM 
antibodies may have interfered with, or nullified the experimental model. The lack of 
specificity of the antiFLAGTM  antibodies could have been overcome by instead using 
35S-methionine labeling to detect recombinant PrPC  expression, however, the failure 
of the construct RNAs to be correctly spliced meant that this was not possible. As 
such it has not been possible to further investigate the role of the ovine PrP gene 
3'UTR in the regulation of PrP gene expression during this study. Therefore, it was 
decided to concentrate on the remaining aspects of the thesis, which involved 
analysing the role of the ovine PrP gene promoter region in the regulation of PrP 
gene expression (Chapters 5 & 6). 
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Chapter 5: Characterisation of the ovine PrP gene 
promoter region 
5.1 Introduction 
The PrP gene promoter region regulates the expression of the PrP gene and 
this regulation is controlled by transcription factors. Gene expression is primarily 
regulated by specific sequence elements within the promoter region, which form 
binding motifs for transcription factors (Mitchell & Tjian, 1989). These factors either 
aid in the formation of the basal transcription complex, in conjunction with RNA 
polymerase II, or they act to regulate the rate of transcription of a particular gene 
through interactions with other transcriptional elements (Mitchell & Tjian, 1989, 
Roeder, 1996, Tjian, 1995, Zawel & Reinberg, 1995). Gene transcription is a highly 
complex process, and the number of factors involved allows for a large number of 
potential combinations of these factors to associate together on a given gene 
promoter (Hochheimer & Tjian, 2003, Tjian, 1995). However, only certain 
combinations will result in the transcription of a particular gene, and by limiting the 
availability of different factors in particular cell-types, an organism is able to regulate 
the tissue-specific expression of a given gene (Tjian, 1995). Gene transcription can 
also be regulated by controlling the cellular levels of transcription factors, and the 
expression of transcription factors can be influenced by a wide variety of 
extracellular stimuli (Kagoshima, Cosio & Adcock, 2003). These stimuli can include 
stress, ion concentrations and responses to viral infections (Morimoto, Sarge & 
Abravaya, 1992, Sassone-Corsi, 1995, Tamai, Monaco, Nantel et al., 1997, 
Whitmarsh & Davis, 2000). In addition, the expression levels of some transcription 
factors has been shown to be regulated in a circadian manner (Cowell, 2002, 
Holzberg & Albrecht, 2003, Takahashi, 1993, Wuarin, Falvey, Lavery etal., 1992). 
To date, very few transcription factor binding motifs have been identified in 
the ovine PrP gene promoter. An upstream AP-2 motif, and a downstream AP-2 
motif in Suffolk sheep have been noted (Figure 1.9) (O'Neill et al., 2003). In 
addition, a polymorphic change of C to G within the downstream AP-2 motif exists 
in the Cheviot PrP promoter and appears to create an SP- 1 binding motif (O'Neill et 
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al., 2003). The non-ruminant PrP gene promoters contain a single consensus binding 
motif for the transcription factor AP- I. In addition, all of the mammalian promoters, 
with the exception of the published Suffolk promoter, contain between two and three 
SP-1 binding motifs (Baybutt & Manson, 1997, Funke-Kaiser et al., 2001, Inoue et 
al., 1997, Mahal etal., 2001, O'Neill etal., 2003, Saeki etal., 1996, Westaway etal., 
1994a). O'Neill et a! (2003) performed a series of targeted deletions of a 0.5 kb 
Cheviot PrP gene promoter fragment linked to a CAT reporter gene. The deletion of 
a section of 99 bases from the 5' end of this promoter sequence resulted in an initial 
loss of promoter activity (O'Neill et al., 2003). Furthermore, deletion of a region 
containing the upstream AP-2 binding motif resulted in a considerable reduction in 
promoter activity (O'Neill et al., 2003). A number of other single nucleotide 
polymorphisms have been discovered in the ovine PrP gene promoter, including a 
change of T to C within conserved motif I and the significance of this motif is 
investigated in further detail in Chapter 6. A single base polymorphism of C to A is 
found in positive line (scrapie susceptible) sheep in the NPU Cheviot flock, although 
its functional significance is currently unknown. These polymorphisms may have an 
influence on the binding of transcription factors to the promoter and may therefore 
influence expression of the PrP gene and the biology of the disease. 
During this study, the ovine PrP promoter was subjected to extensive 
sequence analysis in order to identify any known transcription factor binding motifs. 
This analysis was carried out using the GCG Wisconsin package, version 10.3 
(Fuchs, Stoehr, Rice et al., 1990), and with the TRANSFAC 
(www.traiist'ac. _gbf.de/I'RANSFAC/, (Wingender, Chen, HehI et al., 2000, 
Wingender, Dietze, Karas et al., 1996)) and the TFSEARCH 
(www.chrc.iprcsearchdbTFSE ARCH. lit ml)  databases. DNA sequence analysis was 
concentrated on the area of the ovine PrP promoter between 4000-7000 bp using the 
Suffolk PrP promoter numbering (GenBank accession number = U67922) which 
represents approximately I kb upstream and downstream of the core ovine PrP 
promoter identified by O'Neill et al. (2003). 
The biochemical functionality (i.e. DNA-protein interaction) of the ovine PrP 
promoter binding motifs was assessed by the gel shift assay technique (Section 
2.4.6). The gel shift assay involved the radiolabeling of a double stranded DNA 
178 
oligonucleotide containing the DNA sequence to be analysed. The gel shift assays 
could also have been performed using restriction fragments prepared from the 0.5 kb 
Cheviot PrP promoter, however, this was not possible due to a distinct lack of 
suitable restriction enzyme sites within this DNA sequence and, as such, a decision 
was made to use synthetic oligonucleotides. The double stranded, radiolabeled 
oligonucleotide was incubated in a binding assay with a nuclear extract; in this study 
the nuclear extracts were prepared from the ovine and murine cell cultures available 
at the NPU (Sections 2.5.1-2.5.3). The binding of nuclear factors to the labeled 
oligonucleotides was assessed by separating the reaction products by non-denaturing 
gel electrophoresis. Unbound radiolabeled oligonucleotides run freely to the bottom 
of the gel, whereas, oligonucleotides that have become complexed with protein 
factors have reduced mobility and are observed on the gel as a retarded complex, or 
gel shift. Specificity of binding was assessed by the use of unlabeled competitor 
oligonucleotides (same DNA sequence but not radiolabeled), and unlabeled non-
competitor oligonucleotides (different DNA sequence but not radiolabeled). Upon 
the identification of binding, selected mutations were introduced into the DNA 
sequences in order to test the binding specificity and to help to elucidate which 
specific factor was involved. Sequence analysis and gel shift experiments carried out 
in this study would help to elucidate the role of the ovine PrP gene promoter in the 
transcriptional control of gene expression. In addition, the analysis of sequence 
polymorphisms within the ovine PrP promoter would provide further insights into the 
role of gene transcription in scrapie disease susceptibility. 
5.2 Results 
5.2.1 Sequence analysis of the ovine PrP promoter 
Sequence analysis revealed the presence of numerous transcription factor 
binding motifs within the ovine PrP promoter sequence. All of the motifs identified 
were found within the DNA sequence lying approximately 500 bp upstream of the 
potential transcription start sites identified by Westaway et al. (1994b) and are 
detailed in Figure 5.1 (boxed motifs were identified during this study). The motifs 
found on the ovine PrP promoter included two heat shock elements (HSE- I & HSE- 
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2), and binding motifs for a number of transcription factors including activator 
protein-I (AP-1), early gene transcription factor-i (EGR-I), and a GATA-1 factor 
binding motif (Amin, Ananthan & Voellmy, 1988, Angel & Karin, 1991, Sukhatme, 
Cao, Chang et al., 1988, Tsai, Martin, Zon et al., 1989, Yan, Small, Desplan et al., 
1996). The influence of the C to A polymorphism found in the positive line in the 
NPU Cheviot flock was analysed and discovered to lie within a binding motif for the 
signal transducers & activators of transcription (STAT) family of transcription 
factors (Figure 5.1). 
The expression of the ovine PrP gene is controlled by a TATA-less promoter, 
therefore, the ovine PrP gene promoter sequence was searched for the presence of 
initiator (Inr) elements (Section 1.10.1), the consensus sequence for which is 
PyPyA, 1 NT/APyPy (where Py = pyrimidine) (Lo & Smale, 1996, Smale, 1997). 
Certain sequence changes in this consensus sequence can be tolerated, however, the 
core sequence for an mr element is PyA+ 1 NT/A, where A+1 is the transcription start 
site. In addition, pynmidines need to surround the sequence in at least two of the four 
positions detailed in the consensus (Smale, 1997). Westaway et al. (1994b) mapped 
approximate positions of the major start sites at positions 5666 & 5669 bp in the 
Suffolk PrP gene promoter (GenBank accession number = U67922). Interestingly, 
the start site of transcription in the bovine PrP gene has been mapped to a similar 
sequence to that seen in the ovine PrP gene (TAGTT, 1 GCCAGTCGCT), and lies 
immediately downstream of the three bovine SP-1 motifs (Inoue etal., 1997). Five 
sequences were found, which fitted the core sequence for an mr element at the 3' end 
of the ovine PrP gene promoter region. Three of these sequences were located 
downstream of the 5' splice site and were therefore excluded as candidates, the other 
two are listed in Appendix 2, Figure Al (underlined sequences). The two candidate 
mr elements both fit the core sequence and are flanked on either side by pyrimidines. 
Interestingly, their positions would place the transcription start sites at positions 5663 
& 5670 bp on the Suffolk PrP promoter, therefore only 3, and 1 bases away, 
respectively, from the positions mapped in previous studies (Westaway et al., 
1994b). 
The mr elements are perfectly conserved in the bovine PrP gene promoter 
(underlined sequences, Appendix 2, Figure A2.), suggesting that the transcriptional 
11 M-1 
start site of the PrP gene may be the same in these two species (Inoue et al., 1997). 
Analysis of the mouse PrP gene promoter revealed the presence of three mr elements 
(underlined sequences, Appendix 2, Figure A2), all of which are situated very close 
to potential transcription start sites as identified by Westaway et al. (1994a). In 
addition, a number of potential mr elements were observed in the Syrian hamster, 
human and rat PrP gene promoters (underlined sequences, Appendix 2, Figure A2). 
The ovine PrP gene promoter was also analysed for the presence of 
downstream promoter elements (DPEs) (Section 1.10.1) at approximately +30 bases 
from the potential transcription start sites/ mr elements. The sequence of the DPE has 
been elucidated by a number of researchers and fits the broad consensus of 
(AIG/T)(G!C)(AIT)(C/T)(G/AIC)(T!C)G (Burke & Kadonaga, 1996, Burke & 
Kadonaga, 1997, Kadonaga, 2002, Kutach & Kadonaga, 2000). A single candidate 
DPE (bold text, Appendix 2, Figure A3) was found at position +31 from the first of 
the two potential ovine transcription start sites, although this sequence (AGA( 10 I) 
varies in three positions (red text) from the DPE consensus (Burke & Kadonaga, 
1997). However, this potential DPE sequence is perfectly conserved in the bovine 
PrP promoter, and as found in the ovine promoter it lies at position +31 bases from 
the first mr element. Sequence analysis of the human promoter revealed the presence 
of two potential DPEs (GGTCCC( ) and (AG( CCG) at position +31 bases from 
the first and third mr elements, respectively (bold text, Appendix 2, Figure A3). In 
addition, the rodent PrP promoters each contain a single conserved DPE sequence 
(AG( TA:\G, bold text, Appendix 2, Figure A3), which varies at two positions from 
the consensus, and is located at position +35 (mouse), +30 (rat and Syrian hamster). 
A line up of the mammalian mr and DPEs is presented in Appendix 2, Figure A3. 
The location of the DPEs in the mammalian PrP promoters may indicate 
which mr elements are functional in each promoter, and hence may indicate the 
location of the transcriptional start sites in these promoters. For example, the DPE in 
ruminants is located at position +31 bases from the first mr element, therefore this 
first mr element may be functional (Appendix 2, Figure A3). The same principal may 
be applied to the other mammalian promoters. 
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-445 TGACGGCAGG 	CTAATATCCTTTCTAGGCCTCAP.ATTTTAATCT 	 CATTGGGC 
GATA-1 	 HSE-1 





Motif 1 	Motif 2 
-235 CTCTAAAGATGATTTTTATCGTCAACAAGCAATTTCAGGGAGTGA 	GGGAGC;CGGTGTTAGTTG 
Motif 3 	 Motif 4 i 	AP-1 	Motif 4 ii 
-165 ATGCTAGCGTTTATGCTAGTCTCAACTCGTTTTTCCCAGGGACTTAGATTCCTGGGTCTGCCGGTAAACC 
Motif 4 iii 
-95 CCGGG 	AGCGGGCGCGCCTGAGCGTGCGCGCGCCGTCGCCTCCCCCCCCCCGCAGCTCCTCCTC 




+46 GAGG 	ATAGCCGCGTAGTCCTTTAAACTCC +81 
5' Splice Motif 
Figure 5.1 Suffolk sheep PrP gene promoter transcription factor 
binding motifs 
Motifs 1-4 are conserved sequence elements found in ovine, murine, hamster, cattle and 
human PrP gene promoters, as identified by Westaway et al. (1994a) which may form 
binding sites for as yet unidentified transcription factors. Arrowheads indicate location of 
transcription start sites as experimentally shown by Westaway et al. (1994a). Suffolk sheep 
PrP gene promoter sequence from -445 to +81 bp, numbering based on the use of the 5' 
transcription start site (Genbank = U67922). Also highlighted are a potential binding site for 
the AP-2 transcription factor and a polymorphic AP-2/SP-1 site seen in Cheviot sheep 
(O'Neill et al., 2003). Boxed factors are putative transcription factor binding motifs identified 
in this study and correspond to the sequence (indicated in red text) above the boxed title. 
Polymorphic base changes are indicated by base change (different colour) under the wild 
type (Suffolk, Genbank = U67922) sequence. 
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5.2.2 Analysis of binding to ovine PrP promoter AP-2 motifs 
Factor binding to the upstream ovine AP-2 site and the downstream ovine 
AP-2 cluster motif, and its polymorphic variant previously identified by other 
researchers were analysed using gel shift assays carried out with nuclear extracts 
prepared from ovine cell cultures (sA80BR, pA80BR, IS12OCer & IS12OLiv). 
Double stranded radiolabeled oligonucleotides (20 bp) were produced (Section 2.4.1 
& 2.4.2) each of which contained the specific binding motif along with the native 
DNA flanking sequence (Tables 2.3 & 5.1 & Figure 5.1). Comparisons of mutated 
and wild type DNA sequences were made within the same batch of nuclear extract. 
In addition, all of the gel shift assays in this chapter were repeated on at least two 
occasions using different batches of nuclear extracts, unless stated otherwise. 
Name Abbreviation DNA binding motif Location 
AP-1 AP-1 5'1GA(iCC'A3 
Upstream AP-2 uAP-2 5'CCCCGGG'3 -97 





dAP-2c 5'CCCC CCCC'3 -48 
EGR-1 EGR-1 5'çGCCCGC'3 -90 
GATA-1 GATA-1 5'TGATGG'3 -434 
HSE-1 HSE-1 5'GAAAATTCACAAA'3 -396 
HSE-2 HSE-2 5'CCTTTTCAGAAATTTCTG'3 -349 
Wild type motif I MIT 5'CTTTCATTTTCTCCA'3 -286 
Variant motif 1 MIC 5'CTT' CATTTTCTCCA'3 -286 
Ruminant motif 2 M2C 5'TTACGTAACG'3 -271 
Non-ruminant motif 2 M2T 5'TTA I GTAACG'3 -271 
Motif 3 M3 5'TAAAGATGATTTTTA'3 -232 
Motif 4 (i) M4i 5'TCAGGGAG'3 -201 
Motif 4 (ii) M4ii 5'CCAGGGAGG'3 -186 
Motif 4 (iii) M411i 5'CCAGGGAC'3 -130 
Wild type STAT STAT-C 5'TTCCCGAA'3 -321 
Variant STAT STAT-A 5'TTCC\GAA'3 -321 
Table 5.1 	Ovine PrP promoter potential transcription factor binding motifs 
Details the putative transcription factor binding sites on the ovine PrP promoter. Location of 
each site is given relative to the 5' transcription start site as experimentally determined by 
Westaway et al. (1994a). Red text indicates the presence of a polymorphic or species 
specific base change. 
183 
5.2.2.1 Characterisation of binding to the upstream ovine PrP 
promoter AP-2 motif 
The ovine PrP promoter contains a consensus binding motif for the AP-2 
transcription factor (CCCCGGG) (upstream AP-2, -97 bp, Figure 5.1), and binding 
to this motif was investigated by gel shift assay using the uAP-2 oligonucleotide. A 
double stranded oligonucleotide containing this motif was produced (Section 2.4.1 & 
table 2.3), and radiolabeled with 32P (Section 2.4.2). The uAP-2 oligonucleotide was 
incubated in gel shift assays (Section 2.4.6) with a variety of ovine cell culture 
nuclear extracts (IS12OCer, IS12OLiv, sA80BR, pA80BR) (Section 2.4.3), and the 
results are shown in Figure 5.2. 
IS12OCer 	IS12OLiv 	sA80BR 	pA80BR 





oligonucleotide 	 All 
I 	I $ I I 	I 
diA ili 
uAP-2 
NucI. Extract 	 + i- + 	 + + + 	 + + -t- 	 + + + 
COMP. oligo(lOOx) 	 + + + 	 + 
Non-comp. oligo (NC- 1) (1 OOx) 	 + 	 + 	 + 	 + 
Lane 	 1 2 3 4 5 6 7 8 9 10 1112 13 14 1516 
Figure 5.2 Gel shift assay: upstream ovine AP-2 motif 
Gel shift assay indicating that the uAP-2 oligonucleotide is specifically bound by at least one 
transcription factor in all of the ovine cell line nuclear extracts tested. The presence of each of 
the separate assay components is indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
lS120Cer: nuclear extract from the lS120Cer (cerebellum) cell line 
IS1 20Liv: nuclear extract from the IS1 20Liv (liver) cell line 
sA80BR: nuclear extract from the sABOBR (scrapie susceptible) neuronal cell line 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
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Two DNA-complexes of different mobilities were observed with the uAP-2 
oligonucleotide with all of the ovine nuclear extracts tested (Lanes 2, 6, 10 & 14, 
Figure 5.2). These complexes were dissociated following the addition of 100 fold 
molar excess unlabelled competitor oligonucleotide, uAP-2 (Lanes 3, 7, 11 &12, 
Figure 5.2), however, they were not affected by the addition of 100 fold molar excess 
unlabelled non-competitor oligonucleotide, NC-1 (Table 2.3, Promega, UK) (Lanes 
4, 8, 12 & 16, Figure 5.2), indicating that they were specific complexes. The factor 
binding to this motif is likely to be the transcription factor AP-2, and the different 
complexes may represent the monomeric (molecular weight of-50 kDa) and dimenc 
(molecular weight of -100 kDa) forms of the AP-2 protein (Lanes 2, 6, 10 & 14, 
Figure 5.2). A purified form of the murine AP-2 transcription factor was obtained 
from Promega, UK, and this factor was incubated in a gel shift assay (2.4.6) with a 
consensus AP-2 motif oligonucleotide (NC-2, Table 2.3, Promega, UK). The results 
of this gel shift assay were compared to that of the upstream ovine AP-2 motif gel 
shift assay (Figure 5.3). The mobility of the complex observed with the consensus 
AP-2 oligonucleotide (NC-2) and the purified munne AP-2 protein (Lanes 1-4, 
Figure 5.3) was similar to that observed with the larger complex of the upstream 
ovine AP-2 motif in the ovine cell culture nuclear extracts (Lanes 5-8, Figure 5.3). 
However, no equivalent of the lower band was seen with the purified munne AP-2 
protein. These results indicate that it is likely that the factor binding to the ovine 
upstream AP-2 motif is AP-2 (Figure 5.3). The upstream AP-2 and EGR-1 binding 
motifs overlap each other, therefore the uAP-2 oligonucleotide also contains the 
entire EGR-1 binding site. (Figure 5.1). As such, the possibility that the lower band 









uAP-2 	 + 
NC-2 ± + ++ 
pA80BR NucI. Extract 	 + + + 
Purified murine AP-2 extract 	 + + + 
Comp. oligo NC-2 (lOOx) + 
Comp. oligo uAP-2(I00x) 	 + 
Non-comp. oligo NC-I (I 00x) 	 + 	 + 
Lane 	 1234 5678 
Figure 5.3 Gel shift assay: Consensus AP-2 oligonucleotide with purified 
murine AP-2 protein compared to uAP-2 oligonucleotide 
with pA80BR nuclear extract (NE) 
Gel shift assay indicating that the uAP-2 oligonucteotide is specifically bound by at least one 
transcription factor (top band, lane 6) with a similar electrophoretic mobility to recombinant 
murine AP-2. The presence of each of the separate assay components is indicated by the + 
signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non- 
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
bOX indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
5.2.2.2 Characterisation of binding to the downstream ovine PrP 
promoter AP-2 motif cluster 
Compared with the published Suffolk PrP gene promoter, in most cases the 
Cheviot promoter contains a single base polymorphism of C to G, which lies within 
the downstream AP-2 motif cluster (48 bp, Figure 5.4). This single base change has 
MTOI 
a dramatic affect on the number of available AP-2 motifs within this cluster. 
Following the polymorphic change, five of the six AP-2 motifs in this AP-2 cluster 
are ablated, and a novel SP-1 motif is created (Figure 5.4). Therefore, the Cheviot 
PrP gene promoter has only one AP-2 motif and one SP-1 motif available (Figure 
5.4). In contrast, the Suffolk PrP gene promoter has six overlapping AP-2 motifs 
available in a cluster and no SP-1 motif (Figure 5.4). 
Al'-2 motifs (0) 
TCCCCCCCCCCGCAGCT 




Cheviot promoter motif 
AGGGG GGGGGCGTCGA 
AP-2 motif (xl) 
Figure 5.4 Potential effect of the polymorphic change within the 
downstream ovine AP-2 motif cluster 
Diagram shows the Suffolk and Cheviot sheep polymorphic AP-2/SP-1 promoter 
motifs. The Cheviot sheep sequence contains a C to G polymorphic change at position 
6 within this motif which appears to ablate five of the six overlapping AP-2 sites in this 
cluster motif, in addition this single base change creates a consensus SP-1 binding 
site. Sequences shown are of double stranded DNA from the Suffolk (Genbank = 
U67922) and Cheviot sheep promoters. Red bases indicate polymorphic base change. 
Two double stranded oligonucleotides were prepared (Section 2.4.1 & table 
2.3), one contained the Cheviot PrP promoter motif (dAP-2c, CCCC( CCCC), the 
other contained the Suffolk PrP promoter motif (dAP-2s, CCCCCCCCC) and both 
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were radiolabeled with 32P (Section 2.4.2). Binding to the dAP-2c & dAP-2s 
oligonucleotides was analysed by gel shift assay (Section 2.4.6) with ovine pA80BR 
nuclear extracts (Section 2.4.3), and the results are shown in Figure 5.5. 
Suffolk motif 	 Cheviot motif 
Specific No. I III binding , 	 • 
liii gills 
Unbound labeled 
oligonucleotide  0' ~ 
dAP-2s 
dAP-2c 	 + + + ± + + 
Nuci. Extract 	 + + + + + 	+ + + + + 
Comp. oligo (dAP-2s) (1 OOx) 	 + 
Comp. oligo (dAP-2c) (1 OOx) + 
Non-comp. oligo (dAP-2s)(l00x) 	 + 
Non-comp. oligo (dAP-2c) (I 00x) + 
Non-comp. oligo(NC-1)(IOOx) 	 + 	 + 
Non-comp. oligo (NC-2) (I 00x) + 	 + 
Lane 	 123456 789101112 
Figure 5.5 Gel shift assay: polymorphic variants of the downstream ovine 
PrP promoter AP-2 motif cluster with pA80BR nuclear extract (NE) 
Gel shift assay indicating that the uAP-2s and uAP-2c oligonucleotides are specifically bound by 
transcription factors with different electrophoretic mobilities. The presence of each of the 
separate assay components is indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
bOX indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
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Two DNA-complexes of different mobilities were observed with the two 
variants of the downstream ovine AP-2 binding motif in pA80BR nuclear extract 
(Suffolk & Cheviot, Figure 5.5). The complex observed with the dAP-2s 
oligonucleotide was not fully dissociated following the addition of 100 fold molar 
excess unlabelled competitor oligonucleotide, dAP-2s (Lane 3, Figure 5.5). 
However, the same complex was not affected by the addition of 100 fold molar 
excess unlabelled non-competitor oligonucleotides, dAP-2c, NC-1 & NC-2 (Lanes 4, 
5, & 6, Figure 5.5), indicating that it was a specific complex. The complex observed 
with the dAP-2c oligonucleotide was fully dissociated following the addition of 100 
fold molar excess unlabelled competitor oligonucleotide, dAP-2c (Lane 9, Figure 
5.5), and was not affected by the addition of 100 fold molar excess unlabelled non-
competitor oligonucleotides, dAP-2s, NC-1 & NC-2 (Lanes 10, 11 & 12, Figure 5.5) 
indicating that it was a specific complex. The dAP-2s and dAP-2c protein-DNA 
complexes were not competed out by the addition of each others unlabelled 
competitor oligonucleotides (Lanes 4 & 10, Figure 5.5) and this combined with the 
differing mobilities observed with the two complexes suggested that they are very 
likely to be different transcription factors. The Cheviot motif (Lanes 1-6, Figure 5.5) 
was bound by what appears to be a slightly larger complex than the Suffolk motif 
(Lanes 7-12, Figure 5.5), consistent with SP-1 (--106 kDa) binding to the Cheviot 
motif, and AP-2 (-100 kDa) binding to the Suffolk motif. This result is as expected, 
as the Cheviot motif contains a consensus SP-1 motif (CCCC( CCCC), whilst the 
Suffolk motif contains an AP-2 motif cluster (CCCC( CCCC) (Figure 5.5). This is 
further supported by studies by Nardelli, Gibson, Vesque et al. (1991) which showed 
that SP-1, which is a zinc finger DNA binding protein, binds to its DNA motif with 
three zinc fingers of two different types (type I & type II). Zinc fingers 1 & 3 are 
type II fingers, which recognise the CCC sequence on either end of the SP-1 motif, 
whilst zinc finger 2 is a type I finger, which recognises the CGC sequence at the 
centre of the SP-1 motif (Nardelli et al., 1991). Therefore, the Suffolk AP-2 motif 
cluster would be unlikely to be bound by SP-1, as the centre zinc finger of SP-1 
would not be able to bind. In contrast, SP-1 would be able to specifically recognise 
the Cheviot motif, due to the presence of the CGC sequence at its core. 
5.2.3 Characterisation of binding to the ovine PrP promoter heat shock 
elements (HSE-1 and HSE-2) 
The ovine PrP promoter contains two potential heat shock element (HSE-1 (-
387 bp) & HSE-2(-340 bp)) binding sequences, to which the heat shock transcription 
factor (HSF) can bind (Figure 5.1). HSEs contain multiple copies of a repeating five 
base pair motif (nGAAn), usually arranged in alternating orientations 
(nGAAnnTTCnnGAAn) (Amin et al., 1988, Fernandes, Xiao & Lis, 1994, Wu, 
1995). A minimum of three repeats is required for the binding of HSF, which will 
bind cooperatively as a protein tnmer to the HSE (Bonner, Ballou & Fackenthal, 
1994). Each single repeat sequence can vary from the consensus of (nGAAn), for 
example (nAAAn) and (nGAGn) have been shown to be functional (Santoro, 
Johansson & Thiele, 1998). In addition, a functional HSE can tolerate up to a five 
base pair insertion between repeats, provided that the spacing and orientation of the 
repeats is maintained (Amin et al., 1988, Wu, 1995). The ovine HSE-1 motif 
contains three alternate repeats of the (nGAAn) element, with just one base change 
from the consensus motif, marked in red text (nGAAnnTTCnn( 'AAn). The ovine 
HSE-2 motif also contains three alternating repeats, this time in a reverse direction, 
and with a one base insertion, marked in red text (nCTTninGAAnnTTCn). 
Therefore, it is possible that the ovine HSE motifs could be bound by HSF and may 
be functional. These sequences are conserved in the other mammalian PrP promoters 
analysed. For example, HSE-1 (TGAAATTCACAAA) is perfectly conserved in the 
bovine PrP promoter, and is also present in the human PrP promoter, but with one 
base change (TGAAATTCA IAAA). HSE-2 (CCTTTTAGAAATTTCTG) is 
conserved in all of the mammalian PrP promoters, although there are some base 
changes between the different species. Expression of the HSF is regulated by cellular 
stress and heat shock. Once its expression is upregulated it binds to the HSE, and by 
doing so it promotes the expression of specific heat shock genes (Tanguay, 1988). In  
order to check the functionality of these HSE motifs in the ovine PrP promoter, 
oligonucleotides containing the ovine HSE-1 and HSE-2 motifs were prepared 
(Section 2.4.1 & table 2.3), and radiolabeled with 32P (Section 2.4.2). Binding to 
these motifs was assessed with both normal, and a variety of heat shocked ovine 
pA80BR nuclear extracts (Section 2.4.3). In summary, nuclear extracts were 
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prepared from pA80BR cells that had been heat shocked at 42 °C for 30 minutes. 
Three sets of nuclear extracts were prepared, the first were heat shocked as above, 
and nuclear extracts were prepared immediately. Other cells were heat shocked and 
allowed to recover at 33 °C for one, or three hours prior to the preparation of nuclear 
extracts, in order to allow the cells time to activate the expression of HSF. The 








Comp. oligo (lOOx) 
Non-comp. oligo (NC-1)(lQOx) 
Lane 






+ + 1 	++ + 	 r + ± 	+ + + + + + + + + + + 
I 2 3 4 	5 6 7 8 	9 1011 12 	13 1415 16 
KEY: A = non-heat shocked pA80BR nuclear extract (NE); B = heat shocked 
pA80BR NE, no recovery time; C = heat shocked pA80BR NE, 1 hour 
recovery time; D = heat shocked pA80BR NE, 3 hour recovery time. 
Figure 5.6 Gel shift assay: ovine HSE-1 oligonucleotide 
Gel shift assay indicating that the ovine HSE-1 oligonucleotide is not specifically bound by 
transcription factors in either heat shocked or non-heat shocked pA80BR cell line nuclear 
extracts. The presence of each of the separate assay components is indicated by the + signs 
underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
bOX indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
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Binding was observed to the HSE-1 & HSE-2 elements with both the normal 
and the heat shocked pA80BR cell culture nuclear extracts (only HSE-1 shown, 
Figure 5.6), however, the binding was competed out by both 100 fold molar excess 
unlabelled competitor (HSE-1, Lanes 3, 7, 11 & 12, Figure 5.6) and 100 fold molar 
excess unlabelled non-competitor oligonucleotide (NC-I, Lanes 4, 8, 12 & 16, Figure 
5.6), indicating that it was not specific. No difference in binding was observed 
between the non-heat shocked nuclear extract (Set A, Figure 5.6), the nuclear 
extracts which were prepared from cells which had been allowed to recover for I or 3 
hours (Sets B & C, Figure 5.6), following heat shock and those that were processed 
immediately after heat shock treatment (Set B, Figure 5.6). These results suggested 
that heat shock treatment had no effect on binding to the ovine HSE-1 and HSE-2 
motifs. 
5.2.4 Characterisation'of binding to the ovine PrP promoter AP-1, EGR-
I & GATA-I transcription factor binding motifs 
A potential AP-1 binding motif (-190 bp, ATGAG CAG) was identified in 
the ovine PrP promoter, located between motifs 4 (i) and (ii) (Figure 5.1). This motif 
varies by one base (marked in red text) from the AP-I consensus binding motif of 
(A!T)T(G/T)(A/C)(G/C)TCA(G/C/A). AP-1 is a dimenc transcription factor, which 
consists of two monomers of the Jun protein in a homodimeric complex, or one Fos 
& one Jun monomer in a heterodimeric complex (Bohmann, Bos, Admon et al., 
1987, Landschulz, Johnson & McKnight, 1988, Landschulz, Johnson & McKnight, 
1989, Turner & Tjian, 1989). AP-1 has been shown to tolerate single base changes to 
its consensus binding motif, although multiple sequence changes may abolish 
binding (Risse, Jooss, Neuberg et al., 1989). In addition, slight variations to the 
consensus motif may allow the binding of other members of the leucine zipper 
family to bind, such as the activating transcription factor (ATF) protein family, thus 
forming more complex hetero-dimers (Angel & Karin, 1991). The bovine PrP 
promoter contains a similar sequence at the same location (ATGAG( C 
However, this motif varies at two positions from the AP-1 consensus, and is 
therefore less likely to form a binding motif for AP-1, although this was not tested in 
this study. In addition, the rodent and human PrP promoters all contain at least one 
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consensus AP-1 motif (Baybutt & Manson, 1997, Funke-Kaiser et al., 2001, Saeki et 
al., 1996). The presence of EGR-1 (-90 bp) & GATA-1 (429 bp) motifs in the ovine 
PrP gene promoter was interesting as both of these factors have been shown to 
interact with SP-1 to regulate the expression of specific genes (Ebert & Wong, 1995, 
Fischer, Haese & Nowock, 1993, Sukhatme et al., 1988, Tsai et al., 1989). 
Oligonucleotides containing the ovine AP-1, EGR-1 & GATA-1 motifs were 
prepared (Section 2.4.1 & table 2.3), labeled with 32P (Section 2.4.2) and incubated 
in gel shift assays (Section 2.4.6) with ovine pA80BR nuclear extracts (Section 







AP-1 	 + -- ± + 	 I 
EGR-1 +±± + 	 I 
GATA-1 	 + +++ I 
NucI. Extract 	 + + ± 	+ + ± 	+ + + I 
Comp. oligo(100x) 	 + + + 	I 
Non-comp. oligo (NC- 1) (I OOx) 	 + 	+ 	+ I 
Lane 	 1234567891011121 
Figure 5.7 Gel shift assay: ovine AP-I, EGR-1 & GA TA-I 
oligonucleotides with pA80BR nuclear extract (NE) 
Gel shift assay indicating that the ovine AP-1, EGR-1 & GATA-1 oligonucleotides are not 
specifically bound by transcription factors in the ovine pA80BR cell line nuclear extract. The 
presence of each of the separate assay components is indicated by the + signs underneath 
each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
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Very faint binding was observed to the AP-1, EGR-1 and GAlA-I 
oligonucleotides with the ovine pA80BR nuclear extracts (Lanes 2, 6 & 10, Figure 
5.7). However, the binding was competed out by both 100 fold molar excess 
unlabelled competitor (Lanes 3, 7 & 11, Figure 5.7) and 100 fold molar excess 
unlabelled non-competitor oligonucleotide (Lanes 4, 8, 12, Figure 5.7), indicating 
that it was not specific. In addition, binding was observed in the GAlA-i gel shift 
assay after the addition of the 100 fold molar excess unlabelled competitor 
oligonucleotide (Lane 11, Figure 5.7), indicating the possibility of an interaction 
between the labeled complex and the unlabelled competitor oligonucleotide. 
However, this binding was also observed following the addition of 100 fold molar 
excess non-competitor oligonucleotide, NC-1 (Lane 12, Figure 5.7), indicating that 
this binding was not relevant. Finally, as no specific binding was observed to the 
EGR- 1 oligonucleotide, which also contains a section of the uAP-2 oligonucleotide, 
but not the entire upstream AP-2 binding motif, it is reasonable to assume that the 
lower band observed with the uAP-2 oligonucleotide (Figure 5.2) could be that of the 
AP-2 monomer and not EGR- I. 
5.2.5 Characterisation of binding to the ovine PrP promoter 
polymorphic STAT motif 
The ovine PrP promoter contains a C to A polymorphism (-317 bp), which is 
associated with the positive line in the NPU Cheviot flock and is present in the 
human and bovine PrP promoters (O'Neill et al., 2003) (Figure 5.1). Sequence 
analysis of this polymorphism revealed that the wild type sequence (-321 bp, 
TTCC('GAAA) closely fits the consensus binding motif (TTCCCGGAA) for the 
STAT family of transcription factors, with only one base change (Yan et al., 1996). 
In contrast, the polymorphic change of C to A creates a variant STAT motif (-321 bp, 
TTCC \GAAA) with two base changes from the STAT consensus motif. Similar 
STAT motifs are present in the rodent PrP promoters, but with some sequence 
variations (rat = TTCCAGATG; mouse = TTCAACGAT; Syrian hamster = 
TTCAGCAAT). Interestingly, different STAT family proteins have been shown to 
bind to slightly different STAT binding motifs, for example STAT-I, 3 & 4 favour a 
G or C at position 5, whilst STAT-5 & 6 favour an A or T at the same position (Ihle, 
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1996). It is therefore possible that different STAT proteins could bind to the two 
polymorphic variations of the ovine STAT motif. Oligonucleotides were produced 
(Sections 2.4.1 & 2.4.2), which contained the two variations of this polymorphic 
motif (Table 2.3). Binding to the two oligonucleotides (STAT-C and STAT-A) was 
investigated using gel shift assays (Section 2.4.6), carried out on only one occasion, 
with the sA80BR, pA80BR, ISI2OCer & ISl2OLiv ovine cell culture nuclear extracts 
with the same result (Section 2.4.3) (only pA80BR shown, Figure 5.8). 
Non-specific 	 I 





STAT-A 	 + + + + 
Nuci. Extract 	 + + + 	+ + + 
Comp. oligo (lOOx) 	 + + 
Non-comp. oligo(NC-l)(lOOx) 	 + 	 + 
Lane 	 123 4 56 78 
Figure 5.8 Gel shift assay: STAT-C & STAT-A 
oligonucleotides with pA80BR nuclear extract (NE) 
Gel shift assay indicating that the ovine polymorphic STAT-C & STAT-A oligonucleotides are 
not specifically bound by transcription factors in the ovine pA80BR cell line nuclear extract. The 
presence of each of the separate assay components is indicated by the + signs underneath 
each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
bOX indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
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As can be seen from Figure 5.8, the results with the STAT motif 
oligonucleotides were inconclusive. Two complexes were observed with both of the 
STAT oligonucleotides (Lanes 2 & 6, Figure 5.8). Both of the complexes observed 
with the STAT-C oligonucleotide were competed out by the addition of 100 fold 
molar excess unlabelled competitor and non-competitor (NC-1) oligonucleotides, 
indicating that this represented non-specific binding (Lanes 3 & 4, Figure 5.8). The 
smaller complex observed with the STAT-A oligonucleotide was competed out by 
the addition of 100 fold molar excess unlabelled competitor and non-competitor 
(NC-1) oligonucleotides (Lanes 7 & 8, Figure 5.8). In contrast, the larger complex 
observed with the STAT-A motif, was competed out by the addition of 100 fold 
molar excess unlabelled competitor oligonucleotide (Lane 7, Figure 5.8), but was not 
competed out by the addition of 100 fold molar excess unlabelled non-competitor 
(NC-1) oligonucleotide (Lane 8, Figure 5.8), indicating that this binding may have 
been specific, however further studies are required to confirm this. 
5.3 Discussion 
Sequence analysis of the ovine PrP gene promoter revealed the presence of a 
number of transcription factor binding motifs, which had not been previously 
identified. All of these motifs were found within a section of DNA stretching to 
approximately 500 bp upstream from the potential transcription start sites identified 
by Westaway et al. (1994b). These included potential binding motifs for the HSF, 
STAT family, AP-1, EGR-1 & GATA-I transcription factors. The biochemical 
functionality of these motifs, along with those for upstream ovine AP-2 motif, and 
the downstream AP-2 motif cluster, were analysed by gel shift assay and binding to 
the polymorphic variations of these motifs, where appropriate, was assessed. 
All of the mammalian PrP promoters analysed contained mr elements, and in 
most cases these were located at, or very close to the positions of previously 
identified transcription start sites (Appendix 2, Figures Al & A2). The conserved 
nature of these mr elements indicates that they may be functional, and the position of 
the A+1 residues in these sites may constitute the transcription start sites of the 
respective PrP genes. 
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Transcription in TATA-less promoters, such as the PrP gene promoter, is 
initiated by the binding of a complex of general transcription factors (GTFs) termed 
TFIID, comprised of TBP and TBP-associated factors or TAF11s (Conaway & 
Conaway, 1993, Green, 2000, Ptashne, 1988, Verrijzer & Tjian, 1996). TFIID binds 
specifically to an mr element (PyPyA +1 N(T/A)PyPy), where A+1 is the 
transcriptional start site (Lo & Smale, 1996, Smale, 1997). In addition, the binding of 
the TFIID complex is aided in some TATA-less promoters by the presence of a DPE 
(Burke & Kadonaga, 1996, Burke & Kadonaga, 1997, Kadonaga, 2002, Kutach & 
Kadonaga, 2000, Smale, 1997). The DPE sequence acts as a specific binding motif 
for a GTF termed TAF 1 I50, and in promoters, which contain a DPE, a specific TBP -
DNA interaction may not be required (Smale, 1997). Instead the mr element is bound 
specifically by a GTF termed TAF 11 250 in association with TBP, and the DPE is 
bound by TAF 1 I5O (Smale, 1997) (Figure 5.9). TAF 11250 and TAF 1 15O, each bound 
to their respective promoter elements, are then able to interact with each other and 
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Figure 5.9 Transcription initiation in TA TA-less euka,yotic 
promoters with a DPE 
Diagram shows the potential interactions of general transcription factors (GTFs) on a 
promoter sequence that contains an initiator (Inr) element and a downstream promoter 
element (DPE). TBP = TATA binding protein, RNA p01. II = RNA polymerase II, HA - IIH = 
GTFs and TAF15O & TAF250 = TBP associated factors. 
Conserved downstream promoter elements (DPEs) were also found in all of 
the mammalian PrP promoters, located between +30 to +35 bases from the respective 
mr elements. The discovery of conserved DPEs may help to further pinpoint the 
location of the actual transcription start sites in the PrP promoters, as most of the 
promoters analysed contained more than one mr element (Appendix, Figure A3). For 
example, in ruminants and mice it appears that the first mr element may be 
functional, as this mr has a DPE located at approximately +30 bases downstream 
(Appendix 2, Figure A3). In the rat and hamster PrP promoters, the second mr site 
may be functional, as in these species the DPE is located at +30 bases downstream 
from this mr element (Appendix 2, Figure A3). Finally, the human PrP promoter 
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contains two DPEs, each located at approximately +30 bases downstream of an mr 
element, indicating that either could be functional in this promoter. 
This study has resulted in the identification of potential mr elements and 
DPEs, located at what may be functional positions, in all of the PrP promoter 
sequences examined. These elements are conserved to a certain extent in the 
mammalian species tested, although some sequence variations are present (Appendix 
2, Figure A3). Further studies will be necessary to characterise any binding to these 
elements in gel shift and super-shift assays, and analysis of the sequence variations 
may provide further clues as to the nature of PrP gene expression regulation in the 
different mammalian species. 
The binding of TFIID to the mr element may occur cooperatively with the 
transcription factors AP-2 & SF-i (Laity et al., 2001). As such AP-2 & SF-i binding 
motifs are commonly found in TATA-less promoters (Hilton & Wang, 2003, 
Kadonaga et al., 1987, Laity et al., 2001, Mavrothalassitis, Watson & Papas, 1990, 
Philipsen & Suske, 1999, Salbaum et al., 1989, Weis & Reinberg, 1997, Zhou & 
Chiang, 2002). All of the mammalian PrP promoters, with the exception of the ovine 
promoter, contain either two (human) or three (bovine & rodent) SF-I motifs, located 
close to the 3' end of the promoter. In addition, all of the mammalian PrP promoters 
analysed contain varying numbers of AP-2 binding motifs. The Cheviot PrP 
promoter contains a single SP-1 motif, and this is likely to be the wild type situation, 
due to the conservation of SP-1 motif(s) in the other mammalian promoters. In 
contrast, the Suffolk PrP promoter does not contain a SF-I motif, and instead 
contains an AP-2 binding motif cluster in the same location (Figure 5.4). 
Transcriptional initiation of the Cheviot, human, bovine & rodent PrP genes may 
therefore be regulated by a combination of SP-1 and AP-2 transcription factors. 
Whilst transcriptional initiation in the Suffolk PrP gene may be regulated by the 
binding of the AP-2 transcription factor. It is unclear what effect this differential 
regulation would have on PrP gene expression between Cheviot and Suffolk sheep, 
but it is certainly worthy of further investigation. 
199 
5.3.1 Upstream ovine AP-2 motif 
Analysis of the upstream ovine AP-2 motif (Figure 5.1), showed that an 
oligonucleotide containing this sequence (uAP-2) was specifically bound by a 
nuclear protein factor present in all of the ovine cell line nuclear extracts tested 
(Figure 5.2). This factor is likely to be AP-2 and a comparison of this complex with a 
gel shift of a recombinant murine AP-2 protein with a consensus AP-2 
oligonucleotide (NC-2) showed that the two complexes had very similar mobilities. 
However, a gel super-shift assay with an anti-AP-2 antibody could be used to 
confirm that this factor is AP-2. 
The AP-2 transcription factor can act as either a repressor or an activator of 
transcription, depending on the promoter and the cellular context of its target gene 
(Roberts & Green, 1995). AP-2 may compete with other transcription factors for the 
sole occupation of a single binding motif, and this may contribute to the tissue-
specific expression of target genes (Courtois, Lafontaine, Lemaigre et al., 1990, 
Jiang, DeFrances, Machen et al., 2000, Mercurio & Kann, 1989, Ren & Liao, 2001). 
It is unclear what role AP-2 may play in the regulation of PrP gene expression. 
However, deletion of a region of DNA containing the upstream AP-2 motif from the 
ovine PrP promoter linked to a CAT reporter gene, resulted in a considerable 
reduction in CAT activity in transiently transfected ovine sA80BR cells (O'Neill et 
al., 2003). This region of the ovine PrP promoter also contains binding motifs for 
EGR-1, and motif 4 (iii), however, binding assays carried out in this study have 
shown that these two motifs are unlikely to be functional in the cell cultures used 
(EGR-1, Figure 5.7; motif 4 (iii), Chapter 6). In addition, the deletion of a region 
containing an AP-2 motif in the human and rat PrP gene promoters, results in a 
significant reduction in reporter gene expression in transiently transfected human and 
rat cells, respectively (Funke-Kaiser et al., 2001, Saeki et al., 1996). Therefore, the 
PrP promoter AP-2 motif appears to be functional and its deletion results in a loss of 
promoter activity in ovine, rat and human cells. This may indicate a role for the AP-2 
transcription factor in transcriptional activation of the ovine PrP gene, although its 
actual role could be much more complex. 
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5.3.2 Downstream ovine AP-2 motif cluster 
Analysis of the Suffolk sheep downstream ovine AP-2 motif cluster (dAP-2s) 
and the Cheviot variant of this motif (dAP-2c), revealed that the two variants are 
bound by proteins with different electrophoretic mobilities in ovine pA80BR nuclear 
extract (Figures 5.1, 5.4 & 5.5). However, in order to confirm these results it would 
be necessary to carry out super-shift assays with anti-AP-2 and anti-SP-1 antibodies, 
respectively. The transcription factors SP-1 and AP-2 have both been shown to 
activate the transcription of specific genes, and they may both play important roles in 
the binding of RNA polymerase II to the promoter (Kadonaga et al., 1987, Pugh & 
Tjian, 1990, Zhou & Chiang, 2002). SP-1 and AP-2 are transcription factors, which 
bind specifically to GC boxes within gene promoter regions (Kadonaga et al., 1987). 
SF-i has been shown to interact with other nuclear factors, such as Yin Yang 1 
(YY1), TBP, and the TBP associated factors TAF 11 I i0/TAF 11 130 and TAF 11 55 
(Chiang & Roeder, 1995, Emili, Greenblatt & Ingles, 1994, Hoey et al, 1993, Lee, 
Galvin & Shi, 1993, Seto et al., 1993, Tanese, Saluja, Vassallo et al., 1996). SP-1 is 
an important factor in the regulation of transcriptional initiation from TATA-less 
promoters, and it is thought that it acts as a tethering moiety, to recruit the basal 
transcription complex to TATA-less promoters (Pugh & Tjian, 1990). However, SP-
1 is not vital for transcriptional initiation from TATA-less promoters, and AP-2 may 
also be able to fulfill a similar role (Zhou & Chiang, 2002). Although SP-1 has 
defined roles in transcriptional activation, it has been shown to act as a repressor of 
transcription, by recruiting histone deacetylase activity (Doetzlhofer, Rotheneder, 
Lagger et al., 1999). Finally, SP-1 may be involved in the tissue specific expression 
of its target genes by competing for the sole occupation of GC boxes with other 
factors, which recognise the same consensus motifs, such as SP-3, SP-4 and AP-2 
(Kwon, Kim, Edenberg etal., 1999, Suske, 1999). 
It is still not known how the binding of either AP-2, or SP-1 to the ovine PrP 
gene promoter would affect gene expression. Deletion of the first of three SPA 
motifs in the bovine PrP gene promoter, linked to a CAT reporter gene resulted in a 
reduction in CAT activity in transiently transfected bovine fibroblast (CK-1) cells 
(Inoue et al., 1997). In addition, deletion of the second SP-1 motif in the rat PrP 
promoter linked to a luciferase reporter gene, resulted in a reduction in luciferase 
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activity in transiently transfected rat pheochromocytoma (PC 12) and glioma (C6) 
cell lines (Saeki et al., 1996). Finally, studies by Baybutt & Manson (1997) showed 
that the first 80 bases upstream of the mouse PrP gene promoter transcription start 
site, which contains binding motifs for SP-1, AP-2 and AP-1, are required for full 
promoter activity. These results indicate that SP-1 may play an important role in the 
activation of PrP gene expression, at least in mice, rats and cattle, although its role in 
the regulation of ovine PrP gene expression is still to be elucidated. 
Studies by O'Neill et al. (2003) have indicated that the upstream ovine AP-2 
motif may activate ovine PrP gene expression. However, this activating role may not 
necessarily apply to the downstream AP-2 motif cluster, as the activation observed at 
the upstream motif could be triggered by its specific location within the promoter. 
The significance of the downstream ovine AP-2 motif cluster, consisting of six 
overlapping AP-2 motifs, in the Suffolk PrP promoter is unclear (Figures 5.4 & 5.5). 
However, the presence of AP-2 clusters within a variety of promoters has been noted 
by other researchers (Imagawa, Chiu & Karin, 1987, Novikov & Kamps, 2001, 
Shachaf, Skorecki & Tzukerman, 2000, Terzano, Flora, Clementi et al., 2000). The 
mouse PrP promoter also contains an AP-2 motif cluster, and polymorphisms within 
this cluster, alter the number of AP-2 binding motifs available in different breeds of 
mice. For example, SV and L129 mice have four overlapping AP-2 motifs, VL mice 
have six motifs, and RIlI mice have only one AP-2 motif at the same location 
(Baybutt & Manson, 1997). Interestingly, Imagawa, Chui & Karin (1987) showed 
that a cluster of five overlapping AP-2 motifs acted as an efficient cell-type specific 
enhancer element. In contrast, AP-2 has been shown to have a role in transcriptional 
repression, by competing with activating transcription factors for the same binding 
motif (Getman, Mutero, Inoue et al., 1995, Jiang et al., 2000, Ren & Liao, 2001). 
Therefore, these AP-2 clusters could potentially be acting as binding blocks, 
preventing the binding of other factors to an overlapping, or nearby motif. Further 
studies are required to investigate the role of AP-2 motif clusters in the murine and 
ovine PrP gene promoters. For example, binding activity to the murine polymorphic 
AP-2 motif cluster may reveal breed specific differential binding to these elements 
and may provide further insights into the role of these motifs in the regulation of PrP 
gene expression. 
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5.3.3 Ovine HSE-1 & HSE-2 
The ovine PrP promoter contains two potential heat shock elements (HSE-I 
& HSE-2, Figure 5.1) which could act as binding motifs for the HSF (Amin et al., 
1988, Wu, 1995). HSF is an inducible transcription factor which binds to the HSE in 
the promoters of heat shock genes (Morimoto, 1993). The expression of HSF is 
activated in response to cellular stress, caused by elevated temperatures or a variety 
of chemical and physiological stresses, and this is known as the heat shock response 
(Amin et al., 1988, Wu, 1995). Shyu, Ham, Saeki et al. (2002) identified two HSEs 
further upstream in the rat PrP promoter (-680 bp & -1653 bp). The authors showed 
that both motifs were occupied by HSF in gel shift and super-shift assays carried out 
in nuclear extracts prepared from heat shocked human NT-2 cells (NTERA-2, 
pleuripotent, embryonal carcinoma cells), whilst only slight binding was observed in 
nuclear extracts prepared from non-heat shocked cells (Shyu et al., 2002). The 
human -amyIoid precursor protein gene promoter also contains a single HSE, and 
specific binding by HSF was observed to an oligonucleotide containing this motif in 
gel shift and super-shift assays performed in nuclear extracts prepared from heat 
shocked human cells (Dewji & Do, 1996, Dewji, Do & Bayney, 1995). Binding to 
the ovine HSE-1 & HSE-2 oligonucleotides was assessed with nuclear extracts 
prepared from normal, and heat shocked pA80BR ovine cultured cells (Figure 5.6). 
The results showed that the ovine HSE motif oligonucleotides are not specifically 
bound by factors present in nuclear extracts prepared from pA80BR cells cultured, in 
either normal cellular conditions, or following heat shock treatment (Figure 5.6). 
However, the cell cultures used for the characterisation of the ovine PrP promoter 
HSEs (pA80BR) are normally cultured at 33 °C, and were heat shocked at 42 °C in 
these studies. It is possible that an increase of 9 °C may have had detrimental effects 
on these cells, and this may explain the lack of binding observed to the ovine HSEs. 
It may therefore be prudent to repeat these studies by heat shocking the pA80BR 
cells at 37 °C (a 4 °C increase), alternatively these studies could be repeated by heat 
shocking the ISl2OCer cell line at 42 °C, as these are normally cultured at 37 °C. 
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5.3.4 Ovine AP-1, GATA-1 & EGR-1 motifs 
The presence of an AP- 1 motif on the ovine PrP promoter is very interesting, 
as the rodent and human PrP promoters all contain at least one consensus AP-1 
motif. However, no specific binding was observed to the AP-1 oligonucleotide in gel 
shift assays carried out with nuclear extracts prepared from the ovine pA80BR cell 
culture (Figure 5.7). These results show that this motif is not functional in this 
system, at least in normal cellular conditions, as tested in this study. It may be the 
case that transcription of the ovine PrP promoter is not regulated by AP-1, however, 
the role of AP-1 in the other mammalian promoters remains unclear. In addition, no 
specific binding was observed to the GATA-1 and EGR-1 oligonucleotides with the 
ovine pA80BR nuclear extracts (Figure 5.7). The results show that these motifs are 
not functional in this system, however, binding of these factors could be activated by 
specific cellular stimuli, that may not have been replicated accurately in these 
studies. 
5.3.5 Ovine PrP promoter STAT motif 
No specific binding was observed to the STAT-C oligonucleotide, however, 
specific binding may have occurred with the STAT-A oligonucleotide with the 
pA80BR nuclear extract (Figure 5.8). However, this result would have to be repeated 
and could be combined with a gel super-shift assay using an anti-STAT antibody to 
identify the bound factor. The STAT family of transcription factors, are latent 
transcription factors, which are found in the cytoplasm of resting cells, and are 
thought to be involved in the transcriptional activation of a variety of genes (Darnell, 
1997, Levy & Darnell, 2002). In response to a variety of stimuli, STAT proteins 
become phosphorylated, this induces them to form homo-dimers, which are able to 
translocate to the nucleus, where they are able to function as transcriptional 
activators (Darnell, 1997, Levy & Darnell, 2002). Therefore, binding to the ovine 
PrP promoter STAT motifs may occur only in response to specific stimuli, which 
have not been replicated in this system. Interestingly, the expression of STAT 
proteins is regulated by the cellular levels of specific cytokines, such as interleukin-2 
(IL-2), IL-6, IL-b, IL-12, IL-4, interferon-y (IFN-'y) and IFNa/IFN (Ihle, 1996, 
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Lackmann, Harpur, Oates et at., 1998, Takeda & Akira, 2000), and the expression of 
proinflammatory cytokines, like IL-6 appear to be elevated in the brains of scrapie 
infected mice (Kim, Ju, Choi et al., 1999). The ovine PrP promoter STAT motifs 
may therefore be occupied by disease specific factors, and it would be interesting to 
analyse binding to the ovine PrP promoter STAT motifs in nuclear extracts prepared 
from scrapie infected brain tissue. It would be very interesting to analyse binding to 
the ovine PrP promoter STAT motifs with nuclear extracts prepared from cells, 
which have been treated with the cytokine, IFN-'y, as this factor has been shown to 
induce the nuclear translocation of STAT proteins (Darnell, 1997, Lackmann et al., 
1998, Leonard & O'Shea, 1998, Schindler & Strehlow, 2000). In addition, it is 
possible that the observed binding to the STAT-A oligonucleotide could constitute 
the binding of a STAT factor to this motif, and that this binding does not occur to the 
wild type STAT motif. This may indicate that binding only occurs to the variant 
STAT motif within the ovine PrP promoter, which is associated with the positive line 
(scrapie susceptible) in the NPU Cheviot flock. The functionality of the ovine PrP 
promoter STAT motifs remains unclear, however, further studies into these motifs 
are necessary, and could provide insights into their role in the regulation of PrP gene 
expression, and possibly in scrapie susceptibility. 
5.3.6 Conclusions 
In summary, the results observed in this study have identified potential 
transcription factor binding motifs within the ovine PrP promoter. Gel shift assays 
showed that the upstream ovine AP-2 motif was specifically bound by a protein 
factor present in the ovine cell culture nuclear extracts. The downstream ovine AP-2 
motif was also bound specifically and the C to G polymorphic change within this site 
resulted in the binding of what appeared to be a completely different factor to this 
element. Two potential mr elements were identified at the 3' end of the ovine PrP 
promoter, which mapped potential transcription start sites to within 1-3 bases of 
those identified by other researchers. Potential mr elements were identified within all 
of the other mammalian PrP promoters and where the information was available 
these sites were found to lie within a few bases of previously published transcription 
start sites. In addition, putative DPEs were identified at approximately +30 bases 
205 
from selected mr elements within all of the mammalian PrP promoters analysed. 
Furthermore, the positioning of the mr elements and DPEs indicated the potential 
location of transcription start sites within all of the mammalian PrP promoters. The 
worked carried out during this study has demonstrated specific binding to selected 
transcription factor motifs within the ovine PrP promoter. It has also shown that at 
least one polymorphic change within this sequence results in differential binding to 
this site. This study has demonstrated the functionality of a number of transcription 
elements within the ovine PrP promoter and has provided further insights into the 
role of the promoter region in the regulation of PrP gene expression. 
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Chapter 6: Characterisation of motifs 1-4 in the ovine 
PrP gene promoter region 
6.1 Introduction 
Four DNA sequence motifs have been identified in the ruminant, rodent and 
human PrP promoters based upon their conserved sequence homology (motifs 1-4, 
Figure 6.1 & Table 5.1) (Westaway et al., 1994a). It was suggested that these 
conserved motifs may be binding sites for as yet unidentified transcription factors. 
However, to date, specific binding to these sites has not been demonstrated, and few 
candidate factors have been identified from sequence analysis of these motifs. 
O'Neill el al. (2003) noted that motif 2 shares sequence homology with the human 
bZIP repressor protein, and motif 4 shares homology with conserved sequences in 
muscle-specific genes (Inoue et al., 1997, Westaway et al., 1994a). In sheep a T to C 
polymorphism within motif I (I CATTTT versus CATTTT) has been identified 
(O'Neill & Cairns, Unpublished). In addition, motif 2 contains a species-specific 
sequence variation, where the ruminant PrP promoter contains a C within the motif 
(TTA& GTAA), whilst the non-ruminant promoter contains a T at the same position 
(TTA IGTAA). Similarly, the PrP promoter contains a species-specific C to T 
variation in motif 3, with the rat promoter containing a C within the motif 
(TAAAGATGA( TTTTA), whilst the other mammalian promoters contain a T at the 
same position (TAAAGATGA I TTTTA). These variations/ polymorphisms provide 
complex targets for the investigation of an association between the role of 
transcription factors and regulation of the PrP gene. Therefore this study focused on 
the characterisation of the conserved motifs in the ovine PrP promoter with the 
specific aims of identifying candidate transcription factors and analysing the binding 
activity of nuclear proteins to oligonucleotide probes containing the motif sequences. 
As yet it is not known whether the motifs are actually occupied by DNA 
binding proteins. Potential binding of nuclear protein factors to these motifs was 
assessed by gel shift assays carried out with nuclear extracts from the ovine cell lines 
available at the NPU (Section 2.5). For a description of the gel shift assay technique 
see section 5.1. Finally, work was carried out to identify the proteins which bind to 
207 
the motifs using antibodies specific for the candidate proteins in gel super-shift 
assays. These assays are similar to the gel shift assay, however, the addition of an 
antibody specific for a protein present in the binding assay results in a further shift of 
the DNA-protein complex (super-shift). It is proposed that this study will provide 
insights into the potential role of the PrP promoter motifs in the regulation of PrP 
gene expression. In order to assess their relevance to disease control, the results of 
this work were analysed with respect to the cell lines from scrapie susceptible and 
resistant sheep that are available at NPU. 
Motif 1 	 Motif 2 
Ovine 	AGTTCCCGAP. ATTGCTTTCT CATTCCCT ..... AATCTTT ATTTTCT. .. ... . CCAT TACGTAACGA GAAGCTGGGG 
Bovine AGTTCCAGAA ATTGCTTTCT CATTCCCT .....AATCTTT CATTTTCT. 	,...CCAT TACGTAACGA GAAGCTGGGG 
Human 	AGTTCCAGAA ATTGCTTCCT CATTCCTG .....AGCCTTT CATTTTCTCG ATTTCTCCAT TATGTAACGG GGAGCTGGAG 
Rat AG . TTCCACG ATGGCTTTTT CTTTCCGTTA GGTAACCTTT CATTTTCTCG AC. TACOCAT TATGTAACG. GGAGCGCTGG 
Mouse 	AG . TTCAACG ATGGCTTCCT CGCTCCGTTA GGTAACCTTT CATTTTCTCA AC . TACCCAT TATGTAP.CG. GGAGCATTGG 
Hamster AGTTTCAGCA ATTGCTTTCT CGCTCCATTA GGCAACCTTT CATTTTCTCA CCTTCCCCAT TATGTAACC. GGAGCAATGG 
Motif 3 	 Motif 4 1 	Motif 4 ii 
Ovine 	CTTT . GGCCG ATTTTCCCTC TAAAGATGAT TT TATCGTC AACAAGCAAT TI_'A _~ G,!;AGT  GATGAGCCAG 1A3GCGGTG 
Bovine CTTT.GGCCG ATTTTCCCTT TAAAGATGAT TTTTATCGTC AACAAGCAAT TTCAGGGAGT GATGAGCCGG GGAGGCGGTA 
Human 	CTTTGGGCCG AATTTCCAAT TAAAGATGAT TTTTACAGTC AATGAGCCAC GTCAGGGAGC GATGGCACCC GCAGGCGGTA 
Rat GTTCTGGATC AGTCTTCCAT TAAAGATGAC TTTTATAGTC TGTGAGCGTC GTCACAGAGT GCTGACACTG GGGTGGGGAG 
Mouse 	GTACTGGATC AGTCTTCCAT TAAAGATGAT TTTTATAGTT GCTGAGCGTC GTCAGGGAGT GCTGACACTG GGGGCGGTTT 
Hamster GTTCTGGACC AGTCTTCCAT TAAGATGAT TTTTATAGTC GGTGAGCGCC GTCAGGGAGT GATGACACCT GGGGGCGGTT 
Motif 4 iii 
Ovine 	TTAGTTGATG CTAGCGTTTA TGCTP.GTCTC AACTCGTTTT TCCCAGGGAC TTAGATTCCT GGGTCTGCCG GTAAACCCCG 
Bovine TTAGCTGATG CTAGCGTTTA AGCTAGTCTC AACTCGTTTT TCCCAGGGAC TTAGATTCCT GGGTCTGCCA GTAAACCCCG 
Human 	TCAACTGATG CAAGTGTTCA AGCGAATCTC AACTCGTTTT TTCCGGTGAC TCATTCCCGG CCCTGGTTGG CAGCGCTGCA 
Rat GGGAGTACGG GGGGAGGGGG TTAAACAGAT AACAAGCATT TAAGCCAGTA CGGAGCGGTG ACTCATCCCA CCGCGAGAAG 
Mouse 	AAACAGATAC AAGCATTTAA GCCAGTCCGG AGCGGTGACT CATCCCCCCC CACCCCCACC CCCCCGCGAG AGACGCGGCG 
Hamster TAAACCGTAC AATCCCTTAA ACCAGTCTGG AGCGGTGACT CATTTCCCCA GGGAGAAGTG GCGCGGCCAT TGGTGAGCAC 
Figure 6.1 Mammalian PrP promoter motifs 
Motifs 1-4 (indicated in blue text) are conserved sequence elements found in ovine, murine, 
hamster, cattle and human PrP gene promoters, as identified by Westaway et al. (1994a) 
which may form binding sites for as yet unidentified transcription factors. Numbering is based 
on the use of the 5 transcription start site as experimentally defined by Westaway et al. 
(1 994a) as +1. NB: Sequence alignments performed on GCG (Wisconsin) using local pile-up 
program, artificial gaps (indicated by dots) were introduced into the above sequences in 
order to line-up potential transcription start sites. 
6.2 Results 
Complimentary single stranded oligonucleotides (approximately 20 bp in 
length) containing each of the four conserved motif sequences, along with the motif 
4 degenerate repeat sequences (motif 4 (i), (ii) & (iii), were annealed to form double 
stranded oligonucleotides (Section 2.4.1) and radiolabeled with 32P (Section 2.4.2) 
(Table 6.1). These oligonucleotides were incubated in binding assays (Section 2.4.6) 
with nuclear extracts (Section 2.4.3) prepared from the ovine cell cultures (IS l2OCer, 
ISl201-iv, sA80BR & pA80BR) and the murine neuroblastoma cell line (N2a) 
(Section 2.5). The amount of nuclear extract added in each assay was between 1-2 tl 
(10-20 jig of total nuclear protein per binding assay). Care was taken to ensure that 
the same batch of nuclear extract was used for each reaction in a single binding assay 
and comparisons of mutated and wild type DNA sequences were made within the 
same batch of nuclear extract. All of the assays in this chapter were repeated on at 
least three occasions with similar results and always using different batches of 
nuclear extracts, unless stated otherwise. The DNA sequences of the oligonucleotides 
used for each of the binding assays can be seen in table 2.3, the sequences used to 
flank the motif sequence were the same as those observed in the actual ovine PrP 
promoter sequence. 
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Name Abbreviation DNA binding motif Location 
Wild type motif I M IT 5CTTTCATTTTCTCCA'3 -286 
Variant motif I MI C 5'CTT CATTTTCTCCA'3 -286 
Ruminant motif 2 M2C 5'TTACGTAACG'3 -271 
Non-ruminant motif 2 M2T 5'TTAT GTAACG'3 -271 
Motif 3 M3 5'TAAAGATGATTTTTA'3 -232 
Motif 4 (i) M41 5TCAGGGAG'3 -201 
Motif 4(u) M4ii 5'CCAGGGAGG'3 -186 
Motif 4 (iii) M4i11 5'CCAGGGAC'3 -130 
Variant Ml + Ruminant 
M2 
MIC/M2C 5'TAATCTTCCATTTTCTCCATTACG 
 TAACGAGA'3  
N/A 
Wild type Ml + Non- 
ruminant M2 
MIT/M2T 5'TAATCTTTCATTTTCTCCATTATG 
 TAACGAGA'3  
N/A 
Variant Ml + Non- 
ruminant M2 
MICIM2T 5'TAATCTTCCATTTTCTCCATTATG 
 TAACGAGA3  
N/A 
Wild type M 1+ Ruminant 
M2 
M1T/M2C 5'TAATCTTTCATTTTCTCCATTACG 
 TAACGAGA'3  
N/A 
Humanised Ovine Ml + 
M2 
hovMl/M2 5'GAGCCTTCCATTTTCTCGAlTTCT 
 CCATTACGTAACGGGGG'3  
N/A 
Human Ml + M2 hM1IM2 5'GAGCCTTTCATTTTCTCGATlTCT 
CCATTATGTAACGGGG'3  
N/A 
Table 6.1 	PrP promoter motifs 
Details the sequences of the PrP promoter conserved motifs as described by Westaway et 
al. (1 994a), which may form putative transcription factor binding sites. The location of each 
site is given relative to the 5' transcription start site as experimentally determined by 
Westaway et al. (1994a). Red text indicates the presence of a polymorphic or species 
specific base change. 
6.2.1 Motif I 
6.2.1.1 Characterisation of ovine motif I binding 
The T to C polymorphism within motif 1 (-286 bp, Table 6.1) was analysed 
for any affect on protein binding. A gel shift assay comparing the wild type motif 1 
(MIT, top strand of double stranded motif I oligonucleotide = 
5'TAATCTT i CATTTTCTCCAT'3) and variant motif I (M1C, 
5'TAATCTT CATTTTCTCCAT'3) oligonucleotides was performed with all of the 
ovine cell culture nuclear extracts (sA80BR, pA80BR, IS I 20Liv & IS 1 20Cer). The 
results obtained with the sA80BR nuclear extract are shown in Figure 6.2. 
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Figure 6.2 Gel shift assay: motif I (MIC & MiT) oligonucleotides with 
sA80BR nuclear extract (NE) 
Gel shift assay indicating that the wild type motif 1 oligonucleotide (MiT) is not specifically 
bound by a transcription factor (lane 2), but the variant motif 1 oligonucleotide (M1C) is 
specifically bound by a transcription factor present in the sA80BR nuclear extract (lane 8). The 
presence of each of the separate assay components is indicated by the + signs underneath 
each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
Nucl. Extract: nuclear extract. 
sA80BR: nuclear extract from the sA80BR (scrapie susceptible) neuronal cell line 
lOX, bOX or 200X indicates the inclusion of a 10, 100 or 200 fold molar excess of the 
appropriate unlabelled oligonucleotide. Sequences of the oligonucleotides used are detailed in 
Table 2.3. 
As can be seen, the Ml C oligonucleotide bound strongly to a nuclear protein 
present in the sA80BR nuclear extract (Lane 8, Figure 6.2), and this binding was 
competed out by the addition of increasing concentrations (10, 100 & 200 fold molar 
excess) of unlabeled MIC oligonucleotide (Lanes 9, 10 & 11, Figure 6.2). In 
addition, competition with an unassociated non-competitor oligonucleotide 
(unlabeled NC-1, Table 2.3) had no effect on binding, indicating that the binding to 
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the MIC oligonucleotide was specific (Lane 12, Figure 6.2). However, the MIT 
oligonucleotide failed to show any specific binding in the ovine nuclear extract (Lane 
2, Figure 6.2). The same result was also observed when this assay was repeated in 
the ovine pA80BR, IS12OLiv and IS12OCer nuclear extracts (data not shown). In 
order to ensure that the observed results were not due to mistakes in the synthesist 
preparation of the oligonucleotides, both the M1C and MIT oligonucleotides were 
re-ordered and the gel shift assay shown in Figure 6.2 was repeated with these newly 
synthesised oligonucleotides with the same results. 
6.2.1.2 Variant motif I (MIC) oligonucleotide gel super-shift assay 
Search of transcription factor databases revealed the transcription factor Yin 
Yang 1 (YY1) (Shi, Lee & Galvin, 1997) to be a strong candidate for binding to the 
variant motif 1 sequence. The possibility that YYI was the factor bound to the MIC 
oligonucleotide was further supported by comparisons with a purified murine AP-2 
protein which has a molecular weight of 100 kDa (Lane 2, Figure 5.3). This 
comparison indicates that the factor bound to Ml C (Lane 8, Figure 6.2) would have 
an approximate molecular weight of 50 kDa as it appears to have a mobility of 
approximately twice that of the purified murine AP-2 (Lane 2, Figure 5.3). To 
characterise the DNA/protein complex observed with the MIC oligonucleotide, an 
anti-YY1 antibody was employed in a gel super-shift assay. This antibody is reported 
to react with human, rat and mouse YY1 and is designed for use in gel super-shift 
assays (anti-YY1, Santa Cruz Biotechnology, USA). Assuming that the candidate 
factor had been correctly identified the antibody should bind to its epitope, and this 
binding may then cause one of two possible changes in the shift pattern. Firstly, the 
antibody may bind to the protein with no affect on protein-DNA binding, causing the 
mobility of the observed DNA-protein complex to change, a so-called super-shift. 
Alternatively, by binding to the protein the antibody may disrupt the DNA-protein 
complex and cause the DNA-protein complex to dissociate, consequently the initial 
shift will either be reduced or completely blocked (Bakalkin, Yakovieva & Terenius, 
1997, Johansson, Hjortsberg & Thelander, 1998). Super-shift assays were performed 
with M1C oligonucleotide incubated with sA80BR or N2a nuclear extracts. 
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The anti-YY1 antibody was added after the radiolabeled M I C 
oligonucleotide and the samples were incubated at room temperature for 45 minutes 
(Figure 6.3). No super-shift of the DNA-protein complex was observed, instead the 
addition of the anti-YY I antibody resulted in the dissociation of the initial complex 
(Lane 3, Figure 6.3 and compare with Lanes 8-12, Figure 6.2). This result suggested 
that a specific reaction had occurred between the M1C DNA-protein complex and 
the anti-YYI antibody. The super-shift assay was repeated in nuclear extracts 
prepared from the murine N2a cells with the same result (data not shown). In 
addition, the assay was repeated with a shorter incubation time of 20 minutes, and 
also with the anti-YY1 antibody being added beibre the radiolabeled MIC 
oligonucleotide and on each occasion the same result was observed (data not shown). 
As an additional control, the ruminant motif 2 (M2C) oligonucleotide was incubated 
in a super-shift assay with the same anti-YY1 antibody, and no change in the M2C 
DNA-complex was observed, indicating that the reaction observed with the M1C 
oligonucleotide was specific (Lane 9, Figure 6.3). Finally the assay was also repeated 
using the anti-E4BP4 antibody, the results showed that this antibody had no effect on 
the M I C DNA complex indicating that the blocking reaction seen with the anti-YY1 
antibody was specific and not caused by a component of the antibody solution (data 
not shown). 
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M2C 	 + + + + + + 
Nuci. Extract 	 + + 	+ + 	+ + 	+ + 
Comp. oligo(lOOx) 	 + 	 + 
Non-comp.oligo(NC-l)(lOOx) 	 + 	 + 
Anti-YYI antibody 	 + + + + ± + + + 
Lane 	 123456 	789101112 
Figure 6.3 Gel super-shift assay: variant motif 1 (MIC) and ruminant motif 2 
(M2C) oligonucleotides with anti-YYI antibody with pA80BR nuclear extract 
(NE) 
Gel super-shift assay indicating that the variant motif 1 oligonucleotide (M1C) is specifically 
bound by a transcription factor (lane 2) and this binding is ablated following the addition of an 
anti-YY1 (Yin Yang 1) antibody (lane 3). In addition the presence of each of the separate assay 
components is indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
bOX indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. Antibody 
added was an anti-YY1 antibody (Santa Cruz, USA). 
In order to further confirm this result, the M I C oligonucleotide was incubated 
with ovine sA80BR nuclear extract and increasing amounts of the anti-YY1 antibody 
(Figure 6.4). The amount of the shift complex (Lane 2, Figure 6.4) gradually 
decreased as more anti-YY1 antibody was added (Lanes 3-12, Figure 6.4). This 
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concentration dependent inhibition of the formation of a MIC DNA / protein 
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Figure 6.4 Ge/super-shift assay: variant motif I (M1C) oligonucleotide with 
increasing concentrations of anti-YY1 antibody with pA80BR nuclear extract 
(NE) 
Gel super- shift assay indicating that the variant motif 1 oligonucleotide (M1C) is specifically 
bound by the YY1 transcription factor (lane 2) and that this binding is inhibited by the addition of 
an anti-YY1 antibody in a concentration dependent manner. The presence of each of the 
separate assay components is indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
Nucl. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. Antibody 
added was an anti-YY1 antibody (Santa Cruz, USA). 
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6.2.2 Motif 2 
6.2.2.1 Characterisation of motif 2 binding 
A single base species difference of C to T (red text) is present in the non-
ruminant PrP promoter, which changes motif 2 (-271 bp, Table 6.1) from 
TTA GTAA to TTA 1 GTAA. Double stranded oligonucleotides containing both 
variations of motif 2 (ruminant motif 2 (M2C) & non-ruminant motif 2 (WT), 
Tables 2.3 & 6.1) were produced (Section 2.4.1) and radiolabeled (Section 2.4.2) 
with 32P. The affect of this species specific sequence difference on motif 2 binding 
was assessed by gel shift assays (Section 2.4.6) carried out with ovine cell and 
murine N2a cell nuclear extracts (only pA80BR and N2a results shown, Figure 6.5). 
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Figure 6.5 Gel shift assay. ruminant (M2C) & non-ruminant 
motif 2 (M2T) oligonucleotides with pA80BR & N2a nuclear extracts (NEs) 
Gel shift assay indicating that the ruminant (M2C) & non-ruminant (M2T) oligonucleotides are 
specifically bound by a similar transcription factor (based on electrophoretic mobilities), however 
the factor appears to have a greater affinity for the M2C oligonucleotide, indicated by increased 
binding activity. The presence of each of the separate assay components is indicated by the + 
signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
The M2C oligonucleotide was shown to bind to a protein factor present in the 
ovine sA80BR, pA80BR, ISl2OCer & ISl2OLiv cell nuclear extracts (only pA80BR 
shown) and also in the munne N2a cell nuclear extract (Lanes 2, 6 10 & 14, Figure 
6.5). Binding was competed out by the addition of 100 fold molar excess unlabeled 
217 
competitor oligonucleotide, M2C (Lanes 3, 7, 11 & 15, Figure 6.5). In contrast, 
binding was not affected by the addition of 100 fold molar excess non-competitor 
oligonucleotide (NC-1), indicating that the binding was specific (Lanes 4, 8, 12 & 
16, Figure 6.5). The M2T oligonucleotide appears to bind to the same factor as the 
M2C oligonucleotide in the same nuclear extracts (Figure 6.5). However, the M2C 
oligonucleotide binds strongly to the protein factor (Lanes 2 & 10, Figure 6.5), whilst 
the M2T oligonucleotide binds to what appears to be the same factor, but with much 
lower affinity in the ovine cell culture and murine N2a cell nuclear extracts (Lanes 6 
& 14, Figure 6.5). 
The ruminant motif 2 but not the non-ruminant motif 2 contains a potential 
CpG island (TTACpGTAA). The effect of methylation at this site on protein binding 
was investigated by the use of a M2C oligonucleotide methylated at this position in 
gel shift assays (data not shown). No difference in binding affinity was observed 
between the methylated and unmethylated M2C oligonucleotides, indicating that 
methylation at this position does not effect protein binding (data not shown) 
6.2.2.2 Ruminant motif 2 oligonucleotide (M2C) gel super-shift assay 
A strong candidate for the factor binding to motif 2 is the bZJP transcription 
factor E413P4, which is a dimeric PAR-like factor composed of two 52 kDa 
monomers (Cowell, 2002, Cowell et al., 1992). This candidate was identified 
following analysis of the motif 2 sequence using the TFSEARCH and TRANSFAC 
databases. This is supported by comparisons of the protein bound to the M2C 
oligonucleotide with what are believed to be AP-2 (100 kDa) & SP-1 (106 kDa) 
bound to the dAP-2s & dAP-2c oligonucleotides, respectively (Lanes 2 & 8, 
respectively, Figure 5.5). These factors have similar mobilities to the protein bound 
to the M2C oligonucleotide (Lanes 2, 6, 10 & 14, Figure 6.5) indicating that this 
protein could be E413P4 (molecular weight = -400 kDa) (Cowell, 2002, Cowell et 
al., 1992). More evidence for the binding of E413P4 to motif 2 was provided by gel 
shift assays, which showed that the M2C oligonucleotide was bound strongly by a 
protein factor present in the cell culture nuclear extracts (Figure 6.5). In contrast, the 
M2T oligonucleotide was bound much more weakly by what appeared to be the same 
factor, based on comparisons of electrophoretic mobilities. E413P4 recognises the 
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palindromic consensus motif of TTACGTAA, indicating that it would bind strongly 
to the M2C oligonucleotide (TTACGTAA), whilst binding of E4BP4 to the non-
palindromic, M2T oligonucleotide (TTA 1 GTAA) may be less likely (Cowell, 2002, 
Cowell et al., 1992). The possibility that another PAR factor could be bound to motif 
2 was ruled out as it has been shown that the PAR factors, unlike E4BP4, will bind 
with equal affinity to the TTATGTAA and TTACGTAA motifs, as such E4BP4 was 
considered to be the prime candidate for binding to motif 2 (Falvey, Marcacci & 
Schibler, 1996, Hunger, Brown & Cleary, 1994). In addition, the two PAR family 
bZ[P factors, hepatic leukemia factor (HLF - two 33 kDa monomers) and the 
albumin gene promoter binding protein (DBP - single 34 kDa monomer) which 
recognise the same binding site as E4BP4 were ruled out as candidate factors for the 
binding to motif 2 on the basis of their molecular weights. An antibody is available 
which reacts with human, rat and mouse E4BP4 and is specifically designed for use 
in gel super-shift assays (anti-E413P4, Santa Cruz Biotechnology, USA). Gel super-
shift assays (Section 2.4.7) were performed with the M2C oligonucleotide incubated 
with pA80BR nuclear extract (Section 2.4.3). The super-shift assays (Section 2.4.7) 
were carried out by adding the antibody either before (Lanes 3-6, Figure 6.6), or after 
the addition of the radiolabeled oligonucleotide (Lanes 7-11, Figure 6.6). In addition, 
two different sets of incubation conditions were used, either 45 minutes at room 
temperature (Lanes 3-9, Figure 6.6) or overnight at +4 °C (Lanes 10-11, Figure 6.6). 
No super-shift of the original shift complex was observed with any of the variations 
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KEY: Conditions: Lanes 3-6, anti-E4BP4 added prior to radiolabeled oligo, incubated at room 
temperature (r/t) for 45 minutes; Lanes 7-9, anti-E4BP4 added after oligo, incubated at nt for 
45 minutes; Lanes 10-1 1, anti-E4BP4 added after oligo, incubated at +4 °C overnight. All 
samples were run on a single gel, which was reorganised using the draw facility on Microsoft" ,  
Word. 
Figure 6.6 Gel super-shift assay: ruminant motif 2 (M2C) oligonucleotide, 
with anti-E4BP4 antibody with pA80BR nuclear extract (NE) 
Gel super-shift assay indicating that the ruminant (M2C) oligonucleotide is specifically bound by 
a transcription factor which is not recognized by an antibody specific for E4BP4. The presence 
of each of the separate assay components is indicated by the + signs underneath each lane of 
the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. Antibody 
used is an anti-E4BP4 antibody (Santa Cruz, USA). 
The anti-E4BP4 antibody was further tested by carrying out a gel super-shift 
assay (Section 2.4.7), with murine N2a nuclear extracts (Section 2.4.3) with the M2C 
oligonucleotide. The reason for this is that although the anti-E4BP4 antibody has not 
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been shown to react with ovine E4BP4, it does react with the munne form of the 
protein (Santa Cruz Biotechnology, personal communication). It was therefore 
expected that the antibody would be able to react with the murine E4BP4, if present 
in the N2a nuclear extract (Figure 6.7). 
N2a NE 	N2a NE 	HeLa NE 
E413P4 super- 
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Figure 6.7 Gel super-shift assay: motif 2 (M2C & M2T) oligonucleotides 
with anti-E4BP4 antibody with murine N2a and human HeLa cell nuclear 
extracts (NEs) 
Gel super-shift assay indicating that the transcription factor bound to the ruminant M2C (Murine 
N2a & Human HeLa nuclear extracts) & non-ruminant M2T (Murine N2a nuclear extract) 
oligonucleotides are specifically bound by a transcription factor which is recognized by an 
antibody specific for E4BP4. The presence of each of the separate assay components is 
indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
Nucl. Extract: nuclear extract. 
N2a: Murine neuroblastoma cell line nuclear extract 
HeLa: Human cell line nuclear extract 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. Antibody 
used is an anti-E413P4 antibody (Santa Cruz, USA). 
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As can be seen from Figure 6.7, the anti-E4BP4 antibody reacted specifically 
with the original M2C DNA-protein complex formed with the murine N2a cell 
nuclear extract causing a super-shift to occur (Lane 3, Figure 6.7). In addition, no 
super-shift reaction was observed when the nuclear extract was omitted (Lane 4, 
Figure 6.7) indicating that the initial super-shift (Lane 3, Figure 6.7) was due to 
factors present in the nuclear extract and not a reaction between the M2C 
oligonucleotide and the antibody. Furthermore, the initial shift and the super-shift 
were both competed out by the addition of 100 fold molar excess unlabelled 
competitor oligonucleotide, M2C (Lane 5, Figure 6.7) but were not affected by the 
addition of unlabelled non-competitor oligonucleotide, NC-1 (Lane 6, Figure 6.7). 
The super-shift reaction (Section 2.4.7) was repeated with the M2T oligonucleotide 
with human HeLa cell line nuclear and munne N2a cell nuclear extracts and similar 
super-shifts were observed (Lanes 9 & 15, respectively, Figure 6.7). 
6.2.3 Characterisation of binding to motifs I & 2 in nuclear extracts 
prepared from ovine and murine brain tissue 
Binding to the MI C oligonucleotide was analysed with nuclear extracts 
prepared from fresh ovine (NPU Cheviot) & murine (C57BL) brain tissue (Section 
2.4.4) (Figure 6.8). 
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NB: All shift assays were run on the same gel but were aligned using possible motif I binding 
factor (marked with arrowhead) using Microsoft TM  Word. Ml C oligonucleotide additional 
specific complexes marked by Y. GSA = gel shift assay, GSSA = gel super-shift assay. 
Figure 6.8 Gel shift assay and gel super-shift assay: motif 1 (M1C) 
oligonucleotide with ovine & murine brain tissue derived nuclear extracts (NEs) 
Gel shift assay indicating that the variant motif 1 (M1C) oligonucleotide is specifically bound by 
three transcription factors, one of which is YY1. The presence of each of the separate assay 
components is indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
Nucl. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
GSA: gel shift assay, GSSA: gel super-shift assay 
bOX indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. Antibody 
used is an anti-YY1 antibody (Santa Cruz, USA). 
The electrophoretic mobility of the complexes observed in the binding assays 
carried out with nuclear extracts from the ovine and murine brain tissues (Figure 6.8) 
were consistent with those observed with the MIC oligonucleotide with the ovine 
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cell culture nuclear extracts (Lane 8, Figure 6.2). Specific binding was observed to 
the MIC oligonucleotide with murine brain nuclear extract (Lane 6, Figure 6.8) and 
the intensity of the binding detected was comparable to that observed with the same 
oligonucleotide with ovine pA80BR nuclear extract (Lane 2, Figure 6.8). Specific 
binding was also observed to the Ml C oligonucleotide with the ovine brain nuclear 
extract (Lane 10, Figure 6.8). At least two other larger complexes were observed 
using the MIC oligonucleotide with the murine and ovine brain tissue derived 
nuclear extracts (Marked by 'x', Lanes 6 & 10, respectively, Figure 6.8) that were 
not observed in any of the other nuclear extracts analysed. The additional Ml C 
oligonucleotide complexes were competed out by the addition of 100 fold molar 
excess unlabelled competitor oligonucleotide, Ml C (Marked by 'x', Lanes 7 & 11, 
respectively, Figure 6.8). However, the complexes were not affected by the addition 
of 100 fold molar excess unlabelled non-competitor oligonucleotide, NC-i (Marked 
by 'x', Lanes 8 & 12, respectively, Figure 6.8), indicating that they were specific. 
These additional complexes could represent an association between YY1, bound to 
the M  C oligonucleotide, and other transcription factors. In order to determine if the 
additional complexes contained YYI, a gel super-shift assay was performed with 
ovine brain nuclear extract using the anti-YYI antibody (blocking assay), if the 
additional complexes were blocked then it would be reasonable to assume that they 
also contained the YYI transcription factor (Lanes 13-19, Figure 6.8). However, only 
the lower band (similar mobility to YYI) was blocked by the anti-YYI antibody 
(Lane ii, Figure 6.8), confirming that YY1 also binds to the M1C oligonucleotide in 
the ovine brain tissue nuclear extract. The additional complexes (Marked by 'x', 
Lane 10, Figure 6.8) are therefore likely to represent the binding of other, as yet 
unidentified, factors to the M I C oligonucleotide. 
Binding to the M2C oligonucleotide was analysed with nuclear extracts 
prepared from murine (C57BL) brain and liver tissue and ovine (NPU Cheviot) brain 
tissue that had been flash frozen in liquid nitrogen and stored at —70 O  C for 2 weeks 
prior to the preparation of nuclear extracts (Section 2.4.4) (Figure 6.9). 
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Frozen 
Murine Murine pA80BR 0% i Ile 
brain NE liver NE 	NE 	Brain NE 
Motif 2 specific f 
binding 
Unbound labeled 
Nuci. Extract 	+ -- ± 	± - + 	- 	-r 	+ + + 
Comp. oligo(lOOx) 	+ + + + 
Non-comp. oligo + 	+ 	+ 	+ 
(NC- I) (lOOx) 
Lane 	 I 2 3 4 5 6 7 8 9 101112 13 1415 16 
NB: Murine brain, liver & pA80BR shift assays from same gel. Ovine frozen brain tissue shift 
assay from separate gel 
Figure 6.9 Gel shift assay: motif 2 (M2C) oligonucleotide with ovine 
& murine tissue derived nuclear extracts (NEs) 
Gel shift assay indicating that the ruminant motif 2 (M2C) oligonucleotide is specifically bound 
by transcription factors with slightly differing electrophoretic mobilities in nuclear extracts 
derived from murine brain & liver and previously frozen ovine brain tissue. The presence of 
each of the separate assay components is indicated by the + signs underneath each lane of the 
gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
The complexes observed with nuclear extracts prepared from ovine and 
munne tissues (Figure 6.9) were consistent with those observed with the M2C 
oligonucleotide with the murine and ovine cell culture nuclear extracts (Figure 6.5). 
Specific binding was observed with the M2C oligonucleotide with the murine brain 
and murine liver tissue derived nuclear extracts (Lanes 2 & 6, Figure 6.9). In 
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addition, specific binding was observed to protein factors present in the nuclear 
extracts produced from frozen ovine brain tissue (Lane 14, Figure 6.9). The complex 
observed with the M2C oligonucleotide with mouse brain tissue nuclear extract, was 
slightly smaller than that seen with the mouse liver tissue nuclear extract (Lanes 2 & 
6, respectively, Figure 6.9). A similar difference was also observed with the M2C 
oligonucleotide with the IS12OCer and IS12OLiv nuclear extracts (Lanes 2 & 6, 
respectively, Figure 6.10). The complex observed with the IS I 20Cer nuclear extract 
(Lane 2, Figure 6.10) was slightly larger than that seen with the same oligonucleotide 
with the IS12OLiv nuclear extract (Lane 6, Figure 6.10). These complexes are 
compared with the complexes from the murine brain tissue (Lane 10, Figure 6.10) 
and liver tissue nuclear extracts (Lane 14, Figure 6.10). The significance of these 
differences in mobilities is unclear, however, it is possible that they represent the 
binding of slightly different complexes (homo- and hetero-dimers) to the same motif 





lSI2OCer NE lSI2OLiv NE brain NE liver NE 
NB: Murine brain & liver NE gel shift assays from same gel, IS12OCer & ISl2OLiv NE gel 
shift assays from a single different gel 
Figure 6.10 Gel shift assay: comparison of ruminant motif 2 (102C) 
oligonucleotide with liver & brain derived nuclear extracts (NEs) 
Gel shift assay indicating that the ruminant motif 2 (M2C) oligonucleotide is specifically bound 
by transcription factors with slightly differing electrophoretic mobilities in nuclear extracts 
derived from murine brain & liver tissue and from Icelandic sheep cell lines of neuronal and liver 
origin. The presence of each of the separate assay components is indicated by the + signs 
underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
lS12OCer: nuclear extract from the lS12OCer (cerebellum) cell line 
lS12OLiv: nuclear extract from the lS12OLiv (liver) cell line 
bOX indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
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6.2.4 Analysis of interactions between motif I and motif 2 binding 
factors 
In the ovine PrP promoter the sequences specifying motifs 1 & 2 run almost 
directly into each other, and due to this close proximity it may be that the factors 
which bind to these motifs could interact in some way with one another. To test this 
hypothesis a series of double motif oligonucleotides were produced (Sections 2.4.1 & 
2.4.2), which contained different combinations of motifs I and 2 and their variants 
(Tables 2.3 & 6.1). By using double motif oligonucleotide in gel shift assays it was 
expected to be possible to explore whether both factors could bind at the same time 
or whether double occupancy was not possible due to sterical hindrance or similar 
mechanisms. In the first case the mobility of that new complex would be distinct 
from that observed with either of the single motif oligonucleotides, in the second 
case similar retarded bands to those seen with the single motif oligonucleotides 
would be expected. Based on the results from the single oligonucleotide experiments, 
the strongest binding for both factors is predicted for the combination of variant 
motif 1 and ruminant motif 2 (M 1C/M2C) generating the highest chance to observe 
the formation of an additional complex. 
Additionally, oligonucleotides were used with a sequence insertion ('linker') 
between motifs I and 2, this arrangement resembles the human and mouse PrP 
promoter sequence. It was hypothesised that the 'linker' sequence between motifs 1 
and 2 in these species could in some way influence the binding of YY1 and E4BP4 
to these motifs. The first oligonucleotide contained the variant motif 1 (MIC) and the 
ruminant motif 2 (M2C), as observed in the ovine PrP promoter, separated by the 8 
base linker (CGATTTCT) from the human PrP promoter (Humanised ovine Ml + 
M2 (hovMl/M2), Tables 2.3 & 6.1). A second oligonucleotide reflected the exact 
human PrP promoter sequence containing motifs 1 and 2 (Human Ml + M2 
(hMl/M2), Tables 2.3 & 6.1) and was used as a control for the artificial hovMl/M2 
oligonucleotide. The results are shown in Figure 6.11, only MIC/M2C, hovMl/M2 
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Figure 6.11 Gel shift assay: motif I & motif 2 double oligonucleotides with 
pA80BR nuclear extract (NE) 
Gel shift assay indicating that a double motif oligonucleotide, containing both the variant motif 1 
(M1C) and the ruminant motif 2 (M2C) sites is specifically bound only by the individual 
transcription factors and not by both factors at one time. The presence of each of the separate 
assay components is indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled 
probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
100X indicates the inclusion of a 100 fold molar excess of the appropriate unlabelled 
oligonucleotide. Sequences of the oligonucleotides used are detailed in Table 2.3. 
As can be seen from Figure 6.11, two individual retarded bands were 
observed with the M1C/M2C double oligonucleotide, which were consistent with the 
separate formation of a motif I complex or a motif 2 complex (Lane 2, Figure 6.11). 
The lower complex (motif I binding) was competed out by the addition of 100 fold 
molar excess unlabelled M1C oligonucleotide (Lane 4, Figure 6.11) and was not 
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affected by the addition of 100 fold molar excess unlabelled M2C oligonucleotide 
(Lane 5, Figure 6.11), indicating that the factor bound here was the same as that 
bound to the single M1C oligonucleotide (Lane 8, Figure 6.2). The upper complex 
(motif 2 binding) was not competed out by the addition of 100 fold molar excess 
unlabelled Ml C oligonucleotide (Lane 4, Figure 6.11) and was competed out by the 
addition of 100 fold molar excess unlabelled M2C oligonucleotide (Lane 5, Figure 
6.11), indicating that the factor bound was the same as that bound to the single M2C 
oligonucleotide (Lane 2, Figure 6.5). 
At no time was an intermediate shift complex observed, indicating that the 
binding of these factors is mutually exclusive when presented with a close sequence 
motif arrangement (Lane 2, Figure 6.11). The binding to the artificial 8 base linker 
oligonucleotide (hovMl/M2, Lane 8, Figure 6.11) was similar to that observed with 
the MIC/M2C double oligonucleotide (Lane 2, Figure 6.11). Again it appeared that 
only one factor was able to bind at any one time to the double motif oligonucleotides 
tested (Lane 8, Figure 6.11). As expected no significant binding was observed to the 
hMl/M2 double oligonucleotide (Lane 14, Figure 6.11), a result consistent with that 
observed with the individual MIT (no binding, Lane 2, Figure 6.2) and the M2T 
oligonucleotides (weak binding, Lane 6, Figure 6.5) seen on the human PrP 
promoter. These experiments failed to identify any interaction between the factors 
bound to motifs I & 2, however, they indicated that the binding of these two factors 
to their respective binding motifs may be mutually exclusive. 
Another method used to analyse interactions between the two binding factors 
in gel shift assays was to radiolabel only one of the two oligonucleotides in question 
(Section 2,4.2), in this case the M1C oligonucleotide. This labeled oligonucleotide 
was incubated in a binding assay (Section 2.4.6) with a nuclear extract and the 
resulting MIC DNA-protein complex was competed with an unlabeled M2C 
oligonucleotide. If an interaction occurred between the factors which bind to the two 
oligonucleotides (labeled MIC and unlabeled M2C), then this would be seen as a 
reduction in the original Ml C DNA-complex. Interestingly, the results showed that 
the unlabeled M2T oligonucleotide competed out the M1C DNA-complex in a 
concentration dependent manner (Figure 6.12). The original Ml C DNA-protein 
complex was almost completely competed out following the addition of 1000X 
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unlabelled M2C oligonucleotide (Lane 6, Figure 6.12). At this level the reduction in 
the amount of the original complex was similar to that observed following the 
addition of 100 fold molar excess unlabeled MIC competitor oligonucleotide (Lane 
3, Figure 6.12). In addition, no reduction of the original variant motif I DNA-protein 
complex was observed with three different non-specific unlabeled competitor 
oligonucleotides (EGR- I, AP-1 & dAP-2c), indicating that the ruminant motif 2 
competition may have been specific (EGR-1, Lanes 7-9; AP-1, Lanes 10-12; dAP-2c, 
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KEY: Lanes 4-6 unlabeled M2C oligo; Lanes 7-9, unlabeled EGR-1 oligo; Lanes 10-12, 
unlabeled AP-1 oligo; Lanes 13-15, unlabeled dAP-2c oligo. 
Figure 6.12 Gel shift competition assay: labeled variant motif I (MIC) 
and unlabeled competitor & non-competitor oligonucleotides with 
pA80BR nuclear extract (NE) 
Gel shift assay indicating that a DNA protein complex formed by the variant motif 1 (M1C) 
oligonucleotide and the YY1 transcription factor is competed out by the addition of a 1000X excess 
of the ruminant motif 2 (M2C) oligonucletide, but is not affected by the same excess of the EGR-1, 
AP-1 or SP-1 oligonucteotides. The presence of each of the separate assay components is 
indicated by the + signs underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled probe. 
Nuci. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
lOX, bOX or 1000X indicates the inclusion of a 10, 100 or 1000 fold molar excess of the 
appropriate unlabelled oligonucleotide. Sequences of the oligonucleotides used are detailed in 
Table 2.3. 
6.2.5 DNase I footprinting of 0.5 kb ovine promoter region in ovine 
pA80BR nuclear extract 
DNase I footprinting (Section 2.4.9) of the 0.5 kb Cheviot PrP gene promoter 
region was performed in order to supplement the results seen with the gel shift 
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assays. The footprinting method works on the basis that an interaction with a 
regulatory protein protects the DNA in the region of the binding motif from digestion 
by DNase 1. The 0.5 kb promoter fragment was labeled at the 5' end with 32P 
(Section 2.4.9). This fragment was incubated either with, or without ovine pA80BR 
nuclear extract (Section 2.4.3) and then digested with a sufficient quantity of DNase I 
to ensure that each molecule of the 0.5 kb Cheviot promoter DNA was cut at a single 
phosphodiester bond. The footprint product with no proteins attached to it produces a 
family of labeled fragments, which differ in size by one nucleotide appearing as a 
ladder of bands on the denaturing gel. In contrast, the footprint product with proteins 
attached to it produces an incomplete family of DNA fragments, with the absent 
fragments appearing as a footprint or protected area on the denaturing gel. The 
footprint was separated on a denaturing 4 % polyacrylamide gel (Section 2.3.4) and 
analysed for binding to the ovine variant motif I and ruminant motif 2 binding sites 
present on the 0.5 kb Cheviot promoter fragment. Additional footprints were carried 
out in the presence of unlabeled competing oligonucleotides (MIC & M2C), and a 
non-competing, unlabeled oligonucleotide (NC-1). Finally, the Cheviot 0.5 kb 
promoter fragment was sequenced by Sanger sequencing (Section 2.3) using a primer 
designed to bind specifically to the 5' end of the promoter (FPI, Table 2.2). This 
sequence was loaded on to the polyacrylamide gel next to the footprint sequence in 
order to allow identification of the motif sequences from the footprint analysis. The 
DNA sequence is represented in a diagrammatic form to the left of the DNase I 
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0.5 kb promoter 	 + 	-1- 	+ 	+ 	+ 
NucI. Extract (2 1.11) 	 + 	 + + + 
Nuci. Extract (4.tl) + 
Unlabelled MIC oligo (17x) 	 + 
Unlabelled M2C oligo (17x) + 
Non-comp. oligo (NC-1)(17x) 	 + 
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KEY: k 	= variant motif I protected DNA footprint, Black line = variant motif 1 
unprotected DNA footprint, Blue line = ruminant motif 2 unprotected DNA footprint. 
Figure 6.13 DNase /footprint: 0.5 kb ovine promoter fragment 
with pA80BR nuclear extract (NE) 
DNasel Footprinting assay of the Cheviot sheep promoter region containing motifs 1 & 2, indicating 
that the area containing motif 1 may be protected by bound nuclear proteins, whilst motif 2 may not 
be protected. The presence of each of the separate assay components is indicated by the + signs 
underneath each lane of the gel. 
Comp. oligo: unlabelled competitor oligonucleotide, same sequence as the labelled probe. Non-
comp. oligo: unlabelled non-competitor oligonucleotide, different sequence from the labelled probe. 
NucI. Extract: nuclear extract. 
pA80BR: nuclear extract from the pA80BR (scrapie resistant) neuronal cell line 
17X indicates the inclusion of a 17 fold molar excess of the appropriate unlabelled oligonucleotide. 
Sequences of the oligonucleotides used are detailed in Table 2.3. 
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Following the addition of pA80BR nuclear extract the DNase I footprint of 
the 0.5 kb fragment indicated that there may be some protection in the region of the 
Cheviot promoter fragment containing the variant motif 1 (potential protection 
marked by red line, Lane 2, Figure 6.13). Furthermore, this section of DNA was 
clearly unprotected in the footprint performed without nuclear extract (Black line, 
Lane 1, Figure 6.13). In contrast, the area of DNA containing the ruminant motif 2 
sequence did not appear to be protected following the addition of pA80BR nuclear 
extract (marked by blue line, lane 2, Figure 6.13). However, the potential protection 
of the variant motif I was not competed out by the addition of a 17 fold molar excess 
of unlabeled competitor oligonucleotides M1C (Lane 4, Figure 6.13) or M2C (Lane 
5, Figure 6.13), nor was it affected by the addition of a 17 fold molar excess of an 
unlabeled non-competitor oligonucleotide, NC-I (Lane 6, Figure 6.13). DNase I 
footprints of the Cheviot promoter fragment were performed on three separate 
occasions with the same result, however, time constraints did not allow further 
analysis. 
6.2.6 Characterisation of motif 3 & motif 4 binding 
Binding to the motif 3 (M3, -232 bp, Table 6.1) and motif 4 (i)(M4i, -201 bp, 
Table 6.1) oligonucleotides was assessed with the ovine cell culture nuclear extracts 
(sA80BR, pA80BR, ISl2OCer and ISl2OLiv) by gel shift assay (Section 2.4.6). Only 
non-specific binding was observed with these oligonucleotides in all of the nuclear 
extracts tested (data not shown). The degenerate repeats of motif 4 (motif 4 (ii) and 
motif 4 (iii) (M411 & M4iii, -186 & -130 bp, respectively, Tables 6.1 & 2.3) were 
analysed, and no specific binding was observed with any of the nuclear extracts 
tested (data not shown). 
6.3 Discussion 
During this study the PrP gene promoter conserved motifs I and 2 have been 
characterised in a variety of cell culture and tissue-derived nuclear extracts using a 
series of gel shift, gel super-shift, and DNase I footprinting techniques. The results of 
this study have shown that of the four PrP promoter motifs only two, motifs I and 2 
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appear to be bound by transcription factors under the assay conditions used in this 
study. 
6.3.1 Motif I 
These experiments have shown that the wild type motif 1 sequence (MIT, 
CTTTCATTTTCT) as published for human, mouse and Suffolk sheep PrP promoters 
is not capable of forming a nuclear protein complex under the conditions used in the 
gel shift assays. However, a single base pair change from T to C, which has been 
found as a polymorphism in the ovine motif I sequence appears to have a dramatic 
effect on protein binding. The variant motif I (MIC, CTT( CATTTTCT) 
oligonucleotide shows strong, consistent and highly specific binding by gel shift 
assays in nuclear extracts from all ovine cell culture (Figure 6.2). 
Sequence analysis of the wild type and variant motif I binding sites using the 
TFSEARCH and TRANSFAC databases revealed that the variant motif 1 sequence 
((CATTTT) presents a potential binding motif for the YY1 transcription factor. 
Further evidence for this was provided by a comparison of the M1C DNA-protein 
complex with that observed with a recombinant munne AP-2 protein of known 
molecular weight (Figure 5.3). This showed that the molecular weight of the MIC 
DNA-protein complex would be expected to be approximately 50 kDa, a result 
consistent with a factor of a similar size to YYI binding to this motif. The binding 
motif for YYI contains either an ACATNTT core or a CCATNTT core (Hyde-
DeRuyscher, Jennings & Shenk, 1995, Shi et al., 1997, Yant, Zhu, Millinoff et al., 
1995). The YYI transcription factor is a zinc finger protein with a predicted 
molecular weight of 44 kDa, it is located on a number of mammalian gene promoters 
and plays an important role in transcriptional regulation (Shi et al., 1997). In 
contrast, the wild type motif I sequence (I CATTTT) does not form a consensus 
binding site for YY 1, due to the presence of a I at position I which deviates from the 
core binding sequence of CATNTT (Shi et al., 1997, Yant et al., 1995). This 
observation is further supported by Houbaviy, Usheva, Shenk et al. (1996) who 
produced a co-crystal structure of YYI bound to DNA, which highlighted the 
importance of the CCATNTT core motif for binding. Interestingly, the interaction 
between the YY I transcription factor and its DNA binding site depends more on 
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bonds formed with the complementary DNA strand. Therefore, YY 1 forms strong 
interactions with the complimentary bases in the YY1 binding site, i.e. GGTANAA 
instead of CCATNTT (Houbaviy et al., 1996, Hyde-DeRuyscher et al., 1995). In 
particular YY 1 forms strong interactions with the GG dinucleotide on the 
complimentary DNA strand (Houbaviy et al., 1996). Therefore, it is highly likely 
that changes to the GG dinucleotide, as seen in the wild type motif I (AG), would 
affect the affinity of the YYI protein for its DNA binding motif. This may explain 
the observed differences in binding of the motif I oligonucleotides (MIT & MIC), 
and suggests that YY 1 is a candidate binding factor for variant motif I. Interestingly, 
a similar situation has been described within the human cystic fibrosis 
transmembrane conductance receptor (CFTR) gene promoter region, where a single 
base change of A to T produces a novel YY1 binding site (Romey, Pallares-Ruiz, 
Mange et al., 2000). The presence of this polymorphism causes a significant increase 
in the expression of the CFTR protein, and the authors hypothesise that this may 
have a beneficial effect on patients with cystic fibrosis. 
The gel super-shill assay performed with the anti-YY1 antibody failed to 
produce a super-shift reaction. However, a specific blocking of the original MIC 
DNA-protein complex was observed (Figures 6.3 & 6.4). Interestingly, a number of 
researchers have reported a similar blocking reaction with the same anti-YY1 
antibody (Bakalkin et al., 1997, Johansson et al., 1998). In contrast, Dyer & 
Rosenberg (2001) noted a definite super-shift reaction with the same antibody in 
their gel super-shift assays. 
The YY 1 transcription factor has defined roles in transcriptional repression 
and activation, it can also act as a transcriptional mr element binding protein (Shi et 
al., 1997, Smale, 1997). Intriguingly, it has been hypothesised that YY1 may act to 
repress the transcription of certain genes by causing the displacement of other 
regulatory factors, and YY1 sites are commonly found close to, or overlapping other 
binding sites (Ericsson, Usheva & Edwards, 1999). YY I may repress transcription 
by recruiting histone deacetylases to the promoter (Shi et al., 1997). In addition, YY 1 
is able to control gene transcription by associating with other regulatory proteins 
present on distant areas of DNA, and it is thought that YY I achieves this by bending 
the DNA backbone to bring itself into close proximity with other regulatory factors, 
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such as SP-1 (Shi et a!, 1997). The ovine PrP gene promoter region has been 
sequenced in a limited number of sheep at the NPU, and these results have so far 
failed to show any strong association between the motif I polymorphism that creates 
the YY1 binding site and altered scrapie susceptibility (Dr Gerry O'Neill, NPU, 
personal communication). From the presented experiments it is not possible to 
predict how the binding of YY 1 affects the expression of the PrP gene, indeed it may 
act as either a repressor, or an activator of transcription. Further studies will therefore 
be required to elucidate the effect of YY I binding on transcription of the ovine PrP 
gene. 
6.3.2 Motif 2 
The ovine PrP gene M2C oligonucleotide was bound by a factor present in 
the ovine and N2a cell culture nuclear extracts (Figure 6.5). A species-specific 
sequence difference exists within motif 2, where the ruminant sequence is 
TTA( 'GTAA, whilst the non-ruminant sequence contains a C to T change creating 
the following sequence TTA) GTAA. The ruminant (M2C) and non-ruminant (M2T) 
motif 2 oligonucleotides were assessed for their ability to bind the same factor 
(Figure 6.5). The M2C oligonucleotide binds strongly to a protein factor, whilst the 
M2T oligonucleotide binds to what appears from gel mobility, to be the same factor 
but with much lower affinity (Figure 6.5). Interestingly, the same oligonucleotides 
bind to what appears to be the same factor from gel mobility, with the munne N2a 
nuclear extracts and with similar binding affinities (Figure 6.5). Sequence analysis of 
the ruminant and non-ruminant motif 2 binding sites using the TFSEARCH and 
TRANSFAC databases revealed that the ruminant sequence (TTA( 'GTAA) forms a 
consensus binding site (TTACGTAA) for the bZIP repressor protein (Cowell et al., 
1992, O'Neill et al., 2003). This is a transcription factor, also known as NF-1L3, and 
as E413P4 (Cowell, 2002, Cowell et al., 1992). The expression of E413P4 is 
upregulated by cellular levels of both, interleukin-3 (IL-3) and glucocorticoids 
(Cowell, 2002, Cowell et al., 1992, Wallace, Wheeler & Young, 1997). E413P4 
shares homology with the proline alanine rich (PAR) family of transcription factors 
(Cowell, 2002, Cowell et al., 1992). However, whilst E413P4 contains a PAR factor-
like DNA binding domain, it lacks the PAR region required for transcriptional 
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activation (Cowell, 2002, Cowell et al., 1992). Therefore, E413P4 is able to compete 
for the same binding site as the PAR factors, but unlike PAR family members, 
E413P4 acts as a repressor of transcription (Cowell, 2002, Cowell et al., 1992, 
Ikushima, lnukai, Inaba et al., 1997, Ishida, Ueda, Ohkawa et al., 2000). The 
mechanism by which E413P4 represses transcription remains unclear (Cowell, 2002). 
However, it may act by either displacing other factors from the same DNA site, or by 
binding site occlusion, preventing other factors from binding to the same site, and 
this may be controlled in a concentration dependent manner (Ikushima et al., 1997, 
Ishida et al., 2000, Lai & Ting, 1999). Ikushima et al. (1997) proposed that 
competition between E413P4 and PAR factors for the same binding site could act as a 
form of rheostat switch. Therefore, as the concentration of one factor increases, it is 
able to bind to the DNA site, however, if hormones or other external stimuli act to 
increase the levels of the opposing factor, then it will dislodge the bound factor and 
bind itself to the DNA. In this way gene expression can be carefully controlled by the 
relative concentrations of two transcription factors, one that functions as a repressor 
of transcription and one that activates transcription (Ikushima et al., 1997). E4BP4 is 
a member of the bZIP family of proteins which are characterised by their DNA 
binding (leucine zipper or b/H) and dimerisation (basic region or DZIP) domains 
(Landschulz et al., 1988, McKnight, 1991). This factor is formed by two monomers 
(homo- or hetero-monomers) coming together through a leucine zipper domain to 
form the dimeric E413P4 transcription factor which is then, and only then, able to 
bind to its specific DNA binding site (McKnight, 1991). Haas, Cantwell, Johnson et 
al. (1995) showed that PAR family factors may be able to interact with other bZIP 
factors (like CIEBP and CREB/ATF) forming hetero-dimers, which would then be 
able to bind to imperfect palindromic DNA binding sites. The consensus binding site 
for E413P4 is the palindromic sequence (5'TTACGTAA'3 and 3'TTACGTAA5'), 
and this is very common in dimeric transcription factor binding sites, as each 
monomer will bind to one identical half-site (Cowell, 2002, McKnight, 1991). The 
ruminant motif 2 sequence is palindromic (5'TTACGTAA3' and 3'TTACGTAA'5), 
however, the non-ruminant motif 2 sequence is not a palindrome (5'TTATGTAA'3 
and 3'TTACATAA'5). Therefore, the single base change in the motif 2 sequence 
between ruminants and non-ruminants could have serious consequences for the 
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binding of a homo-dimeric transcription factor, and this is reflected in the results 
observed with the respective binding assays (Figure 6.5). The palindromic M2C 
oligonucleotide binds strongly to the factor in the nuclear extracts (likely to be 
E4BP4), whilst the non-palindromic M2T oligonucleotide binds with much lower 
affinity to what appears to be the same factor (Figure 6.5). Interestingly, these results 
are entirely consistent with those observed by Fujii, Shimizu, Toda et al. (2000) 
which indicated that a similar bZIP factor in yeast (Papi) binds specifically to 
residues on the opposite strand of the Papi DNA binding site (TTACGTAA). Fujii et 
al. (2000) showed that interactions with the G in the sequence TTACGTAA were 
important in DNA binding. These results indicated that the palindromic nature of this 
motif is important for DNA binding to occur at an optimum level (Fujii etal., 2000). 
bZIP factors may therefore be expected to show lower affinity for the non-
palindromic motif 2 site observed in the non-ruminant PrP gene promoters. An 
important chemical modification, which may be involved in the regulation of the 
level of chromasomal packaging at the sites of expressed genes is cytosine 
methylation at 5'CG'3 dinucleotides, known as CpG methylation (Jones & Wolffe, 
1999, Kundu & Rao, 1999, Selker, 1990, Wolffe, 1998). Methylation of DNA 
binding motifs may affect gene expression by interrupting the binding of proteins to 
these sites (Meehan, Lewis, McKay et al., 1989, Tate & Bird, 1993). CpG islands are 
normally methylated, however, islands of unmethylated CpG exist where the 
proportion of 5'CG'3 dinucleotides is higher than average and these sites surround 
the promoter regions of certain genes (Kundu & Rao, 1999, Selker, 1990, Wolf & 
Migeon, 1985). The Suffolk sheep PrP gene (GenBank accession number = U67922) 
was mapped for the presence of potential CpG islands using the CpG island searcher 
program (Takai & Jones, 2003). The Suffolk PrP gene contains one CpG island 
which lies between bases 5279-6771 (a region which encompasses the Suffolk PrP 
gene promoter, exon I and intron I) and has a GC content of 59.4 %. Two regions 
within this CpG island have particularly high levels of 5'CG'3 dinucleotides, the first 
lies within the promoter regionlexon I and spans 5567-5776 bp with 71 % of CG 
nucleotides. The second region lies within intron I and spans 6117-6316 bp with 74.5 
% of CG nucleotides. The ruminant motif 2, but not the non-ruminant motif 2, 
contains a potential CpG island (TTA¼ TAA). The methylation of cytosine at C-5 
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gives the cytosine residue a very similar structure to that of a thymidine residue. It 
would therefore be expected that the methylated oligonucleotide (5'TTA mCGTAA'3) 
may have a similar effect on protein binding as the non-ruminant motif 2, which has 
a thymidine residue at the same position (5'TTA I GTAA'3). As this was not the 
case, it is reasonable to assume that the corresponding adenine residue on the 
opposite strand of the non-ruminant motif 2 (3'AAT \CATT'5) has a greater affect 
on protein binding, further highlighting the importance of the palindromic nature of 
this motif for protein binding. 
Gel super-shift assays of the M2C oligonucleotide with an anti-E4BP4 
antibody with ovine nuclear extracts failed to produce a super-shift, or blocking 
reaction (Figure 6.6). However, when these super-shift assays were repeated, with 
murine N2a cell extracts a definite super-shift was observed (Figure 6.7). This 
reaction was also repeated, in a human HeLa nuclear extract, and an equally 
impressive super-shift reaction was observed (Figure 6.7). In addition, the M2T 
oligonucleotide was super-shifted with the N2a nuclear extract, although, the relative 
intensity of the original DNA-complex and the super-shifted complex was lower than 
that observed with the M2C oligonucleotide (Figure 6.7). The fact that the protein 
binding to motif 2 is specifically super-shifted by an anti-E4BP4 antibody with both 
murine and human cell culture nuclear extracts indicates that the factor, which binds 
to the M2C oligonucleotide with the ovine cell culture nuclear extracts may be 
E413P4. The lack of a super-shift, or blocking reaction with this factor in the ovine 
cell extracts may be due to sequence changes in the ovine E413P4 protein. These 
changes may result in a failure of the anti-E4BP4 antibody to recognise the ovine 
protein, and interestingly, the anti-E4BP4 antibody has to date, only been shown to 
react with the human, mouse and rat forms of E413P4. These results indicate that, at 
least in mice and humans the factor which binds to motif 2 is the E413P4 transcription 
factor and that this is very likely to be the factor which binds to motif 2 in sheep. 
However, the possibility that the factor bound to the M2C oligonucleotide in the 
ovine cell culture nuclear extracts could be another bZIP transcription factor, and 
possibly another PAR factor, cannot be ruled out. Although, further gel super-shift 
assays using antibodies specific for other bZIP factors could be used to confirm the 
identity of the bound nuclear protein. 
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The E4BP4 transcription factor has defined roles in the regulation of a number 
of cellular processes (Cowell, 2002). E4BP4 has been shown to play a pivotal role in 
the regulation of circadian rhythms, and this is extremely interesting from the point 
of view of TSEs, as PrP null transgenic mice with no functioning PrP gene have been 
shown to exhibit altered circadian rhythms (Cowell, 2002, Doi, Nakajima, Okano et 
al., 2001, Mitsui, Yamaguchi, Matsuo et al., 2001, Tobler et al., 1996). In addition, 
Cagampang, Whatley, Mitchell et al. (1999) showed that PrP niRNA is itself 
regulated in a circadian manner, and furthermore, fatal familial insomnia is a TSE 
disease that results in patients suffering from interrupted sleep patterns (Gambetti, 
Petersen, Monari et al., 1993). Therefore, the identification of a protein with defined 
roles in the regulation of circadian rhythms, which interacts specifically with the PrP 
gene promoter is potentially an important finding for the field of TSE research. The 
E4BP4 transcription factor has also been shown to have defined roles in the control 
of apoptosis and in signal transductance pathways (Furlow & Brown, 1999, Ikushima 
et al., 1997, Kuribara, Kinoshita, Miyajima et al., 1999, Nishimura & Tanaka, 2001, 
Wallace et al., 1997, Yu, Chiang & Yen, 2002). Interestingly, apoptosis has been 
hypothesised as a possible mechanism of pathogenesis in prion diseases (Ferrer, 
1999, Forloni et al., 1996, Jamieson et al., 2001, Jesionek-Kupnicka et al., 1997, 
Kretzschmar et al., 1997). There is some evidence for the involvement of PrP' in 
signal transductance pathways (Chiarini et al., 2002, Mouillet-Richard et al., 2000, 
Spielhaupter & Schatzl, 2001). 
As E4BP4 exhibits transcriptional repression by competing for the same 
binding site with members of the PAR family of bZIP transcription factors, this 
raises the possibility that the motif 2 site could be occupied by E4BP4 as a default 
therefore repressing PrP gene expression. This initial repression may be regulated by 
external stimuli, which lead to either an increase in the cellular concentration of 
factors competing for the same site or a reduction in the cellular concentration of 
E4BP4, therefore increasing the expression of the PrP gene. Therefore, elucidating 
the role that E4BP4 plays in the expression of the PrP gene is important if we are to 
further understand the effect, if any, that this factor has on scrapie susceptibility. 
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6.3.3 Motif I & 2 gel shift assays in tissue derived nuclear extracts 
The gel shift assays of the MIC and M2C oligonucleotides were repeated 
with murine (C57BL) and ovine (NPU Cheviot) tissue derived nuclear extracts, and 
the results confirmed those seen with the cell culture nuclear extracts (Figures 6.8 & 
6.9). The M2C oligonucleotide bound specifically to what appears to be the same 
factor (likely to be E4BP4), with mouse and sheep brain nuclear extracts (Figure 
6.9). The M2C oligonucleotide was also able to successfully bind to a factor (likely 
to be E4BP4) in nuclear extracts prepared from ovine brain tissue, that had been 
previously flash frozen, and stored at —70 °C for two weeks prior to preparation 
(Lane 14, Figure 6.9). Interestingly, the mobilities of the complexes seen with the 
M2C oligonucleotide with the murine tissue extracts seemed to differ. The complex 
observed with the murine brain tissue nuclear extract was of approximately the same 
size (mobility) as the complex observed with the sheep brain derived pA80BR 
nuclear extract (Lanes 2 & 10, respectively, Figure 6.9). However, the complex seen 
with the murine liver tissue was slightly larger than that observed with the other 
nuclear extracts (Lane 6, Figure 6.9). In addition, the complexes observed with the 
M2C oligonucleotide with nuclear extracts prepared from the sheep primary cell 
cultures IS12OCer & IS12OLiv derived from brain and liver respectively, showed 
differing mobilities (Figure 6.10). The complex observed with the IS12OLiv nuclear 
extract was slightly smaller than that seen with the IS I 20Cer nuclear extract (Lanes 6 
& 2, respectively, Figure 6.10). It is not clear why these complexes have different 
mobilities, however, it could be due to the binding of different monomer 
combinations to the oligonucleotides in the different tissue-types. For example, it 
may be that in brain tissue a homo-dimeric factor (likely to be E4BP4) binds to the 
M2C oligonucleotide, whilst in liver tissue a different combination, i.e. a 
heterodimeric factor binds to the same oligonucleotide, thus explaining the different 
mobilities. It could also be caused by the binding of completely different factors to 
this oligonucleotide in the two different tissue-types. In fact, E4BP4 has been shown 
to compete with other bZIP transcription factors for the same binding motif and this 
may be used to control the tissue specific expression of certain genes (Ikushima et 
al., 1997). The binding of hetero-dimeric and/or different homo-dimeric transcription 
factors to motif 2 could be further analysed with different tissue derived nuclear 
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extracts by performing gel super-shift assays with the M2C oligonucleotide, utilising 
antibodies specific for a variety of bZIP factors. 
The M1C oligonucleotide binds specifically to a nuclear protein factor (likely 
to be YYI) in the murine and ovine brain tissue nuclear extracts (Lane 6 & 10, 
Figure 6.8). Two additional specific complexes (slower mobility) were observed with 
the Ml C oligonucleotide in the murine and ovine brain nuclear extracts. The 
possibility that these additional complexes were associated with YY1 was 
investigated with a gel super-shift assay using the anti-YYI antibody (Lanes 13-19, 
Figure 6.8). The anti-YYI antibody specifically blocked the lower complex, 
indicating that it was in fact YY1. In contrast, the two additional complexes were 
unaffected by the anti-YY1 antibody, indicating that they were not associated with 
YY1. 
The ability to extract nuclear proteins from munne and ovine tissues, both 
fresh and frozen, and to obtain clear and effective shift results with these proteins is 
important if we are to further our understanding of the factors identified during this 
study. The use of fresh and frozen archive tissue in gel shift assays may enable us to 
analyse the role, and expression of these, and other factors in a variety of tissue types 
and at various stages of disease. In this way it may be possible to elucidate if there 
are differences in their expression in different cell- or tissue-types, and to analyse the 
role of these factors in the regulation of scrapie susceptibility. 
63.4 Analysis of potential interactions between factors bound to ovine 
motifs I & 2 
The close proximity of motifs 1 and 2 raised the possibility that the YYI and 
E4BP4 transcription factors may interact in some way. In order to investigate this a 
series of double motif oligonucleotides were produced (Tables 2.3 & 6.1), and gel 
shift assays were performed with ovine pA80BR nuclear extracts (Figure 6.11). The 
results showed that in all of the combinations of the variant and wild type motifs 
tested, only one of the two factors appeared to be able to bind at any one time (Figure 
6.11). In addition, at no time was a binding-intermediate observed, which may have 
indicated the binding of both factors to the same oligonucleotide at once (Figure 
6.11). The non-ruminant PrP promoters contain a small gap between motifs 1 and 2 
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(7-8 bases), therefore, two double motif oligonucleotides were produced to analyse 
the effect of this gap on binding. The first oligonucleotide was that of the human PrP 
promoter motifs I and 2 (hMl/M2, Tables 2.3 & 6.1). A second oligonucleotide was 
produced which contained the variant motif 1 site and the ruminant motif 2 site, as 
observed in the ovine PrP promoter, separated by the 8 base gap from the human PrP 
promoter (hovMl/M2, Tables 2.3 & 6.1). The results showed that the gap appeared 
to have no effect on binding, and again it appeared that only one factor was able to 
bind at any one time (Figure 6.11). These results indicate that the binding of YY1 
and E4BP4 to their respective DNA motifs may be mutually exclusive, and this may 
be caused by steric hindrance between the two factors, preventing them from both 
binding together. 
Another method used to assess the interaction between the YY 1 and E4BP4 
transcription factors was to incubate a labeled oligonucleotide containing the binding 
site of one of the factors in a normal binding assay. The DNA-complex that forms 
was then titrated by the addition of an unlabeled oligonucleotide, which contained 
the binding site of the other factor. A radiolabeled MIC oligonucleotide was 
incubated with pA80BR nuclear extracts and the subsequent YY1 DNA-protein 
complex was titrated by the addition of an unlabeled M2C (E4BP4 binding) 
oligonucleotide (Figure 6.12). The results showed that the addition of 1000X 
unlabeled M2C (E4BP4 binding) oligonucleotide competed out the original YYI 
DNA-protein complex, indicating that there may be an interaction between YYI and 
E4BP4 (Figure 6.12). Furthermore, the addition of 1000X unlabeled non-specific 
oligonucleotides (EGR-1, AP-1 & dAP-2c) failed to titrate the original YYI DNA-
protein complex, indicating that the interaction between YYI and E4BP4 was 
specific (EGR-1, Lanes 7-9; AP-1, Lanes 10-12; & dAP-2c, Lanes 13-15; Figure 
6.12). The fact that the unlabeled dAP-2c oligonucleotide, which contains a 
consensus SP-1 binding site, failed to affect the YYI DNA-protein complex 
indicated that YY1 and SP-1 may not interact with each other in this system. The 
transcription factor SP-1 has been shown to specifically interact with YY1 to 
regulate gene transcription in a number of other systems, and the presence of YYI 
and SP-1 (dAP-2c) binding motifs on the ovine PrP promoter raised the possibility 
that these two factors could interact in some way (Lackner & Muzyczka, 2002, Lee 
245 
et a!, 1993, Seto et al., 1993, Vassias, Hazan, Michel et al., 1998). However, the 
results in this study indicate that a reaction between SP-1 and YY 1 may not occur 
with the single motif oligonucleotides used in this study, although as the two binding 
sites are over 200 bases apart, any interaction between YYI and SP-1 may involve 
DNA bending, which may not have been accurately replicated in this study. 
Interestingly, YYI and E4BP4 binding sites are also found adjacent to each other on 
the p6 promoter of the parvovirus B 19, indicating that the positioning of these sites 
may have some biological significance (Raab, Bauer, Gigler et al., 2001). In 
addition, Zhou, Gedrich & Engel (1995) showed that transcriptional repression by 
VY1 may be mediated by interaction with the bZIP factors ATF/CREB, indicating 
that an interaction between YY1 and E4BP4, which is also a bZIP factor, may be 
possible. A hypothetical model for the interaction of YY1 and E4BP4 on the ovine 
PrP promoter is presented in Figure 6.14. 
Wild type motif 1 	
Motif I 	 i 
E413P4  
Not obs&r ed 	
1otil i 	 Nholl 
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Figure 6.14 Hypothesised interactions between YY1 and E4BP4 
on the ovine PrP promoter 
Wild type motif 1 indicates the Suffolk sheep PrP promoter sequence, variant motif 1 indicates 
the Cheviot sheep PrP sequence. E4BP4 = the bZlP repressor protein (or E4BP4 
transcription factor) also known as nuclear factor of interleukin 3 (NF-11-3). YY1 = the Yin 
Yang 1 transcription factor. Motif iT = Suffolk sheep, rodent, bovine & human PrP promoter 
motif 1 sequence (TCAI III), Motif 1C = Cheviot sheep polymorphic motif 1 sequence 
(CCAT I II), Motif 2C = bovine & ovine motif 2 sequence (TTACGTAA), Motif 2T = rodent & 
human motif 2 sequence (TTATGTAA). 
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As the binding of these two factors appears to be mutually exclusive, it is 
possible that one of the factors could act to dislodge the other. In the ovine PrP 
promoter, with the wild type motif 1 site, it is likely that only E4BP4 will bind, as no 
YYI binding was observed to this motif (Figure 6.2). However, in an ovine PrP 
promoter that contains the variant motif I site it is likely that YY1 will bind. By 
doing so YYI may prevent E4BP4 from binding to the motif 2 site, or it may act to 
dislodge E4BP4 from the motif 2 site due to steric hindrance (Figure 6.14). It is not 
clear what affect this would have on PrP gene expression, however, the dislodging of 
E4BP4, which is a repressor protein may act to increase the expression of PrP, 
therefore, YY I could be acting as an activator of transcription in this situation. 
Exactly when a particular transcription factor with dual functions (like YYI) acts as 
an activator, or as a repressor, depends not only on its intrinsic features, 
concentration and on the presence of other transcription factors, but also on the 
structure, relative position, and orientation of the promoter itself (Roberts & Green, 
1995, Tjian, 1995). Therefore, it is very difficult to predict how a single transcription 
factor will function on a given promoter, let alone how two individual factors will 
interact. Time constraints did not allow further analysis but a number of additional 
techniques are available to assess interactions between two proteins, these include 
the yeast two hybrid system, co-immunoprecipitation and the chromatin 
immunoprecipitation (ChIP) assay (Spencer, Sun, Li et al., 2003). In addition a novel 
technique, the TranSignalTM TF-TF Interaction Array II (Panomics, USA) is 
available. This technique enables the researcher to determine how a particular 
transcription factor interacts with multiple other transcription factors, and could be 
used to further characterise the interaction between YY I and E4BP4, and may 
provide a clearer picture of the role that these two factors play in PrP gene 
expression. 
From the information available to date, it is unclear how the binding of the 
E4BP4 and YYI transcription factors would affect PrP gene expression, or disease 
susceptibility. There are no obvious disease associations with the T to C 
polymorphism in the ovine PrP gene promoter motif I which creates the YYI 
binding motif (Dr Gerry O'Neill, NPU, personal communication). Sequential 
deletion analysis of the motifs in a variety of mammalian PrP promoters failed to 
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reveal any significant effect on reporter gene expression (Baybutt & Manson, 1997, 
Funke-Kaiser et al., 2001, Inoue el al., 1997, Mahal et al., 2001, Saeki et al., 1996, 
Westaway et al., 1994a), however, O'Neill et al. (2003) showed that deletion of the 
ovine motif I and truncation of motif 2 caused a slight reduction in expression of an 
ovine PrP promoter linked to a CAT reporter gene in sA80BR cells. However, the 
results of these deletion experiments should be carefully interpreted as a single 
deletion may remove more than one control element, in addition, two separate 
control elements may co-operate to produce a single response. 
E4BP4 expression is controlled by cellular levels of IL-3, however, Lewicki, 
Tishon, Homann et al. (2003) showed that levels of IL-3 were not altered or were 
absent in TSE affected mouse brain. It should be remembered that E4BP4 is a 
repressing transcription factor, and by binding to the PrP promoter it would be 
expected to have a repressing affect on gene expression. Therefore, upregulation of 
E4BP4 would be unexpected in a TSE disease state, as PrP gene expression is crucial 
for the development of disease. It is possible that in the disease state factors other 
than IL-3, such as other cytokines, could be involved in the suppression of E4BP4 
expression, or in the upregulation of factors that could compete for the same binding 
site with E4BP4. In fact, the expression of a number of cytokines has been shown to 
be increased in scrapie affected mouse brain, and the levels of certain transcription 
factors vary between the disease state and the healthy brain (Kim et al., 1999, Park, 
Choi, Jin etal., 2000). The expression of E4BP4 mRNA is upregulated by increased 
levels of cellular calcium (Nishimura & Tanaka, 2001), this is very interesting, as 
calcium regulation has been shown to be altered in TSEs, and PrP null mice show 
altered calcium homeostasis (Florio, Grimaldi, Scorziello et al., 1996, Forloni, 
Angeretti, Chiesa et al., 1993, Herms et al., 2000, Herms et al., 1997, Herms et al., 
2001, Kristensson, Feuerstein, Taraboulos etal., 1993, Silei, Fabrizi, Venturini etal., 
1999, Wong, Qiu, Hyun et al., 1996). Interestingly, E413P4 mRNA is expressed at 
high levels in tissues, which are normally associated with low levels of PrP', such as 
the liver and lung, in contrast E4BP4 mRNA is expressed at much lower levels in 
brain, where PrP' levels are normally high (Lai & Ting, 1999, Mitsui et al., 2001). 
This observation suggests that E413P4 may act to repress the expression of the PrP 
gene and that this repression could be carried out in a tissue-specific manner. 
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6.3.5 DNase I footprint analysis of PrP promoter motifs 
Attempts were made to supplement the results seen with the gel shift assays 
using the DNase I footprinting technique (Galas & Schmitz, 1978). DNase I 
footprints of the 0.5 kb Cheviot PrP promoter fragment labeled with 32P with ovine 
pA80BR nuclear extracts, revealed that the area of the DNA containing the variant 
motif I sequence may have been protected following the addition of pA80BR 
nuclear extract (Red line, Figure 6.13). The presence of a potential protected area of 
DNA at the same position as the variant motif 1 sequence on the Cheviot promoter 
may indicate that motif 1 was occupied by a nuclear factor (likely to be YY1). In 
contrast, the DNA sequence containing motif 2 did not appear to be protected 
following the addition of pA80BR nuclear extract (Blue line, Figure 6.13), a result 
consistent with YY1 binding to the Cheviot promoter at the variant motif 1, 
preventing the potential binding of E4BP4 to motif 2 (Figure 6.14). However, the 
potential variant motif I protected area was not inhibited by the addition of a 17 fold 
molar excess of unlabeled M1C and M2C competitor oligonucleotides (Figure 6.13), 
nor was it inhibited by the addition of a 17 fold molar excess of an unlabeled non-
competitor oligonucleotide (Figure 6.13). Therefore, it is difficult to confirm the 
specificity of this protection. However, the addition of higher concentrations i.e 100 
fold molar excess of the unlabeled competitor and non-competitor oligonucleotides 
may have resulted in the inhibition of this protection, and could be used to confirm if 
the observed potential protection was specific. In addition, the potential protection of 
variant motif I on the Cheviot promoter could be confirmed by repeating the DNase 
I footprint using the Suffolk promoter, which contains the wild type motif 1. 
6.3.6 Motifs 3&4 
No specific binding was observed in binding assays to the motif 3 (M3) and 
motif 4 (M41, M4ii & M411i) oligonucleotides with any of the ovine and murine 
nuclear extracts tested (data not shown). However, binding to these sites in abnormal 
cellular conditions cannot be ruled out, and it may be that these sites are, in fact, 
occupied, but only under specific cellular conditions, or in response to stimuli, or in 
tissue types not replicated/ assessed in these studies. Interestingly, motif 4 shares 
homology with conserved sequences in muscle-specific genes, therefore, it may be 
prudent to analyse binding activity to motif 4 and its degenerate repeats in nuclear 
extracts derived from muscle tissue (Inoue et al., 1997, Westaway et al., 1994a). 
6.3.7 Conclusions 
In summary, the results observed in this study have characterised the 
conserved PrP gene promoter motifs 1 and 2. It was shown that ovine and murine 
cell lines contained nuclear proteins capable of binding specifically to an ovine motif 
1 variant and to the ruminant motif 2. The use of antibodies specific for the candidate 
proteins YYI and E4BP4 confirmed that YYI is very likely to be the transcription 
factor, which binds to variant motif 1, whilst the factor binding to motif 2 is very 
likely to be E4BP4. 
The binding studies also revealed a potential new mechanism of 
transcriptional regulation of PrP gene expression through the mutual exclusive 
binding of these two factors. 
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Chapter 7: Final discussion 
7.1 Summary of results and discussion 
The PrP gene is involved in the control of TSEs, as transgenic PrP null mice, 
which do not express endogenous PrPC,  exhibit resistance to infection (Bueler et al., 
1993, Manson et al., 1999). It is hypothesised that the presence of even small 
differences in PrP' expression levels, especially in the periphery, could lead to 
significant differences in the survival time of, or pathology of, individual animals 
(Hunter et al., 1997). This is supported by scrapie infection experiments in PrP gene 
knockout mice, which showed a gene dosage effect, whereby homozygote PrP null 
mice were resistant to disease (ME7 scrapie strain) for at least 475 days, 
heterozygotes with one null allele and one functioning PrP allele showed mean 
incubation periods of 220 days and wild type mice with two normal PrP alleles 
showed incubation periods with a mean of 130 days (Manson et al., 1994b). Amino 
acid variants of PrPC  particularly at codons 136, 154 & 171 have been linked to 
disease susceptibility in sheep. However, not all variation in sheep disease phenotype 
can be explained by polymorphic changes within the PrP gene open reading frame. It 
is hypothesised that other regions of the PrP gene involved in control of transcription 
and/or translation, for example the PrP gene promoter region and 3'UTR, may be 
involved in the modulation of disease pathogenesis. Therefore, unravelling the 
mechanisms that control the expression of the PrP gene is vital to our understanding 
of disease progression. 
Alternative polyadenylation of the ovine PrP gene results in the production of 
two mRNA transcripts, a 2.1 kb and a 4.6 kb transcript, and in addition, a third 3.3 kb 
transcript may exist in peripheral tissues (Goldmann et al., 1999, Horiuchi et al., 
1995, Hunter et al., 1994c). This alternative polyadenylation may be involved in 
tissue-specific expression of the PrPC  protein as the 2.1 and 4.6 kb mRNA transcripts 
are found at different levels in different tissue-types (Goldmann et al., 1999). 
However, the use of alternative polyadenylation does not fully explain certain 
observations made in gene expression experiments, as a PrP gene construct with a 
full length 3'UTR was expressed at lower levels than PrP constructs with shorter 
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3'UTRs (Goidmaim et al., 1999). More recently, Marshall (2000) confirmed that a 
sequence between 2000-2700 bp in the ovine PrP 3UTR appeared to inhibit gene 
expression possibly via interactions with RNA binding proteins. The 2.1 kb transcript 
lacks this inhibitory region, and this may explain why a PrP construct with a full 
length 3'UTR was expressed at lower levels than those containing a shorter 3'UTR 
(Goldmann et al., 1999, Marshall, 2000). In addition, this inhibition only occurred in 
ovine brain-derived cells, which encoded at least one copy of the ARQ allele. 
Therefore, it is possible that the expression of an RNA binding protein may either be 
limited to animals of specific PrP genotypes, or its expression may be higher in those 
genotypes (Marshall, 2000). 
In order to further investigate the role of alternative polyadenylation on the 
expression of the PrP gene, a series of five PrP mini-gene constructs were produced 
(Chapter 4). The constructs differed only by their availability of polyadenylation 
signals located within the 3'UTR and were placed under the direct control of the 0.5 
kb ovine PrP gene promoter. In addition, the ovine PrP ORF used in the construction 
of the mini-genes was tagged with the 3XFLAGTM  epitope to enable the detection of 
recombinant PrPC  against a background of endogenous PrPC  normally expressed in 
these cells. The ovine PrP mini-gene constructs were then used to investigate the 
influence of alternative polyadenylation on PrP' expression following the transient 
transfection of ovine and murine cell cultures. 
Work carried out in the initial stages of this thesis resulted in the successful 
development of techniques for the extraction, inimunoprecipitation and detection of 
endogenous PrP', from ovine and murine cell extracts and murine tissue (Chapter 3). 
Previous studies by Marshall (2000) had shown that endogenous PrPC  could be 
detected from approximately 2 x 10 N2a cells, in this study endogenous PrPC  was 
successfully detected from cell extracts prepared from 100-fold fewer cells 
(approximately 2 x 105  cells). Additional enhancements made to this system during 
this study, such as the use of a protein G sepharose matrix and a novel buffering 
system further improved the recovery of endogenous PrPC  from these cell cultures. 
The amount of PrPC  isolated from the cell cultures with the present system was 
comparable to that achieved by other researchers from cultured neuronal cells using 
similar methods (Lehmann & Harris, 1996, Parizek et al., 2001, Winkihofer et al., 
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2003). The techniques developed for the isolation of endogenous PrPC  during this 
study were used to extract recombinant PrP' from ovine and murine cell lines which 
had been transiently transfected with the ovine PrP mini-gene constructs (Chapter 4). 
It was anticipated that the immunoprecipitation system developed during this study 
would be capable of successfully isolating recombinant PrP' from the transiently 
transfected cell cultures. However, no recombinant PrPC  expression was detected 
from ovine and murine cell cultures transiently transfected with the ovine PrP mini-
gene constructs. Sequencing of the ovine PrP mini-gene constructs confirmed their 
sequence integrity and highlighted the presence of the required sequence elements 
identified to date, including: 5' & 3' splice sites, a branch-point sequence and an 
ovine PrP gene intron region of approximately 700 bases. RT-PCR analysis of total 
RNA isolated from transiently transfected ovine cell cultures failed to detect any 
correctly spliced construct RNA, however the experiment was compromised by the 
presence in the reaction mixture of contaminating construct DNA due to the failure 
to treat the samples with DNase. In addition no control sample was included without 
the use of the reverse transcriptase reaction (a minus RT control). Due to the absence 
of important controls it remians unclear if the ovine PrP mini-gene construct RNAs 
were being correctly spliced or not, however incorrect splicing could also have been 
caused by the design of the constructs themselves, as they could be lacking sequence 
elements other than those identified in this study. 
Following the failure of these mini-genes to be correctly processed and a lack 
of obvious sequence defects in the constructs it was decided not pursue the mini-gene 
constructs any further. Time constraints ruled out the production of a new series of 
constructs and it was entirely possible that even if a working series of mini-gene 
constructs were produced, the lack of specificity of the antiFLAGTM  antibodies, as 
determined in control experiments, may have interfered with, or nullified the 
experimental model. However, the problem of the antiFLAGTM  antibodies may have 
been overcome by instead using 35 S-methionine labeling to detect recombinant PrPC 
expression. As such a decision was made to pursue the remaining aspects of the 
thesis, which involved analysing the role of the ovine PrP gene promoter in the 
regulation of PrP gene expression. 
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Gene expression is regulated by the binding of transcription factors to 
specific sequence elements within the promoter region (Mitchell & Tjian, 1989). 
These proteins aid in the formation of the basal transcription complex, in conjunction 
with RNA polymerase 11 (Mitchell & Tjian, 1989, Tjian, 1995). In addition, they can 
regulate the rate of transcription of a particular gene through specific interactions 
with other transcriptional elements (Mitchell & Tjian, 1989, Tjian, 1995). Before the 
work described in this thesis very few binding motifs for transcription factors had 
been identified in the ovine PrP promoter and only a single AP-2 motif (upstream 
AP-2), and an AP-2 motif cluster (downstream AP-2) in Suffolk sheep which is 
altered to a SP- I motif following a C to G polymorphic change in Cheviot sheep, had 
been identified (O'Neill et al., 2003) (Figure 5.1). The non-ruminant PrP promoters 
contain an AP-1 transcription factor binding motif, in addition, all of the mammalian 
promoters, with the exception of the Suffolk promoter, contain between two and 
three SP-1 binding motifs (Baybutt & Manson, 1997, Funke-Kaiser et al., 2001, 
Inoue et al., 1997, Mahal et al., 2001, O'Neill et al., 2003, Saeki et al., 1996, 
Westaway et al., 1994a). A number of polymorphic changes have been identified 
within the ovine PrP promoter including a polymorphic change of T to C and a single 
base polymorphism of C to A which is associated with the positive line (scrapie 
susceptible) of sheep in the NPU Cheviot flock. 
Gel shift assays carried out in this thesis showed that the upstream ovine AP-
2 motif (uAP-2) oligonucleotide was specifically bound by a protein factor present in 
the ovine cell culture nuclear extracts, and that this protein may be the AP-2 
transcription factor (Chapter 5). In addition, the downstream ovine AP-2 motif 
cluster oligonucleotides (dAP-2s & dAP-2c), which represent the Suffolk and 
Cheviot sheep variants of this motif, respectively, were bound specifically by what 
appeared to be different nuclear proteins. Comparisons of the mobilities of these 
different factors suggested that AP-2 may bind to the Suffolk motif (dAP-2s), whilst 
SP-1 may bind to the Cheviot motif (dAP-2c). Suffolk and Cheviot sheep differ in 
genetic linkage with scrapie and this is not explained by polymorphic changes within 
the ovine PrP gene ORF (Hunter, 1997, Hunter et al., 1994a). For example, Cheviot 
sheep in the NPU flock with the ARQ/ARQ genotype exhibit resistance to natural 
scrapie, whilst Suffolk sheep of the same genotype exhibit a high degree of 
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susceptibility to natural scrapie infection (Hunter, 1997, Hunter et al., 1994a). One 
possible explanation of these observations is that the expression of PrPC  is higher in 
ARQ/ARQ Suffolks than in ARQ/ARQ Cheviots and that this is controlled by 
variation in the PrP gene promoter regions. A potential candidate for this variation is 
the polymorphic downstream AP-2 motif. From the data currently available it is not 
apparent how differential binding to this site in the Suffolk and Cheviot promoters 
would effect PrP gene expression. Deletion of SP-1 sites in the mouse, rat and cattle 
PrP promoters linked to a reporter gene resulted in a reduction in reporter expression, 
indicating that SP-1 may play an important role in the activation of PrP gene 
expression (Baybutt & Manson, 1997, Inoue et al., 1997, Saeki et al., 1996). 
Therefore, it is tempting to speculate that the putative binding of SP-1 to the ovine 
PrP gene promoter in Cheviot sheep may have a similar activating effect, thus 
resulting in the expression of the PrP gene. All of the mammalian PrP promoters 
analysed in this study, with the exception of the Suffolk sheep promoter, contain at 
least one SP-1 motif, therefore it is likely that the presence of a SP-1 motif represents 
the wild type situation of the PrP gene promoter. The putative binding of AP-2 to the 
Suffolk PrP promoter may therefore represent a variant situation, in that the putative 
binding of AP-2 to the downstream AP-2 motif in Suffolk sheep could result in the 
alternative activation of transcription, whereby the degree of activation exhibited by 
SP-1 and AP-2 could vary. O'Neill et al. (2003) showed that the upstream ovine AP -
2 motif may activate PrP gene expression and this activating role may also apply to 
AP-2 bound to the downstream AP-2 motif cluster. Therefore, it is possible that 
differential binding of transcription factors to the downstream AP-2 motif cluster in 
Suffolk and Cheviot sheep of the ARQ/ARQ genotype could influence the rate of 
transcription of the ovine PrP gene. Differences in the level of PrP gene expression 
would be likely to affect the amount of PrPC  protein present, and may therefore affect 
the disease susceptibility of these two sheep breeds. These differences in expression 
could be exhibited in CNS tissues or in peripheral tissues involved in TSE 
pathogenesis, i.e. the lympho-reticular system. This is supported by studies which 
showed that the expression of the PrP gene in transgenic mice is directly related to 
disease susceptibility in a dose dependent manner (Manson et al., 1994b). In 
addition, it is possible that even small differences in PrPC  expression levels, 
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especially in the periphery, could lead to significant differences in the survival time 
of, or pathology of, individual animals (Hunter et al., 1997). Further studies using 
constructs containing the Cheviot and Suffolk PrP promoters linked to a reporter 
gene could be used to determine the influence of the C to G polymorphic change 
within the AP-2 cluster, following their transient transfection into ovine cell cultures. 
During this study, the ovine PrP promoter was subjected to extensive 
sequence analysis and two potential initiator (Inr) elements were identified and 
mapped potential transcription start sites to within 1-3 bases of those identified 
previously (Westaway et al., 1994b) (Chapter 5). These putative mr elements are 
conserved to a certain extent in all of the mammalian species tested, although some 
sequence variations are present. Where the information was available these sites 
were found to be located within a few bases of previously identified transcription 
start sites (Funke-Kaiser et al., 2001, Inoue et al., 1997, Mahal et al., 2001, 
Westaway et al., 1994a, Westaway et al., 1994b). Potential downstream promoter 
elements (DPEs) were also identified approximately +30 bases from the selected mr 
elements in all of the mammalian PrP promoters analysed and the positioning of the 
mr and DPEs may indicate the location of transcription start sites. 
The initiation of transcription is the primary mechanism by which cells are 
able to regulate whether or not a particular gene is transcribed (Mitchell & Tjian, 
1989, Tjian, 1995). Only the correct combination of protein factors will allow the 
initiation of a particular gene to be switched on, and the rate of this initiation can be 
regulated by interactions between the basal transcription complex and other 
transcription factors (Tjian, 1995). Therefore, the identification of potential mr and 
DPEs, which play a critical role in the formation of the basal transcription complex, 
allows us to further understand the potential mechanisms which regulate the 
expression of the PrP gene. In addition, the presence of transcription factor binding 
motifs upstream of these elements may provide further means by which the rate of 
PrP gene transcription could be modified. For example, mr elements have been 
shown to play a vital role in the formation of the basal transcription complex by 
allowing the binding of the TFIID complex to the promoter (Lo & Smale, 1996, 
Smale, 1997). The binding of TFIID to the mr element may also occur in a 
cooperative manner with the AP-2 and SP-1 transcription factors (Laity et al., 2001). 
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Therefore, the binding of either AP-2 or SP-1 to the downstream AP-2 motif cluster 
in the ovine PrP promoter may differentially influence the expression of the PrP gene 
by affecting the formation of the basal transcription complex. As such, the C to G 
polymorphic change within the downstream AP-2 motif could be related to disease 
susceptibility by control of the cellular PrP level. 
Further sequence analysis of the ovine PrP promoter identified potential 
binding motifs for a number of transcription factors including HSE-1 & HSE-2, 
STAT family, AP-1, EGR-1 and GATA-1 (Chapter 5). No specific binding was 
observed to the HSE-1, HSE-2, AP-1, EGR-1, GATA-1 and STAT-C 
oligonucleotides. There was an indication of binding to the ovine STAT-A 
oligonucleotide, although the assay needs to be repeated for confirmation. The STAT 
family of transcription factors, are inducible cytoplasmic proteins, which can be 
activated to translocate to the nucleus by proinflammatory cytokines such as IFN-y 
and IL-6 (Darnell, 1997, IhIe, 1996, Lackmann et al., 1998, Leonard & O'Shea, 
1998, Schindler & Strehlow, 2000, Takeda & Akira, 2000). Therefore, binding to the 
putative STAT motifs, which are conserved in the mammalian PrP promoters, 
requires further investigation and could be analysed with nuclear extracts prepared 
from cells which have been pre-treated with proinflammatory cytokines like IFN-y. 
These experiments may reveal whether, or not the binding of STAT transcription 
factors to the PrP promoter is responsive to environmental changes, i.e. cytokine 
activation of cells. Interestingly, the expression of proinflammatory cytokines like 
IL-6 has been shown to be upregulated following scrapie infection and this could 
suggest a mechanism by which PrP gene expression could be altered in disease 
(Bacot, Lenz, Frazier-Jessen et al., 2003, Kim et al., 1999). For example, the 
upregulation of cytokines like IL-6 during a scrapie infection could potentially lead 
to the translocation of STAT transcription factors to the nucleus, where they may 
bind to the STAT binding motif on the PrP gene promoter. The binding of STAT 
proteins may act to increase the level of PrP gene expression, thus increasing the 
level of PrPC  and potentially increasing the spread of infectivity. 
Binding to the four promoter motifs identified by Westaway et al. (1994a) 
was analysed and for the first time specific binding was observed to two of these 
motifs (motifs 1 & 2). No binding was detected to the wild type motif I 
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oligonucleotide (MIT), however, specific binding was observed to a polymorphic 
variant of this motif (M1C). Further sequence analysis of this site revealed that only 
the variant motif 1 sequence formed a binding motif for the YY 1 transcription factor 
and the specific binding of YYI to this motif was confirmed by gel super-shift assay 
using an anti-YY1 antibody (Chapter 6). YY1 is a well-studied transcription factor 
which can act as either a repressor or an activator of transcription depending on its 
DNA sequence environment, i.e. interactions with other proteins (Lackner & 
Muzyczka, 2002, Lee et al., 1993, Seto et al., 1993, Shi et al., 1997, Smale, 1997, 
Vassias et al., 1998). YYI can act as a transcriptional mr element binding protein, 
and may act to repress the transcription of certain genes by displacing other 
transcription factors or by recruiting histone deacetylases to the promoter (Shi et al., 
1997, Smale, 1997). Interestingly, YY1 motifs are often found close to, or 
overlapping, other binding motifs (Ericsson et al., 1999). Finally, YYI is able to 
regulate gene transcription by associating with other regulatory proteins present on 
distant areas of DNA (Shi etal., 1997). This is possible due to the ability of YY1 to 
bend the DNA backbone, bringing itself into close proximity with other regulatory 
factors, such as SP-1 (Seto et al., 1993, Shi et al., 1997). During the studies in this 
thesis no interaction was observed between YY 1 bound to the Ml C oligonucleotide 
and the dAP-2c oligonucleotide, which had been shown here to be bound by a 
nuclear protein with a similar electrophoretic mobility to SP-1. However, any 
potential interaction may have been dependent on DNA bending, which was unlikely 
to be replicated with the conditions and oligonucleotides used in this study. 
Specific binding was observed to the ruminant motif 2 oligonucleotide (M2C) 
and binding affinity was reduced with the non-ruminant motif 2 oligonucleotide 
(M2T). The major candidate for binding to motif 2 was identified as the bZIP 
transcription factor E4BP4 and this was later confirmed by gel super-shift assay with 
an anti-E4BP4 antibody with murine and human cell culture nuclear extracts 
(Chapter 6). Therefore, it is likely that E4BP4 binds to the ovine motif 2, although 
the binding of another bZIP factor to the ovine motif 2 cannot be ruled out. E4BP4 is 
a repressing transcription factor, which is known to be involved in a variety of 
cellular processes including circadian rhythms, apoptosis and signal transduction, all 
of which are pathways important for PrP biology (Cowell, 2002). 
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Differential binding to the M2C oligonucleotide was revealed using ovine 
(NPU Cheviot) liver and brain tissue-derived nuclear extracts. Similar differences 
were also observed between murine brain and liver (C57BL) tissue-derived nuclear 
extracts. Interestingly, E4BP4 has been shown to compete with other bZIP 
transcription factors for the same binding motif and this can be used to control the 
tissue specific expression of certain genes (Ikushima et al., 1997). Therefore, it is 
possible that motif 2 may be bound by one bZIP transcription factor, i.e. E4BP4, in 
one tissue-type and by another factor in a different tissue-type, thus suggesting a 
mechanism for the tissue-specific regulation of PrP gene expression. For example, 
previous studies have shown that E4BP4 mRNA is expressed at high levels in tissues 
that are normally associated with low levels of PrPC,  such as, the liver and lung (Lai 
& Ting, 1999, Mitsui et al., 2001). In contrast, E4BP4 mRNA is expressed at much 
lower levels in brain, where the levels of PrPC  are normally much higher (Lai & Ting, 
1999, Mitsui et al., 2001). This may suggest that E4BP4 is able to act as a repressor 
of PrP gene expression, which could be tissue-specific and could be controlled by the 
binding of different bZIP factors to motif 2 on the PrP promoter. The tissue/ cell 
types analysed during this study have been limited to four ovine cell cultures and one 
murine cell culture. The cell cultures used were derived from either neuronal tissue 
(ovine sA80BR, pA80BR, & IS12OCer and murine N2a) or liver tissue (IS12OLiv). 
The analysis of DNA binding to ovine promoter sequence elements, and especially to 
motif 2 with nuclear extracts prepared from other tissue/ cell types would therefore 
be highly desirable. The ability to successfully carry out gel shill assays with nuclear 
extracts prepared from fresh and frozen tissue samples provides the means by which 
binding to PrP promoter sequence elements could be analysed in a variety of tissue 
types including archive tissue samples and potentially disease state tissues. 
The close proximity of motifs 1 and 2 on the PrP promoter raised the 
possibility of an interaction between the YYI and E4BP4 transcription factors, 
suggesting a complex mechanism of transcriptional PrP regulation by these factors 
could exist. As the binding of these two factors appeared to be mutually exclusive, it 
is possible that one of the factors could dislodge the other, or prevent it from binding 
to the PrP promoter (Figure 7.1). In the ovine PrP promoter with the wild type motif 
1 (sheep haplotype 1), it is likely that only E4BP4 will bind (Figure 7.1). However, 
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in an ovine PrP promoter that contained the variant motif 1 (sheep haplotype 2) it is 
likely that YY1 will bind, dislodging E4BP4 from motif 2 due to steric hindrance 
(Figure 7.1). Finally, the rodent/human haplotype of the wild type motif I and the 
non-ruminant motif 2 (Figure 7.1) is likely to be bound only by E4BP4. However, 
the binding of E4BP4 to the rodent/human PrP promoter will be with a lower affinity 
than that observed with the sheep haplotype I (Strong binding affinity indicated by 
dark blue E4BP4, weaker binding affinity indicated by light blue E4BP4, Figure 7.1). 
Therefore, differential binding to motifs 1 and 2 as observed with the three 
haplotypes presented in Figure 7.1, could potentially lead to species-specific 
differences in PrP gene expression. However, this idea is based on the limited 
number of mammalian promoter sequences tested to date, and in order to ascertain if 
more haplotypes exist, further promoter sequence analysis will be required. 
As E4BP4 is a repressing transcription factor its binding to the PrP promoter 
would be expected to have a repressing affect on gene expression. Therefore, by 
dislodging E4BP4, the YYI transcription factor could be functioning as an activator 
of transcription. 
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Figure 7.1 Potential interactions of YYI and E4BP4 on the PrP 
promoter 
Motif iT = Suffolk sheep, rodent, bovine & human PrP promoter motif 1 sequence 
(TCAI Ill), Motif 1C = Cheviot sheep polymorphic motif 1 sequence (CCATTTT), Motif 2C 
= bovine & ovine motif 2 sequence (TTACGTAA), Motif 2T = rodent & human motif 2 
sequence (TTATGTAA). E4BP4 = the bZIP repressor protein (or E4BP4 transcription factor) 
also known as nuclear factor of interleukin 3 (NF-1L3). YY1 = the Yin Yang 1 transcription 
factor. 
The binding of YY 1 to the Cheviot promoter in preference to E4BP4 was 
supported by DNase I footprinting experiments carried out during this study which 
indicated that the area of the Cheviot promoter containing the variant motif 1 may 
have been protected by the binding of a nuclear protein. In contrast, the DNA 
sequence containing motif 2 did not appear to be occupied, a result consistent with 
YY I binding to the Cheviot promoter at the variant motif 1, preventing the potential 
binding of E4BP4 to motif 2 (Sheep haplotype 2, Figure 7.1). However, as the 
DNase I footprints of the Cheviot promoter were only carried out on three occasions, 
further repeats are necessary and could also be investigated using the Suffolk 
promoter which contains the wild type motif 1. 
It is unclear how the binding of the E4BP4 and YYI transcription factors 
would affect PrP gene expression, or disease susceptibility. The polymorphic change 
which results in the binding of YY 1, appears not to be linked to any obvious scrapie 
susceptible or resistant genotypes (Dr Gerry O'Neill, NPU, personal 
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communication). In addition, the deletion of motifs I and 2 in a variety of 
mammalian PrP promoters has failed to reveal any significant effect on reporter gene 
expression (Baybutt & Manson, 1997, Funke-Kaiser et al., 2001, Inoue et al., 1997, 
Mahal et al., 2001, O'Neill et al., 2003, Saeki et al., 1996). However, these deletion 
experiments would not have taken into account potential interactions between factors 
bound to the motifs and other transcription factors, which could play an important 
role in their influence on PrP gene expression. A number of techniques are available 
to further analyse potential interactions between two proteins including the yeast two 
hybrid system, co-.immunoprecipitation, the chromatin immunoprecipitation (ChIP) 
assay and the TranSignalTM TF-TF Interaction Array II. These techniques could be 
used to characterise any potential interaction between YYI and E4BP4, and may 
provide a clearer picture of the role that these two factors play in the control of PrP 
gene expression. 
This study has used a selection of in vitro techniques to investigate the 
binding of transcription factors to selected motifs within the ovine PrP promoter. 
These techniques enable the identification of proteins that bind to free radiolabeled 
oligonucleotides, however, they may not accurately replicate the in vivo situation. 
Eukaryotic DNA is condensed into a highly ordered complex (a nucleosome) with 
small basic proteins termed histories (Travers, 1994). This complex is known as 
chromatin and serves to package and organise chromosomal DNA within the nucleus 
(Travers, 1994, Wade, Pruss & Wolffe, 1997). The positioning of nucleosomes along 
eukaryotic DNA can determine the accessibility of specific DNA sequences to 
transcription factors, thus providing an additional level of gene transcription 
regulation (Kornberg & Lorch, 1992, Kornberg & Lorch, 1999, Workman & 
Buchman, 1993, Workman & Kingston, 1998). Therefore, the in vitro assays used in 
this study may not be representative of the whole picture as they do not accurately 
reflect the role of DNA packaging on gene transcription. 
The positioning of nucleosomes can be regulated by specific enzymes termed 
histone acetyltransferases (HATs) that acetylate histone proteins in a reversible 
reaction, causing the DNA within the nucleosome to become less condensed (Cosma 
et al., 1999, Kornberg & Lorch, 1999). This acetylation event may act to promote the 
binding of other transcription factors or it may enable the basal transcription complex 
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machinery to bind to the promoter. Interestingly, all of the mammalian PrP gene 
promoters with the exception of the human and rat promoters contain a potential 
binding motif for the transcription co-activator protein p300 (GGGAGTG), which 
has been shown to function as a HAT (Korzus et al., 1998, Ogryzko et al., 1996). 
7.2 Concluding remarks 
This thesis has analysed the non-coding regions of the PrP gene with a view 
to expanding current knowledge of the role that these elements play in the regulation 
of PrP gene expression. The main aims of this thesis were addressed by the following 
questions: 
Is endogenous PrPC  expressed in the ovine cell lines? 
What is the role of alternative polyadenylation of ovine PrP mRNA in control 
of PrPC  expression? 
Do sequence specific transcription factors bind to sequence motifs within the 
ovine PrP promoter? 
Do single nucleotide polymorphisms within the ovine PrP promoter affect 
transcription factor binding? 
Is the binding of transcription factors to the ovine PrP promoter cell/ tissue 
specific? 
All of these aims, with the exception of the analysis of the role of alternative 
polyadenylation in PrP gene expression, were successfully fulfilled during this study. 
At the time of writing this was the first study to have analysed the sequence of the 
ovine PrP promoter in depth, with a view to identifying potential transcription factor 
binding motifs. Therefore, the results presented in this thesis constitute the first 
demonstration of sequence specific binding of transcription factors to the ovine PrP 
promoter. It is widely accepted that eukaryotic gene expression is primarily regulated 
at the transcriptional level by the binding of general transcription factors (GTFs) to 
TATA and/or Initiator elements. The binding of GTFs to promoters and the rate of 
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transcription are further regulated by the binding of other transcription factors acting 
as either activators or repressors of transcription. 
Work carried out during this thesis has identified putative Initiator and 
downstream promoter elements which are conserved in all of the mammalian PrP 
promoters analysed, thus elucidating a potential mechanism by which PrP gene 
expression may be initiated. Specific binding to the ovine PrP promoter by 
transcription factors known to interact with the basal transcription complex was also 
demonstrated. The binding of factors such as SP-1 and AP-2 may represent one way 
in which the rate of transcription of the PrP gene is further regulated. In addition, for 
the first time single nucleotide polymorphisms within the ovine PrP promoter were 
shown to be biologically significant, resulting in the differential binding of 
transcription factors to the ovine PrP gene promoter. 
Binding to the four promoter motifs identified by Westaway et al. (1994a) 
was analysed and specific binding to motifs 1 and 2, by the transcription factors YY1 
and E4BP4 respectively, was demonstrated. In addition, a hypothetical model for the 
binding of YY1 and E4BP4 to the ovine promoter was produced, indicating a 
mechanism by which the expression of the PrP gene could be further regulated. 
Furthermore, the binding of YYI and E4BP4 to the ovine PrP gene promoter could 
influence the rate of gene transcription either by interacting with the basal 
transcription complex or by interactions with other transcription factors, for example, 
SP-1 or AP-2. Further studies are therefore required to analyse the role that these 
factors play in the regulation of PrP gene expression. 
The influence of transcription factors like YY 1 and E4BP4 on the expression 
of PrPC  could be subtle, and tissue-specific differences in where PrPSC  infectivity is 
found have been documented and seem to be related to PrP genotype. For example, 
Houston, Halliday, Jeffrey et al. (2002) showed clear genotype-specific differences 
in the distribution and relative levels of PrPSC  accumulation between New Zealand 
sheep experimentally challenged with SSBP/l scrapie. Potentially these differences 
in the distribution of PrPSC  could be caused by variations in the level of PrP' 
expression in sheep of different scrapie genotypes and this could have serious 
implications for any mechanism by which scrapie can spread through the body. For 
example, using the conformational conversion model (Section 1.2.1), if PrPC  was in 
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plentiful supply infectivity could potentially spread faster than if PrPC  was limited 
(Jarrett & Lansbury, 1993). However, few studies have analysed the tissue 
distribution and relative level of PrPC  in sheep. The analysis of PrPSC  and PrP' in 
neuronal tissues has become routine, however, methods for the analysis of PrPC in  
non-neuronal tissues, where the relative levels are frequently much lower than those 
observed in the brain, are much less well defined. Horiuchi et al. (1995) showed that 
PrPC was detectable in non-neuronal tissues such as spleen, lymph node, lung, kidney 
and intestine albeit at much lower levels than observed with neuronal tissue. 
Furthermore, Moudjou, Frobert, Grassi et al. (2001) analysed the distribution of PrPC 
in a variety of non-neuronal tissues of sheep of different scrapie genotypes. 
However, the number of animals used was very low and as such it was not possible 
to determine whether there was a relationship between genotype and the tissue 
specific expression of PrPC  (Moudjou et al., 2001). Therefore, studies into the 
distribution and relative levels of PrPC  in a variety of peripheral tissues of sheep of 
different breeds and scrapie genotypes are required to further our understanding of 
the role of PrPC  expression in the pathogenesis of scrapie. 
Finally, during this study no differences in protein-DNA binding were 
observed with nuclear extracts prepared from the cell cultures derived from sheep of 
known natural scrapie susceptible (sA80BR) and resistant (pA80BR) genotypes. 
However, any genotype specific differences in PrPC  expression could be manifested 
in a tissue-specific manner that was not analysed with the cell cultures tested in this 
study. Therefore, it may be prudent to repeat the gel shift assays carried out in this 
study with nuclear extracts derived from other tissues and in particular from tissue-
types known to be involved in the spread of infectivity, such as follicular dendritic 
cells and Langerhans cells. In addition, the binding of YYI and E413P4 to motifs I 
and 2, respectively, could be analysed in gel shift assays with nuclear extracts 
derived from frozen archive tissues from scrapie pathogenesis studies. These studies 
may highlight potential differential genotype related gel shift results, which could 
help to explain the distribution of PrP. 
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7.3 Future projects 
This thesis has identified potential sequence elements within the ovine PrP 
gene promoter that may act to initiate and regulate gene transcription, and has 
demonstrated sequence specific binding to a number of these elements. Therefore, 
the work carried out in this thesis has expanded upon the existing knowledge of the 
role of the PrP promoter in the regulation of gene expression and therefore 
contributes to our understanding of how disease development might be controlled in 
sheep. It has not provided data to associate the molecular interaction of nuclear 
proteins with the control of PrP gene expression. 
One obvious question arising from this thesis is therefore concerning the 
functional significance of the T I C polymorphism in motif 1 for healthy or scrapie-
affected sheep. To begin answering this important question it would be advisable to 
show differential transcription rates due to the polymorphism, for which one could 
employ two alternative methods of analysis. The first method would be based on the 
haplotype-specific chromatin immunoprecipitation (HaploChlP) technique (Knight, 
Keating, Rockett et al., 2003) which uses the detection of RNA polymerase II 
loading on the promoter to indicate the level of transcriptional activity. In short, 
experiments could be conducted with ovine cell lines or tissue samples known to be 
heterozygous for the motif 1 TIC polymorphism, in which the DNA and nuclear 
proteins would be cross-linked using formaldehyde, sonicated and the resulting DNA 
fragments would be immunoprecipitated with an antibody directed against RNA 
polymerase II. The DNA fragments purified from immunoprecipitation would then 
be selectively quantified using real time PCR analysis with primers specific for either 
the wild type (T) or polymorphic (C) motif 1 sequence. In this way the loading of 
RNA polymerase II and therefore the level of gene transcription could be determined 
for the wild type and variant sequences of motif 1. This approach would represent the 
in vivo environment of the chromatin within the normal cell. The second method 
would be to use in vitro transcription containing ovine PrP promoter plasmid 
constructs with either the wild type (T) or variant (C) sequences of motif 1 carried 
out in the presence of nuclear extracts derived from ovine cell cultures or ovine 
tissue samples. This experiment would allow the level of gene transcription to be 
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determined for the wild type and variant motif 1 sequences in an in vitro 
environment. 
In addition, to the more long term studies detailed above a number of shorter 
term experiments could be conducted to answer the following questions that have 
arisen from the work carried out during this thesis: 
What are the specific requirements for the formation of the transcription 
initiation complex on the PrP promoter? 
Are these requirements maintained or altered with regard to the observed 
polymorphisms in the ovine and niunne PrP promoter? 
Is there a species and/or tissue specificity in these protein-DNA interactions, 
which could help to establish a PrP-specific association between early 
transcriptional regulation and levels of PrP mRNA? 
Are the complexes formed between the motifs and the transcription factors 
responsive to environmental changes, i.e. cytokine activation of cells? 
These questions could be addressed by the following studies: 
Analysis of the mr & DPEs elements identified in the ovine and murine 
promoters: 
Binding to the PrP promoter mr and DPEs could be analysed using gel shill 
assays. Any bound transcription factors could be identified using gel super-shift 
assays with antibodies specific for basal transcription complex proteins, most of 
which are commercially available (at least for the mouse & human proteins). 
Potential interactions between any newly characterised factors could be analysed, 
and furthermore interactions between these factors and AP-2, SP- 1 and YY 1 I E4BP4 
could also be assessed. 
Investigation into the effect of species-specific polymorphic changes 
within AP-2 clusters on transcription factor binding: 
The murine PrP promoter also contains an AP-2 motif cluster and breed 
specific polymorphisms within this cluster alter the number of available AP-2 
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binding motifs (Baybutt & Manson, 1997). Potential differential binding to the 
polymorphic variants of this cluster could be analysed. These experiments could help 
to elucidate any effects that these polymorphisms may have on murine PrP gene 
expression. 
Analysis of tissue-specific binding of transcription factors to binding 
motifs within the ovine PrP gene promoter: 
Differential binding to the ruminant motif 2 was revealed using ovine liver 
and brain-derived NEs. Similar differences were also observed between murine brain 
and liver tissue NEs. Therefore, it may be that different factors are bound to this 
motif in different tissue-types, as E4BP4 has been shown to compete with other bZ[P 
transcription factors for the same binding motif. Gel super-shift assays with the anti-
E4BP4 antibody with NEs produced from these different tissue-types could reveal 
the differential binding of bZIP transcription factors to motif 2 in different tissues. In 
addition, the analysis of binding to motif 2 with NEs produced from other cell types, 
in particular from peripheral tissues shown to be important in scrapie disease control, 
such as follicular dendritic cells could provide further insights into the tissue-specific 
regulation of PrP. Furthermore, in order to assess any differential genotype related 
affects which could explain the distribution of PrP, binding to motif 2 could also be 
assessed in nuclear extracts prepared from stored tissues from TSE pathogenesis 
studies. 
Investigation into the role of pro-inflammatory cytokines on the binding 
of STAT transcription factors to the PrP promoter: 
A conserved binding motif for the STAT family of transcription factors was 
identified in all of the mammalian PrP promoters and a polymorphic change of C to 
A within this motif in sheep is linked to the positive line of NPU Cheviot sheep. Gel 
shift assays carried out to date indicated only weak binding to the variant form of this 
motif, however STAT proteins are inducible transcription factors which are activated 
to translocate to the nucleus only in response to extracellular stimuli such as 
proinflammatory cytokines. Shift assays could be performed with NEs prepared from 
murine and ovine cells which have been pre-treated with IFN-y, which has been 
W. 
shown to induce the translocation of STAT transcription factors to the nucleus 
(Darnell, 1997, Levy & Darnell, 2002). These experiments could provide further 
insights into the role of the STAT motif in PrP gene expression and could highlight a 
possible function for these factors in disease susceptibility. 
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Figure 7.1 Potential interactions of YY1 and E4BP4 on the PrP 
promoter 
Motif iT = Suffolk sheep, rodent, bovine & human PrP promoter motif 1 sequence 
(TCATT Ut), Motif 1C = Cheviot sheep polymorphic motif 1 sequence (CCA I I I I), Motif 2C 
= bovine & ovine motif 2 sequence (TTACGTAA), Motif 2T = rodent & human motif 2 
sequence (TTATGTAA). E4BP4 = the bZIP repressor protein (or E4BP4 transcription factor) 
also known as nuclear factor of intereukin 3 (NF-11-3). YY1 = the Yin Yang 1 transcription 
factor. 
The binding of YY 1 to the Cheviot promoter in preference to E4BP4 was 
supported by DNase I footprinting experiments carried out during this study which 
indicated that the area of the Cheviot promoter containing the variant motif 1 may 
have been protected by the binding of a nuclear protein. In contrast, the DNA 
sequence containing motif 2 did not appear to be occupied, a result consistent with 
YY 1 binding to the Cheviot promoter at the variant motif 1, preventing the potential 
binding of E413P4 to motif 2 (Sheep haplotype 2, Figure 7.1). However, as the 
DNase I footprints of the Cheviot promoter were only carried out on three occasions, 
further repeats are necessary and could also be investigated using the Suffolk 
promoter which contains the wild type motif 1. 
It is unclear how the binding of the E4BP4 and YY 1 transcription factors 
would affect PrP gene expression, or disease susceptibility. The polymorphic change 
which results in the binding of YY1, appears not to be linked to any obvious scrapie 
susceptible or resistant genotypes (Dr Gerry O'Neill, NPU, personal 
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communication). In addition, the deletion of motifs 1 and 2 in a variety of 
mammalian PrP promoters has failed to reveal any significant effect on reporter gene 
expression (Baybutt & Manson, 1997, Funke-Kaiser et al., 2001, Inoue et al., 1997, 
Mahal et al., 2001, OvNeill  etal., 2003, Saeki etal., 1996). However, these deletion 
experiments would not have taken into account potential interactions between factors 
bound to the motifs and other transcription factors, which could play an important 
role in their influence on PrP gene expression. A number of techniques are available 
to further analyse potential interactions between two proteins including the yeast two 
hybrid system, co-immunoprecipitation, the chromatin immunoprecipitation (ChIP) 
assay and the TranSignalTM TF-TF Interaction Array II. These techniques could be 
used to characterise any potential interaction between YY1 and E4BP4, and may 
provide a clearer picture of the role that these two factors play in the control of PrP 
gene expression. 
This study has used a selection of in vitro techniques to investigate the 
binding of transcription factors to selected motifs within the ovine PrP promoter. 
These techniques enable the identification of proteins that bind to free radiolabeled 
oligonucleotides, however, they may not accurately replicate the in vivo situation. 
Eukaryotic DNA is condensed into a highly ordered complex (a nucleosome) with 
small basic proteins termed histories (Travers, 1994). This complex is known as 
chromatin and serves to package and organise chromosomal DNA within the nucleus 
(Travers, 1994, Wade, Pruss & Wolffe, 1997). The positioning of nucleosomes along 
eukaryotic DNA can determine the accessibility of specific DNA sequences to 
transcription factors, thus providing an additional level of gene transcription 
regulation (Kornberg & Lorch, 1992, Komberg & Lorch, 1999, Workman & 
Buchman, 1993, Workman & Kingston, 1998). Therefore, the in vitro assays used in 
this study may not be representative of the whole picture as they do not accurately 
reflect the role of DNA packaging on gene transcription. 
The positioning of nucleosomes can be regulated by specific enzymes termed 
histone acetyltransferases (HATs) that acetylate histone proteins in a reversible 
reaction, causing the DNA within the nucleosome to become less condensed (Cosma 
et al., 1999, Kornberg & Lorch, 1999). This acetylation event may act to promote the 
binding of other transcription factors or it may enable the basal transcription complex 
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machinery to bind to the promoter. Interestingly, all of the mammalian PrP gene 
promoters with the exception of the human and rat promoters contain a potential 
binding motif for the transcription co-activator protein p300 (GGGAGTG), which 
has been shown to function as a HAT (Korzus et al., 1998, Ogryzko et al., 1996). 
7.2 Concluding remarks 
This thesis has analysed the non-coding regions of the PrP gene with a view 
to expanding current knowledge of the role that these elements play in the regulation 
of PrP gene expression. The main aims of this thesis were addressed by the following 
questions: 
Is endogenous PrPC  expressed in the ovine cell lines? 
What is the role of alternative polyadenylation of ovine PrP niRNA in control 
of PrPC  expression? 
Do sequence specific transcription factors bind to sequence motifs within the 
ovine PrP promoter? 
Do single nucleotide polymorphisms within the ovine PrP promoter affect 
transcription factor binding? 
Is the binding of transcription factors to the ovine PrP promoter cell/ tissue 
specific? 
All of these aims, with the exception of the analysis of the role of alternative 
polyadenylation in PrP gene expression, were successfully fulfilled during this study. 
At the time of writing this was the first study to have analysed the sequence of the 
ovine PrP promoter in depth, with a view to identifying potential transcription factor 
binding motifs. Therefore, the results presented in this thesis constitute the first 
demonstration of sequence specific binding of transcription factors to the ovine PrP 
promoter. It is widely accepted that eukaryotic gene expression is primarily regulated 
at the transcriptional level by the binding of general transcription factors (GTFs) to 
TATA and/or Initiator elements. The binding of GTFs to promoters and the rate of 
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transcription are further regulated by the binding of other transcription factors acting 
as either activators or repressors of transcription. 
Work carried out during this thesis has identified putative Initiator and 
downstream promoter elements which are conserved in all of the mammalian PrP 
promoters analysed, thus elucidating a potential mechanism by which PrP gene 
expression may be initiated. Specific binding to the ovine PrP promoter by 
transcription factors known to interact with the basal transcription complex was also 
demonstrated. The binding of factors such as SP-1 and AP-2 may represent one way 
in which the rate of transcription of the PrP gene is further regulated. In addition, for 
the first time single nucleotide polymorphisms within the ovine PrP promoter were 
shown to be biologically significant, resulting in the differential binding of 
transcription factors to the ovine PrP gene promoter. 
Binding to the four promoter motifs identified by Westaway et al. (1994a) 
was analysed and specific binding to motifs I and 2, by the transcription factors YY 1 
and E4BP4 respectively, was demonstrated. In addition, a hypothetical model for the 
binding of YYI and E4BP4 to the ovine promoter was produced, indicating a 
mechanism by which the expression of the PrP gene could be further regulated. 
Furthermore, the binding of YY 1 and E4BP4 to the ovine PrP gene promoter could 
influence the rate of gene transcription either by interacting with the basal 
transcription complex or by interactions with other transcription factors, for example, 
SP- I or AP-2. Further studies are therefore required to analyse the role that these 
factors play in the regulation of PrP gene expression. 
The influence of transcription factors like YY1 and E4BP4 on the expression 
of PrP' could be subtle, and tissue-specific differences in where PrP infectivity is 
found have been documented and seem to be related to PrP genotype. For example, 
Houston, Halliday, Jeffrey et al. (2002) showed clear genotype-specific differences 
in the distribution and relative levels of PrPs  accumulation between New Zealand 
sheep experimentally challenged with SSBP/1 scrapie. Potentially these differences 
in the distribution of PrP could be caused by variations in the level of PrPC 
expression in sheep of different scrapie genotypes and this could have serious 
implications for any mechanism by which scrapie can spread through the body. For 
example, using the conformational conversion model (Section 1.2.1), if PrP' was in 
264 
plentiful supply infectivity could potentially spread faster than if PrPC  was limited 
(Jarrett & Lansbury, 1993). However, few studies have analysed the tissue 
distribution and relative level of PrP' in sheep. The analysis of PrPSC  and  PrPC  in 
neuronal tissues has become routine, however, methods for the analysis of PrPC  in 
non-neuronal tissues, where the relative levels are frequently much lower than those 
observed in the brain, are much less well defined. Horiuchi et al. (1995) showed that 
PrP' was detectable in non-neuronal tissues such as spleen, lymph node, lung, kidney 
and intestine albeit at much lower levels than observed with neuronal tissue. 
Furthermore, Moudjou, Frobert, Grassi et al. (2001) analysed the distribution of PrP' 
in a variety of non-neuronal tissues of sheep of different scrapie genotypes. 
However, the number of animals used was very low and as such it was not possible 
to determine whether there was a relationship between genotype and the tissue 
specific expression of PrPC  (Moudjou et al., 2001). Therefore, studies into the 
distribution and relative levels of PrPC  in a variety of peripheral tissues of sheep of 
different breeds and scrapie genotypes are required to further our understanding of 
the role of PrPC  expression in the pathogenesis of scrapie. 
Finally, during this study no differences in protein-DNA binding were 
observed with nuclear extracts prepared from the cell cultures derived from sheep of 
known natural scrapie susceptible (sA80BR) and resistant (pA80BR) genotypes. 
However, any genotype specific differences in PrPC  expression could be manifested 
in a tissue-specific manner that was not analysed with the cell cultures tested in this 
study. Therefore, it may be prudent to repeat the gel shift assays carried out in this 
study with nuclear extracts derived from other tissues and in particular from tissue-
types known to be involved in the spread of infectivity, such as follicular dendritic 
cells and Langerhans cells. In addition, the binding of YYI and E4BP4 to motifs I 
and 2, respectively, could be analysed in gel shift assays with nuclear extracts 
derived from frozen archive tissues from scrapie pathogenesis studies. These studies 
may highlight potential differential genotype related gel shift results, which could 
help to explain the distribution of PrP. 
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7.3 Future projects 
This thesis has identified potential sequence elements within the ovine PrP 
gene promoter that may act to initiate and regulate gene transcription, and has 
demonstrated sequence specific binding to a number of these elements. Therefore, 
the work carried out in this thesis has expanded upon the existing knowledge of the 
role of the PrP promoter in the regulation of gene expression and therefore 
contributes to our understanding of how disease development might be controlled in 
sheep. It has not provided data to associate the molecular interaction of nuclear 
proteins with the control of PrP gene expression. 
One obvious question arising from this thesis is therefore concerning the 
functional significance of the T / C polymorphism in motif 1 for healthy or scrapie-
affected sheep. To begin answering this important question it would be advisable to 
show differential transcription rates due to the polymorphism, for which one could 
employ two alternative methods of analysis. The first method would be based on the 
haplotype-specific chromatin immunoprecipitation (HaploChlP) technique (Knight, 
Keating, Rockett et al., 2003) which uses the detection of RNA polymerase II 
loading on the promoter to indicate the level of transcriptional activity. In short, 
experiments could be conducted with ovine cell lines or tissue samples known to be 
heterozygous for the motif 1 T/C polymorphism, in which the DNA and nuclear 
proteins would be cross-linked using formaldehyde, sonicated and the resulting DNA 
fragments would be immunoprecipitated with an antibody directed against RNA 
polymerase II. The DNA fragments purified from immunoprecipitation would then 
be selectively quantified using real time PCR analysis with primers specific for either 
the wild type (T) or polymorphic (C) motif I sequence. In this way the loading of 
RNA polymerase II and therefore the level of gene transcription could be determined 
for the wild type and variant sequences of motif 1. This approach would represent the 
in vivo environment of the chromatin within the normal cell. The second method 
would be to use in vitro transcription containing ovine PrP promoter plasmid 
constructs with either the wild type (T) or variant (C) sequences of motif 1 carried 
out in the presence of nuclear extracts derived from ovine cell cultures or ovine 
tissue samples. This experiment would allow the level of gene transcription to be 
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determined for the wild type and variant motif 1 sequences in an in vitro 
environment. 
In addition, to the more long term studies detailed above a number of shorter 
term experiments could be conducted to answer the following questions that have 
arisen from the work carried out during this thesis: 
What are the specific requirements for the formation of the transcription 
initiation complex on the PrP promoter? 
Are these requirements maintained or altered with regard to the observed 
polymorphisms in the ovine and munne PrP promoter? 
Is there a species and/or tissue specificity in these protein-DNA interactions, 
which could help to establish a PrP-specific association between early 
transcriptional regulation and levels of PrP mRNA? 
Are the complexes formed between the motifs and the transcription factors 
responsive to environmental changes, i.e. cytokine activation of cells? 
These questions could be addressed by the following studies: 
Analysis of the mr & DPEs elements identified in the ovine and murine 
promoters: 
Binding to the PrP promoter mr and DPEs could be analysed using gel shift 
assays. Any bound transcription factors could be identified using gel super-shift 
assays with antibodies specific for basal transcription complex proteins, most of 
which are commercially available (at least for the mouse & human proteins). 
Potential interactions between any newly characterised factors could be analysed, 
and furthermore interactions between these factors and AP-2, SP-1 and YY1 I E413P4 
could also be assessed. 
Investigation into the effect of species-specific polymorphic changes 
within AP-2 clusters on transcription factor binding: 
The murine PrP promoter also contains an AP-2 motif cluster and breed 
specific polymorphisms within this cluster alter the number of available AP-2 
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binding motifs (Baybutt & Manson, 1997). Potential differential binding to the 
polymorphic variants of this cluster could be analysed. These experiments could help 
to elucidate any effects that these polymorphisms may have on murine PrP gene 
expression. 
Analysis of tissue-specific binding of transcription factors to binding 
motifs within the ovine PrP gene promoter: 
Differential binding to the ruminant motif 2 was revealed using ovine liver 
and brain-derived NEs. Similar differences were also observed between murine brain 
and liver tissue NEs. Therefore, it may be that different factors are bound to this 
motif in different tissue-types, as E4BP4 has been shown to compete with other bZIP 
transcription factors for the same binding motif. Gel super-shift assays with the anti-
E4BP4 antibody with NEs produced from these different tissue-types could reveal 
the differential binding of bZIP transcription factors to motif 2 in different tissues. In 
addition, the analysis of binding to motif 2 with NEs produced from other cell types, 
in particular from peripheral tissues shown to be important in scrapie disease control, 
such as follicular dendritic cells could provide further insights into the tissue-specific 
regulation of PrP. Furthermore, in order to assess any differential genotype related 
affects which could explain the distribution of PrPSC,  binding to motif 2 could also be 
assessed in nuclear extracts prepared from stored tissues from TSE pathogenesis 
studies. 
Investigation into the role of pro-inflammatory cytokines on the binding 
of STAT transcription factors to the PrP promoter: 
A conserved binding motif for the STAT family of transcription factors was 
identified in all of the mammalian PrP promoters and a polymorphic change of C to 
A within this motif in sheep is linked to the positive line of NPU Cheviot sheep. Gel 
shift assays carried out to date indicated only weak binding to the variant form of this 
motif, however STAT proteins are inducible transcription factors which are activated 
to translocate to the nucleus only in response to extracellular stimuli such as 
proinflammatory cytokines. Shift assays could be performed with NEs prepared from 
murine and ovine cells which have been pre-treated with IFN-y, which has been 
shown to induce the translocation of STAT transcription factors to the nucleus 
(Darnell, 1997, Levy & Darnell, 2002). These experiments could provide further 
insights into the role of the STAT motif in PrP gene expression and could highlight a 
possible function for these factors in disease susceptibility. 
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32 g of LB agar (Roche, UK) to IL of dH 20, split to 3 x 500 ml Duran bottles (-330 
ml) 
Autoclaved for 15 minutes at 121 0C 
Melted in microwave at low setting for 20 minutes with occasional shaking 
Cooled to 55°C and poured, allowed to cool on bench and stored at + 4 °C 
Am pici II in 
0.5 g ampicillin powder (Sigma, UK) to 10 ml dH 20 
Aliquoted into 500 .tl lots in 1.5 ml microcentnfuge tubes and stored at - 20°C 
Ampicillin plates 
When agar cooled to 55°C, ampicillin (Sigma, UK) was added to a final 
concentration of 
I tl / ml. The agar was then mixed and poured as above 
Ampicillin X-Gal/ isopropyl-beta-D-thiogalactopyranoside (IPTG) plates 
for blue-white selection 
When agar cooled to 55°C ampicillin (Sigma, UK) was added as above 
IPTG (Roche, UK) was added to a final concentration of 0.5 mM and X-Gal (Roche, 
UK) was added to a final concentration of 80 jig/ml 
The agar was then mixed and poured as above 
Luria-Bertani (LB) broth 
20 g of LB broth base (Roche, UK) to IL of dH 20 
Autoclaved for 15 minutes at 121°C, added ampicillin (Sigma, UK) if required at 
concentration of 1 tl / ml 
I % Agarose gels 
One gram of agarose (Roche, UK) dissolved in 100 mlix TBE buffer 
Heated in microwave on medium high setting for 1.5 minutes 
Ethidium bromide (Sigma, UK) was added to a final concentration of 0.5 p.g / ml 
Gel was allowed to set at room temperature for 1-2 hours 
Ran in Multipurpose Gel Electrophoresis Tank (IBI, UK) 
4 % acrylamide sequencing gel 
17.5 g of urea (BDH, UK) 
4 ml I Ox TBE buffer 
5.7 ml of 40 % acrylamide solution (BDH, UK) 
700 jil 10 % APS solution (BDH, UK) 
15 ml ofdH2O 
Mixed until dissolved and added 63 jil TEMED (Sigma, UK) whilst stirring 
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6 % acrylamide gel for DNase I footprinting assay 
48 g of urea (BDH, UK) 
15 ml 40% acrylamide/bisacrylamide solution, 37.5:1 (2.6 % C) (Bio-Rad, USA) 
10 ml. lOx TBE buffer 
37 ml dH2O 
700 j.tl 10 % APS solution (BDH, UK) 
Mixed until dissolved and added 50 .tl TEMED (Sigma-Aldrich, UK) whilst stirring 
4 % DNA retardation gel for gel shift and super-shift assays 
32.4 ml dH20 
2.5 ml 40 % acrylamide/bisacrylamide solution, 37.5:1(2.6 % C) (Bio-Rad, USA) 
1.5 ml 40 % acrylamide solution (Bio-Rad, USA) 
2 ml lOx TBE buffer 
1.25 ml 80 % Glycerol solution (BDH, UK) 
300 1.11 10 % APS solution (BDH, UK) 
Mixed until dissolved and added 20 j.il TEMED (Sigma, UK) whilst stirring 
Miniprep solution A 
50 mM glucose (BDH, UK) 
25 mM tris-HCI (pH 8) 
10 mM EDTA (pH 8.5) 
Prepared in 100 ml aliquots without glucose, autoclaved, added glucose and stored at 
4°C 
Miniprep solution B 
7 ml dH2O 
2m1 1MNaOH 
1 ml 10%SDS 
Prepared fresh for each preparation 
Miniprep solution C 
100 ml 5M potassium acetate 
19.1 ml glacial acetic acid (BDH, UK) 
47 ml dH2O 
Autoclaved at 121°C for 15 minutes and stored at room temperature 
10% Ammonium persulphate (APS) 
0.5 g APS (BDH, UK) 
Added to 5 ml dH2 0 and stored at 4°C covered in foil 
10 % sodium dodecyl sulphate (SDS) 
20 g SDS powder (BDH, UK) 
Added to 180 ml dH 20 
Made up to 200 ml with dH 20 when completely dissolved 
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Gel loading buffer 5x 
30 g Ficoll 400 (BDH, UK) 
1 ml 10%SDS 
8 p.1 0.5 M EDTA (pH 8) 
0.25 g Orange G (Sigma, 15K) 
50X TAE buffer 
242 g tris base (Roche, UK) 
57.1 ml glacial acetic acid (BDH, UK) 
100 ml 0.5 M EDTA (pH 8) 
Made up to lL with dH 2 O 
lOx TBE buffer 
108 g tris base (Roche, UK) 
55 g boric acid (BDH, UK) 
40 ml 0.5 M EDTA (pH 8) 
Made up to I L with dH 20 
Ethidium bromide 
One 10 mg ethidium bromide tablet (Sigma, UK) into 1 ml dH 20 and made up to 2 
ml with dH20 
TE buffer, pH 7.4 
10 mM tris-HCI, pH 7.4 
0.25 mM EDTA (pH 8) 
I M Tris buffer 
12.1 g tris base (Roche, UK) into 80 ml distilled dH 20 
Adjusted pH to 7.5 with concentrated HCI and made up to 100 ml with dH 20 
IM NaCl 
5.84 g NaCl (BDH, UK) into 80 ml distilled dH20 
Dissolved and made up to 100 ml with dH20 
0.5 M EDTA (pH 8) 
186.1 g EDTA.2H 20 (BDH, UK) 
Made up to 800 ml with dH 20 
Added solid NaOH (BDH, UK) and stir well to pH 7.8 
Added 10 % NaOH solution to pH 8 
Made up to 1 L with dH 20 and autoclaved for 15 minutes at 121°C 
3M NaAc (pH 5.2) 
408.1 g NaAc.3H20 (BDH, UK) into 800 ml dH 20 
Adjusted pH to 5.2 with glacial acetic acid 
Made up to 1 L with dH20 
Dispensed into 100 ml aliquots and autoclaved at 121'C for 15 minutes 
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3M NaAc (pH 7) 
408.1 g NaAc.31-1 20 (BDH, UK) into 800 ml dH20 
Adjusted pH to 7 with dilute acetic acid 
Made up to 1L with dH 2 0, dispensed into 100 ml aliquots and autoclaved at 121°C 
for 15 minutes 
RNase A Solution 
One j.tl RNase A solution (Roche, UK) was diluted in 100 jil of dH 20 and stored at 
—20 °C until use 
Complete mini - Protease Inhibitor solution 
One tablet (Roche, UK) dissolved in 1 ml dH 20 and mixed by vortexing. Stored at 4 
°C. 
Solutions for tissue culture 
Fetal calf serum (FCS) 
500 ml heat inactivated (56°C for 45 minutes) FCS (Globepharm, UK) aliquoted into 
50 ml lots, stored at -20°C. Centrifuged immediately before use at 2,000 rpm for 10 
minutes 
Standard complete medium (SCM) 
500 ml Dulbecco's MEM + Glutamax (Invitrogen, UK) 
50 ml FCS (Globepharm, UK) 
Penicillin I Streptomycin to final concentration of 100 units / ml i.e. stock 100 units 
per 
0.01 ml therefore added 5 ml Pen I Strep to 500 ml medium 
Nerve growth factor (NGF) complete medium (NCM) 
500 ml Dulbecco's MEM + Glutamax (Invitrogen, UK) 
50 ml FCS (Globepharm, UK) 
Penicillin I Streptomycin (Invitrogen, UK) to final concentration of 100 units / ml 
Nerve growth factor to final concentration of 10 ng/mI, therefore 100 jig stock taken 
up to 10 ml in dH20 and 0.5 ml NGF (Sigma, UK) added to 500 ml culture medium 
to give a final concentration of 10 nglml 
Freezing medium 
30 ml Standard Culture Medium (SCM) 
1.5 ml FCS (Globepharm, UK) 
5 ml DMSO (Sigma, UK) 
Aliquoted into 8 x 6 ml aliquots and stored at - 20°C 
Trypsin/ versene (TVP) 
4 ml 25 % trypsin (Invitrogen, UK) 
16 ml 0.02 % versene (thvitrogen, UK) 
WIN 
0.1 % Gelatin 
0.4 g gelatin (Biorad, UK) into 400 ml dH 20 
Autoclaved for 15 minutes at 121°C and stored at 4°C 
Bio-Rad protein assay II dye reagent 
20 ml Bio-Rad protein assay II dye reagent 
80 ml dH 2O 
Mixed and filtered through Whatman No. I filter paper, stored in glass bottle at room 
temperature for maximum of two weeks. 
Bio-Rad protein assay protein standard 
Lyophilised bovine serum albumin reconstituted in 20 ml dH20 (1.4 mg/ml) 
Aliquoted into 20 x I ml in 0.5 ml microcentrifuge tubes and stored at —20 °C 
Solutions for Immunoprecipitations 
Wash Buffer I 
2.4 ml I M tris-HCI (pH 7.5) 
7.2 ml IMNaCI 
0.48 ml Nonidet P-40 (Sigma, UK) 
38 ml dH2O 
Wash Buffer 2 
2.4 ml I M tris-HC1 (pH 7.5) 
24 ml IMNaCI 
0.48 ml Nonidet P-40 (Sigma, UK) 
21.1 mldH2O 
Wash Buffer 3 
0.24 ml 1M tris-HC1 (pH 7.5) 
23.8 ml dH20 
All wash buffers were prepared fresh for each precipitation 
Solutions for SDS-polyacrylamide-gel electrophoresis (SDS-
PAGE) 
NuPage IVIES SIDS running buffer (20x) 
50 ml running buffer (Invitrogen, UK) 
950 ml dH20 
500 p.1 NuPage Antioxidant (Invitrogen, UK) 
NuPage LDS Sample buffer (4x) 
200 p.1 sample buffer (Invitrogen, UK) 
800 p.! dH 20 
Antioxidant 
NuPage Antioxidant (Invitrogen, UK) 
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Sample reducing agent 
NuPage Sample reducing agent (I Ox) (Invitrogen, UK) 
Protein standards 
Pre-stained protein molecular weight standards (Invitrogen, UK) 
14,300-200,000 molecular weight range, lyophilized powder 
Added 500 tl dH 2 0 and flash frozen in 5 il aliquots, stored at - 20°C 
SDS-PAGE Gels 
NuPage Pre-cast 4-12 % Bis-Tris gel (Invitrogen, UK) 
Solutions for chemiluminescence blotting 
NuPage Transfer buffer (20x) 
25 ml NuPage transfer buffer (Invitrogen, UK) 
424.5 ml dH 20 
50 ml methanol (BDH, UK) 
0.5 ml NuPage antioxidant (Invitrogen, UK) 
TBS 
6.05 g tris base (Roche, UK) 
8.76 g NaCl (BDH, UK) 
Added dH20 to 800 ml 
Adjusted pH to 7.5 with HCI and made up to 1 L with dH 20 
TBST 
For one blot: 0.25 ml Tween 20 (Roche, UK) in 250 ml TBS 
I % Blocking solution 
For one blot: I ml blocking agent (Roche, UK) in 10 ml IRS 
0.5 % Blocking solution 
For one blot: 5 ml blocking agent (Roche, UK) in 100 ml TBS 
Primary Antibody 
6H4 anti-PrP monoclonal antibody (Prionics, CH). Lyophilized powder, added 1 ml 
dH20 and flash frozen in 15 tl aliquots, stored at - 70°C 
Secondary Antibody 
Peroxidase conjugated affinipure rabbit anti-mouse IgG (Jackson Immuno-research 
Lab Inc, Stratech, UK). Lyophilized powder, added 500 p.1 dH 20 and flash frozen in 
5 p.1 aliquots, stored at - 20°C 
Detection solution 
BM Chemi luminescence blotting substrate (POD) (Roche, UK) 
Pre-warmed Solution A (Roche, UK) for 30 minutes at 25°C. 
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APPENDIX 2 
PrP promoter transcriptional initiator (lnr) and downstream 






5' Splice site 
Figure Al Ovine PrP gene mr elements and potential 
transcriptional start sites 
Polymorphic changes are indicated by a base change (different colour) underneath the wild 
type sequence (Suffolk sheep, Genbank = U67922). Arrowheads indicate location of 
transcription start sites as experimentally shown by Westaway et al. (1994a). Suffolk sheep 
PrP gene promoter sequence from -49 to +81 bp, numbering based on the use of the 5' 
transcription start site (Genbank = U67922). Also highlighted is the polymorphic AP-2/SP-1 
site seen in Cheviot sheep (O'Neill et al., 2003). Underlined sequences indicate the location 
of potential initiator (lnr) elements. 5' splice site is indicated in bold text. 
Ovine 	CGCCCCCGCAGCTCCTCCTCTGCACGGCGACTCACCAGCCCTAGTTG ...... CCAGTCGCTGACAGCCGCAGAGCTGAGCGTCTT 
Bovine CCGCCCTGCCCCTCCTCCTCCGCCCGGCGACTTACCCGCCCTAGTTG ...... CCAGTCGCTGACAGCCGCAGAGCTGAGAGCGTC 
Human 	CCGCCGGCCGCCCGCCGGGGGCACAGAGTGTGCGCCGGGGGCACAGAGTGTGCGCCGGGCCGCGCGGCAATTGGTCCCCGCGCCGA 
Rat GCCTGTCGGGTCCCTCACCACGCCCCGCTCCCCCGCGTTGTCAGACCAG ..... CAGACGGAGTCTGAGCGTCGCGTCGGTGGCAG 
Mouse 	CGCCCCTTTCCACTCCCGGCTCCCCCGCGTTGTCGGATCAGCAGACCGATTCTGGGCGCTGCGTCCGATCGGTGGCAGGTAAGCGG 
Hamster TGACTCACTGCCCCGCCCGCTCCCCCGCGGCGTCCGAGCAGCAGACCGAGAAGGCACATCGAGT. . CCACTCGTCGCGTCGGTGGC 
A 	 A 	 A 
+1 +1 +1 
Figure A2 Mammalian PrP gene mr elements and potential transcriptional 
start sites 
Arrowheads indicate location of transcription start sites as experimentally shown by 
Westaway et al. (1994a) (ovine), (Inoue et al., 1997) (bovine), (Baybutt & Manson, 1997) 
(murine), (Funke-Kaiser etal., 2001) (human). Underlined sequences indicate the location of 
potential initiator (lnr) elements. NB: Artificial gaps were introduced into the above 
sequences in order to line-up potential transcription start sites using the GCG (Wisconsin) 
using local pile-up program. 
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Ovine 	GCCCTAGTTG ...... CCAGTCGCTGACAGCCGCA ........ GAGCTGAGAGCGTCTTCTCTCTCGCAGAAAGCAGGTAAATAGCC 
Bovine GCCCTAGTTG ...... CCAGTCGCTGACAGCCGCA ........ GAGCTGAGAGCOTCTTCTCTCTCGCAGAAGCAGGTAAATAGCCG 
Human 	GGGGCACAGAGTGTGCGCCGGGCCGCGCGGCAATT .............. GGTCCCCGCGCCGACCTCCGCCCGCGAGCGCCGCCGCT 
Rat TTGTCAGAGCAG ..... CAGACGGAGTCTGAGCGTCGCGTC . GGTGGCAOOTAAOCGGGCTGCTGAAGCCAGGCGTCAGCGAGCAT 
Mouse 	TCAGCAGACCGATTCTGGGCGCTGCGTCCGAT .......... CGGTGGCAQGTAAGCGGGCTGCTGAAGCCAGGCCTTGGCGAGCAC 
Hamster GCAGCAGACCGAGAAGGCACATCGAGT. CCACTCGTCGCGTCGGTGGCAGGTAAGCGGCTTCTGAAGCCTGGCCCCGGGAAGGGTG 
4 	 £ 	 A 	 A 
	
A 




Figure A3 Line-up of mammalian PrP gene mr & DPEs and potential 
transcriptional start sites 
Arrowheads indicate location of transcription start sites as experimentally shown by 
Westaway et al. (1994a) (ovine), (Inoue et al., 1997) (bovine), (Baybutt & Manson, 1997) 
(murine), (Funke-Kaiser et al., 2001) (human). Underlined sequences indicate the location of 
potential initiator (lnr) elements. Bold sequences indicate the location of putative 
downstream promoter elements (DPE5). NB: Artificial gaps were introduced into the above 
sequences in order to line-up potential transcription start sites using the GCG (Wisconsin) 
using local pile-up program. 
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